<SEC-DOCUMENT>0001125345-19-000112.txt : 20191106
<SEC-HEADER>0001125345-19-000112.hdr.sgml : 20191106
<ACCEPTANCE-DATETIME>20191106160806
ACCESSION NUMBER:		0001125345-19-000112
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191106
DATE AS OF CHANGE:		20191106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		191196342

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20190930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2019 Workiva--><!--r:37c13bdf-fb46-46bd-829a-97a3fb2efa47,g:e81d9694-bb2f-41e2-94f9-94c8f654a663,d:4a0d66b44d8f4009b071cb468d4fbda8--><html xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:mgnx="http://macrogenics.com/20190930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGFibGU6YTcyZDc0ODhkMzIwNDgwMzgxMDQyMmY5OTc1N2EwZGEvdGFibGVyYW5nZTphNzJkNzQ4OGQzMjA0ODAzODEwNDIyZjk5NzU3YTBkYV8yLTEtMS0xLTA_65237a41-bd71-4800-958d-67fe899d8e1a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGFibGU6YTcyZDc0ODhkMzIwNDgwMzgxMDQyMmY5OTc1N2EwZGEvdGFibGVyYW5nZTphNzJkNzQ4OGQzMjA0ODAzODEwNDIyZjk5NzU3YTBkYV80LTEtMS0xLTA_f3907f43-fee3-45d9-9525-bccf11101a21">2019</ix:nonNumeric><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGFibGU6YTcyZDc0ODhkMzIwNDgwMzgxMDQyMmY5OTc1N2EwZGEvdGFibGVyYW5nZTphNzJkNzQ4OGQzMjA0ODAzODEwNDIyZjk5NzU3YTBkYV81LTEtMS0xLTA_dc55f07a-2ded-47fc-996a-4dceb6a788e0">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGV4dHJlZ2lvbjo1MDAxNmMyYWZmMmU0NDcwYTk3MDViMGE5MTc1MDE3MF8xMzA_3a145b30-fcff-4075-9ac6-65a347bc6d90">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGV4dHJlZ2lvbjo1MDAxNmMyYWZmMmU0NDcwYTk3MDViMGE5MTc1MDE3MF8xMzE_89879c39-d5ba-4b77-9226-4dca9b08f4bb">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMi0xLTEtMS0w_22a5eb3f-dcda-4957-8cb7-2400dfcd1d46">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMi0zLTEtMS0w_e427ca02-80a5-4f53-b7d3-7c14d282f103">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMy0xLTEtMS0w_e7161534-90cd-4a36-ac84-a2c18eb5d430">125,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMy0zLTEtMS0w_1b5e3368-363f-4e56-83cd-199a620a4b1f">125,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfNC0xLTEtMS0w_718e3d04-0f39-429e-b49a-251d3f46540d">48,914,284</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfNC0zLTEtMS0w_e896a41c-def4-463e-b4eb-af920b11a858">42,353,301</ix:nonFraction><ix:nonNumeric contextRef="ic1cf9464dcb34891a718fe65cec9ab21_I20190930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDA4_d48d60fa-3511-4c66-ad50-e72151633519">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfOTY1_57414c3c-a125-4d11-ab1b-84005d3778dc">P5Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ied09d3487eed4159b54d3625844a0195_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy0xLTEtMS0w_748009d2-9a3c-44a7-80cf-97f9c5a4716d">73.7</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6891ca0af0c243698d6979e49cb85830_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy0zLTEtMS0w_eb9e18a6-f02a-457e-88dc-feaae2b1244f">76.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ife5de15de5594f5286936ecb877c1796_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy00LTEtMS0w_26078d02-d3ab-4428-8af8-8d4cde6e29e9">67.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3a3d1e16084d4603bb861c52410f4c34_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy02LTEtMS0w_c390dc2b-2f4f-4eca-ade4-b4809c087335">72.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ied09d3487eed4159b54d3625844a0195_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC0xLTEtMS0w_8f633f2b-18bf-495b-8cbf-076330e01528">1.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6891ca0af0c243698d6979e49cb85830_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC0zLTEtMS0w_0bff143f-5851-45a9-addb-5e1aac950e3e">2.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ife5de15de5594f5286936ecb877c1796_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC00LTEtMS0w_889f94b0-933d-4f42-b2d3-a5d620baaa7a">2.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3a3d1e16084d4603bb861c52410f4c34_D20180101-20180930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC02LTEtMS0w_d7eef47f-dde9-417c-a748-97f5c83f87fa">3.1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mgnx-20190930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i675263e40bbe4a209433798168310a91_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib491d902a8ad49b795070a44de412e95_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8841551e05040c396f8fa6fcf8186df_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic670a1b26e2f445cb693f4e6b6d75b2f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8076bbde2d05426b988cb552d4160afc_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473ba08d93ee45e2bf84bce5d72899d3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef682dfc0994eada511c90370c63e40_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia506c971040142629fb54680daa17aec_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d8b967295d4ec9beb9dbef66e34136_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7334327c1546457482bf0f7e50ce6898_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2625cfee254fe5bd022c71b569cc34_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie631656618b44857967833397e06fec9_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e93adb4e9549699596389a12799940_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c511f31dc24326ad7dda4999bb920f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5bd8f3576744dbb9937b8fc5acb46bd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7115c5927b1044988cbc4a7afac5d19a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8211c596a57b4c8fa51ea79890dd7fd5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40997f1539d4ab78b1902ae37f3fdbf_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6863787b8d794480a8e855a8efc726d1_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94bbc3aa63a547e194fd20c0df543168_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f30fa4821c4564ab5fe93c1b6e9f4e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38db183877eb40599f50bca9a09200a9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38b3296be924219aedc8c2eac6ad11a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68e42f1c79454e00b8d9a683c228e703_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19998d9cec804861820443cfaaf99f10_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb4236637bd4d5e9a049f4a03f8595e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb2976a10e846e7966cb2ab49d1a67d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac59364cc9747a995f2b060f07c9b31_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5adf28c49448eba2120a76eb379e91_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296abc347cdb4669b94752b68583d9c5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d08ec7e8585431cbf339ad2f7e1c149_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33faead3aa0448498b5977cd7bbe6061_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief68b2a51bab47d1894d15d2313d332a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c2f4879451425f8a8974eba32bbf5f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbed938c680f40789e9a484426d074c8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a63b971bd34028b45b145cba0b2395_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5528d6cd30546e5a8d7c4dcbfa0313a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e9f3ebcbed4a0a8cdb4c0df74931e7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i684c983bf3ed4ec4802b47cfd412ab10_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74709fe8a874de7af154d53f79304e0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83af315ef660490aa4b885bfa9bfce6c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49611ab05b844f1fb78cf779db2fe26d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e76d66eb5f46628e171bfe49684857_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019d56ef285043cfae4cfcebb2c90346_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d80a56bb96a476ebd48eb643b2f43d6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54746da158ce4bce9b69918fb58a959a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f60dd2a66844bda84a962daf15eed87_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f10c7f52f7b4ba484c7a0eba502e770_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id482aef724c247d3a9dad505cdf6170c_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333effd5cb7d4295a431b14185556574_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6d9c3f705947458160b1cd76174085_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eeaeba07b544a28b10787dd76e88301_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c80d7a709547958bf97b952bcb83fc_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0fd024aaec4139811a323c7b840f17_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib506aba19db74035bc8bbc02c41b43cb_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240b880a602c492dbfb61a21ea0eb5d3_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce004d28e074994bd7938f6ed719131_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i060f194c4a45460da0f50336db3489cb_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847ef2f18d3f476a94b52dd7c886fec4_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54b623b2879241278c6132571917a008_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2bd0e8af1e4fa99300ecb39dac4805_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31943445cf4647e9815814b40fe5c41f_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0ebde6ab2d4004af640da15e05f719_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdea36b22a3849cd89bae3b8659e5552_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1529ce9d9dec4e3999d400290ac6620c_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55dc213d33f2452082c642024e4aaf21_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id724f6a4b17744aaa91365c7ec213e22_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dade5ca02694388a0ce84360f1c804f_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95278dd6162e4f89b1e87fc5805eec36_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b6df7d2858470ea7228c5343664f9b_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a57474836104a719e68ea78c743320b_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5eef8cd6f14c31b7d9d7c5922d0d4d_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23fb65c6630f44d69f9baec8764c89e3_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bec1f6fecbe4fe790e9626d4040450f_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i650df15d071a48f9ad308100e9f9db92_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b903135a134cf39caaf1b9a70d3c0a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b30a1a7cd3c4c3baa990fca6174db72_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969e411a7436433db0a30ec91a49470c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia458119b7c404a179ca653e35a01c75b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33f08df369b2427988e6e11513fa5c38_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3676d61890504a29b1b2f0c9b97bc5b3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bbdfd41050a436d9d2e70b388d897ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7f5c48a4c34073a0af4d2bcef83f3a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cee49232b1741e1b7292d30a0182e3d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d90c76657d84918a66e5ac0515f67d3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44ab6273835479c9cbe51aed6705e61_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15dd70d707b34d789add5ecfa27969eb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica36a3f9d76444ff8117f05911db0082_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701cae7e28bf44fba78f29f859d17485_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e816985f0354d14990486b7d9fa32d9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebf9c8cbcd9454c9ca1746e3cabb812_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b731627c2204358b5c33793a78b3b6f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7335cfa2cb4a56be2db7b2843f2bd1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf30c1ba1e914625955d4027a7c9d97d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d96d8c704af4109b4494741538a09c3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b61365f4c84504907452a393c0c978_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a312ffda8e1499fb683210529f71461_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc438e0b3164ea1934a0d52645e75fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77cb2cbbcc3497190e5e9611541ef32_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13959021e84d4dcc881071aedc143536_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief653dd50f314a66ae8d96c62f649c59_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07d10f6477546e0b1b1d3e46b8fad47_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba076567c05486081a550f00fdc2edc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed260be42124aabb60094700d2e6d2d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21bd9e893e294ae78c62758ac0007634_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701fe9109c104be898d66144c5fdff56_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fcdaba997e14e45bc26beec23bd7875_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69a1a642f0d4979adb8ba239f6c10b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c9d0e3bc9048688ea0d0890580f4e4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf61485c1a34f73be6f360b91caaacd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i943c3dc5d31148128af05f6e108c9796_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d4bf814515415abde86a6c80fbe736_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603ed4709303491bbaf26a1b755d1deb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752d1ee7e5c441c790664845ece3aec0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87490ba462994db1b1ee01e11796fad2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e83105b10aa4d8fa9264667fda8c681_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154da4d6fbc040f69cb4f170cc223a94_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57dfc841ee9417094c91d03520271a9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7038fb1eaaed4930bef39d8439888cd3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1cf9464dcb34891a718fe65cec9ab21_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fcef9f911324937acdbe37c9ab67e7b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ied9b88caa01b437aa817087abe6032ec_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ceb7095584d49fc80652713cb7854c3_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic890dfa175f245fe8e241c46e046dbaf_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e82e0130f64686907e6f18d7557650_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58db151e3a448e7b3ee73f0be5d0b0d_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45db6deb036b486ba26f489e393fc752_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64c499ae2254674a5686716390e3f83_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3a6e8ec3fa4af0b64eee0e868f565a_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c33273de6d410b9cdecf2a5c0debe0_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368bb594cc624e83a77bf733371fae70_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id820317bddf4434e96ff1a911394e774_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9449b1c89445c48a12627858463cf0_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48390acd93f242ebbb42fc23fd256a82_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="performance_obligation"><xbrli:measure>mgnx:performance_obligation</xbrli:measure></xbrli:unit><xbrli:context id="i518fa15db0064fec812c4b780bc7655b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f5e76a013f47d39dc0003413f9d4a4_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae18551f4d2a403db5bd358b0c682d8a_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a39827bd724ee6a7232870c129f33d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb4c3a370434273bd0aefee45b77bf2_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3b1d36356f4d3eac2cc22fbf399979_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic81e31ef601944c49da28eddf02a77de_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db3c7b4a5914f65b0e7482d13d66f9f_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfec87d8a5404f13b27eab46f40228ef_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bec22401c70482e823b9a2e5d36d610_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf29abb47caf4681942fe396155e2ac1_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed40dc4661a49b8968604842ade9122_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a118b8388e14ba9b1059b88d91a8477_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="exclusive_license"><xbrli:measure>mgnx:exclusive_license</xbrli:measure></xbrli:unit><xbrli:context id="ice1c157abfbe45f194053705b2702f65_I20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib959c0e3f072409998cd0f0023270469_D20120901-20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-09-01</xbrli:startDate><xbrli:endDate>2012-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69015b5eb8740b6a029ef0b991a9402_I20120930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>mgnx:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i75bf3bc533454969826e25fc96e3af8f_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970f2dcb0eab418e9a653c77c4d9cc4f_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70674713bb8e4d3683f61a49dbc782c9_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91dc53f73fa84402824473c88b70867e_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="component"><xbrli:measure>mgnx:component</xbrli:measure></xbrli:unit><xbrli:context id="i7828f41496b2476a96ab41b01992b9b4_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12d8b77e71f41e4ad0b803eac53f1a0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6c3b2f59854f77ae4c3719194e6f29_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b6a87cc6bb4e9fa8724ece15b105e0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5c4e22b89924229a57a8eb74bb20cad_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie989ab30d5da4147917fd55e613200bb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8323bafdc34797924db0952bd973d0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27244fec8880414bb6b1cfc52c333374_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic146a3b466194000a57ac908f0e5c5be_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacab77e6779347788a780579fa1a685e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c16b322b44845d9b43c3c5ce1fd49af_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a9f07d07b94663a8cde320960c506a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4087c84e7e44db6bae261d20124a913_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55adada0a7564bdf9cfe077725d854b9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e4673e6a2a448182624726fd572b76_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5eb519ef2e4cbc8181141d7cd9276d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5c21a31445540e69dbc3a6f5f639ab6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie953d43978514183bcdd8c7b4ab3ab96_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd651a75afdd4d7d95c4e21996253290_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb1aca92da74f588459f1372f4a49b2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2a9d94d2dd4bea92a57ffb8904cbee_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie736d7bf024b4ae28e4589d3b604e1df_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5739a109487c4754a883c99176a1efd9_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i054926fddff24ee5807d883aad5e2a1f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c1e47bb3ef4615991f7912494745cf_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54fd08a4f3f743b49797b697a1ce3106_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02cc1ebe209c402a8c800be888313cd7_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie967f030aa6b4bc8aa81afe083e3c526_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2cd88b1fe140d6a7dfa35faadde661_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c8b2113702b464282bfe3e9b94f4d74_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9214916d72546d59baaee9785a7e087_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie723c1c82d87464d9ed56b45a59bacc5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273a5f224d3e4ecf828034c5e3e0f859_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a77af8c6e3e41ff8d11e8fe34dc64fc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49febe140c734397af0ac451febc2e05_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i372a9ad3922943f491a1fa7dd2c30d5d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422a064f422b48ae8e9a505da5963ed5_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1a6fcd218941a6baa89073c11c5da2_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ea6f505d99415186f0268a4bba80ef_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454fbe875e5b4db7a40944d31eb23a84_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b030de878e8406ebf1f621232078e07_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e00c8e472e49d588cd53f7014d9b81_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66184941d714664ae08c0e838d10181_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a913a00b68549eeb34e0b8808b5269e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff895ca6df94222b46a51a086d8de19_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79500c2c7ee4616be6fac7a8cf8e3c0_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccfecbf14a74088903da62adfcb0fa7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31b162e8e37461f9128da55a95f93e6_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff8158fdeb940b6918114f76ea442b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0c8668b262748c89e872fcfa0fb50dc_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d755c340e64be8bdab95b9056b73dc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa5b8cd82a44f608083484c65993b70_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied09d3487eed4159b54d3625844a0195_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6891ca0af0c243698d6979e49cb85830_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5de15de5594f5286936ecb877c1796_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3d1e16084d4603bb861c52410f4c34_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:18pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl84Mg_b004dc42-6409-464b-ba37-168cf449a467">10-Q</ix:nonNumeric></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:3.563690%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.436310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZDhmOTIwOGM4Njc0NGM3MTgwZjRmNWM5OWE2MmVlOTQvdGFibGVyYW5nZTpkOGY5MjA4Yzg2NzQ0YzcxODBmNGY1Yzk5YTYyZWU5NF8wLTAtMS0xLTA_01718024-262b-4517-9dfc-6f047f876b3e">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xMTg_14e8a085-8730-4b34-81ce-3e2f099b4c05">September 30, 2019</ix:nonNumeric></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:3.563690%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.436310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6OTQzN2Q5ZGQ5YWM5NDg4NWI4ZTNmMzQyOTg4NGIxMzYvdGFibGVyYW5nZTo5NDM3ZDlkZDlhYzk0ODg1YjhlM2YzNDI5ODg0YjEzNl8wLTAtMS0xLTA_7a4a6bdc-6894-4cdf-981a-685e45443ae9">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yMTA_6d294b9b-c99c-46f5-860e-21469b6f09e0">001-36112</ix:nonNumeric></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:24pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yMTM_9aa12fde-16df-41ba-97e3-c6098166199d">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:49.683748%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.316252%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8wLTAtMS0xLTA_cf6b29b8-38f6-4f5e-8808-01dd151eddbc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8wLTEtMS0xLTA_ba7de26c-d882-4468-b893-7362b1bace84">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxZDM5OTI0Nzc1MWY0NGVlODRlYmZmZjY2MTc5ZTA4M181_c691109e-d356-4962-8aa6-bc19e8ccbdcc">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxZDM5OTI0Nzc1MWY0NGVlODRlYmZmZjY2MTc5ZTA4M184_83c3b9fd-da5f-4ac1-a420-2ac5cb0c9d92">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxZDM5OTI0Nzc1MWY0NGVlODRlYmZmZjY2MTc5ZTA4M18xMg_823db30a-d1c6-47ed-91bb-e30de883d208">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTEtMS0xLTA_183285a1-7b91-4773-bf89-108107416ea3">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip code)</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yNzM_b6e9443f-6897-46af-8b54-42cf822882c9">301</ix:nonNumeric>-<ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yNzY_6d6012a1-1c98-466e-97c8-e7a33b933f05">251-5172</ix:nonNumeric></span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Registrant's telephone number, including area code)</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.245614%;"><tr><td style="width:1.0%;"></td><td style="width:36.095238%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.815476%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.089286%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6N2NkNDMwNzEzNmM0NGQ0ZTk4ZWU4YjRkY2FlNjE4MjQvdGFibGVyYW5nZTo3Y2Q0MzA3MTM2YzQ0ZDRlOThlZThiNGRjYWU2MTgyNF8xLTAtMS0xLTA_606bfada-2316-43c6-aa23-2ef74eea29dc">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6N2NkNDMwNzEzNmM0NGQ0ZTk4ZWU4YjRkY2FlNjE4MjQvdGFibGVyYW5nZTo3Y2Q0MzA3MTM2YzQ0ZDRlOThlZThiNGRjYWU2MTgyNF8xLTEtMS0xLTA_6fad3a0f-bdf9-40cf-aec6-0ede0bf8915b">MGNX</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6N2NkNDMwNzEzNmM0NGQ0ZTk4ZWU4YjRkY2FlNjE4MjQvdGFibGVyYW5nZTo3Y2Q0MzA3MTM2YzQ0ZDRlOThlZThiNGRjYWU2MTgyNF8xLTItMS0xLTA_9594fc4d-f76c-4686-ade9-7c44d9455e7d">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTQw_b0aeeeb4-f852-40f2-a36a-dfbaca71121c">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTQx_d36fb424-9cb7-44fe-818c-dcfaa62326d4">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.666667%;"><tr><td style="width:1.0%;"></td><td style="width:22.401914%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.687400%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.561404%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.349282%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZTJjYjIyM2EzZGI5NDUwNGIwNzU3YTdiZWVmYmNkMTUvdGFibGVyYW5nZTplMmNiMjIzYTNkYjk0NTA0YjA3NTdhN2JlZWZiY2QxNV8wLTAtMS0xLTA_39d7291f-2507-4976-bf2c-ceac9983a9c6">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZTJjYjIyM2EzZGI5NDUwNGIwNzU3YTdiZWVmYmNkMTUvdGFibGVyYW5nZTplMmNiMjIzYTNkYjk0NTA0YjA3NTdhN2JlZWZiY2QxNV8yLTMtMS0xLTA_f69883dd-acd1-4616-9677-2502e0e97a22">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZTJjYjIyM2EzZGI5NDUwNGIwNzU3YTdiZWVmYmNkMTUvdGFibGVyYW5nZTplMmNiMjIzYTNkYjk0NTA0YjA3NTdhN2JlZWZiY2QxNV80LTEtMS0xLTA_07ca1a31-4408-4d12-ba8d-dabd897408c0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTQy_c452b81e-95ef-4daf-85c5-deb4a99e44c0">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of November&#160;1, 2019, the number of outstanding shares of the registrant's common stock, par value $0.01 per share, was <ix:nonFraction unitRef="shares" contextRef="i675263e40bbe4a209433798168310a91_I20191101" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTMx_8c106d6a-173a-48bd-8fac-324af63f9c02">48,917,095</ix:nonFraction> shares.</span></div><div id="i_0_7"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:18pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:22.193548%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:73.806452%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">PART I.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">Financial Statements</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_19">Consolidated Balance Sheets at </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_19">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_19"> 30, 2019 (unaudited) and December 31, 2018</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Consolidated Statements of Operations and Comprehensive Loss for the three and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25"> months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25"> 30, 2019 and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25"> 30, 2018 (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">Consolidated Statements of Stockholders' Equity for the three and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28"> months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28"> 30, 2019 and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28"> 30, 2018 (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">Consolidated Statements of Cash Flows for the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31"> months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31"> 30, 2019 and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31"> 30, 2018 (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_34">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_64">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">PART&#160;II.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i_0_91">OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">Legal Proceeding</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_508">s</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">Exhibits</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i_0_10"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans to develop and commercialize our product candidates;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential benefits and future operation of our existing collaborations; </span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">significant competition in our industry;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">costs of litigation and the failure to successfully defend lawsuits and other claims against us;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">economic, political and other risks associated with our international operations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to protect and enforce patents and other intellectual property;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss or retirement of key members of management;</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="text-indent:-18pt;padding-left:28pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div id="i_0_13"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="i_0_16"></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i_0_19"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:58.205580%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNC0xLTEtMS0w_09f78667-30ce-424b-a3ea-09bb807b9612">156,593</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNC0zLTEtMS0w_164075fd-0fe5-41f8-99aa-4bc301adfc0f">220,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNS0xLTEtMS0w_d94d853d-160d-4b59-9ae9-87ccd802aa0b">97,823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNS0zLTEtMS0w_fd4d3810-82a8-482b-81b5-c8860161769b">12,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNi0xLTEtMS0w_4b6f95f3-e694-4630-a5eb-428293c276c2">9,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNi0zLTEtMS0w_6c3e6b2e-7b22-4cc6-891b-a96dc35ad656">29,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNy0xLTEtMS0w_c5d23d61-ac19-4c64-9e9f-685b5620563c">12,019</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNy0zLTEtMS0w_fb4bb519-9489-4351-bd24-54a0eb820fec">6,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOC0xLTEtMS0w_cf2e4667-62f7-4db8-a309-443418982c3e">295</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOC0zLTEtMS0w_2fe0c782-aeb3-4539-8bdf-cf63ef0af81b">272</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOS0xLTEtMS0w_b0d0dc82-7f26-4681-a386-79fb9460089c">276,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOS0zLTEtMS0w_773bb720-55fa-46b4-b393-070a303f97ed">269,124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Property, equipment and software, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTAtMS0xLTEtMA_28623869-b483-4d9d-b8e0-0dd339ec8cec">49,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTAtMy0xLTEtMA_a34a4155-efbc-42ed-81fb-3a16bf1e38cd">56,712</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTItMS0xLTEtMA_c7378be5-e46b-4174-bf4d-c63ff30f80d2">25,252</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTItMy0xLTEtMA_3f5ad9c3-357f-48dc-b5a8-8e59ebe880f0">6,294</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTMtMS0xLTEtMA_04b5c901-4dd1-4273-94c2-c370ddbbb3a1">351,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTMtMy0xLTEtMA_f2737e59-6fab-458f-9662-e453c242a751">332,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTctMS0xLTEtMA_9adde04e-d163-439e-ae0e-39251c6a2f4d">2,543</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTctMy0xLTEtMA_28ed8391-311f-47d0-b67d-e3baceb4f11f">4,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTgtMS0xLTEtMA_aeb5a8a9-ef16-4b81-9574-4bd47ccc7820">28,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTgtMy0xLTEtMA_65dd1fd6-c886-40f2-803c-680423ef617b">33,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTktMS0xLTEtMA_9fe46577-cfd6-456d-bf75-1eeeb5840787">23,571</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTktMy0xLTEtMA_80cf0338-b6b9-4bce-84f5-9f039c6357b7">21,721</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjAtMS0xLTEtMA_400ef1ac-feb2-44f2-8f90-d68faf8a8857">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjAtMy0xLTEtMA_c05c4ffb-d1c1-41c1-a3b6-7909ce29c22f">1,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjEtMS0xLTEtMA_9dcb05f9-3b3a-4534-b387-ca3c37f58c3e">2,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjEtMy0xLTEtMA_a85dcb1d-212f-44e5-b66a-9a1a38b9b2dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjItMS0xLTEtMA_2bece2e3-f0e8-4f32-a23a-71e58748be5f">175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjItMy0xLTEtMA_bc6dc633-608e-4773-9936-636a28591bef">175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjMtMS0xLTEtMA_9aa6a7d0-ee2e-4d12-ab43-53ac880f9a39">57,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjMtMy0xLTEtMA_cc4d6194-2d63-4872-8d74-d6cbff3fb1a6">59,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjQtMS0xLTEtMA_2624405e-2630-4b10-b1f9-268d35a625b5">10,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjQtMy0xLTEtMA_2a37be7d-6291-4c09-bd19-61b6b79b77df">19,001</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjUtMS0xLTEtMA_7a5e02ca-44ae-4870-941f-640182ee1383">28,582</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjUtMy0xLTEtMA_a23a3e66-8441-4600-812d-32a25462d15d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent, net of current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjYtMS0xLTEtMA_3842952f-24af-4c6f-9299-98ab0ed120f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjYtMy0xLTEtMA_33b02f1a-ae65-48c7-8a48-88efe84794af">10,312</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjgtMS0xLTEtMA_099d202b-7115-4622-9a86-16ea7879b9ac">96,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjgtMy0xLTEtMA_cfefa3b9-4d8d-40f0-b714-d599fe2cf3e6">89,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, $0.01 par value -- 125,000,000 shares authorized, 48,914,284 and 42,353,301 shares outstanding at September 30, 2019 and December 31, 2018, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzAtMS0xLTEtMA_917056ca-6087-4612-abe7-1391befe1461">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzAtMy0xLTEtMA_cede14f2-c3c0-4216-a4c8-dc29f7b6718c">424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzEtMS0xLTEtMA_83e167e8-0c83-4ce8-ba0a-5e7e6d4ad7e6">866,372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzEtMy0xLTEtMA_b8f85e72-c5d8-4714-88cb-337665b57eb8">732,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzItMS0xLTEtMA_780c0f25-f4a1-4cd1-8336-2966434f311f">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzItMy0xLTEtMA_8b6e92b2-71e9-48a9-9def-bc8a419ca907">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzMtMS0xLTEtMA_76117e31-a08c-4584-81b4-07bf989ace11">611,686</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzMtMy0xLTEtMA_be7f6bce-296b-4bac-a9ed-66c46b318b87">490,271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzQtMS0xLTEtMA_99a2e05f-a6dd-41a4-ad91-af4c6681acb7">255,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzQtMy0xLTEtMA_e0fc95b9-32ad-4210-bd68-e24eb07af1c1">242,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzUtMS0xLTEtMA_9b138a71-a320-4a54-b9fe-0f64e50646b3">351,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzUtMy0xLTEtMA_7b7da4c2-c39e-4954-aa07-de8931799fee">332,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes.</span></div><div id="i_0_25"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:33.233918%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.115789%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative and other agreements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic670a1b26e2f445cb693f4e6b6d75b2f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy0xLTEtMS0w_08bcf249-7411-4d74-97ec-cab7f07c450b">17,984</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8076bbde2d05426b988cb552d4160afc_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy0zLTEtMS0w_540ea6ea-b18c-43f0-8c6c-0809bd69d8de">20,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i473ba08d93ee45e2bf84bce5d72899d3_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy01LTEtMS0w_80f497c5-1c6a-477a-b228-344cf2003f74">37,468</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ef682dfc0994eada511c90370c63e40_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy03LTEtMS0w_15bc8cd2-493e-406a-9caf-04682f177321">43,670</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia506c971040142629fb54680daa17aec_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC0xLTEtMS0w_5fc7fe32-e8d3-4b1b-99e3-18f803833518">757</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3d8b967295d4ec9beb9dbef66e34136_D20180701-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC0zLTEtMS0w_a73e43a9-508d-49da-85c4-7a673be45daa">181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7334327c1546457482bf0f7e50ce6898_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC01LTEtMS0w_52f0a20e-48cc-454c-a9ec-4b08a9d25e83">1,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b2625cfee254fe5bd022c71b569cc34_D20180101-20180930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC03LTEtMS0w_e418430c-8657-4fed-b594-036f332905ab">657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS0xLTEtMS0w_e6a44181-b0a3-49f8-b8a0-4023ece0ed66">18,741</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS0zLTEtMS0w_de330eb7-501f-4795-bb60-375541f69f49">20,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS01LTEtMS0w_c0fbc13f-2ba6-48b8-b013-2273e23b8bbb">38,996</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS03LTEtMS0w_e3b135f6-bb76-42c5-b81f-fabab6a377a4">44,327</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy0xLTEtMS0w_49316c0d-ce53-4a35-ab7a-5cdb5de7056e">44,852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy0zLTEtMS0w_8afbcc56-feab-4d8a-89f4-2d37c6b2c8a3">46,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy01LTEtMS0w_798b8b1c-a226-47eb-96e4-f1747230e23d">143,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy03LTEtMS0w_7a65a2a6-f3b8-4a78-bb56-d09f51c24b8f">143,902</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC0xLTEtMS0w_e15b3a1d-e9cb-4afb-9826-4e5404b535eb">11,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC0zLTEtMS0w_15b97bfa-148d-4da8-85dd-d6cd9e348f63">9,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC01LTEtMS0w_be58308b-f320-42f8-b8fe-0220264fe012">34,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC03LTEtMS0w_11b8b223-bc4e-4dd6-a740-670e03cde818">29,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS0xLTEtMS0w_74c13f0e-4533-4393-87d8-ccbde7372278">56,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS0zLTEtMS0w_bdf4b4d3-83c4-41f0-93dc-9563bfb88019">55,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS01LTEtMS0w_202d2bff-c24a-4479-8d2f-76127920c571">177,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS03LTEtMS0w_f8e767df-2554-4de2-a73d-becad4d30431">173,855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtMS0xLTEtMA_15f0ff07-c45e-4978-8dfa-234bedbccb4e">37,944</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtMy0xLTEtMA_08e31a81-c3b2-4379-98fe-e4ded6abdde4">35,004</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtNS0xLTEtMA_f6a2b1bc-8794-445e-8d21-1897f3239f02">138,530</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtNy0xLTEtMA_4bad4d23-37e7-435b-b74e-75b9375b74bc">129,528</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtMS0xLTEtMA_36969f25-f5f8-420b-9a41-5cd21bf90b1e">6,687</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtMy0xLTEtMA_bbb57271-5b14-4904-98aa-842d97a2ece9">975</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtNS0xLTEtMA_73b3f081-6ac8-4bff-84f8-533baa7f6abc">17,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtNy0xLTEtMA_98d4122e-d27b-4ee7-916c-ea84541bec45">2,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItMS0xLTEtMA_7e9b190d-11e3-4792-88f3-3f6cea119162">44,631</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItMy0xLTEtMA_7c4d8937-16d7-4cd2-948a-1c40d538f043">34,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItNS0xLTEtMA_f2844cf8-5627-432a-acc8-88af6f98f1dc">121,415</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItNy0xLTEtMA_07da916c-acef-4993-86de-e99a1826bd5d">126,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain (loss) on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtMS0xLTEtMA_6f57799f-637e-4211-b3f1-cbf7d074a3ff">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtMy0xLTEtMA_e5adbfa7-db6b-43b3-96b8-939d5c1974f3">18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtNS0xLTEtMA_c25f534c-0dc4-4bda-836d-5549a6a18c81">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtNy0xLTEtMA_5da52e43-38a5-422b-bed2-223da2eaae97">61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtMS0xLTEtMA_4b78263b-467a-4318-af0a-a5cbbbdb0916">44,642</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtMy0xLTEtMA_a2a758c3-4ef2-4506-8b30-2924232a1ff7">34,047</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtNS0xLTEtMA_b475245c-7460-49ae-84c5-d4466352313c">121,389</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtNy0xLTEtMA_8334e74f-a513-413f-8dde-49edec346772">126,748</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctMS0xLTEtMA_a9845b41-4b19-4666-b02a-8a3491954c87">0.91</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctMy0xLTEtMA_54abad7a-27df-405e-9b88-a28f1f9a18b1">0.81</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctNS0xLTEtMA_2d4c9171-c081-4f23-bc95-8a74cdb17c4e">2.54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctNy0xLTEtMA_6b430ca2-66f4-402d-bcd2-4c3eac4fa362">3.13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtMS0xLTEtMA_c7ae04b2-a347-416c-833f-843094f4e82e">48,902,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtMy0xLTEtMA_4f30d43c-6a61-47dd-886c-1cc30314bdac">42,239,327</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtNS0xLTEtMA_1c07ca43-c330-49ff-968d-20dd154101f1">47,796,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtNy0xLTEtMA_af4659fb-8ca3-4e58-89fa-08bee14ea003">40,462,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_28"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share amounts)</span></div><div style="text-align:center;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.706897%;"><tr><td style="width:1.0%;"></td><td style="width:24.783115%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.752547%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.527802%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.714702%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:0.1%;"></td><td style="width:0.527802%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.809316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.527802%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.245997%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.527802%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.828239%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.527802%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.227074%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i31e93adb4e9549699596389a12799940_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xLTEtMS0w_6d099a48-b422-4d33-bd2b-11aa9e4d3167">42,353,301</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31e93adb4e9549699596389a12799940_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0zLTEtMS0w_748c2d94-5ada-46d7-b649-d2e1fbf6675c">424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2c511f31dc24326ad7dda4999bb920f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy05LTEtMS0w_a6b90205-df70-4475-995a-66b51ae50e28">732,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic5bd8f3576744dbb9937b8fc5acb46bd_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xMS0xLTEtMA_b53cd580-aca7-4991-b221-c316d25513b0">490,271</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7115c5927b1044988cbc4a7afac5d19a_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xMy0xLTEtMA_dede03a6-5110-4e0e-ab27-8bfa4e748103">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xNS0xLTEtMA_03e3a079-b7e5-43b3-b13f-9bb4b02082bd">242,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNC05LTEtMS0w_3e125afe-0a3f-4c62-b40e-beab3b622afc">3,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNC0xNS0xLTEtMA_08019706-30b7-48c5-a56e-f5aced603451">3,750</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS0xLTEtMS0w_77201495-ff2d-47de-9b07-51979a925f13">6,325,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS0zLTEtMS0w_16468b3b-d0af-466f-bd13-719eae92a79c">63</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS05LTEtMS0w_c5757815-a7ce-46cc-a91d-ed2c41df0232">118,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS0xNS0xLTEtMA_b9ca51ee-c6f2-4367-be9e-b98513caa10f">118,657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi0xLTEtMS0w_9f39e4db-3771-4ea2-9cfe-f7434df80722">126,707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi0zLTEtMS0w_a0b59610-9316-48ca-bd52-533322e16639">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi05LTEtMS0w_4d0f044b-6223-4778-831c-d5eaab042da0">346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi0xNS0xLTEtMA_4ef40b20-e1f3-40fe-b42f-f2fc92a01b8e">347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8211c596a57b4c8fa51ea79890dd7fd5_D20190101-20190331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNy0xMy0xLTEtMA_a7981477-5115-408e-b781-98c0300df4c3">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNy0xNS0xLTEtMA_f49211cc-eb70-4167-9cf0-b8c353c7089c">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie40997f1539d4ab78b1902ae37f3fdbf_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOC0xMS0xLTEtMA_175482fd-bcf8-43a3-a3ac-7a31e303cf8d">45,017</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOC0xNS0xLTEtMA_ef53d273-f62a-4e4a-af6f-c9b0313d085e">45,017</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6863787b8d794480a8e855a8efc726d1_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xLTEtMS0w_be368fdf-8aaf-4834-883e-37375969fa31">48,805,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6863787b8d794480a8e855a8efc726d1_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0zLTEtMS0w_7959b767-455e-410b-9575-1ac43df37a0f">488</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94bbc3aa63a547e194fd20c0df543168_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS05LTEtMS0w_8160f4dc-6606-4ca3-b9ce-01ed8575e485">855,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i48f30fa4821c4564ab5fe93c1b6e9f4e_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xMS0xLTEtMA_a9742852-442c-417f-af15-6816a3f9d0ae">535,288</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38db183877eb40599f50bca9a09200a9_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xMy0xLTEtMA_3d5e18b9-e509-466a-ab01-0a1dabc8a2fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id38b3296be924219aedc8c2eac6ad11a_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xNS0xLTEtMA_7d81db50-10fc-46b0-bbe4-a1688809509b">320,617</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68e42f1c79454e00b8d9a683c228e703_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTAtOS0xLTEtMA_933b81ab-1f7a-4604-97d6-8111980edeb1">4,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTAtMTUtMS0xLTA_a94e021c-80e8-4f36-b192-3f0fe6c41882">4,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iccb4236637bd4d5e9a049f4a03f8595e_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtMS0xLTEtMA_53166655-6f3b-418e-8adb-e35cc030a5ad">88,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccb4236637bd4d5e9a049f4a03f8595e_D20190401-20190630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtMy0xLTEtMA_b14de136-dc59-45f6-b8a6-e52fd364ef97">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68e42f1c79454e00b8d9a683c228e703_D20190401-20190630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtOS0xLTEtMA_e62e4119-4aed-40a5-bd14-96ef54d93901">633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtMTUtMS0xLTA_105d63df-e6e5-442d-97e7-6c04e239d6e5">634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfb2976a10e846e7966cb2ab49d1a67d_D20190401-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTItMTMtMS0xLTA_65173840-0087-49d7-80c9-fc0c972f2371">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTItMTUtMS0xLTA_b791779d-87f3-4291-be80-af4ce07a9202">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ac59364cc9747a995f2b060f07c9b31_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTMtMTEtMS0xLTA_956529eb-c62b-46f8-9314-9528c9896b9d">31,767</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTMtMTUtMS0xLTA_a3dc45b4-c4ff-4284-845e-efe14cda0708">31,767</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8f5adf28c49448eba2120a76eb379e91_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMS0xLTEtMA_791c1f3d-5bcc-4a98-88f0-2b8343cdf411">48,893,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f5adf28c49448eba2120a76eb379e91_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMy0xLTEtMA_5243536e-71f5-495a-88c7-a2814888c2e7">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i296abc347cdb4669b94752b68583d9c5_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtOS0xLTEtMA_6a1e07ee-2921-41e5-9dec-144abec5a642">860,983</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9d08ec7e8585431cbf339ad2f7e1c149_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMTEtMS0xLTA_32ed8746-edb5-43c1-a938-ae69167a7fac">567,055</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33faead3aa0448498b5977cd7bbe6061_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMTMtMS0xLTA_407a79e1-e584-4b42-9850-f345459c503c">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief68b2a51bab47d1894d15d2313d332a_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMTUtMS0xLTA_04668bca-dec4-4433-9927-ab273d85665f">294,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0c2f4879451425f8a8974eba32bbf5f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTYtOS0xLTEtMA_62280b1d-f29c-48d9-b4b3-89368eca9cc3">5,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTYtMTUtMS0xLTA_ce2c183b-f652-4a83-b3ab-1e636eac72d8">5,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idbed938c680f40789e9a484426d074c8_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTgtMS0xLTEtMA_38c2239b-4c09-4db4-9134-c13edbee4ef4">20,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0c2f4879451425f8a8974eba32bbf5f_D20190701-20190930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTgtOS0xLTEtMA_3eeaf1c9-abb2-4604-824a-c9aeceaf40fb">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTgtMTUtMS0xLTA_dece1ded-a216-405c-ab87-f3b5378bff3c">37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i98a63b971bd34028b45b145cba0b2395_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjAtMTMtMS0xLTA_c30fa655-56be-4c79-b82b-1380cfaa44a5">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjAtMTUtMS0xLTA_4a76117c-77a8-4669-b37d-bebbc9e21b58">11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia5528d6cd30546e5a8d7c4dcbfa0313a_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjEtMTEtMS0xLTA_8e3fdf0c-4069-459d-9f09-52a009dd7181">44,631</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i98a63b971bd34028b45b145cba0b2395_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjEtMTMtMS0xLTA_0374451e-406a-4aea-aae3-b58c452046c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjEtMTUtMS0xLTA_844f23cf-a946-4636-951a-c5bd20584aa9">44,631</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i13e9f3ebcbed4a0a8cdb4c0df74931e7_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMS0xLTEtMA_5b3a831e-8e2f-4367-9843-bc43e04af6c9">48,914,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i13e9f3ebcbed4a0a8cdb4c0df74931e7_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMy0xLTEtMA_776961f1-74dd-42b5-a12b-b5951a28c75b">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i684c983bf3ed4ec4802b47cfd412ab10_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItOS0xLTEtMA_28c0d1a7-5cec-4157-b291-fb26a1201ac8">866,372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic74709fe8a874de7af154d53f79304e0_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMTEtMS0xLTA_a9494a46-f82d-44e8-9bab-5dd6d51e8478">611,686</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83af315ef660490aa4b885bfa9bfce6c_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMTMtMS0xLTA_e4d090d4-5ee7-4d69-9ff9-65efa45b5176">23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMTUtMS0xLTA_cb575426-8573-4d0a-a062-1feb0ff5d0ac">255,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes.</span></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except share amounts)</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.419540%;"><tr><td style="width:1.0%;"></td><td style="width:24.861314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.781022%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.529927%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.737226%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:0.1%;"></td><td style="width:0.383942%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.846715%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.383942%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.284672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.529927%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.868613%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.529927%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.262774%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i49611ab05b844f1fb78cf779db2fe26d_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xLTEtMS0w_52f8d727-192a-4f38-96c2-42a35c27e362">36,859,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49611ab05b844f1fb78cf779db2fe26d_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0zLTEtMS0w_96064da9-9ec6-4b5a-8eff-6503df197ab0">369</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9e76d66eb5f46628e171bfe49684857_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi05LTEtMS0w_1549c6be-8531-447b-b376-1aa1150b88ed">611,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i019d56ef285043cfae4cfcebb2c90346_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xMS0xLTEtMA_f7ac4793-a50b-463b-8571-8d3fe4859601">312,340</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2d80a56bb96a476ebd48eb643b2f43d6_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xMy0xLTEtMA_826dc971-7122-43d9-9508-10858a7a7ac9">61</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54746da158ce4bce9b69918fb58a959a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xNS0xLTEtMA_94b53518-98f9-48af-9835-e7796039437d">299,238</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cumulative effect of adoption of accounting standards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f60dd2a66844bda84a962daf15eed87_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMy0xMS0xLTEtMA_65f3864c-55fc-4012-b9b6-0502ca9c5962">6,479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f10c7f52f7b4ba484c7a0eba502e770_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMy0xNS0xLTEtMA_17250b31-f6c6-4bfb-bcad-0b30e627dd62">6,479</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id482aef724c247d3a9dad505cdf6170c_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNC05LTEtMS0w_a8146a92-33e2-477a-8106-65c9d440ad6e">3,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNC0xNS0xLTEtMA_b0116cc8-55b6-4a30-8ea7-2b7ab703fb22">3,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i333effd5cb7d4295a431b14185556574_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS0xLTEtMS0w_999e3df9-f15c-4843-9bc6-2479dd45c210">165,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i333effd5cb7d4295a431b14185556574_D20180101-20180331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS0zLTEtMS0w_145a3e9c-c82e-4be6-8c3e-876d4d86157c">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id482aef724c247d3a9dad505cdf6170c_D20180101-20180331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS05LTEtMS0w_4ebdf34d-fe09-43f0-abe9-2adc10ae44d3">628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS0xNS0xLTEtMA_ed193e4a-f829-4785-b078-de8d4f3bb730">629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d6d9c3f705947458160b1cd76174085_D20180101-20180331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNi0xMy0xLTEtMA_483ec058-fb95-46e7-8f3c-c0b1d660b004">38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNi0xNS0xLTEtMA_14c8eac4-062e-4915-94af-3ef54cb82432">38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2eeaeba07b544a28b10787dd76e88301_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNy0xMS0xLTEtMA_13777e64-da4c-4d32-9304-d1af8a644f3f">49,536</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNy0xNS0xLTEtMA_f13dde54-87ea-4df8-a4e8-c957b3c535b1">49,536</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i95c80d7a709547958bf97b952bcb83fc_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xLTEtMS0w_bacddca9-949e-49be-8da6-d472280493cc">37,024,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i95c80d7a709547958bf97b952bcb83fc_I20180331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0zLTEtMS0w_b9227aa9-cad8-4413-bf9a-560d425b2373">370</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa0fd024aaec4139811a323c7b840f17_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC05LTEtMS0w_04473200-02bf-400e-b879-777ccc594a86">615,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib506aba19db74035bc8bbc02c41b43cb_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xMS0xLTEtMA_02c082e6-7fef-418e-9d34-ac7e9ee8d711">368,355</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i240b880a602c492dbfb61a21ea0eb5d3_I20180331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xMy0xLTEtMA_bc7d2e85-3e32-4fcd-96ca-800ba71ea6ac">23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ce004d28e074994bd7938f6ed719131_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xNS0xLTEtMA_f8ec8fb9-5527-4ccd-a828-29675854f314">247,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i060f194c4a45460da0f50336db3489cb_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOS05LTEtMS0w_cfe6d012-55a6-45fa-bdfc-4bedbc07e55a">4,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOS0xNS0xLTEtMA_318d52f1-fd05-417d-8f0d-d273e3c4f261">4,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtMS0xLTEtMA_994ee3c4-6f6b-434d-845f-e758d423533c">5,175,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtMy0xLTEtMA_8f7fb863-18a4-44b5-a69c-901229be3c24">52</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i060f194c4a45460da0f50336db3489cb_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtOS0xLTEtMA_2cbbb1e5-c0a8-4976-9f8f-d109e2e25cb7">103,207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtMTUtMS0xLTA_61188545-f5f1-4d7b-b370-b93fffb57e6c">103,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTEtMS0xLTEtMA_25b9d045-1075-44ca-86b1-b8605d1d2143">29,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i060f194c4a45460da0f50336db3489cb_D20180401-20180630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTEtOS0xLTEtMA_d0d2e8f1-a5cb-47b5-9261-755642fb5e37">496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTEtMTUtMS0xLTA_75fdfd1c-e6ea-445c-a413-34567ed2c403">496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i847ef2f18d3f476a94b52dd7c886fec4_D20180401-20180630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTItMTMtMS0xLTA_f6ac0411-c812-4db7-bd87-cb6b7c2bd513">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTItMTUtMS0xLTA_16955486-1bf2-4c3c-b85f-b5ea69d582ae">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i54b623b2879241278c6132571917a008_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTMtMTEtMS0xLTA_44d31c1e-654a-4a1c-b511-197a87808d40">43,244</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTMtMTUtMS0xLTA_c21d9ba1-da3f-41fe-ab7d-157cddd4349f">43,244</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3a2bd0e8af1e4fa99300ecb39dac4805_I20180630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMS0xLTEtMA_cf5977dc-1202-4b7d-80f5-aa89a262e466">42,229,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a2bd0e8af1e4fa99300ecb39dac4805_I20180630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMy0xLTEtMA_118cd179-9d46-4daa-8eef-0e5332110e43">422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31943445cf4647e9815814b40fe5c41f_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtOS0xLTEtMA_c43a4314-d863-43a1-888d-9d270bfe9432">723,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iff0ebde6ab2d4004af640da15e05f719_I20180630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMTEtMS0xLTA_f846f573-5262-42d4-afd9-460772895cef">411,599</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifdea36b22a3849cd89bae3b8659e5552_I20180630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMTMtMS0xLTA_39c3253f-52c8-4637-8545-b99d449b30ca">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1529ce9d9dec4e3999d400290ac6620c_I20180630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMTUtMS0xLTA_6acbe20a-7599-436d-b5ca-2c0bdd9e92a0">312,036</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55dc213d33f2452082c642024e4aaf21_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTYtOS0xLTEtNzA_901683cd-2c78-44db-9114-5a81a1b71a92">4,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTYtMTUtMS0xLTcw_38b6519a-febf-4b51-84c9-3d3d932ca5cd">4,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock plan related activity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id724f6a4b17744aaa91365c7ec213e22_D20180701-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTgtMS0xLTEtNzA_7189124d-82ff-4ca0-8d7f-cc2d8a0ba9d7">19,064</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55dc213d33f2452082c642024e4aaf21_D20180701-20180930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTgtOS0xLTEtNzA_7a691ebe-17d3-4db7-8ba2-ca9d1efaac3e">131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTgtMTUtMS0xLTcw_baa0b570-ae4e-4478-9b45-c35d07048bca">131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6dade5ca02694388a0ce84360f1c804f_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjAtMTMtMS0xLTcw_0c9731de-5728-47a0-9291-21d5ea8b31dc">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjAtMTUtMS0xLTcw_5e2f7117-04ff-49a1-8e4b-89d8ee876763">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i95278dd6162e4f89b1e87fc5805eec36_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjEtMTEtMS0xLTcw_3abce489-fca9-4087-bccf-e08542f9ea24">34,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjEtMTUtMS0xLTcw_860c3e92-55af-4bc7-83b8-61f7f763cdef">34,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic0b6df7d2858470ea7228c5343664f9b_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMS0xLTEtNzA_a315fe4d-95c6-4df7-8dae-29b85f4b0802">42,248,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0b6df7d2858470ea7228c5343664f9b_I20180930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMy0xLTEtNzA_5867e8a6-4186-4dec-996c-7e1d3a83e25a">422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a57474836104a719e68ea78c743320b_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItOS0xLTEtNzA_d78d133c-0687-479c-918b-dfc2a2bfa11f">727,849</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7f5eef8cd6f14c31b7d9d7c5922d0d4d_I20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMTEtMS0xLTcw_613c08f5-77c1-464a-85af-6b42d63a5a27">445,628</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23fb65c6630f44d69f9baec8764c89e3_I20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMTMtMS0xLTcw_95dc35b2-5910-4e54-a19f-c8aa1cdb94e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bec1f6fecbe4fe790e9626d4040450f_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMTUtMS0xLTcw_c9a5cdec-691b-48e6-b7a8-f3706c45a4a4">282,643</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes.</span></div><div id="i_0_31"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:67.603524%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.831131%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.831131%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMy0xLTEtMS0w_811fb0c6-50ee-4697-8958-5aa345842af0">121,415</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMy0zLTEtMS0w_74000aec-937d-4ca5-9e84-8a5942ee80d6">126,809</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNS0xLTEtMS0w_e3547635-6c57-400a-b170-a976461aada9">8,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNS0zLTEtMS0w_dadc0398-b09e-4565-8a0c-09fbf79dc87e">5,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNi0xLTEtMS0w_6d887ee3-b33f-4efc-bd32-ad74c9afbe5c">14,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNi0zLTEtMS0w_4cf64ce3-003f-4195-9e6a-e2bcc50049e5">12,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOC0xLTEtMS0w_f41effd7-3ec9-4ea7-8f43-6f9e611da9e2">20,080</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOC0zLTEtMS0w_e7c91555-68bc-48a5-93eb-83421020e7fd">7,328</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOS0xLTEtMS0w_90b080d0-a8cb-43be-869d-e7eab709341a">5,612</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOS0zLTEtMS0w_dd5b332a-215d-44d9-b346-fc21595f8487">1,164</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTAtMS0xLTEtMA_cdee9301-e750-4c3a-9312-9252a427a575">2,621</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTAtMy0xLTEtMA_56f41ddd-5beb-47f1-aa8c-dc2bbb6f49e7">9,293</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTEtMS0xLTEtMA_b154f17c-3cc5-43fc-8e3b-9ebdce047cf7">913</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTEtMy0xLTEtMA_b9095690-4c36-47da-8a09-16251386df23">1,465</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTItMS0xLTEtMA_e55231b3-b7ff-4d54-88ec-84a1deac49e9">4,678</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTItMy0xLTEtMA_d079b269-3a62-4bee-bc25-b8a21ef8631e">9,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease exit liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInRestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTMtMS0xLTEtMA_8f4c9064-0c2a-4b22-ac56-bf7f74382aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInRestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTMtMy0xLTEtMA_3dc11974-bdbd-48dd-b164-e43334c6301f">298</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Lease liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTQtMS0xLTEtMA_f7d03593-4dbb-4037-898b-edd60f6ca54f">3,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTQtMy0xLTEtMA_70d53324-7ed8-41af-8b7e-599ef568ade4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTUtMS0xLTEtMA_106c2bc9-b71d-4b34-8af3-4cba247f7efd">7,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTUtMy0xLTEtMA_1a7e0ca9-83da-4851-aaa4-cd87c46c85f3">5,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred rent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTYtMS0xLTEtMA_a516b889-d7cf-49e2-8d6e-46d8ec4209ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTYtMy0xLTEtMA_0100639b-8a64-462d-a4fb-91f512ce6fd9">738</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTctMS0xLTEtMA_290c65b4-9fda-415e-9a17-a63416f6b6ef">96,226</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTctMy0xLTEtMA_66201a18-68d0-4d5e-a02c-f9916b56d66b">126,006</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTktMS0xLTEtMA_d7329833-3c6e-4d8b-af30-72131ad44245">214,178</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTktMy0xLTEtMA_88f826f6-c407-4511-b7ac-7a001fa80334">120,039</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjAtMS0xLTEtMA_7ce79604-7164-4779-a070-9589242b690c">130,236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjAtMy0xLTEtMA_41e6a784-1e03-41b6-a5de-4eec5102a769">155,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjEtMS0xLTEtMA_c05c341e-302f-4f27-a2e0-b53ae1e34479">3,042</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjEtMy0xLTEtMA_03e26fff-cfb9-409e-aa72-7abc904c824a">24,239</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjItMS0xLTEtMA_055fe4bd-9ed2-44e4-91f6-17f6ec188148">86,984</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjItMy0xLTEtMA_02e3d2cd-bfa9-43a8-a4cb-95cfdd9e6496">11,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjQtMS0xLTEtMA_d328b796-4498-47f3-a8bc-e4a7f17c7ee3">118,657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjQtMy0xLTEtMA_fd6afc1a-67d8-4efd-a6dc-2f01d281f433">103,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Proceeds from stock option exercises and ESPP purchases</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjUtMS0xLTEtMA_e633eb07-b401-4d79-be78-8cebd5518c11">1,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjUtMy0xLTEtMA_8030b7ad-2228-4d98-b8b9-a7d8db827efd">1,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjYtMS0xLTEtMA_50a47596-c247-485f-bf82-155ea84af0d0">119,675</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjYtMy0xLTEtMA_f1439e2e-efa0-4e80-b29d-54cbfb001bb1">104,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjctMS0xLTEtMA_60810bb6-e318-4f88-9f9d-b7ea7b0d9126">63,535</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjctMy0xLTEtMA_18662004-f7cb-4ccc-b2b0-6c98f8436c2d">9,920</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjgtMS0xLTEtMA_4310a952-77c1-425b-aba4-67217efd567f">220,128</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54746da158ce4bce9b69918fb58a959a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjgtMy0xLTEtMA_596c8d0a-01f8-493f-a64b-8089e9cc45d3">211,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjktMS0xLTEtMA_8f81af59-132e-4974-8de0-1cdfe062a609">156,593</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bec1f6fecbe4fe790e9626d4040450f_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjktMy0xLTEtMA_14fd5b81-9be9-4b78-ae18-0b6dda9a4617">201,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets modified in exchange for operating lease obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzItMS0xLTEtMA_d4081274-e38b-4864-b9e1-addc439bb891">6,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzItMy0xLTEtMA_6be95d6b-25ef-4b1a-800c-0f1316e18b0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of warrants received</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzMtMS0xLTEtMA_44a8ba7a-7ea6-489e-9ed1-85eebd8b07e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:FairValueOfWarrantsReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzMtMy0xLTEtMA_0a62e0d7-3721-42aa-98d8-60e248b6665d">6,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes.</span></div><div style="text-align:center;"><span><br/></span></div><div id="i_0_34"></div><div style="text-align:center;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">MACROGENICS, INC.</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i_0_37"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNTgxNQ_10d554be-3e6e-489f-beb5-abb8a393f655" continuedAt="ia304111ce9894e0b95e752cefa4e552f" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia304111ce9894e0b95e752cefa4e552f" continuedAt="i0ec3684401e4472790ce6ccecce6d082"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNTgxNw_0f856326-c69d-4c6e-825a-321f166f6aa2" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019.</span></div></ix:nonNumeric><div style="margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> (ASU 2016-02) during the nine months ended September 30, 2019, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2018.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements</span></div><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNTgxOQ_d5213f4c-e741-4294-a253-4cae2a75079a" continuedAt="i330ee8c731824e56832c9b4453d06238" escape="true"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases.  Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.  The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated.  Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $<ix:nonFraction unitRef="usd" contextRef="i650df15d071a48f9ad308100e9f9db92_I20190101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNDIwMA_306b94ea-5114-4825-be76-fea32b3788d4">16.4</ix:nonFraction> million and operating lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i650df15d071a48f9ad308100e9f9db92_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNDI0Nw_a6f7984e-76fa-4c1d-a30d-b65c44a2fbb9">27.7</ix:nonFraction> million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets.  Refer to Note 4, Leases, for additional disclosures required by ASC 842. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Recently Issued Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> (ASU 2018-18). The amendments provide guidance on whether certain </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i0ec3684401e4472790ce6ccecce6d082"><ix:continuation id="i330ee8c731824e56832c9b4453d06238"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="i_0_40"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMzMxNQ_ae36ea98-2682-46e2-80bf-bf5b3fe88dc3" continuedAt="i341c18dfbac84cfb91e1c7cb2a38fe21" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i341c18dfbac84cfb91e1c7cb2a38fe21" continuedAt="i9477fb1807694a97acb4f52ed001ebb8"><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMzMxNg_136b2c68-27f2-44c0-b90e-661cde1c81e3" continuedAt="iaf5d8c80c96a47169c64c595cbcd4f69" escape="true"><div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:28.633284%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.789396%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at September 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74b903135a134cf39caaf1b9a70d3c0a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC0xLTEtMS0w_5225913b-6355-4fb6-8555-34b999904e01">67,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b30a1a7cd3c4c3baa990fca6174db72_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC0zLTEtMS0w_84294bbc-7c9a-4996-8b74-c8fc16dfb583">67,321</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i969e411a7436433db0a30ec91a49470c_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC01LTEtMS0w_e7017ef6-d3dc-4104-b040-773780db1878">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia458119b7c404a179ca653e35a01c75b_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC03LTEtMS0w_02c21f9c-b1a5-4240-95ae-ec056acb6e50">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i33f08df369b2427988e6e11513fa5c38_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi0xLTEtMS0w_32635046-ac20-4bc1-9c93-71a6e132e8bb">11,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3676d61890504a29b1b2f0c9b97bc5b3_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi0zLTEtMS0w_38b1add8-6856-40fc-94f4-950f2adfc819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bbdfd41050a436d9d2e70b388d897ba_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi01LTEtMS0w_a74ae2d3-d4a2-40ae-99a9-6906b0ef0307">11,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c7f5c48a4c34073a0af4d2bcef83f3a_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi03LTEtMS0w_4d7d25ca-413d-4ca0-b555-40ea873c8f75">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cee49232b1741e1b7292d30a0182e3d_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy0xLTEtMS0w_7fe483f0-2033-4012-a8d4-b491f591791a">85,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d90c76657d84918a66e5ac0515f67d3_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy0zLTEtMS0w_31c81b69-26ac-4769-b01b-6e1dcfbd7731">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib44ab6273835479c9cbe51aed6705e61_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy01LTEtMS0w_9b590b0b-e783-4ff0-b1f3-30b6103675c2">85,564</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15dd70d707b34d789add5ecfa27969eb_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy03LTEtMS0w_bdaf8fc0-c2d1-4492-b4de-87661b664994">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica36a3f9d76444ff8117f05911db0082_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0xLTEtMS05Nw_261e9194-4cdd-4c18-957f-3628be7c2058">11,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i701cae7e28bf44fba78f29f859d17485_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0zLTEtMS05Nw_d5d61f83-3b79-4615-877f-f552ffe6158f">11,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e816985f0354d14990486b7d9fa32d9_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS01LTEtMS0xMjA_9560fa50-25d7-40ef-90b0-f0b1e16da1cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ebf9c8cbcd9454c9ca1746e3cabb812_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS03LTEtMS0xMjA_4d898f53-570e-483c-aa7b-615ffb2290de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b731627c2204358b5c33793a78b3b6f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0xLTEtMS0w_ac5655f8-a44d-47e0-9234-5e19fe598dba">176,127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c7335cfa2cb4a56be2db7b2843f2bd1_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0zLTEtMS0w_8292de48-7795-4e2c-9c6c-e28649d488c4">78,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf30c1ba1e914625955d4027a7c9d97d_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS01LTEtMS0w_ad8d9234-6c43-44df-b307-58ce5067dae4">97,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7d96d8c704af4109b4494741538a09c3_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS03LTEtMS0w_a4f00e0e-bb41-4277-9c7b-b6e802eb7a36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i9477fb1807694a97acb4f52ed001ebb8"><ix:continuation id="iaf5d8c80c96a47169c64c595cbcd4f69"><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:29.323529%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.617647%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15b61365f4c84504907452a393c0c978_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC0xLTEtMS0w_480c3aad-a300-4fe4-891b-0aeae1b19f67">46,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a312ffda8e1499fb683210529f71461_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC0zLTEtMS0w_445319cd-8991-4311-b5ba-f8d19c41239f">46,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbc438e0b3164ea1934a0d52645e75fe_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC01LTEtMS0w_3ce215b9-b8bd-4f50-821a-5a7b90711c87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie77cb2cbbcc3497190e5e9611541ef32_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC03LTEtMS0w_fe468557-9a6c-4e21-8fb9-4f74612bc410">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i13959021e84d4dcc881071aedc143536_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS0xLTEtMS0w_583727ee-3aaf-4c7c-8de1-ba04b5007a70">12,488</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief653dd50f314a66ae8d96c62f649c59_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS0zLTEtMS0w_f01584ba-5c98-4e3c-8b85-50d0399be43f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic07d10f6477546e0b1b1d3e46b8fad47_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS01LTEtMS0w_cdcf855a-4aef-49b0-ba37-804cb242c1f3">12,488</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ba076567c05486081a550f00fdc2edc_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS03LTEtMS0w_a7d56e35-ccc3-47a9-ad28-6e9406301d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ed260be42124aabb60094700d2e6d2d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy0xLTEtMS0w_f4dfd70f-4e4b-4021-8539-5c089408a04a">100,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21bd9e893e294ae78c62758ac0007634_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy0zLTEtMS0w_864abaea-2500-47ae-8f1a-b8c16a284159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i701fe9109c104be898d66144c5fdff56_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy01LTEtMS0w_dfb3f3f3-c9f2-4a72-b36b-51878a88e3aa">100,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fcdaba997e14e45bc26beec23bd7875_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy03LTEtMS0w_e243aef3-d74b-4eba-a60f-e8863acd0352">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69a1a642f0d4979adb8ba239f6c10b1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC0xLTEtMS0w_732724fd-81f2-4a4c-9d9d-acd7946cc7e9">1,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0c9d0e3bc9048688ea0d0890580f4e4_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC0zLTEtMS0w_b95dcd06-db3f-4ec6-9a55-7f8cc201e90c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iecf61485c1a34f73be6f360b91caaacd_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC01LTEtMS0w_f2bafbd8-a7b5-402a-9157-cf399f4a4920">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i943c3dc5d31148128af05f6e108c9796_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC03LTEtMS0w_9af578d7-4f91-46ed-8db7-0729340a9885">1,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(b)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7d4bf814515415abde86a6c80fbe736_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS0xLTEtMS0w_225fafca-1ead-4fdc-befe-2dfcc084889c">160,849</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i603ed4709303491bbaf26a1b755d1deb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS0zLTEtMS0w_db184504-e10d-4de5-8c1f-21e0a5ae125d">46,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i752d1ee7e5c441c790664845ece3aec0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS01LTEtMS0w_0e508e60-d736-4c7b-b0db-a626b345a807">112,702</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87490ba462994db1b1ee01e11796fad2_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS03LTEtMS0w_d960d283-ade3-4869-808c-3a2e932b8e1d">1,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(a) Total assets measured at fair value at September&#160;30, 2019 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i1b731627c2204358b5c33793a78b3b6f_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMjU1OQ_32cf147e-dd43-4a96-95f9-79da2e154d77">78.3</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2018 includes approximately $<ix:nonFraction unitRef="usd" contextRef="id7d4bf814515415abde86a6c80fbe736_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMjcyMw_52af976a-f5df-4dfd-abe7-a03ba0b67f63">146.2</ix:nonFraction> million reported in cash and cash equivalents on the balance sheet and $<ix:nonFraction unitRef="usd" contextRef="id7d4bf814515415abde86a6c80fbe736_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMjc4OQ_1acc8e41-bb43-435b-9a7e-733ef8db384b">1.9</ix:nonFraction>&#160;million reported in other assets on the consolidated balance sheet.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span><br/></span></div><div id="i_0_43"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfNDk5_b7f65d5a-6b68-44f2-bc17-f4751a880a78" continuedAt="i2a13b547d24049a29e1012ce9e29d059" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i2a13b547d24049a29e1012ce9e29d059" continuedAt="i82adcb4d18c1491d992d80ff859bacd1"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfMzI5ODUzNDg4NDI2Mw_3cffb0fa-4f1d-45ec-b031-a92c877a64d2" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the Company's marketable debt and equity securities (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:51.947368%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.818713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672515%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.818713%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.818713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy0xLTEtMS0w_64055e67-1088-4056-a363-ee3c0abf8f68">11,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy0zLTEtMS0w_84078d3d-0669-4164-b268-e18448781b74">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy01LTEtMS0w_a1417a08-e703-4fc0-8645-4c5db57bd361">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy03LTEtMS0w_5a5583a0-50ed-45f8-b717-b159c8168cb8">11,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC0xLTEtMS0w_310f2d58-675f-4b29-a4bb-6fd64e9834a1">74,563</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC0zLTEtMS0w_e06636d7-85ec-43e6-b875-8dcb1fba74c4">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC01LTEtMS0w_354f9b2a-b1b6-46df-9e2a-b67753ae78a3">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC03LTEtMS0w_3811aa89-f5cf-4d6c-8c30-f2e9caa0e6ea">74,581</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS0xLTEtMS0yMzI3_1e828494-d60b-4b82-9c0d-bc8fbb327f7a">86,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS0zLTEtMS0yMzI3_519bc235-8eef-41ee-a17c-e5bcd1c75ec4">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS01LTEtMS0yMzI3_5b411a0c-be63-4323-8d44-5ef024c14b51">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS03LTEtMS0yMzI3_8c5996a8-cddb-4fc9-beda-c99793c771a9">86,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,555)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,557)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:52.344624%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.751105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.536377%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.898380%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id57dfc841ee9417094c91d03520271a9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC0xLTEtMS0w_21a75178-7162-41bb-b094-125c4146824e">12,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id57dfc841ee9417094c91d03520271a9_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC0zLTEtMS0w_29962fc8-6b33-4f60-8a58-a04d8c71fbdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id57dfc841ee9417094c91d03520271a9_I20181231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC01LTEtMS0w_84a40486-c9ed-4580-a439-c678832e7449">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id57dfc841ee9417094c91d03520271a9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC03LTEtMS0w_dacace6b-896c-41c9-939d-e6a825e08247">12,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">All available-for-sale marketable debt securities held as of September&#160;30, 2019 and December&#160;31, 2018 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2019 and December&#160;31, 2018 were in a loss position for less than 12 months.&#160; There were <ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfNDEy_969dbfc4-cd3f-43f8-b898-01f89fe99591"><ix:nonFraction unitRef="usd" contextRef="i7038fb1eaaed4930bef39d8439888cd3_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfNDEy_a59b281e-7886-473f-9396-a4986beeb5c1">no</ix:nonFraction></ix:nonFraction> unrealized losses on marketable debt securities at September&#160;30, 2019 or December&#160;31, 2018 that the Company determined to be other-than-temporary.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes changes in market value of equity securities as gains or losses in other income (expense) in the consolidated statement of operations and comprehensive loss. The unrealized loss on corporate equity securities of </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i82adcb4d18c1491d992d80ff859bacd1">$<ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfMzI5ODUzNDg4NDY4OA_ca3d333e-67a6-4322-90a4-a64130df3344">7.6</ix:nonFraction>&#160;million was recognized as a loss in other income (expense) in the consolidated statement of operations and comprehensive loss during the three months ended September 30, 2019.</ix:continuation></span></div><div style="margin-bottom:6pt;"><span><br/></span></div><div id="i_0_46"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTQ3Ng_7734206b-a589-4042-9419-f5d653529668" continuedAt="i0b54c4823bab4d01bb8e572e54e0bb56" escape="true">Leases</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:12pt;font-weight:400;line-height:120%;"><ix:continuation id="i0b54c4823bab4d01bb8e572e54e0bb56" continuedAt="if368acce27c646cb85c611bb74ffcd99">&#160;</ix:continuation></span></div><ix:continuation id="if368acce27c646cb85c611bb74ffcd99"><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has non-cancelable operating leases for manufacturing, laboratory and office space in Rockville, Maryland and a non-cancelable operating lease for laboratory and office space in Brisbane, California.  A portion of the space under one of these leases is subleased to a third party.  All of these leases include one or more options to renew, with those renewal periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDA4_d48d60fa-3511-4c66-ad50-e72151633519">five</span> to <ix:nonNumeric contextRef="i5fcef9f911324937acdbe37c9ab67e7b_I20190930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDE0_1fbb485a-e728-4e24-b247-a13933d383d8">14</ix:nonNumeric> years.  At September&#160;30, 2019, the Company's weighted-average remaining lease term relating to its operating leases is <ix:nonNumeric contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNTIw_6b964148-a747-4e9b-a627-3a4745d6a847">seven years</ix:nonNumeric>, with a weighted-average discount rate of  <ix:nonFraction unitRef="number" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNTY2_0438023a-f35e-44ff-ad51-eebd2da1bc0f">9.9</ix:nonFraction>%.   </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of its operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities.  During the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">nine months ended September 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">, the Company exercised the options to extend two leases for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfOTY1_57414c3c-a125-4d11-ab1b-84005d3778dc">five</span> years each, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to these leases.   The Company made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTEzNw_e9975148-0d16-4f04-93ce-a9aef3fdcd82">4.8</ix:nonFraction> million for operating leases during the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">nine months ended September 30, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">  As of September&#160;30, 2019, the Company&#8217;s ROU assets were valued at $<ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTIyNw_e132cfdf-36d8-40e4-9f2b-550511308309">20.9</ix:nonFraction> million and are included in Other assets on the consolidated balance sheet.</span></div><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTQ3Nw_be47a5e4-68e2-4e65-bfff-e61049391259" escape="true"><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The components of lease cost for the nine months ended September 30, 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:86.888889%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.111111%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMC0xLTEtMS0w_769d540d-93a5-4660-9275-323ecf7036d9">4,080</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMS0xLTEtMS0w_458c94e5-877f-48d4-b508-8856da764f8d">1,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Sublease income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMi0xLTEtMS0w_9a87729f-aa92-4202-b203-41524b9db66d">706</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMy0xLTEtMS0w_5a674690-a3b8-40a6-b115-9634ce61a0a7">4,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;"><span><br/></span></div><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTQ3OA_1fb0ac40-ab49-413b-ab4a-152e80c62c6f" escape="true"><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the maturities of our operating lease liabilities were as follows (in thousands): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:85.573099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426901%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMC0xLTEtMS0w_62dd1beb-a7cf-44c7-ad64-84b7c6a0679b">1,616</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMS0xLTEtMS0w_942106da-bf9d-4a6c-932d-b6edc79eea39">5,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMi0xLTEtMS0w_2405d79d-b751-4d01-8102-9a46914446e8">6,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMy0xLTEtMS0w_91a5116d-d5f5-4f86-9eb6-b0c620fa3578">6,720</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNC0xLTEtMS0w_627917f4-ab90-4f26-bbb6-032cb86dd0d3">6,568</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNS0xLTEtMS0w_6a583fe0-e037-464f-9f21-b59e1e25f001">5,621</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNi0xLTEtMS0w_cb5c86cc-8768-41cf-9b50-95a891f09c43">11,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNy0xLTEtMS0w_73d1add5-27a4-465c-bbb5-87e0e734d3c2">44,088</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfOC0xLTEtMS0w_e293fc34-d723-4775-b16f-0a92eb13da48">12,550</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfOS0xLTEtMS0w_b18128b6-4bd8-43c8-aef2-0cb4d350c15c">31,538</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i_0_49"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">5.  <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTExMA_931ccca6-827c-4024-8f57-746f094f0c09" continuedAt="i25ea6cf10aa04877a5cfb2a179a34dde" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i25ea6cf10aa04877a5cfb2a179a34dde" continuedAt="ia8b1be0a2921460b9144779ab8f2e96f"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="ied9b88caa01b437aa817087abe6032ec_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTQx_69c8204a-89cf-4925-bf9a-8f90b5cd2a0f">4,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ceb7095584d49fc80652713cb7854c3_I20180430" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTg1_6e19cc88-12b3-45a6-9b6b-eb2082bbb9ce">21.25</ix:nonFraction> per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="ic890dfa175f245fe8e241c46e046dbaf_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMzQz_242d22f5-d0bf-4db6-8af0-b4a4c9db37ec">675,000</ix:nonFraction> shares of the Company's common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i41e82e0130f64686907e6f18d7557650_I20180430" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMzk3_0012cd24-3a7e-439c-9cfe-92b59b13e42b">21.25</ix:nonFraction> per share.  Upon closing, the Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ied9b88caa01b437aa817087abe6032ec_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfNDc3_89dd2406-266d-415c-bad3-bb94cf2aa5ea">103.0</ix:nonFraction> million from this offering, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company completed a </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">firm-commitment underwritten public</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="ic58db151e3a448e7b3ee73f0be5d0b0d_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfNjkx_ca9c2384-571f-4a91-988a-5ed22bef105a">5,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i45db6deb036b486ba26f489e393fc752_I20190228" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfNzM1_cb2d2db5-9da1-405e-9a91-c55119cf285b">20.00</ix:nonFraction> per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="if64c499ae2254674a5686716390e3f83_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfODkz_fb02f8b8-f64f-4bb9-8fee-b36f6259aca5">825,000</ix:nonFraction> shares of the Company&#8217;s </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia8b1be0a2921460b9144779ab8f2e96f">common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e3a6e8ec3fa4af0b64eee0e868f565a_I20190228" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfOTQ3_7ae2e4d6-64d8-4aac-9dcb-619d16586fd4">20.00</ix:nonFraction> per share.  The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ic58db151e3a448e7b3ee73f0be5d0b0d_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTAxMw_ec1c722c-22ed-4427-86ea-618a6a74db20">118.7</ix:nonFraction> million from this offering, net of underwriting discounts and commissions and other offering expenses.</ix:continuation></span></div><div><span><br/></span></div><div id="i_0_52"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc2NzQ_85cb1fe9-7735-4e78-841d-4c9d0f188bb9" continuedAt="i12a696e52fac44898fe20a87a1d3f64f" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="i12a696e52fac44898fe20a87a1d3f64f" continuedAt="ie7bdc4e1064c4f04996e11124cc893c7"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incyte</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $<ix:nonFraction unitRef="usd" contextRef="i58c33273de6d410b9cdecf2a5c0debe0_D20171001-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTcx_ce35254d-d45d-4ac4-98f3-12163b4cad64">150.0</ix:nonFraction> million upfront payment from Incyte when the transaction closed in 2017.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i368bb594cc624e83a77bf733371fae70_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODM5_641bfa86-6e48-4684-80d9-aedc20250c8d">420.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i368bb594cc624e83a77bf733371fae70_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODkz_88abe69d-26f0-4674-a171-d725faf23cdc">330.0</ix:nonFraction> million in commercial milestones. Through December&#160;31, 2018, the Company had recognized $<ix:nonFraction unitRef="usd" contextRef="id820317bddf4434e96ff1a911394e774_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTYx_33ddb037-63cd-4b45-bf18-5d1aad15255b">15.0</ix:nonFraction> million in development milestones under this agreement.  If MGA012 is commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="idd9449b1c89445c48a12627858463cf0_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTEwMw_db6f54aa-aa89-4cdb-bc28-9d540bd7e261">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i48390acd93f242ebbb42fc23fd256a82_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTEwOQ_aa0838fe-874d-45a3-81ef-8c23f6a3d9c1">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.  </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company evaluated the Incyte Agreement under the provisions of ASU No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue from Contracts with Customer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">s and all related amendments (collectively, ASC 606) and identified the following <ix:nonFraction unitRef="performance_obligation" contextRef="i518fa15db0064fec812c4b780bc7655b_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTkwMQ_30317e05-0f2b-43c8-96d4-a0ac408e70db">two</ix:nonFraction> performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i368bb594cc624e83a77bf733371fae70_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjY3OA_3f5f409b-7bea-4081-a0e5-4f4776cfaf74">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three deve</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">lopment milestones totaling $<ix:nonFraction unitRef="usd" contextRef="id820317bddf4434e96ff1a911394e774_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDI4Mg_248ae9c4-f2f5-4aa7-b625-a07484fb0ffb">15.0</ix:nonFraction> million related to MGA012 meeting certain clinical proof-of-concept criteria.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  During the three and nine months ended September 30, 2019, there were no adjustments to the transaction price of the Incyte Agreement.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:42pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i15f5e76a013f47d39dc0003413f9d4a4_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDYxNw_49355ec5-5b89-43ba-9909-2fe785a556ae">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $<ix:nonFraction unitRef="usd" contextRef="iae18551f4d2a403db5bd358b0c682d8a_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDc0Mg_f5f12717-4d5f-4757-99b0-78b22cc30674">4.0</ix:nonFraction> million allocated to the clinical activities was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018.  During the three months ended September 30, 2019 and 2018, the Company recognized <ix:nonFraction unitRef="usd" contextRef="i73a39827bd724ee6a7232870c129f33d_D20190701-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTE5MA_69bc1f6c-a8b1-40b1-9b7f-1b446d40e842">no</ix:nonFraction> revenue and revenue of $<ix:nonFraction unitRef="usd" contextRef="ifbb4c3a370434273bd0aefee45b77bf2_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTIxNg_263d1cd1-a409-4874-9159-c766e10261d2">10.5</ix:nonFraction> million, respectively, under the Incyte Agreement.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i3a3b1d36356f4d3eac2cc22fbf399979_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTI5Nw_89377d63-3328-4708-bb23-b0c73d8d9abc">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic81e31ef601944c49da28eddf02a77de_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTMwNA_2994918f-5788-4596-a656-7c36611cc026">13.6</ix:nonFraction> million under the Incyte Agreement during the nine months ended September 30, 2019 and 2018, respectively.  Revenue recognized during the three and nine months ended September 30, 2018  included $<ix:nonFraction unitRef="usd" contextRef="i9db3c7b4a5914f65b0e7482d13d66f9f_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMzI5ODUzNDk0NDQ1MA_0d88b7d3-97bc-4374-a785-eec612dc2834"><ix:nonFraction unitRef="usd" contextRef="ibfec87d8a5404f13b27eab46f40228ef_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMzI5ODUzNDk0NDQ1MA_3c44d91d-4e7e-4988-8ebd-ec71f4b1547f">10.0</ix:nonFraction></ix:nonFraction>&#160;million in development milestones. </span></div></ix:continuation><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie7bdc4e1064c4f04996e11124cc893c7" continuedAt="ie8d0b5bb84cf4b2b8bb282bd53bbe062"><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of MGA012 (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the three months ended September 30, 2019 and 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i6bec22401c70482e823b9a2e5d36d610_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjE2MQ_3fe5a9bd-3ea6-4f79-bec5-bebf55ebb94e">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idf29abb47caf4681942fe396155e2ac1_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjE2OA_e1ce7906-7bdf-45cf-b8cc-0d759f361384">6.1</ix:nonFraction>&#160;million, respectively, for services performed under the Incyte Clinical Supply Agreement. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i6ed40dc4661a49b8968604842ade9122_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjI2NQ_9308ada0-9282-4bf4-b55a-c187563f7bb5">13.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a118b8388e14ba9b1059b88d91a8477_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjI3Mg_d61ce730-56b5-4692-9ef2-ccd709200d99">16.0</ix:nonFraction>&#160;million for services performed under the Incyte Clinical Supply Agreement during the nine months ended September 30, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Les Laboratoires Servier </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain <ix:nonFraction unitRef="exclusive_license" contextRef="ice1c157abfbe45f194053705b2702f65_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfExclusiveOptionsToLicense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjU3MQ_622a481f-40d9-4331-8b8b-3dbb417ef4ba">three</ix:nonFraction> separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab.  During the term of the agreement, Servier did not exercise its options for either MGD007 or the third DART molecule.  In July 2019, Servier informed the Company of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  As a result of this termination, the Company will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Upon execution of the agreement, Servier made a nonrefundable payment of $<ix:nonFraction unitRef="usd" contextRef="ib959c0e3f072409998cd0f0023270469_D20120901-20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNzQ1Mw_63b612e1-8233-4f9c-b082-df03edf26e53">20.0</ix:nonFraction> million to the Company.  The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the <ix:nonFraction unitRef="exclusive_license" contextRef="ice1c157abfbe45f194053705b2702f65_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfExclusiveOptionsToLicense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNzYyNg_622a481f-40d9-4331-8b8b-3dbb417ef4ba">three</ix:nonFraction> options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of <ix:nonFraction unitRef="performance_obligation" contextRef="ia69015b5eb8740b6a029ef0b991a9402_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODcxOA_328f496a-e173-47fc-83ae-320aa8afc1c2">three</ix:nonFraction> performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="ice1c157abfbe45f194053705b2702f65_I20120930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODg1NA_6dcd7811-9b8b-414a-b9e0-66b8684b0baf">20.0</ix:nonFraction> million upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the <ix:nonFraction unitRef="performance_obligation" contextRef="ia69015b5eb8740b6a029ef0b991a9402_I20120930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTA1Ng_328f496a-e173-47fc-83ae-320aa8afc1c2">three</ix:nonFraction> performance obligations based on their relative standalone selling price. The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.  <ix:nonFraction unitRef="milestone" contextRef="i75bf3bc533454969826e25fc96e3af8f_D20140101-20141231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTM2Ng_0fffc904-78a2-47bf-874a-cf83c8b17ab0">Two</ix:nonFraction> milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone in 2014, the constraint related to the $<ix:nonFraction unitRef="usd" contextRef="i75bf3bc533454969826e25fc96e3af8f_D20140101-20141231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTYxNA_19350660-48b7-45ef-b833-d84d395bb9f9">5.0</ix:nonFraction> million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligation.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i970f2dcb0eab418e9a653c77c4d9cc4f_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwOTk3OQ_5e679914-44be-493f-b833-7bef5f1c8938">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i70674713bb8e4d3683f61a49dbc782c9_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwOTk5Mw_fdf6757f-f37a-41c3-8e90-1078e43c030f">1.4</ix:nonFraction>&#160;million in revenue during the three and nine months ended September 30, 2018, respectively, related to the transaction price allocated to the MGD007 option.  All revenue related to the upfront payment was recognized by December 31, 2018.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $<ix:nonFraction unitRef="usd" contextRef="i91dc53f73fa84402824473c88b70867e_I20141231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTA3NTI_e2b029fb-2e39-46ba-941a-ceaadd43513f">15.0</ix:nonFraction> million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie8d0b5bb84cf4b2b8bb282bd53bbe062" continuedAt="i009b858243ae4e568d74eddd4175bc30"><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">arrangement within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (ASC 808).  The arrangement consists of <ix:nonFraction unitRef="component" contextRef="i7828f41496b2476a96ab41b01992b9b4_I20141231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfComponentsInLicenseAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTE1Mzc_aa00765d-e6ea-425c-92be-d30b2da592b6">two</ix:nonFraction> components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $<ix:nonFraction unitRef="usd" contextRef="i91dc53f73fa84402824473c88b70867e_I20141231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:OptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTIwNjA_e2b029fb-2e39-46ba-941a-ceaadd43513f">15.0</ix:nonFraction> million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company is recognizing the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. As noted above, in July 2019, Servier informed the Company of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  Therefore, the Company reassessed the end date of its performance obligations under the contract to be January 2020.  </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> During the three months ended September&#160;30, 2019 and 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ia12d8b77e71f41e4ad0b803eac53f1a0_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwODMyNw_19d8309c-5a6c-40da-882b-d6e81e8fe34b">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1c6c3b2f59854f77ae4c3719194e6f29_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwODMzMA_a44f3a93-1202-4d98-9600-39ec954d574b">0.3</ix:nonFraction> million, respectively, related to the flotetuzumab license grant fee.  The Company recognized revenue related to the flotetuzumab license grant fee of $<ix:nonFraction unitRef="usd" contextRef="i09b6a87cc6bb4e9fa8724ece15b105e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2MzY_11fcd5bd-85c6-4f5f-8392-7a637f026168">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if5c4e22b89924229a57a8eb74bb20cad_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2NDM_bbe8452d-13f7-494e-8fb3-39ea6b84ea62">0.9</ix:nonFraction> million during the nine months ended September 30, 2019 and 2018, respectively.  At September&#160;30, 2019, $<ix:nonFraction unitRef="usd" contextRef="ie989ab30d5da4147917fd55e613200bb_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2OTA_7d0413e5-0056-43c2-a516-7f8596303e80"><ix:nonFraction unitRef="usd" contextRef="ie989ab30d5da4147917fd55e613200bb_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2OTA_a68d8c7b-fdaf-4775-ba22-ddf3ee5596ab">7.5</ix:nonFraction></ix:nonFraction> million of revenue related to the flotetuzumab license grant fee was deferred, all of which was current.  At December&#160;31, 2018, $<ix:nonFraction unitRef="usd" contextRef="i6f8323bafdc34797924db0952bd973d0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI4Mjk_6e650bec-5f39-467b-82b4-ed52723081f0">12.6</ix:nonFraction>&#160;million of revenue related to the flotetuzumab license grant fee was deferred, $<ix:nonFraction unitRef="usd" contextRef="i6f8323bafdc34797924db0952bd973d0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI5MDM_cc1f5736-e684-440f-8f6e-1b37300a53d2">0.9</ix:nonFraction>&#160;million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i6f8323bafdc34797924db0952bd973d0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI5MzE_24aec17c-9ef4-40d3-8a45-09fb60eb5c02">11.7</ix:nonFraction> million of which was non-current.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and reimbursements received from Servier are recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three months ended September 30, 2019 and 2018, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i27244fec8880414bb6b1cfc52c333374_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMTY2MA_409345cb-428a-4ff7-bc5b-3a3e21f37e77">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic146a3b466194000a57ac908f0e5c5be_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDM5ODA0NjU3MzA3Mg_d505916a-2de1-4193-b5f0-94fd067267ca">2.1</ix:nonFraction> million, respectively, as an offset to research and development expense under this collaborative arrangement.  During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="iacab77e6779347788a780579fa1a685e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTM1OTM_c644f489-574b-41cf-bd89-9951922855ba">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c16b322b44845d9b43c3c5ce1fd49af_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTM2MDA_5f595c11-a98a-4dbb-abce-b70fce8f4f98">4.9</ix:nonFraction> million, respectively, as an offset to research and development expense under this collaborative arrangement.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Zai Lab</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-enhancing anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTQ0NjQ_687b49fa-1354-4855-b1c1-3d68e358e4a2">25.0</ix:nonFraction> million, less foreign withholding tax of $<ix:nonFraction unitRef="usd" contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTQ1MDA_e50beae4-25f6-4f4b-95d2-8c4b4f1c669a">2.5</ix:nonFraction> million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i30a9f07d07b94663a8cde320960c506a_I20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTQ2Nzc_f4c6f730-6daa-474b-86ea-73d55697e671">140.0</ix:nonFraction> million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities.  The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate.  Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract.  The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule.  The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTYwNDg_687b49fa-1354-4855-b1c1-3d68e358e4a2">25.0</ix:nonFraction> million (less foreign withholding tax of $<ix:nonFraction unitRef="usd" contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTYwODQ_e50beae4-25f6-4f4b-95d2-8c4b4f1c669a">2.5</ix:nonFraction> million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price.  The standalone selling price of each performance obligation was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i009b858243ae4e568d74eddd4175bc30" continuedAt="ibcda2a08e5d44ab186c9cf0857b4c67e"><div style="margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> &#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate.  The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  During the three and nine months ended September 30, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie4087c84e7e44db6bae261d20124a913_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxMTI_ac4d5650-73e2-4cae-a873-6fb7ca66df9e">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i55adada0a7564bdf9cfe077725d854b9_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxMTk_05a632ba-341b-4264-a65a-ce989e1f911d">12.1</ix:nonFraction> million, respectively, related to the Zai Lab Agreement.  At September&#160;30, 2019, $<ix:nonFraction unitRef="usd" contextRef="i30a9f07d07b94663a8cde320960c506a_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxNzk_ddb77f89-0c02-4cb6-b63f-f66ebd20d864"><ix:nonFraction unitRef="usd" contextRef="i30a9f07d07b94663a8cde320960c506a_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxNzk_f4de5ea6-db8e-49ad-b7e9-bde9faed7b20">9.0</ix:nonFraction></ix:nonFraction> million of revenue was deferred under this agreement, all of which was current. At December&#160;31, 2018, $<ix:nonFraction unitRef="usd" contextRef="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgyOTI_d2562646-0614-4ab9-a09a-0d7664b47168">21.1</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgzNDE_64a4734b-2819-4c81-9450-c6398a3578e0">16.1</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgzNjk_c186a9cc-a1b6-4934-8689-b93c53cabf64">5.0</ix:nonFraction> million of which was non-current.</span></div><div style="text-indent:31.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three months ended September 30, 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and MGD013 (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of margetuximab and MGD013.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three and nine months ended September 30, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i08e4673e6a2a448182624726fd572b76_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjIyOQ_a57cd98d-7d6d-4870-9bdd-645338446dd4"><ix:nonFraction unitRef="usd" contextRef="i3a5eb519ef2e4cbc8181141d7cd9276d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjIyOQ_fb9871cb-a88a-4f41-8b3f-67dd1d0c2ff7">1.2</ix:nonFraction></ix:nonFraction> million related to the Zai Lab Clinical Supply Agreements.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">I-Mab Biopharma</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In July 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan, will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI1Mw_6bcd51f3-adb6-4fba-8dc2-e22112ec96bb">15.0</ix:nonFraction> million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI2OQ_29443cef-da0e-42b4-924c-0ae6f2c2bfc6">135.0</ix:nonFraction> million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered double-digit royalties (ranging from mid teens to twenty percent) on annual net sales in its territories.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study.  The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation.  The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjUzMw_6bcd51f3-adb6-4fba-8dc2-e22112ec96bb">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities.  The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzM0OTE3NA_f7b2cdc8-9e59-48fd-ad7c-3632f3f699f4">1.0</ix:nonFraction> million.    I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> &#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three and nine months ended </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ibcda2a08e5d44ab186c9cf0857b4c67e" continuedAt="i3bfb59697bae49e2884d02ca9ccfd4d5"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">September 30, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI3Nw_1e4d5711-b101-42d7-9d48-2628f4683d61"><ix:nonFraction unitRef="usd" contextRef="ie953d43978514183bcdd8c7b4ab3ab96_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI3Nw_dc3d3127-e0e8-45c4-951e-d29b21a28b11">1.1</ix:nonFraction></ix:nonFraction> million under the I-Mab Agreement.  At September&#160;30, 2019, $<ix:nonFraction unitRef="usd" contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI5MQ_a914fe67-71e8-4f17-bbe0-e48ad8db55af">14.4</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjMwNA_964b464e-2398-4151-96ec-0759bff7d05d">4.4</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjMxNw_29f297bc-9449-46b2-b337-a5b04e0e5c07">10.0</ix:nonFraction> million of which was non-current.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets  (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies, to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company would be responsible for its own expenses during the research period.  In August 2019, Roche informed the Company of its intention to terminate the Roche Agreement effective November 2019. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="idd651a75afdd4d7d95c4e21996253290_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTkyODE_70435f5c-6205-4838-b12e-ca4c27bfa405">10.0</ix:nonFraction> million which was received in January 2018. The Company was also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTkzNzE_f61cbfc7-bee8-4f20-bc5d-0ed01e79f24e">370.0</ix:nonFraction> million in potential milestone payments and royalties on future sales.  As of September 30, 2019, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license was capable of being distinct, but was not distinct in the context of the contract because it had limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there was <ix:nonFraction unitRef="performance_obligation" contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjAxMTI_c7500f53-e60a-4223-a38a-d85f6710aee5">one</ix:nonFraction> performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $<ix:nonFraction unitRef="usd" contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjAyMzc_f380a30f-f382-4060-9fb9-dbea36d2ce2c">10.0</ix:nonFraction> million.  The potential milestone payments were fully constrained and have been excluded from the transaction price.  Any consideration related to sales-based royalties would be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore were also excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The $<ix:nonFraction unitRef="usd" contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA1OTk_12778c8d-64f7-4f04-aa3d-cfba5e9d8e95">10.0</ix:nonFraction> million transaction price was being recognized over the expected research period, which was originally <ix:nonNumeric contextRef="i3b2a9d94d2dd4bea92a57ffb8904cbee_D20171201-20171231" format="ixt-sec:durmonth" name="mgnx:UpfrontPaymentRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA2ODQ_d3ba9020-564a-4a89-8f5f-b5d30af8aa54">30</ix:nonNumeric> months, using a cost-based input method to measure performance.  Upon notice of Roche's intent to terminate the agreement in August 2019, the recognition period was adjusted to end in November 2019. The Company recognized revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="ie736d7bf024b4ae28e4589d3b604e1df_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA4MDA_362a885a-6de0-4bf3-8a7e-3d58ce26c775">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5739a109487c4754a883c99176a1efd9_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjk5Mw_856961f4-a60d-4bc3-95c3-af6f1e80e450">1.0</ix:nonFraction> million during the three months ended September&#160;30, 2019 and 2018, respectively.  The Company recognized revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i054926fddff24ee5807d883aad5e2a1f_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA4NjM_0c73764f-8979-4e83-8f1d-6eb61e422c3a">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i62c1e47bb3ef4615991f7912494745cf_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMzE1NA_3f62b5e0-2c6e-44ed-8921-b7f23e4be529">3.0</ix:nonFraction> million during nine months ended September 30, 2019  and 2018, respectively.  At September&#160;30, 2019, $<ix:nonFraction unitRef="usd" contextRef="i54fd08a4f3f743b49797b697a1ce3106_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA5Mjg_904affc6-3cbe-483d-b0aa-86ba609fe9c3">2.2</ix:nonFraction> million of revenue was deferred under this agreement, all of which was current.&#160;At December&#160;31, 2018, $<ix:nonFraction unitRef="usd" contextRef="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjEwMTA_27a55a5e-f7f9-4b2a-ad69-556e4a35c06e">6.0</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjEwNTk_2cba9ac6-3b90-4cf8-bf82-ae70f3aa536f">4.0</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjEwODc_82801e15-087b-45cd-abee-970e6826c1c8">2.0</ix:nonFraction> million of which was non-current.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provention</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement).  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i02cc1ebe209c402a8c800be888313cd7_D20180531-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE2NzU_f835c783-c95b-4a24-bd42-4715cdbfd041">2.50</ix:nonFraction> per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie967f030aa6b4bc8aa81afe083e3c526_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE4NzE_07728fc8-af9f-44cc-b94d-79d09391c00c">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="ie967f030aa6b4bc8aa81afe083e3c526_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5MjU_770284c9-a8df-41bb-8a20-ae65270e24af">225.0</ix:nonFraction> million in commercial milestones.  As of September 30, 2019, the Company has not recognized any milestone revenue under this agreement.  If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Provention Asset Purchase Agreement).  As partial consideration for the Provention Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8e2cd88b1fe140d6a7dfa35faadde661_D20180531-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjI5Nzg_ddf85c6b-ecdd-443e-b124-84abcbed2a00">2.50</ix:nonFraction> per share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i5c8b2113702b464282bfe3e9b94f4d74_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjMxNzQ_9920dfb9-ca2a-44a8-83c3-1c97507bc344">170.0</ix:nonFraction> million in regulatory </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i3bfb59697bae49e2884d02ca9ccfd4d5" continuedAt="i51808b51a99240439ba5c812b10ca339"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i5c8b2113702b464282bfe3e9b94f4d74_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjMyMTI_7177f7fc-4a82-4f01-9ed4-a25d631f9c2f">225.0</ix:nonFraction> million in commercial milestones.  If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i5c8b2113702b464282bfe3e9b94f4d74_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjM1OTA_5e9ed124-85fb-4c2a-9753-037543bed0ec">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified <ix:nonFraction unitRef="performance_obligation" contextRef="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjQxOTI_c986e23c-e6b3-45d2-b554-56d8873e3ae4">two</ix:nonFraction> performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjQzODU_7e198599-e0a4-4775-88c5-8a7cae1c2c60">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjQ0NTQ_2b117f1d-1b87-49a3-aff9-c33448546366">2,432,688</ix:nonFraction> shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant, which represents the relative fair value of each performance obligation.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ib9214916d72546d59baaee9785a7e087_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjU0Njg_289e040d-9a5f-4f31-8e58-70e85a2fbe31">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in May 2018.  The warrants are reported in Other assets on the December&#160;31, 2018 consolidated balance sheet and were revalued at each reporting period based on current Black-Scholes parameters until the warrants were exercised.  The resulting increase or decrease is reflected in Other income (expense) on the consolidated statement of operations and comprehensive loss.  There was no material change in the valuation of the warrants during the three and nine months ended September 30, 2018.  The warrants were valued at $<ix:nonFraction unitRef="usd" contextRef="if69a1a642f0d4979adb8ba239f6c10b1_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxODE1MQ_035e8c1d-7431-465a-8898-8c92a47f10dc">1.9</ix:nonFraction> million as of December&#160;31, 2018, and through the date that they were exercised, the Company recorded an increase in the valuation of the warrants of $<ix:nonFraction unitRef="usd" contextRef="ie723c1c82d87464d9ed56b45a59bacc5_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxNTk5OQ_1e682a94-eb61-4881-9cc3-eab12e58ecb0">20.5</ix:nonFraction> million.  In July 2019, the Company exercised the warrants on a cashless basis, and the remaining shares of Provention's common stock acquired are reported in Marketable securities on the September&#160;30, 2019 balance sheet.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NIAID Contract</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjY0NzU_f4188fd8-9e7f-4b82-aa15-633dabf22772">two</ix:nonFraction> DART molecules, including MGD014 (NIAID Agreement). Under the NIAID Agreement, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.</span></div></ix:continuation><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i51808b51a99240439ba5c812b10ca339">The NIAID Agreement includes a base period of up to $<ix:nonFraction unitRef="usd" contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915" decimals="-5" format="ixt:numdotdecimal" name="mgnx:FundedValueOfBasePeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjcwNDQ_c3687ccc-01c6-4c9a-b16d-ca8296b8daea">7.5</ix:nonFraction> million to support development of MGD014 through IND application submission with the FDA, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjcxNDY_3a05a80c-abf8-4611-8a3c-c9db76771119">17.0</ix:nonFraction> million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $<ix:nonFraction unitRef="usd" contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjcyOTQ_a1e392d9-4a40-4404-8508-a27ea02c623d">24.5</ix:nonFraction> million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $<ix:nonFraction unitRef="usd" contextRef="i273a5f224d3e4ecf828034c5e3e0f859_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc0NDQ_b69c0e0b-0b95-421a-94f3-75d489890b0e">10.8</ix:nonFraction> million.  During the three months ended September 30, 2019 and 2018, the Company recognized revenue of  under the NIAID Agreement of $<ix:nonFraction unitRef="usd" contextRef="i7a77af8c6e3e41ff8d11e8fe34dc64fc_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc1MzU_b628d699-09d1-485b-88e5-0ea122a2e605">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i49febe140c734397af0ac451febc2e05_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc1NDI_3b5c774a-c13e-4734-854a-2ce058e169d9">0.2</ix:nonFraction> million, respectively.  During the nine months ended September 30, 2019 and 2018, the Company recognized revenue of  under the NIAID Agreement of $<ix:nonFraction unitRef="usd" contextRef="i372a9ad3922943f491a1fa7dd2c30d5d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc2NDc_571c08b4-8a40-4905-bd68-4dd003682762">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i422a064f422b48ae8e9a505da5963ed5_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc2NTQ_d609e9c9-05f0-409a-81b4-3de65d4837ab">0.6</ix:nonFraction> million, respectively.</ix:continuation>  </span></div><div id="i_0_55"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY1Ng_082d0e3a-fc76-4edd-8569-3aecbbc6ec5e" continuedAt="i397dd243718f4761939ec090523f5e25" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i397dd243718f4761939ec090523f5e25" continuedAt="i95fbd5d45334473a9db9bc8d2986298c"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="i6e1a6fcd218941a6baa89073c11c5da2_I20170531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDI3_eb42780c-5553-4f21-9492-ab387b7ef448">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i93ea6f505d99415186f0268a4bba80ef_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNjI2_c626bec0-ada6-4e8a-9f86-d986815f1815">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i93ea6f505d99415186f0268a4bba80ef_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfODcz_cba998e7-893d-47aa-bd91-bbb9717e354f">85</ix:nonFraction>% of the fair </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i95fbd5d45334473a9db9bc8d2986298c" continuedAt="ib9e37e674a97463bb06b03314e1c2c6d"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2019, <ix:nonFraction unitRef="shares" contextRef="i454fbe875e5b4db7a40944d31eb23a84_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMTAwMw_ea64e9f7-70b2-4b76-8700-73e0c4e564c5">25,722</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i9b030de878e8406ebf1f621232078e07_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMTExMw_ba8a6dd4-7845-44a0-9d34-8cae30437fdd">0.4</ix:nonFraction>&#160;million.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employee Stock Option Plans</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2019, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic3e00c8e472e49d588cd53f7014d9b81_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMTk3Ng_a6466a68-5ca4-4302-88d6-cbe5105c2f94">559,357</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3e00c8e472e49d588cd53f7014d9b81_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjA1NA_cc75f57a-84c1-4160-9da7-9e6de1a25762">2.30</ix:nonFraction> per share.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="ib66184941d714664ae08c0e838d10181_I20190930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjQ2Ng_8ab92f48-b99d-4771-baeb-e0d09d062e9a">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i1a913a00b68549eeb34e0b8808b5269e_D20190101-20190930" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjQ4MQ_5598da1d-a772-48e4-94eb-8d8fa54a078d">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2019, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="ib66184941d714664ae08c0e838d10181_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjgyMw_38b30594-b73c-4d66-b6d7-d56ca045d1ad">9,938,263</ix:nonFraction>.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2019, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib66184941d714664ae08c0e838d10181_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMzM5OQ_47077669-eb13-4022-8c50-079fd342ed35">6,689,172</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib66184941d714664ae08c0e838d10181_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMzQ3Nw_61bd1b19-3711-4cd5-852e-341960a81ebb">22.55</ix:nonFraction> per share under the 2013 Plan.</span></div><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY1OA_af44e020-c3e0-411b-acf0-ccfadb316016" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:32.808260%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.781711%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.127434%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.601770%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.569912%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.896755%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.012389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.601770%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icff895ca6df94222b46a51a086d8de19_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi0xLTEtMS0w_22759e17-3c2c-4d4a-850b-44ce6215df4b">2,765</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic79500c2c7ee4616be6fac7a8cf8e3c0_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi0zLTEtMS0w_3a3705cc-bed3-489a-9f68-543d52467a02">2,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ccfecbf14a74088903da62adfcb0fa7_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi01LTEtMS0w_b554a278-e15d-4149-a7d8-e350cc9e26a4">7,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if31b162e8e37461f9128da55a95f93e6_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi03LTEtMS0w_f1da6259-58b4-4c76-af20-f30cd444f3c3">6,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ff8158fdeb940b6918114f76ea442b3_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy0xLTEtMS0w_e27c79d1-7c13-4186-9f00-262c10f1eab9">2,633</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0c8668b262748c89e872fcfa0fb50dc_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy0zLTEtMS0w_c4c6171c-6ff3-498e-b8bd-8fe67e09f257">2,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8d755c340e64be8bdab95b9056b73dc_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy01LTEtMS0w_ab4fb905-e322-49f4-bdde-2b4651dcacc5">7,049</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idfa5b8cd82a44f608083484c65993b70_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy03LTEtMS0w_09ef2bee-a7bc-4b0d-80a5-ddc553d05ebb">5,821</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC0xLTEtMS0w_825ca174-bbd3-44b9-b573-22a9154ebf41">5,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC0zLTEtMS0w_f19902df-1565-4cbb-8eb5-3eb6dc23678c">4,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC01LTEtMS0w_cf1d2b07-598b-402c-9c5b-45b86e5a9c12">14,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC03LTEtMS0w_cd810bac-93a1-44fa-b237-2cc275e95a60">12,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY2MA_e413e755-fecf-4c78-adf0-2b501f201c0f" escape="true"><div style="text-indent:36pt;margin-top:15pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:63.491924%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.767988%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.005874%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfMi0xLTEtMS0w_75f7ea0a-120a-44c3-8a8f-fae2dd2e7e7f">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfMi0zLTEtMS0w_1cbde17d-f9e3-4a04-afcf-97de5218d9ac">0</ix:nonFraction>%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73.7% - 76.6%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67.8% - 72.2%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.4% - 2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfNS0xLTEtMS0w_d0cb0cd8-fa97-4afb-b79f-4dd2f8596d44">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfNS0zLTEtMS0w_4bddb3aa-23e7-4643-9b8f-cd306b052928">6.25</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ib9e37e674a97463bb06b03314e1c2c6d"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY2Mg_9cb4ad33-22ba-4522-aafd-725217f18ea4" escape="true"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity during the nine months ended September&#160;30, 2019:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:26.970588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535294%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.205882%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMS0xLTEtMS0w_eccef515-a06b-47e1-bb8e-f1f3a7719691">5,273,964</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMS0zLTEtMS0w_65436f3a-1caf-4e7f-9e51-42bfefc41965">22.23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i7038fb1eaaed4930bef39d8439888cd3_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMS01LTEtMS0w_e24faea8-33e1-46c3-94dd-dfa1fa23e55d">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMi0xLTEtMS0w_d5f91844-ad4c-4459-9886-2528fce45be1">2,384,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMi0zLTEtMS0w_e5583ce1-afbc-436f-b518-3eadd7c46082">16.87</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMy0xLTEtMS0w_740a90fb-e86a-4960-aab9-cfcc0f25210a">210,261</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMy0zLTEtMS0w_78b84773-598e-499c-9e86-16b6a16b4d87">3.11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNC0xLTEtMS0w_4f4e9998-db91-4a32-a3b5-df84fa3ae395">199,944</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNC0zLTEtMS0w_9df755da-7d57-4f86-aa3b-c9b5a185ac35">23.44</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS0xLTEtMS0w_46f1309d-74db-4c93-84da-740458d59164">7,248,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS0zLTEtMS0w_b766a0b6-de77-4f3e-96ce-9c2e4757f562">20.98</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS01LTEtMS0w_42c92d70-97e9-4c6b-8a10-8cf23c750085">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS03LTEtMS0w_320e5d91-8bbe-4414-b1a9-15406f3cc168">11,733</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy0xLTEtMS0w_e4326e24-9acb-40fc-a6df-cacfebcabb9f">4,074,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy0zLTEtMS0w_87e6f5f8-66e5-49e0-b23b-f2aea9d944f1">22.13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy01LTEtMS0w_3551a425-cc8c-4ab6-a862-f16659137ae1">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy03LTEtMS0w_0bbb8abb-1d8e-4a2b-b48c-ffc956f5ae89">5,849</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC0xLTEtMS0w_80b816da-5a79-483e-b1a3-bd04377c8bb5">6,936,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC0zLTEtMS0w_3f713a84-33a0-45da-827a-c9f8db48c6d6">20.98</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC01LTEtMS0w_4ae4f550-9206-45f5-b757-6dd92ec266ab">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC03LTEtMS0w_72fc3f03-c969-4666-89d6-6aeca3b45335">11,367</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDAxNg_0308fbcb-0391-4fb0-b905-ea5831d56cf3">14.33</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDAyMw_6ffc5f53-44ed-48a0-9689-5d2253740c0a">18.07</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2019 and 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDE0Mw_892eb53c-1033-4e89-b3bf-8e6fdcdcee17">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDE1MA_28176e6a-3637-4e28-8d82-b34f7577f46f">4.0</ix:nonFraction> million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2019 and 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDI3MQ_8974067c-041a-441b-a8b0-ea7887460c78">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDM5ODA0NjUxNTg0Mg_cfad3ab3-6931-494d-a470-a3f9729b7081">0.9</ix:nonFraction> million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2019 and 2018 was approximately $<ix:nonFraction unitRef="usd" contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDM4NQ_b458281f-aa7c-4972-9368-561ba313fc49">12.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDM5Mg_ffe0f4c2-2641-4338-8660-2659d30e75ea">11.9</ix:nonFraction> million, respectively. As of September&#160;30, 2019, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="ib491d902a8ad49b795070a44de412e95_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDU1Ng_5131f985-999c-4a9f-b028-2ee060e84498">40.8</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY0Nw_f060afaa-4094-4f33-b3d7-b3f8f54861ce">2.6</ix:nonNumeric> years.</span></div></ix:continuation><div id="i_0_61"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF82MS9mcmFnOmE4MTNjM2Q3MmZjOTQ1ZjA5NWM5ZWM4NzNmYTEzODRiL3RleHRyZWdpb246YTgxM2MzZDcyZmM5NDVmMDk1YzllYzg3M2ZhMTM4NGJfMzI5ODUzNDg4NzA2Mg_ca59af99-2544-492e-84f4-ca712ad71b2e" continuedAt="i2e381da170ca4705a8de8c1964eb1229" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2e381da170ca4705a8de8c1964eb1229">On September 13, 2019, a class action suit, entitled Todd Hill v. MacroGenics, Inc. (Case No. 8:19-cv-02713), was filed in the U.S. District Court for the District of Maryland against the Company and certain of its officers and/or directors, alleging violations of securities laws during 2019.  The suit asserts certain claims under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's margetuximab Phase 3 SOPHIA study.  The Company believes this suit is without merit and plans to vigorously defend against these claims.  Currently, no reserve has been established for any potential liability related to this suit.</ix:continuation>  </span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_64"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:6.187135%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.812865%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="text-indent:45pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">&#160;</span></div><div style="text-indent:45pt;"><span><br/></span></div><div id="i_0_67"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics to modulate the human immune response for the treatment of cancer.  We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms. We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160; Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of September&#160;30, 2019, as well as collaboration payments we anticipate receiving, will enable us to fund our operations into 2021 based on our current business plan.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Through September&#160;30, 2019, we had an accumulated deficit of $611.7 million. We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_70"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Strategic Collaborations</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current strategic collaborations include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Incyte. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In October 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while we retain the right to develop our pipeline assets in combination with MGA012. The transaction closed in the fourth quarter of 2017 and we received a $150.0 million upfront payment from Incyte upon the closing. </span></div><div style="padding-left:54pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the collaboration, Incyte will lead global development of MGA012. Assuming successful development and commercialization of MGA012 by Incyte, we could receive development and regulatory milestones of up to approximately $420.0 million, of which we have already received $15.0 million, and up to $330.0 million in commercial milestones. If MGA012 is commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote with Incyte.  We retain the right to develop our pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of MGA012.  In addition, we retain the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement.  </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Servier. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In September 2012, we entered into an agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) to develop and commercialize three DART molecules in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  We received a $20.0 million upfront option fee upon execution of the agreement.  In February 2014, Servier exercised its option to develop and commercialize flotetuzumab, for which we received a $15.0 million license option fee. In July 2019, Servier informed us of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  As a result of this termination, we will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Zai Lab</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">.  In November 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab)  under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-enhancing anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development in its territory. </span></div><div style="padding-left:54pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the agreement, Zai Lab paid us an upfront payment of $25.0 million less foreign withholding tax of $2.5 million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones. In addition, Zai Lab would pay us double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_73"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:39pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting policies is presented in Part II, Item&#160;7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2018. Except as described in Note 1 to our accompanying consolidated financial statements with respect to our adoption of the requirements of ASC 842, there have been no significant changes to our critical accounting policies and estimates during the nine months ended September 30, 2019. </span></div><div style="text-indent:39pt;"><span><br/></span></div><div id="i_0_76"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following represents a comparison of our revenue for the three and nine months ended September&#160;30, 2019 and 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:38.350877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789474%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.204678%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.846784%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596491%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.257310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative and other agreements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The decrease in revenue of $2.1 million for the three months ended September 30, 2019 compared to the three months ended September 30, 2018 was primarily due to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased revenue recognized under the Incyte Agreement.  Revenue recognized during the three months ended September 30, 2018 included $10.0 million in milestones and higher revenue related to development and manufacturing services performed under the clinical supply agreement than during the three months ended September 30, 2019.  </span></div><div style="padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">This decrease was partially offset by:  </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increased revenue recognition of the Servier flotetuzumab license grant fee during the three months ended September 30, 2019 due to Servier's notice of their intention to terminate the agreement effective January 15, 2020;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">revenue recognition of the deferred upfront payment under the Zai Lab collaboration and license agreement of $4.0 million during the three months ended September 30, 2019; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">recognition of $1.2 million in revenue during the three months ended September 30, 2019 related to manufacturing services performed under the Zai Lab clinical supply agreements.</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.830409%;"><tr><td style="width:1.0%;"></td><td style="width:40.603550%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.940828%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.018935%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.644970%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.018935%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.502959%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.575148%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.094675%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from collaborative and other agreements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">37.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">43.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(14)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue from government agreements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">44.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(5.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:38.350877%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.473684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.473684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.473684%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.473684%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The decrease in revenue of $5.3 million for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018 was primarily due to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">revenue recognized under the Provention  License Agreement and Provention Asset Purchase Agreement of $6.1 million during the nine months ended September 30, 2018; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased revenue recognized under the Incyte Agreement.  Revenue recognized during the nine months ended September 30, 2018 included $10.0 million in milestones, revenue related to certain clinical activities performed, and higher revenue related to development and manufacturing services performed under the clinical supply agreement than during the nine months ended September 30, 2019.</span></div><div style="text-indent:36pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">These decreases were partially offset by:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increased revenue recognition of the Servier flotetuzumab license grant fee during the nine months ended September 30, 2019 due to Servier's notice of their intention to terminate the agreement effective January 15, 2020;</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">revenue recognition of the deferred upfront payment under the Zai Lab collaboration and license agreement of $12.1 million during the nine months ended September 30, 2019; and </span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">recognition of $1.2 million in revenue during the nine months ended September 30, 2019 related to manufacturing services performed under the Zai Lab clinical supply agreements.</span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following represents a comparison of our research and development expense for the three and nine months ended September&#160;30, 2019 and 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:40.251462%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.228070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.812865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.842105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.964912%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Margetuximab</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Enoblituzumab</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(46)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Flotetuzumab</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(54)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">113&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(45)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGD009</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other immune modulator programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Discovery and other pipeline programs, collectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">44.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:9pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(a)   Expenses are shown net of reimbursements from collaborator.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our research and development expense for the three months ended September 30, 2019 decreased by $1.3 million compared to the three months ended September 30, 2018 primarily due to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased development and manufacturing costs related to MGA012 and flotetuzumab.</span></div><div style="text-indent:31.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">These decreases were partially offset by:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">increased clinical trial costs related to our ongoing MGD013 Phase 1 study.</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:33.964912%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.497076%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:3pt;margin-bottom:3pt;"><span><br/></span></div><div style="margin-top:15pt;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.538012%;"><tr><td style="width:1.0%;"></td><td style="width:40.581602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.611276%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.025519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.023739%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.470623%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.424332%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.135312%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.127596%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/(Decrease)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Margetuximab</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">39.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">51.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(11.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(23)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Enoblituzumab</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Flotetuzumab(a)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">13.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGA012</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGD013</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGD009</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(21)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGC018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">8.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MGD007</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(35)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Other immune modulator programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Discovery and other pipeline programs, collectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">21.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">17.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">143.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">143.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(a)   Expenses are shown net of reimbursements from collaborator.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our research and development expense for the nine months ended September 30, 2019 decreased by $0.5 million compared to the nine months ended September 30, 2018 primarily due to:</span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased clinical trial costs due to completed enrollment in our margetuximab Phase 3 SOPHIA study; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased manufacturing and development costs for flotetuzumab.</span></div><div style="padding-left:27pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">These decreases were partially offset by:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increased clinical trial costs related to our ongoing MGD013 Phase 1 study; and</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:9pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">initiation of our MGC018 Phase 1 study.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expense</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following represents a comparison of our general and administrative expense for the three and nine months ended September&#160;30, 2019 and 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:36.596491%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.374269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.812865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719298%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.450292%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">9.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:36.450292%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619883%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.888889%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.969591%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.888889%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Increase</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">34.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">30.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:36.304094%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.374269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.374269%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384795%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.035088%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865497%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense increased for the three and nine months ended September&#160;30, 2019 compared to the three and nine months ended September&#160;30, 2018 primarily due to consulting expenses and other professional service fees. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The change from other income for the three months ended September 30, 2018 to other expense for the three months ended September 30, 2019 is primarily due to $7.6 million in net unrealized losses recognized on equity securities during the three months ended September 30, 2019.  Other income increased by $14.4&#160;million for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018.  This increase was primarily due to an increase in the valuation of the warrants received under the Provention License Agreement and Provention Asset Purchase Agreement of $20.5 million prior to the exercise of the warrants in July 2019, and an increase in interest income.  This increase was partially offset by $7.6 million in net unrealized losses recognized on equity securities subsequent to the warrant exercise.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_79"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have historically financed our operations primarily through public and private offerings of equity, upfront fees, milestone payments and license option fees from collaborators and reimbursement through government grants and contracts.&#160;&#160;&#160; As of September&#160;30, 2019, we had $254.4 million in cash, cash equivalents and marketable securities. In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive additional reimbursement from our collaborators, including under various government grants or contracts, for certain research and development services rendered and additional milestone payments. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and development activities and is therefore uncertain at this time.</span></div><div style="margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval for and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to generate revenue from product sales and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials, preclinical development and potential commercialization of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of September&#160;30, 2019, as well as collaboration payments we anticipate receiving, will enable us to fund our operations into 2021, assuming all of our programs and collaborations advance as currently contemplated.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table represents a summary of our cash flows for the nine months ended September&#160;30, 2019 and 2018:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:64.079295%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.593245%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.593245%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(96.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(126.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(87.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">119.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">104.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net change in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(63.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(9.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and preclinical activities.  The principal use of cash in operating activities for all periods presented was to fund our net loss, adjusted for non-cash items, with the nine months ended September 30, 2019 benefiting from the $22.5 million upfront payment from Zai Lab and the $15.0 million upfront payment from I-Mab, and the nine months ended September 30, 2018 benefiting from the $10.0 million upfront payment from Roche.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Investing Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities during the nine months ended September 30, 2019 is primarily due to purchases of marketable securities partially offset by sales of marketable securities.  Net cash provided by investing activities during the nine months ended September 30, 2018 is primarily due to maturities of marketable securities partially offset by purchases of marketable securities and making significant leasehold improvements to our facilities, including the build-out of our manufacturing suite at our headquarters location.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing Activities</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities for the nine months ended September 30, 2019 and 2018 is primarily due to the proceeds from two firm-commitment underwritten public offerings, which closed in February 2019 and April 2018, respectively.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="i_0_82"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission (SEC).</span></div><div id="i_0_85"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567251%;"><tr><td style="width:1.0%;"></td><td style="width:6.750000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.250000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of September&#160;30, 2019, we had cash, cash equivalents and marketable securities of $254.4 million.&#160;&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div id="i_0_88"></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567251%;"><tr><td style="width:1.0%;"></td><td style="width:6.750000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.250000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">ITEM 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2019. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of September&#160;30, 2019, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control</span></div><div style="text-indent:36pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">There were no changes in the Company's internal control over financial reporting that occurred during the nine months ended September 30, 2019 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div id="i_0_91"></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div id="i_0_508"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Item 1.  Legal Proceedings</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">From time to time we are involved in legal proceedings in the ordinary course of our business.  We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations.  </span></div><div id="i_0_94"></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.713450%;"><tr><td style="width:1.0%;"></td><td style="width:6.892356%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:89.107644%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Factors</span></td></tr></table></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2018, aside from the risk factors included below:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Business and the Development and Commercialization of Our Product Candidates</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification based on the complete analysis of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration (FDA) or non-U.S. regulatory authorities or may not be deemed sufficient to warrant regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number </span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we recently announced second interim overall survival data for the SOPHIA trial of margetuximab for the treatment of certain metastatic breast cancer patients. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved. For example, the achievement by margetuximab of its first sequential endpoint for progression-free survival events in the SOPHIA trial does not indicate whether the second sequential endpoint of overall survival will be achieved. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In particular, the second interim overall survival analysis, based on 270 events, did not  show statistically significant results in the intent to treat population. We currently expect to receive final overall survival results in 2020, and such results may not show statistical significance.  Failure to achieve statistical significance in the second sequential endpoint of overall survival in the SOPHIA trial may have an adverse effect on our ability to obtain or retain regulatory approval of margetuximab in the U.S. or in other jurisdictions. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration trials. For example, we intend to submit a Biologics License Application (BLA) to the FDA for margetuximab by the end of 2019.  We expect the BLA to be subject to a 10-month target review period from the time of FDA acceptance of the BLA for filing. We also expect that the FDA will convene an advisory committee meeting to discuss the application, and the FDA will take the recommendation of the advisory committee into account in assessing the application.  Regardless of any advisory committee recommendation, FDA may decline to approve the BLA for a number of reasons including, if the clinical benefit, safety profile or effectiveness of the drug is not deemed by the FDA to warrant approval. The FDA or other non-U.S. regulatory authorities may disagree with our trial design for SOPHIA or other trials, and our interpretation of data from preclinical studies and clinical trials. In particular, the FDA may not view our data as being clinically meaningful or statistically persuasive. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial. Any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Our Common Stock</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to securities litigation, which is expensive and could divert management attention and adversely impact our business.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. We are currently a target of this type of securities litigation. Specifically, on September 13, 2019, a putative securities class action complaint was filed against us, and certain of our officers and/or directors in the U.S. District Court for the District of Maryland.  [See Part II, Item 1, &#8220;Legal Proceedings&#8221; in this Quarterly Report on Form 10-Q for further information related to the litigation.]  This or any future securities litigation could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities.</span></div><div><span><br/></span></div><div id="i_0_97"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:92.251462%;"><tr><td style="width:1.0%;"></td><td style="width:5.448494%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:90.551506%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibits</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:17.883041%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.116959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-1q32019.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-2q32019.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-1q32019.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-2q32019.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Schema Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div id="i_0_100"></div><div style="text-align:center;margin-bottom:9pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">SIGNATURES</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:46.973607%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.692082%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:44.334311%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">MACROGENICS, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">BY:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">BY:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">James Karrels</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Dated: November 6, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span><br/></span></div><div id="i_0_103"></div><div style="text-align:center;margin-bottom:9pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:18pt;width:100%;"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.491228%;"><tr><td style="width:1.0%;"></td><td style="width:16.636364%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:79.363636%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit&#160;Page&#160;Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-1q32019.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit31-2q32019.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-1q32019.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">32.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit32-2q32019.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Schema Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Presentation Linkbase Document</span></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1q32019.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:63pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2019 of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">President and Chief Executive Officer</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(Principal Executive Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Dated&#58; November&#160;6, 2019 </font></div><div style="position:relative;width:100%;height:63pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2q32019.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:63pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">EXHIBIT 31.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2019 of MacroGenics, Inc.&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:-27pt;padding-left:27pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-27pt;padding-left:63pt;text-align:justify;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(Principal Financial Officer)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Dated&#58; November&#160;6, 2019 </font></div><div style="position:relative;width:100%;height:63pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1q32019.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">EXHIBIT 32.1</font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Certification of Principal Executive Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Pursuant to 18 U.S.C. 1350</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">)</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;September&#160;30, 2019&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="text-indent:-22pt;padding-left:22pt;"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Date&#58; November&#160;6, 2019 </font></div><div style="padding-left:252pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2q32019.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Certification of Principal Financial Officer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">Pursuant to 18 U.S.C. 1350</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:700;line-height:120%;">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;September&#160;30, 2019&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Name&#58; James Karrels</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Date&#58; November&#160;6, 2019 </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mgnx-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:37c13bdf-fb46-46bd-829a-97a3fb2efa47,g:e81d9694-bb2f-41e2-94f9-94c8f654a663-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:mgnx="http://macrogenics.com/20190930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20190930">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FirmCommitmentPublicUnderwrittenOfferMember" abstract="true" name="FirmCommitmentPublicUnderwrittenOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_FundedValueOfBasePeriod" abstract="false" name="FundedValueOfBasePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FollowOnEquityOfferingMember" abstract="true" name="FollowOnEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" abstract="false" name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_LesLaboratoiresServierMGD007Member" abstract="true" name="LesLaboratoiresServierMGD007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfExclusiveOptionsToLicense" abstract="false" name="NumberOfExclusiveOptionsToLicense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_NumberOfComponentsInLicenseAgreement" abstract="false" name="NumberOfComponentsInLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_OptionExerciseFee" abstract="false" name="OptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_UpfrontPaymentRecognitionPeriod" abstract="false" name="UpfrontPaymentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionBioInc.Member" abstract="true" name="ProventionBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" abstract="false" name="PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ServierDARTMember" abstract="true" name="ServierDARTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfMilestonesAchieved" abstract="false" name="NumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FairValueOfWarrantsReceived" abstract="false" name="FairValueOfWarrantsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" abstract="true" name="F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementServicesMember" abstract="true" name="IncyteMGA012AgreementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Details" roleURI="http://macrogenics.com/role/Details">
        <link:definition>1406401 - Statement - Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2104102 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2406403 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2107103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2409404 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://macrogenics.com/role/Leases">
        <link:definition>2110104 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://macrogenics.com/role/LeasesTables">
        <link:definition>2311303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://macrogenics.com/role/LeasesNarrativeDetails">
        <link:definition>2412405 - Disclosure - Leases Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseCostsDetails" roleURI="http://macrogenics.com/role/LeaseCostsDetails">
        <link:definition>2413406 - Disclosure - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseCostsDetails_1" roleURI="http://macrogenics.com/role/LeaseCostsDetails_1">
        <link:definition>2413406 - Disclosure - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2114105 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2415407 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2116106 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails">
        <link:definition>2417408 - Disclosure - Collaboration and Other Agreements - Incyte (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsLesLaboratoiresServierDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails">
        <link:definition>2418409 - Disclosure - Collaboration and Other Agreements - Les Laboratoires Servier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsRocheDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails">
        <link:definition>2419410 - Disclosure - Collaboration and Other Agreements - Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2420411 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2421412 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsProventionDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails">
        <link:definition>2422413 - Disclosure - Collaboration and Other Agreements - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2423414 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2124107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2325304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2426415 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2427416 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2428417 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2129108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mgnx-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:37c13bdf-fb46-46bd-829a-97a3fb2efa47,g:e81d9694-bb2f-41e2-94f9-94c8f654a663-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19a3800d-381c-449e-a8ae-360c452aaad5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3eb9fe3a-083d-4b94-b5a8-2842852328e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19a3800d-381c-449e-a8ae-360c452aaad5" xlink:to="loc_us-gaap_CommonStockValue_3eb9fe3a-083d-4b94-b5a8-2842852328e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5203fdad-6f17-49c1-a4e5-c0164caf796e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19a3800d-381c-449e-a8ae-360c452aaad5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5203fdad-6f17-49c1-a4e5-c0164caf796e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5fb85db5-8d30-444d-a1c4-6281b687becf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19a3800d-381c-449e-a8ae-360c452aaad5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5fb85db5-8d30-444d-a1c4-6281b687becf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d8a8ca1f-4188-4d85-8c8f-b6f6c0bc7fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19a3800d-381c-449e-a8ae-360c452aaad5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d8a8ca1f-4188-4d85-8c8f-b6f6c0bc7fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0dcf1267-881c-4e00-9ae4-731d3bac6653" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:to="loc_us-gaap_AccountsPayableCurrent_0dcf1267-881c-4e00-9ae4-731d3bac6653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_362b7654-8f0d-423b-b3cf-90b829e6016f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_362b7654-8f0d-423b-b3cf-90b829e6016f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_a6c57775-ea07-4098-8717-c8a5152d2f90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_a6c57775-ea07-4098-8717-c8a5152d2f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_958f8dd9-826c-44b5-852f-6e6ef250e976" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_958f8dd9-826c-44b5-852f-6e6ef250e976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0d2ccc77-0b78-4176-9b49-d71716f2300a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0d2ccc77-0b78-4176-9b49-d71716f2300a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1270b3f0-daff-4aaf-995c-746e57f9bc18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35b0c7f7-d7f5-415f-a366-494ea8a3b055" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1270b3f0-daff-4aaf-995c-746e57f9bc18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e1c4d715-c799-428e-afc5-d16941aecc66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d516c36c-f3bf-4a7a-a233-d6dc031d277f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e1c4d715-c799-428e-afc5-d16941aecc66" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d516c36c-f3bf-4a7a-a233-d6dc031d277f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d27ceda5-30b0-4dc3-9451-ef8e974e5957" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e1c4d715-c799-428e-afc5-d16941aecc66" xlink:to="loc_us-gaap_Investments_d27ceda5-30b0-4dc3-9451-ef8e974e5957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_af05a3d5-dae6-4237-9f80-d786a6e8c5df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e1c4d715-c799-428e-afc5-d16941aecc66" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_af05a3d5-dae6-4237-9f80-d786a6e8c5df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_37353645-f50d-4c27-8c12-75d898e7269b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e1c4d715-c799-428e-afc5-d16941aecc66" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_37353645-f50d-4c27-8c12-75d898e7269b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_c8869cea-9919-4191-b4d5-d5c52b3ec989" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e1c4d715-c799-428e-afc5-d16941aecc66" xlink:to="loc_us-gaap_OtherAssets_c8869cea-9919-4191-b4d5-d5c52b3ec989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb6aba2f-bf71-4b2a-9baa-409cd75785ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52924a4d-8a97-4b63-a33a-8a7eab78acb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb6aba2f-bf71-4b2a-9baa-409cd75785ef" xlink:to="loc_us-gaap_Liabilities_52924a4d-8a97-4b63-a33a-8a7eab78acb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4cd13695-7099-40a0-844a-4022376430a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb6aba2f-bf71-4b2a-9baa-409cd75785ef" xlink:to="loc_us-gaap_StockholdersEquity_4cd13695-7099-40a0-844a-4022376430a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e948d398-7441-421e-a452-0f327fd430fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f0316c56-bb55-4d36-a3a5-98a8422c31d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e948d398-7441-421e-a452-0f327fd430fd" xlink:to="loc_us-gaap_AssetsCurrent_f0316c56-bb55-4d36-a3a5-98a8422c31d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7151873b-5c4c-473f-bb62-9e0e546f6b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e948d398-7441-421e-a452-0f327fd430fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7151873b-5c4c-473f-bb62-9e0e546f6b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0b724a5f-21f6-4a33-882c-406224e461d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e948d398-7441-421e-a452-0f327fd430fd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0b724a5f-21f6-4a33-882c-406224e461d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d04dd010-eeb8-4b87-bf0a-2aa9dbfd32dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4c50cdb5-464e-44cb-abde-37b1d9639d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d04dd010-eeb8-4b87-bf0a-2aa9dbfd32dc" xlink:to="loc_us-gaap_LiabilitiesCurrent_4c50cdb5-464e-44cb-abde-37b1d9639d9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_d21dde8d-12a0-423c-a11c-072ab2d7d856" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d04dd010-eeb8-4b87-bf0a-2aa9dbfd32dc" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_d21dde8d-12a0-423c-a11c-072ab2d7d856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b21af48f-21fe-4f25-b3dc-fec3fc35a5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d04dd010-eeb8-4b87-bf0a-2aa9dbfd32dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b21af48f-21fe-4f25-b3dc-fec3fc35a5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3dec6464-3c24-4b1e-a091-295d230f9212" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d04dd010-eeb8-4b87-bf0a-2aa9dbfd32dc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3dec6464-3c24-4b1e-a091-295d230f9212" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b9a3e0db-4467-482d-a5e7-7def2e28b1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0f267a3-d2bf-4a87-be73-9f40498ab001" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b9a3e0db-4467-482d-a5e7-7def2e28b1c8" xlink:to="loc_us-gaap_NetIncomeLoss_a0f267a3-d2bf-4a87-be73-9f40498ab001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_833865e8-5647-4165-8bc5-9fd9b6cf3544" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b9a3e0db-4467-482d-a5e7-7def2e28b1c8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_833865e8-5647-4165-8bc5-9fd9b6cf3544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1ecad342-a7ea-4c68-8a31-1e1056a69e69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_581bc47d-8cc4-4ef3-bdeb-a768c2e22752" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1ecad342-a7ea-4c68-8a31-1e1056a69e69" xlink:to="loc_us-gaap_Revenues_581bc47d-8cc4-4ef3-bdeb-a768c2e22752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6485ef60-f362-4dc9-924b-c1067258cbb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1ecad342-a7ea-4c68-8a31-1e1056a69e69" xlink:to="loc_us-gaap_CostsAndExpenses_6485ef60-f362-4dc9-924b-c1067258cbb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_614ddfe3-3d65-428a-b012-77ecc939e483" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_17285407-043a-40c3-a798-eab33fee1749" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_614ddfe3-3d65-428a-b012-77ecc939e483" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_17285407-043a-40c3-a798-eab33fee1749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_202ed8ce-0cf1-41be-842e-7f33a401e750" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_614ddfe3-3d65-428a-b012-77ecc939e483" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_202ed8ce-0cf1-41be-842e-7f33a401e750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_494c4c4b-76cc-46e2-a03f-c89d53d766af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7d4cd6ae-ca33-4947-8d3a-19c91039a2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_494c4c4b-76cc-46e2-a03f-c89d53d766af" xlink:to="loc_us-gaap_OperatingIncomeLoss_7d4cd6ae-ca33-4947-8d3a-19c91039a2d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6e58c502-c385-445c-965e-705767519c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_494c4c4b-76cc-46e2-a03f-c89d53d766af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6e58c502-c385-445c-965e-705767519c1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40f36569-c08d-4eb1-ad8f-dc7e4260ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e122a13-1cdf-46a2-ac14-961b3d1cec36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40f36569-c08d-4eb1-ad8f-dc7e4260ef3d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e122a13-1cdf-46a2-ac14-961b3d1cec36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_bfd5f00d-d28f-4a53-83cd-5eb0eb29bc2c" xlink:href="mgnx-20190930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_40f36569-c08d-4eb1-ad8f-dc7e4260ef3d" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_bfd5f00d-d28f-4a53-83cd-5eb0eb29bc2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc02934-4d71-4dfa-9a3c-aba01da2e47f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2fd3e77e-24be-4cce-8145-b49f4d2349e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc02934-4d71-4dfa-9a3c-aba01da2e47f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2fd3e77e-24be-4cce-8145-b49f4d2349e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7155da8b-2940-4918-9f88-c29d2c29f417" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc02934-4d71-4dfa-9a3c-aba01da2e47f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7155da8b-2940-4918-9f88-c29d2c29f417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e39de3fc-8fc8-4093-9724-defae2023c86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fc02934-4d71-4dfa-9a3c-aba01da2e47f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e39de3fc-8fc8-4093-9724-defae2023c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d44d11a9-188f-4197-96d8-788e644433a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41d325d0-1182-4860-9ae1-a85b81c92186" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d44d11a9-188f-4197-96d8-788e644433a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_41d325d0-1182-4860-9ae1-a85b81c92186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e11d5e54-9f1f-475d-b113-3dd396b6ae6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d44d11a9-188f-4197-96d8-788e644433a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e11d5e54-9f1f-475d-b113-3dd396b6ae6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d960b1-612f-442e-b21c-603d178b0484" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d44d11a9-188f-4197-96d8-788e644433a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d960b1-612f-442e-b21c-603d178b0484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_03dc79ea-9744-4d97-9eb8-053d321ba4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_NetIncomeLoss_03dc79ea-9744-4d97-9eb8-053d321ba4a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_97b97af3-a502-4e54-8b86-63ef9b885db1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_97b97af3-a502-4e54-8b86-63ef9b885db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_339b4025-a826-480b-85af-c5d049a0dce6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_ShareBasedCompensation_339b4025-a826-480b-85af-c5d049a0dce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ec5729c2-c3d1-41e4-ade7-1bb9f247e074" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ec5729c2-c3d1-41e4-ade7-1bb9f247e074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_497f28a9-3c79-4564-8827-21042fecab5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_497f28a9-3c79-4564-8827-21042fecab5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9cd2251a-6031-482d-85fb-4b7a057181f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9cd2251a-6031-482d-85fb-4b7a057181f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_f00e3332-8418-4053-9347-1b6e0f5f518e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_f00e3332-8418-4053-9347-1b6e0f5f518e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_93c841d5-c598-4d9f-afe0-25ca3b46a191" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_93c841d5-c598-4d9f-afe0-25ca3b46a191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_64c16790-6d49-4d8e-afe9-183557d7cc60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_64c16790-6d49-4d8e-afe9-183557d7cc60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_dd6c9138-6e0a-42b4-90c4-9df406cd9b9c" xlink:href="mgnx-20190930.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_dd6c9138-6e0a-42b4-90c4-9df406cd9b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bb8f1d6c-36a9-4a56-b619-e4bee53d5352" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bb8f1d6c-36a9-4a56-b619-e4bee53d5352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_b215464d-9e89-4d4a-a056-392a8175e15f" xlink:href="mgnx-20190930.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_110d21dc-9220-4e46-b358-a4ef14027110" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_b215464d-9e89-4d4a-a056-392a8175e15f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Details" xlink:type="simple" xlink:href="mgnx-20190930.xsd#Details"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_441fc41b-1ac4-46e4-9e4d-903cdc2061bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_465bac14-06b3-4ab7-ae49-69a68b6121b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_441fc41b-1ac4-46e4-9e4d-903cdc2061bd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_465bac14-06b3-4ab7-ae49-69a68b6121b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f6b646c-5449-4a1b-ac1a-1ef14a1e5d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_441fc41b-1ac4-46e4-9e4d-903cdc2061bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f6b646c-5449-4a1b-ac1a-1ef14a1e5d9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc9852be-d144-429f-b274-74c9ec91eb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3fd5a1f4-0111-4b0d-a70c-b76fc1cbcf6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc9852be-d144-429f-b274-74c9ec91eb2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3fd5a1f4-0111-4b0d-a70c-b76fc1cbcf6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93a6084b-75b5-49ac-b6f9-891bf8af2619" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc9852be-d144-429f-b274-74c9ec91eb2d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_93a6084b-75b5-49ac-b6f9-891bf8af2619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aec3a20c-3d55-42d1-b68f-4d6553072d00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc9852be-d144-429f-b274-74c9ec91eb2d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aec3a20c-3d55-42d1-b68f-4d6553072d00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20190930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bb160973-69e1-49b1-8314-dae8d5ba97b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e58ca199-0954-463f-84c6-27ade12237be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bb160973-69e1-49b1-8314-dae8d5ba97b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e58ca199-0954-463f-84c6-27ade12237be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f34fa2cd-c281-4858-9668-389130f2ec2e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bb160973-69e1-49b1-8314-dae8d5ba97b5" xlink:to="loc_us-gaap_OperatingLeaseLiability_f34fa2cd-c281-4858-9668-389130f2ec2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f9fe8721-e309-40ed-801c-6d2c60551208" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_53069cfe-4d3c-4234-aa61-a66d651dcc99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9fe8721-e309-40ed-801c-6d2c60551208" xlink:to="loc_us-gaap_OperatingLeaseCost_53069cfe-4d3c-4234-aa61-a66d651dcc99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_bb36f17e-d1b6-41e6-97c3-de47ff5457e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9fe8721-e309-40ed-801c-6d2c60551208" xlink:to="loc_us-gaap_SubleaseIncome_bb36f17e-d1b6-41e6-97c3-de47ff5457e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9557d139-25af-42d4-8f03-fa2c77321909" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9fe8721-e309-40ed-801c-6d2c60551208" xlink:to="loc_us-gaap_VariableLeaseCost_9557d139-25af-42d4-8f03-fa2c77321909" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails_1" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeaseCostsDetails_1"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c1e5e30d-0499-4aed-9e93-47260b60f8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c1e5e30d-0499-4aed-9e93-47260b60f8b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8fcb8eda-be9a-4d33-b084-08cdfdd996de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8fcb8eda-be9a-4d33-b084-08cdfdd996de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_de0c95b7-dc25-4a66-943f-7a4748f70586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_de0c95b7-dc25-4a66-943f-7a4748f70586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e03c28a3-44a7-4106-b608-c33574fda26b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e03c28a3-44a7-4106-b608-c33574fda26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ab4dc8c4-9778-4d4b-99f3-330708c9be12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ab4dc8c4-9778-4d4b-99f3-330708c9be12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_5b1d0ffb-98f2-4e0c-b93c-199dae60f1cf" xlink:href="mgnx-20190930.xsd#mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_5b1d0ffb-98f2-4e0c-b93c-199dae60f1cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_b82585f7-43b5-43c5-8dee-45b120254758" xlink:href="mgnx-20190930.xsd#mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cfd9339-adb3-4bb5-8d59-ef7281786e76" xlink:to="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_b82585f7-43b5-43c5-8dee-45b120254758" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreements"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsIncyteDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsLesLaboratoiresServierDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mgnx-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:37c13bdf-fb46-46bd-829a-97a3fb2efa47,g:e81d9694-bb2f-41e2-94f9-94c8f654a663-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended" id="i86d2196a7a7c4c5d8fe2f273cc3f7b1d_b298129b-08fe-4161-a865-4dbbc02f83b6"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i86cadd3ee5084adabe55c9566b6258d2_57f16da0-f4bb-4c01-ab4c-0c968c0b6b1c"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i25f414869c8c44b49f0da875fc8945f9_a5c4e481-5fa1-4237-a13e-6d1cfecdfb0e"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i6ecdfa6a932c4a27a6f6263d52d0d856_3b08ccc0-5b2b-4f59-b4e7-04e6845a94a4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f87c39ee-cbd2-4c5b-a7f0-e785b19f78fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_RevenuesAbstract_f87c39ee-cbd2-4c5b-a7f0-e785b19f78fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_51477a62-24d0-4fd4-a4d8-897489ccb13b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f87c39ee-cbd2-4c5b-a7f0-e785b19f78fc" xlink:to="loc_us-gaap_Revenues_51477a62-24d0-4fd4-a4d8-897489ccb13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d92f722e-44a6-41ad-b7af-36d8dacc972d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d92f722e-44a6-41ad-b7af-36d8dacc972d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_14084345-2840-455c-9d67-a75bdd173ece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_14084345-2840-455c-9d67-a75bdd173ece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1a6959cc-f1e9-4c53-b16c-6b6e5a8dc5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_CostsAndExpenses_1a6959cc-f1e9-4c53-b16c-6b6e5a8dc5ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40455a55-b423-459b-b629-11fe869b7235" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_OperatingIncomeLoss_40455a55-b423-459b-b629-11fe869b7235" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f8ce72f3-8c3f-45a2-98e2-183fc724d270" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f8ce72f3-8c3f-45a2-98e2-183fc724d270" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74772854-45fe-4a29-b7ed-b1fbc0ebd4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_NetIncomeLoss_74772854-45fe-4a29-b7ed-b1fbc0ebd4e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e677fe7b-7a83-4da7-8cc4-4d241fce6799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e677fe7b-7a83-4da7-8cc4-4d241fce6799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b097ebe8-1466-4a6d-a963-6b43c50a1b84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b097ebe8-1466-4a6d-a963-6b43c50a1b84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8705f1ff-d072-4bda-a675-34a5bd2e5906" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8705f1ff-d072-4bda-a675-34a5bd2e5906" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9366ecc9-9841-48ed-854a-c297f2c8d9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9366ecc9-9841-48ed-854a-c297f2c8d9ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:to="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0deabdb6-480d-4258-9b2c-3c568e3a0db0_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:to="loc_srt_ProductsAndServicesDomain_0deabdb6-480d-4258-9b2c-3c568e3a0db0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:to="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_4cd97435-4027-4bae-b904-107326e20dd5" xlink:href="mgnx-20190930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_4cd97435-4027-4bae-b904-107326e20dd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_c927f8fb-e6d2-437a-b25c-50a352a1060b" xlink:href="mgnx-20190930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_c927f8fb-e6d2-437a-b25c-50a352a1060b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i08551c5d56824df4a5b3d0918592cbdf_50d19641-c640-4ea3-8dd4-ecb736016289">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f1fe742-ad1a-42f5-a2a1-b8b0fb114e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f1fe742-ad1a-42f5-a2a1-b8b0fb114e85" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7a513dc6-a459-4bff-b8ec-4423f6f64adc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_SharesIssued_7a513dc6-a459-4bff-b8ec-4423f6f64adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf06a89d-de24-453c-a616-89f26fb71f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf06a89d-de24-453c-a616-89f26fb71f6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_241b88f5-1e5f-491f-bc6f-80f30bf0ed70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_241b88f5-1e5f-491f-bc6f-80f30bf0ed70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3fd5a158-bb44-493f-8006-69ea598def8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3fd5a158-bb44-493f-8006-69ea598def8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51d31078-d8ad-4832-abde-e6494fedcf54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51d31078-d8ad-4832-abde-e6494fedcf54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d8d57309-317e-42d3-8589-9ab5f667d479" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d8d57309-317e-42d3-8589-9ab5f667d479" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_7ad8ed47-844e-44cc-a2d4-97a6652cee35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_7ad8ed47-844e-44cc-a2d4-97a6652cee35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3011b5ed-382e-4eac-9d89-d15595bc57f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3011b5ed-382e-4eac-9d89-d15595bc57f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_040c197e-d303-48eb-be37-f0967fe88bff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_040c197e-d303-48eb-be37-f0967fe88bff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39696099-9234-4b61-972e-48f7bc2ddf98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_ProfitLoss_39696099-9234-4b61-972e-48f7bc2ddf98" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1fdd2fdb-2d0f-4585-be62-80124f96b48a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccdbf380-d431-4c4b-926d-8c34511510ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4f1fe742-ad1a-42f5-a2a1-b8b0fb114e85" xlink:to="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3fa2bc86-218c-41e5-98e0-80254d3973b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:to="loc_us-gaap_EquityComponentDomain_3fa2bc86-218c-41e5-98e0-80254d3973b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:to="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_683b6c6f-bbce-4068-818f-0d06cf51092c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_CommonStockMember_683b6c6f-bbce-4068-818f-0d06cf51092c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef0c2092-1f56-40c8-bd89-4102bb54b971" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef0c2092-1f56-40c8-bd89-4102bb54b971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ae76f76c-091d-486e-a3bb-8b116bd7054f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_RetainedEarningsMember_ae76f76c-091d-486e-a3bb-8b116bd7054f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_51db73b0-0b90-4c34-ad3a-69e837e63482" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_51db73b0-0b90-4c34-ad3a-69e837e63482" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i1315dd3134ea44a2aae4f2ed3d992ce1_d38c8547-9209-42ff-b12e-03c97b9897df"/>
  <link:roleRef roleURI="http://macrogenics.com/role/Details" xlink:type="simple" xlink:href="mgnx-20190930.xsd#Details"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/Details" xlink:type="extended" id="i3a8b81f0906747139d257895d9f66a44_59fe5cb5-77c8-4435-85d7-61656ed5cee9"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended" id="i63b05505bd7746aea3733d3ff1be21f7_ae2caedf-8457-4c9b-9264-f4aafee3346c"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i72b498fd88a34f1ab0270cb409d1f103_47ff6d8f-cbfc-4855-9845-587842a00671"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i8fe4394a5983464aaebb35dcc668a871_bec3010a-bf5b-42be-b9ef-8bd11ec5688f"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended" id="i07479bbd583846859293b4d615d43d98_49d07aef-f86a-418b-a2d4-5624e2049782"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended" id="i5c07919bfbca4ea2bdd2558079ddcbfc_c64af29f-7eb8-443a-82b9-5a258e2a041c"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i970e0e00caf441e88e2615c612fe4457_69d5e61e-9465-47ae-b8f2-06eee3ecf5b0">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_beb3aef3-1c74-49ea-9adc-d0ecc4d11798" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_beb3aef3-1c74-49ea-9adc-d0ecc4d11798" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a89e767e-9886-4af3-aff3-a1469734f3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a89e767e-9886-4af3-aff3-a1469734f3d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a7091cf-5791-4030-ad53-5fb326af5ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a7091cf-5791-4030-ad53-5fb326af5ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a06a7dba-134e-4ba0-9e8b-c25fb4048cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a06a7dba-134e-4ba0-9e8b-c25fb4048cd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7162d9a5-0fb1-4989-ab73-c46a987fbf52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7162d9a5-0fb1-4989-ab73-c46a987fbf52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_beb3aef3-1c74-49ea-9adc-d0ecc4d11798" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_33b754dd-1ae2-403a-9c2f-86ea618c8bb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_33b754dd-1ae2-403a-9c2f-86ea618c8bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1dc5fd81-1131-436f-ac77-901d7e22d610" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1dc5fd81-1131-436f-ac77-901d7e22d610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7de9232e-e14c-44c3-8511-04e3ff2e66bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1dc5fd81-1131-436f-ac77-901d7e22d610" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7de9232e-e14c-44c3-8511-04e3ff2e66bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0808598d-9d79-49e8-ac56-a3e00a1b2b26_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0808598d-9d79-49e8-ac56-a3e00a1b2b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_650f66bd-f5df-4571-b011-c5c89a6d3091" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_MoneyMarketFundsMember_650f66bd-f5df-4571-b011-c5c89a6d3091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_194997fd-db30-41ad-b191-68bbeee33960" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_194997fd-db30-41ad-b191-68bbeee33960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d139c248-5e77-404d-a3c7-49b0d11af820" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d139c248-5e77-404d-a3c7-49b0d11af820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f1cf0b0f-eb73-42ba-873c-9fa12e4496e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f1cf0b0f-eb73-42ba-873c-9fa12e4496e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_867a4435-f6c1-4744-b17c-c9a7ccc056df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_EquitySecuritiesMember_867a4435-f6c1-4744-b17c-c9a7ccc056df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_00ea527d-d3fd-49d6-8b82-931dcb4f39ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_WarrantMember_00ea527d-d3fd-49d6-8b82-931dcb4f39ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_013c0ace-44fb-4008-a537-50df401452a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_013c0ace-44fb-4008-a537-50df401452a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3954a11c-fc68-48e0-865e-a936371c28c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3954a11c-fc68-48e0-865e-a936371c28c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a7941f9-14c8-4416-b676-fd3fa3e6b52a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a7941f9-14c8-4416-b676-fd3fa3e6b52a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_238a6032-13a9-4a7c-82df-32a75e8d682d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_238a6032-13a9-4a7c-82df-32a75e8d682d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" id="i759fd32588c745ffba78892b5c7605b2_782f4d34-1dd6-43e0-97d7-f9eacfb22b6d"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" id="iae87435644a14e2cb71876c34237c6d4_0116717c-a00b-4cb7-a5e4-a03644514b37"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="id7693ec17d264060a51c05905fff3ad0_6f2384a9-42d0-4922-8490-16aff5d9f669">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54bc3d75-5c17-4a98-9cc2-9200b8d11d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54bc3d75-5c17-4a98-9cc2-9200b8d11d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1aeec617-6bff-4c6e-9046-58751d3af630" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1aeec617-6bff-4c6e-9046-58751d3af630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f76f565-14e8-40c9-a9be-0abe884d5d20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f76f565-14e8-40c9-a9be-0abe884d5d20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f41508a2-efa3-43d5-b30e-dfc41cdb92f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f41508a2-efa3-43d5-b30e-dfc41cdb92f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_9fcb7ea3-0eb8-4a16-815d-6159eccf7c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_9fcb7ea3-0eb8-4a16-815d-6159eccf7c6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_dcce9b95-3bfc-4b6e-8618-070f62130984" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_dcce9b95-3bfc-4b6e-8618-070f62130984" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_291a1cb6-ee09-4aea-8727-237b2659a7df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_291a1cb6-ee09-4aea-8727-237b2659a7df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_079ac7c9-067c-4c8c-93d6-c7639eb8fd25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_079ac7c9-067c-4c8c-93d6-c7639eb8fd25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_88e9883c-5c8f-4d6b-9109-26fd66ba3cde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_88e9883c-5c8f-4d6b-9109-26fd66ba3cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1df45129-4d8a-48d8-8580-43b975f28a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1df45129-4d8a-48d8-8580-43b975f28a5d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20190930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended" id="i0c75c936b43046499c6df8585d9bd9c8_fed515db-a967-4e01-a8eb-c8231600de80"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended" id="i7dd0705546914a2ca79c1d5707ebc39a_dabdc570-1838-4287-8754-6c725ae717d3"/>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i90f6b25600694d03aee80a90ea21fe7c_7a39d3dc-7c6a-43b5-9c11-2f91e3c4aff8">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7dfef847-08bc-44be-ae6d-8bdfa2b8e319" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7dfef847-08bc-44be-ae6d-8bdfa2b8e319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4600a8b7-b0d1-4067-840e-a4fb634efe1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4600a8b7-b0d1-4067-840e-a4fb634efe1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_cb5a4191-b0b6-4bb3-b0e5-04212f70f105" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_cb5a4191-b0b6-4bb3-b0e5-04212f70f105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ea0bfcdf-2677-4a41-8088-0ea11a80aee0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ea0bfcdf-2677-4a41-8088-0ea11a80aee0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a0330df3-956b-4975-83a0-254a4b1e931f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_OperatingLeasePayments_a0330df3-956b-4975-83a0-254a4b1e931f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:to="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ca96d86-4be4-49b9-80f8-8b3979cb2874_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:to="loc_srt_RangeMember_7ca96d86-4be4-49b9-80f8-8b3979cb2874_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:to="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_446ea61e-34ca-4919-833d-dd34bc5ccc63" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:to="loc_srt_MaximumMember_446ea61e-34ca-4919-833d-dd34bc5ccc63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ff2dae2-de1d-401a-bd4a-1b0c9a54c63c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:to="loc_srt_MinimumMember_6ff2dae2-de1d-401a-bd4a-1b0c9a54c63c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="extended" id="id6e981d083a84d84990f479e8bf48717_df67012b-85d3-4172-b833-8ddc41469eee"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" id="i8f068d6e5317470cb43695b75ecaa100_deb4c337-01d7-428c-a4f9-c7ebdfcde1e0"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="i787ce24fa5654d4ebc0c639a4040ad9a_282dcc43-96d2-410a-89dc-2450d6e0c060">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce5625c6-6f45-49e0-98b2-aa46588ce990" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce5625c6-6f45-49e0-98b2-aa46588ce990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_ab03f5a8-3889-4440-85c4-4b16f6aa09b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_ab03f5a8-3889-4440-85c4-4b16f6aa09b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_625c5282-701d-41ae-b72f-dc7eeb8895f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_625c5282-701d-41ae-b72f-dc7eeb8895f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8f4893f-cc6b-446b-a251-40166215ebad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8f4893f-cc6b-446b-a251-40166215ebad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_d6c700e3-0568-413f-853b-f8d3da71fcf2" xlink:href="mgnx-20190930.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:to="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_d6c700e3-0568-413f-853b-f8d3da71fcf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_81b840a9-e102-4616-bc42-50b76e48dd81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:to="loc_us-gaap_OverAllotmentOptionMember_81b840a9-e102-4616-bc42-50b76e48dd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember_bba87611-ce0c-4337-80db-de128a315805" xlink:href="mgnx-20190930.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:to="loc_mgnx_FollowOnEquityOfferingMember_bba87611-ce0c-4337-80db-de128a315805" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreements"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended" id="ibf4250db5c204c6e929f6e8abd9e361b_fd6b55a1-edd7-4e2d-b06b-1ce82af8c670"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsIncyteDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="extended" id="i38ea9a1efe7e468abaea6b9e5de11fc6_1108f942-0860-40d2-99f4-386c0a8ccf36">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_02b8c869-8059-449b-8d52-754fb0654c5a" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_NonRefundableUpfrontFees_02b8c869-8059-449b-8d52-754fb0654c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3f9dc68f-c3a0-4943-9033-9bfed4ba851d" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3f9dc68f-c3a0-4943-9033-9bfed4ba851d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ca77e429-347b-408f-bb42-6f74c7950b84" xlink:href="mgnx-20190930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ca77e429-347b-408f-bb42-6f74c7950b84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e821aa42-c6ed-4038-83b4-065013c920f7" xlink:href="mgnx-20190930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e821aa42-c6ed-4038-83b4-065013c920f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_44761501-f0e0-4ea7-a3dd-1bf0ffaa962f" xlink:href="mgnx-20190930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_44761501-f0e0-4ea7-a3dd-1bf0ffaa962f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_0baf94c0-bbbe-4771-8f8f-546b561740bb" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_NumberOfPerformanceObligations_0baf94c0-bbbe-4771-8f8f-546b561740bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_f8cd6f66-58f3-469b-865f-b644314fb62f" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_f8cd6f66-58f3-469b-865f-b644314fb62f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c71668c-032d-4235-a866-9547a6e14dea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_Revenues_4c71668c-032d-4235-a866-9547a6e14dea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_82a0e086-06d5-47d2-a1be-bbedb26faf4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_82a0e086-06d5-47d2-a1be-bbedb26faf4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3011e0b4-66a2-4ebd-b186-2d83a80143c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3011e0b4-66a2-4ebd-b186-2d83a80143c4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c8e7fc77-9307-4f71-993f-9bd631142f74_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:to="loc_srt_ProductsAndServicesDomain_c8e7fc77-9307-4f71-993f-9bd631142f74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09853ced-5b76-4d8c-9458-570812309990" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:to="loc_srt_ProductsAndServicesDomain_09853ced-5b76-4d8c-9458-570812309990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_625bf79a-bc05-455e-a4c9-a12be32133ea" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_09853ced-5b76-4d8c-9458-570812309990" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_625bf79a-bc05-455e-a4c9-a12be32133ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f037310d-f817-4d5a-a115-25263af15c9b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:to="loc_srt_RangeMember_f037310d-f817-4d5a-a115-25263af15c9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:to="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1dabba5-52b7-4717-b635-5672fa7ec469" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:to="loc_srt_MaximumMember_f1dabba5-52b7-4717-b635-5672fa7ec469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff404160-3a22-47be-8ca3-7c85ddafa5c1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:to="loc_srt_MinimumMember_ff404160-3a22-47be-8ca3-7c85ddafa5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6bea469-84ff-4452-8fb4-b77f574cc9bd_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6bea469-84ff-4452-8fb4-b77f574cc9bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f117bf4-3903-47b2-857e-0d155ff9a27e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f117bf4-3903-47b2-857e-0d155ff9a27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_046cb4fc-2059-4c61-b117-d5e61f46e2b1" xlink:href="mgnx-20190930.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f117bf4-3903-47b2-857e-0d155ff9a27e" xlink:to="loc_mgnx_IncyteCorporationMember_046cb4fc-2059-4c61-b117-d5e61f46e2b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_50ab4884-1938-4a59-82e2-f7aaa698bf0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_50ab4884-1938-4a59-82e2-f7aaa698bf0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63b87939-752d-4f7d-beec-3e00da01fba4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63b87939-752d-4f7d-beec-3e00da01fba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63b87939-752d-4f7d-beec-3e00da01fba4" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_514d032b-0a23-4a02-81c8-06eec082fed9" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_514d032b-0a23-4a02-81c8-06eec082fed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember_c2c4a664-c22c-4b1c-ac13-74cda11c90f8" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:to="loc_mgnx_IncyteMGA012AgreementServicesMember_c2c4a664-c22c-4b1c-ac13-74cda11c90f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsLesLaboratoiresServierDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="extended" id="i9a9b76cbcfc64ad0a1d673801f1167d1_a723cb0c-0333-4cc9-b564-a6e9487987b9">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfExclusiveOptionsToLicense_b059ee09-0b1f-4ada-8297-473488ac46ce" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfExclusiveOptionsToLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfExclusiveOptionsToLicense_b059ee09-0b1f-4ada-8297-473488ac46ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_946cd959-a040-4921-8186-089f56b59df6" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NonRefundableUpfrontFees_946cd959-a040-4921-8186-089f56b59df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_e0251cae-cabe-4456-8860-4081cbb9d577" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_e0251cae-cabe-4456-8860-4081cbb9d577" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_201e3982-5aaa-4698-b984-674d7f1d706b" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfPerformanceObligations_201e3982-5aaa-4698-b984-674d7f1d706b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_b9f00318-db67-4f8e-9bad-cf31ea1be504" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfMilestonesAchieved_b9f00318-db67-4f8e-9bad-cf31ea1be504" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_65ce7bb1-c8e9-4338-9022-0e3fa34c1224" xlink:href="mgnx-20190930.xsd#mgnx_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_MilestonePayment_65ce7bb1-c8e9-4338-9022-0e3fa34c1224" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_a306e75a-8022-479b-ad38-c7bcdb42ab6d" xlink:href="mgnx-20190930.xsd#mgnx_OptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_OptionExerciseFee_a306e75a-8022-479b-ad38-c7bcdb42ab6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfComponentsInLicenseAgreement_dfd63f36-fa89-4054-8f27-fb785388b753" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfComponentsInLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfComponentsInLicenseAgreement_dfd63f36-fa89-4054-8f27-fb785388b753" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_95eb017e-a78f-40ab-8dc5-31e4d7a7bdf5" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_95eb017e-a78f-40ab-8dc5-31e4d7a7bdf5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_26c91951-2f70-4080-bbe2-3bf64e7f2372" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_Revenues_26c91951-2f70-4080-bbe2-3bf64e7f2372" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ba5edf39-ece9-4420-96a6-2ceeb677a615" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ba5edf39-ece9-4420-96a6-2ceeb677a615" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2da05b7f-3656-4870-8dda-f39d9ecc0951" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2da05b7f-3656-4870-8dda-f39d9ecc0951" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_31f94209-2634-43a0-bc0a-e47b7f3aa63b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_31f94209-2634-43a0-bc0a-e47b7f3aa63b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c69bd3e1-9745-426d-955b-51403e285dac_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:to="loc_srt_ProductsAndServicesDomain_c69bd3e1-9745-426d-955b-51403e285dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d0646d7-4f1f-470f-9080-5fe7fca3b1db" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:to="loc_srt_ProductsAndServicesDomain_4d0646d7-4f1f-470f-9080-5fe7fca3b1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_159cf2a9-1004-4651-8d33-dcca08957629" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4d0646d7-4f1f-470f-9080-5fe7fca3b1db" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_159cf2a9-1004-4651-8d33-dcca08957629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_43db08b2-9005-4236-8b9b-c4bee0d0f9e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_43db08b2-9005-4236-8b9b-c4bee0d0f9e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dd143d3e-9996-442a-8492-98c21b8911cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dd143d3e-9996-442a-8492-98c21b8911cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierMGD007Member_067e9aa7-9995-41cb-8e05-f0c66fef9907" xlink:href="mgnx-20190930.xsd#mgnx_LesLaboratoiresServierMGD007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dd143d3e-9996-442a-8492-98c21b8911cb" xlink:to="loc_mgnx_LesLaboratoiresServierMGD007Member_067e9aa7-9995-41cb-8e05-f0c66fef9907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_426aeee3-cbfc-45f9-8bdd-77376a0ca89a_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_426aeee3-cbfc-45f9-8bdd-77376a0ca89a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0445a8e-6946-46b1-a7ca-2107cc4c7c1b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0445a8e-6946-46b1-a7ca-2107cc4c7c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_36609254-4250-4ce9-92bc-a23aa3272686" xlink:href="mgnx-20190930.xsd#mgnx_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0445a8e-6946-46b1-a7ca-2107cc4c7c1b" xlink:to="loc_mgnx_ServierMember_36609254-4250-4ce9-92bc-a23aa3272686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7e6e39da-d1af-4755-8903-0315d995a9d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7e6e39da-d1af-4755-8903-0315d995a9d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc220327-0c20-4058-bbf3-e5d1fc9bcb06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc220327-0c20-4058-bbf3-e5d1fc9bcb06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_7e8eac79-72ef-4ecd-9d91-1d126c30f1ca" xlink:href="mgnx-20190930.xsd#mgnx_ServierDARTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc220327-0c20-4058-bbf3-e5d1fc9bcb06" xlink:to="loc_mgnx_ServierDARTMember_7e8eac79-72ef-4ecd-9d91-1d126c30f1ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b28d2080-dd46-4b69-a412-f81a9260699b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:to="loc_srt_RangeMember_b28d2080-dd46-4b69-a412-f81a9260699b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76e2ae7c-d698-41c4-8c2c-3d79565fbefb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:to="loc_srt_RangeMember_76e2ae7c-d698-41c4-8c2c-3d79565fbefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e308e0c2-861d-4eba-ba3d-a49d3870c712" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76e2ae7c-d698-41c4-8c2c-3d79565fbefb" xlink:to="loc_srt_MaximumMember_e308e0c2-861d-4eba-ba3d-a49d3870c712" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended" id="ic9feb2b78ef04db38d8b850e8f893a04_d1f6b47c-aba1-4d9f-b3cd-32fcf20d9e63">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_93cc91e4-5e3d-47f6-9458-5e39e8521d3c" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_NonRefundableUpfrontFees_93cc91e4-5e3d-47f6-9458-5e39e8521d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_8fbd755a-7bf2-49b5-8fa0-30e2da983f85" xlink:href="mgnx-20190930.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_8fbd755a-7bf2-49b5-8fa0-30e2da983f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_134f6327-da6d-4362-a2cf-e6c15fac5e58" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_NumberOfPerformanceObligations_134f6327-da6d-4362-a2cf-e6c15fac5e58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0e3352cb-5cbb-43f6-b856-41b832f20572" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0e3352cb-5cbb-43f6-b856-41b832f20572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_80348843-9635-40d7-9de9-460efbb30163" xlink:href="mgnx-20190930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_80348843-9635-40d7-9de9-460efbb30163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f6ed4cc9-f2a0-4bc1-b699-56ce0684657c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_Revenues_f6ed4cc9-f2a0-4bc1-b699-56ce0684657c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_53a37079-f940-458a-be6b-5f5881cf77d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ContractWithCustomerLiability_53a37079-f940-458a-be6b-5f5881cf77d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7186ba4f-2b7c-422f-b5d2-f24240b12792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7186ba4f-2b7c-422f-b5d2-f24240b12792" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fb164e4-916a-4359-9c64-f3e993a872bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fb164e4-916a-4359-9c64-f3e993a872bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:to="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:to="loc_srt_ProductsAndServicesDomain_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a16b960-f60a-41ab-ba60-e51ad2c8e2b6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:to="loc_srt_ProductsAndServicesDomain_8a16b960-f60a-41ab-ba60-e51ad2c8e2b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_83426aca-b5e5-4cff-b4d5-52bef5f1c409" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a16b960-f60a-41ab-ba60-e51ad2c8e2b6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_83426aca-b5e5-4cff-b4d5-52bef5f1c409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:to="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05ad1808-a4e3-4408-95aa-453cea52798c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05ad1808-a4e3-4408-95aa-453cea52798c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_c1a5a0f1-087f-4c9e-932a-6ea1e98110e5" xlink:href="mgnx-20190930.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05ad1808-a4e3-4408-95aa-453cea52798c" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_c1a5a0f1-087f-4c9e-932a-6ea1e98110e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="ie865b0c23d6b4595a70764a7fdbb08d7_0e30b90c-3c0b-4fb9-acb6-4b11653cb044">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2c41c1a1-95bd-4e29-bbea-329b5515f854" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2c41c1a1-95bd-4e29-bbea-329b5515f854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_1d9fd374-6776-423a-90cb-3536ff1aaafc" xlink:href="mgnx-20190930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_1d9fd374-6776-423a-90cb-3536ff1aaafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_42319374-076f-440e-8902-a7b57325343d" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_42319374-076f-440e-8902-a7b57325343d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0b747e19-475a-42ca-808e-db1be811d1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_Revenues_0b747e19-475a-42ca-808e-db1be811d1c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_408721d9-2202-4ae8-9af0-fcb1420fafc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ContractWithCustomerLiability_408721d9-2202-4ae8-9af0-fcb1420fafc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_70df73fe-6c55-40c7-80e6-8b84d47ae068" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_70df73fe-6c55-40c7-80e6-8b84d47ae068" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b1209e48-bba9-4d5a-a9c9-ff4cfe72d7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b1209e48-bba9-4d5a-a9c9-ff4cfe72d7d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_64600a1b-ecdf-4898-a4bd-0d0dc42f416b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:to="loc_srt_ProductsAndServicesDomain_64600a1b-ecdf-4898-a4bd-0d0dc42f416b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3da4825-2d70-40a1-9eef-1251eae5ffc5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:to="loc_srt_ProductsAndServicesDomain_f3da4825-2d70-40a1-9eef-1251eae5ffc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_0bbe1dde-bc15-442c-9978-0dbde968de82" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3da4825-2d70-40a1-9eef-1251eae5ffc5" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_0bbe1dde-bc15-442c-9978-0dbde968de82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_897ac7a1-7daf-4eb5-9196-0f4c9b982524_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_897ac7a1-7daf-4eb5-9196-0f4c9b982524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_0e36246a-3ba3-4061-9b5e-f88a25143b6f" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_0e36246a-3ba3-4061-9b5e-f88a25143b6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_abfe07a6-a923-4fca-bd51-1eae0df924bb" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_abfe07a6-a923-4fca-bd51-1eae0df924bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93555c62-d26e-4b88-8adf-031d9c8ce8dc_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93555c62-d26e-4b88-8adf-031d9c8ce8dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58eced0e-daee-400d-9cb9-4b2cb9251fe9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58eced0e-daee-400d-9cb9-4b2cb9251fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_489c6185-f4d1-42c7-8cfb-055f0654f758" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58eced0e-daee-400d-9cb9-4b2cb9251fe9" xlink:to="loc_mgnx_ZaiLabMember_489c6185-f4d1-42c7-8cfb-055f0654f758" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="i1d1a5c2d141f480f88ee79c20e54693e_cc6b4e1a-112b-4661-b8f4-24d31935c682">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_3389b45a-f776-4564-9657-5300f35a4181" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_mgnx_NonRefundableUpfrontFees_3389b45a-f776-4564-9657-5300f35a4181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4c8a112c-f8ea-4bb8-86fc-48339060e81a" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4c8a112c-f8ea-4bb8-86fc-48339060e81a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_5f7ff765-89cf-4e05-9d48-189995b237aa" xlink:href="mgnx-20190930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_5f7ff765-89cf-4e05-9d48-189995b237aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8548a980-6a16-4719-9066-9c05272734fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_Revenues_8548a980-6a16-4719-9066-9c05272734fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_889fb5bc-4c2e-44d3-980b-5c2b21211058" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ContractWithCustomerLiability_889fb5bc-4c2e-44d3-980b-5c2b21211058" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b095692-05bd-487b-9a34-ef72cd5d52e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b095692-05bd-487b-9a34-ef72cd5d52e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3da243a0-b85e-4829-bba4-be54738ea2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3da243a0-b85e-4829-bba4-be54738ea2e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_059533ab-472d-4ebc-9ea4-47fa89001779" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_059533ab-472d-4ebc-9ea4-47fa89001779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_d1745faa-485d-47d8-9f39-a047475833c6" xlink:href="mgnx-20190930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_059533ab-472d-4ebc-9ea4-47fa89001779" xlink:to="loc_mgnx_IMabBiopharmaMember_d1745faa-485d-47d8-9f39-a047475833c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e0f5c359-d11d-4d34-b217-bcfb4538b77c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e0f5c359-d11d-4d34-b217-bcfb4538b77c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37a4482c-f852-43af-ae1f-2e4bce4584af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37a4482c-f852-43af-ae1f-2e4bce4584af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_83804d90-5944-421f-b56c-21430d50e3d3" xlink:href="mgnx-20190930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37a4482c-f852-43af-ae1f-2e4bce4584af" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_83804d90-5944-421f-b56c-21430d50e3d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_39894340-abf9-4906-a0fa-765f63ec7a48_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:to="loc_srt_ProductsAndServicesDomain_39894340-abf9-4906-a0fa-765f63ec7a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53ca3395-7acd-48b4-b4e5-34bdc76d63bc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:to="loc_srt_ProductsAndServicesDomain_53ca3395-7acd-48b4-b4e5-34bdc76d63bc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended" id="i08697cbb53a94d27a49b729530f139a4_74957198-b756-4d2a-bc77-d0ce91ccf6c4">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_520236ba-fb9f-4ccc-9c4c-ae7f7b320c7b" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_520236ba-fb9f-4ccc-9c4c-ae7f7b320c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_00220e81-5fb4-4558-b839-9ca876d0d023" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_00220e81-5fb4-4558-b839-9ca876d0d023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_2cd4324c-f61d-4a5a-ab27-b768706356c9" xlink:href="mgnx-20190930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_2cd4324c-f61d-4a5a-ab27-b768706356c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7b779a0b-49da-4815-89e6-35e297fd8c15" xlink:href="mgnx-20190930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7b779a0b-49da-4815-89e6-35e297fd8c15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_65bd8cb4-bba7-4188-ab42-36633975e8c3" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_NumberOfPerformanceObligations_65bd8cb4-bba7-4188-ab42-36633975e8c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0c43c657-67b8-4394-bfdc-0522d684a536" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0c43c657-67b8-4394-bfdc-0522d684a536" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_72de81c6-7b29-4f55-b45a-85066ab46a3f" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_72de81c6-7b29-4f55-b45a-85066ab46a3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ae2cbda1-2391-43f3-802f-8b7d2baa4eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_Revenues_ae2cbda1-2391-43f3-802f-8b7d2baa4eb3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_6021aab7-486d-4c5c-9392-cf9dd9d96dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_6021aab7-486d-4c5c-9392-cf9dd9d96dbf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897a799c-9104-4904-99fa-5301c6e1d1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897a799c-9104-4904-99fa-5301c6e1d1b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25f0a68f-7845-4b1c-911b-91eb24235e10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25f0a68f-7845-4b1c-911b-91eb24235e10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2f8b58d-16b0-42ca-b6e5-6a3da0d04a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2f8b58d-16b0-42ca-b6e5-6a3da0d04a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cfe0fc7c-e95f-4cd2-8e42-0e00eb643621" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2f8b58d-16b0-42ca-b6e5-6a3da0d04a5b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cfe0fc7c-e95f-4cd2-8e42-0e00eb643621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6853c97a-a8c4-4ba9-9f52-dc96484c4237_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6853c97a-a8c4-4ba9-9f52-dc96484c4237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1804aa-e02d-4da1-9e4e-a4ef2f66a049" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1804aa-e02d-4da1-9e4e-a4ef2f66a049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e6949ad0-7f57-4332-b29d-6f244ed79191" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1804aa-e02d-4da1-9e4e-a4ef2f66a049" xlink:to="loc_us-gaap_WarrantMember_e6949ad0-7f57-4332-b29d-6f244ed79191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be006754-b630-427c-8ae8-e3631908892f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:to="loc_srt_ProductsAndServicesDomain_be006754-b630-427c-8ae8-e3631908892f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_367a7107-0886-428a-8261-e392f8379450" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:to="loc_srt_ProductsAndServicesDomain_367a7107-0886-428a-8261-e392f8379450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_86edcf95-2c2b-44dc-9677-aa01b37d492f" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_367a7107-0886-428a-8261-e392f8379450" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_86edcf95-2c2b-44dc-9677-aa01b37d492f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5411ad1c-4664-4249-a769-e331b828d3c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5411ad1c-4664-4249-a769-e331b828d3c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_143b7854-0c5b-451c-bf44-5b603a274cd0" xlink:href="mgnx-20190930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_143b7854-0c5b-451c-bf44-5b603a274cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_8c949d7e-368d-4d0e-8707-9180211a6bcf" xlink:href="mgnx-20190930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_8c949d7e-368d-4d0e-8707-9180211a6bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e34b3b5c-1167-4383-9d0f-f30ca0d2e395_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e34b3b5c-1167-4383-9d0f-f30ca0d2e395_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adee9a0-4250-45c5-bfb1-344b6b494813" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adee9a0-4250-45c5-bfb1-344b6b494813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member_aee90459-c0a9-4fa6-9fc3-506be302eef0" xlink:href="mgnx-20190930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adee9a0-4250-45c5-bfb1-344b6b494813" xlink:to="loc_mgnx_ProventionBioInc.Member_aee90459-c0a9-4fa6-9fc3-506be302eef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a83adc0-63d7-457c-9c43-18d41f1e079c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a83adc0-63d7-457c-9c43-18d41f1e079c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_565d403b-4536-42fe-8757-f68f35753310" xlink:href="mgnx-20190930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:to="loc_mgnx_ProventionPRV3279Member_565d403b-4536-42fe-8757-f68f35753310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_9439d1a0-d22a-44c1-84ec-520960a105ac" xlink:href="mgnx-20190930.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:to="loc_mgnx_ProventionPRV031Member_9439d1a0-d22a-44c1-84ec-520960a105ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="ie4e1bcf0a2ca40ad9401502cd412c63c_137df307-e21c-44b6-8aee-90b8ca307c20">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6b806cc0-2529-4b14-a1ae-d1f10ca3a215" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6b806cc0-2529-4b14-a1ae-d1f10ca3a215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_b6c0f56b-62a6-4494-a942-aae76d5c5d03" xlink:href="mgnx-20190930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_FundedValueOfBasePeriod_b6c0f56b-62a6-4494-a942-aae76d5c5d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_09343c3f-2e70-4dc5-b54d-91e1ccb25808" xlink:href="mgnx-20190930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_09343c3f-2e70-4dc5-b54d-91e1ccb25808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_85898517-3e2a-40ad-bb89-62c3dc1c10c5" xlink:href="mgnx-20190930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_85898517-3e2a-40ad-bb89-62c3dc1c10c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_61d76fc9-03ed-45b0-af27-8f756b33a444" xlink:href="mgnx-20190930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_61d76fc9-03ed-45b0-af27-8f756b33a444" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6647fda7-3c57-4505-8a46-54877d4863b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_us-gaap_Revenues_6647fda7-3c57-4505-8a46-54877d4863b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8ffc5de3-0882-454a-8c35-1cad204e3da5_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:to="loc_srt_ProductsAndServicesDomain_8ffc5de3-0882-454a-8c35-1cad204e3da5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2af4042-7a51-4f25-8095-1f4afffacd3e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:to="loc_srt_ProductsAndServicesDomain_d2af4042-7a51-4f25-8095-1f4afffacd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_9cb499e9-5c16-44ba-aa4b-25e9d04ea50f" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d2af4042-7a51-4f25-8095-1f4afffacd3e" xlink:to="loc_mgnx_RevenuesFromGrantsMember_9cb499e9-5c16-44ba-aa4b-25e9d04ea50f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94c7a688-0910-4e54-a5c5-350f67659e51_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_94c7a688-0910-4e54-a5c5-350f67659e51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0e27aa5-0db2-4ff3-bf10-78395aaa1c62" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0e27aa5-0db2-4ff3-bf10-78395aaa1c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_9fead7b2-ee89-4849-9828-090dd6ab19f2" xlink:href="mgnx-20190930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0e27aa5-0db2-4ff3-bf10-78395aaa1c62" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_9fead7b2-ee89-4849-9828-090dd6ab19f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45a126a3-e234-43fa-888f-2b063c1537ce_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:to="loc_srt_RangeMember_45a126a3-e234-43fa-888f-2b063c1537ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf9b2c73-1e9b-46c3-9c9e-a267a7d398c4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:to="loc_srt_RangeMember_bf9b2c73-1e9b-46c3-9c9e-a267a7d398c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d073d77-72c5-4786-bff4-e0f1247a7daa" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf9b2c73-1e9b-46c3-9c9e-a267a7d398c4" xlink:to="loc_srt_MaximumMember_1d073d77-72c5-4786-bff4-e0f1247a7daa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" id="i189f14e64f244d6797b9719b30997fb9_58a22177-51e0-42b5-b789-56555b0e7483"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" id="ie23db5ed63e64ff89d0148b13ceefa2a_6ecc2f23-c171-4501-a13c-51da371a00fd"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ifcca9e25c5fb4f019df8974b0ee7f591_1194d47d-9ba8-4d6a-9703-d9555966dd7d">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15017e2c-f4e2-4b58-a01b-12ffe65d2fef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15017e2c-f4e2-4b58-a01b-12ffe65d2fef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_02c08ba6-404b-42d6-89fe-fd7530253cd2" xlink:href="mgnx-20190930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_02c08ba6-404b-42d6-89fe-fd7530253cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3ef15f67-2e05-45e6-ac57-65ce30df179a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3ef15f67-2e05-45e6-ac57-65ce30df179a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2cbf442b-ada7-4304-a698-b579ea8591f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2cbf442b-ada7-4304-a698-b579ea8591f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_48a46cf8-bda5-42f7-aca7-f19a667ab937" xlink:href="mgnx-20190930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_48a46cf8-bda5-42f7-aca7-f19a667ab937" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_a89c4dc0-1d6d-49c9-b473-ebcab58ba460" xlink:href="mgnx-20190930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_a89c4dc0-1d6d-49c9-b473-ebcab58ba460" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44057d95-e236-4409-a9eb-a900646a30b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44057d95-e236-4409-a9eb-a900646a30b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bba3df-d362-467e-be68-56bab0bbb799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bba3df-d362-467e-be68-56bab0bbb799" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_6849f95c-5f60-4c4f-b126-cde8e51133d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ProceedsFromStockPlans_6849f95c-5f60-4c4f-b126-cde8e51133d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:to="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5683e543-f1b6-43a2-8f9c-b5892562ad3b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:to="loc_us-gaap_PlanNameDomain_5683e543-f1b6-43a2-8f9c-b5892562ad3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:to="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_f7bd30d9-4de3-40c2-bdec-9cb5cdc97d78" xlink:href="mgnx-20190930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_f7bd30d9-4de3-40c2-bdec-9cb5cdc97d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_ce1f1072-e9a3-45b4-892e-43eea0cdb25a" xlink:href="mgnx-20190930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_ce1f1072-e9a3-45b4-892e-43eea0cdb25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_10c1d5f1-7bf5-4bf6-8100-365d1a5cf94b" xlink:href="mgnx-20190930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:to="loc_mgnx_StockIncentivePlan2013Member_10c1d5f1-7bf5-4bf6-8100-365d1a5cf94b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dae3392a-e288-4634-a129-e4de8793cf02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3232040f-f4e6-47e0-b65e-bfa6c4e96f00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dae3392a-e288-4634-a129-e4de8793cf02" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3232040f-f4e6-47e0-b65e-bfa6c4e96f00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dae3392a-e288-4634-a129-e4de8793cf02" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_64c81a21-a567-4394-9aad-ec4600ac3870_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_64c81a21-a567-4394-9aad-ec4600ac3870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9babe21e-0b13-4cb6-b3a1-cd03ede6f1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9babe21e-0b13-4cb6-b3a1-cd03ede6f1d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3dd87835-5d29-4c02-b437-cdf206b6e2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3dd87835-5d29-4c02-b437-cdf206b6e2e8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="i6c1b2fb9d8bd4391963d152a1f8833ee_a63a20bd-64f2-4c76-b466-54b52027b496">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_309fab38-94a0-468f-9671-8dcdb0c8196c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_309fab38-94a0-468f-9671-8dcdb0c8196c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_28d0317c-b654-48d1-bdf1-94368216a7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_28d0317c-b654-48d1-bdf1-94368216a7ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e691394a-fd0f-4b60-b0e1-905772f5798d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e691394a-fd0f-4b60-b0e1-905772f5798d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9cb73c2f-ac9f-4ec3-afac-282b3bb61af4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9cb73c2f-ac9f-4ec3-afac-282b3bb61af4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:to="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9311a00-2029-4e55-8489-b9ba4fd3ed8f_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:to="loc_srt_RangeMember_c9311a00-2029-4e55-8489-b9ba4fd3ed8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:to="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_efdc46ea-c5aa-46f7-9042-41cd1a94b777" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:to="loc_srt_MinimumMember_efdc46ea-c5aa-46f7-9042-41cd1a94b777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fd2d876d-f8ae-464e-91a6-7ff725622da8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:to="loc_srt_MaximumMember_fd2d876d-f8ae-464e-91a6-7ff725622da8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i23e42e38cdd9406fbdfe40d9eec10dfd_e30ea174-be98-47ae-81a1-1e7058f06a52"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended" id="ia250ca5f2ca548678e11b251e51679ec_f536fc18-4d71-405a-9b55-ac8652ef5295"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mgnx-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:37c13bdf-fb46-46bd-829a-97a3fb2efa47,g:e81d9694-bb2f-41e2-94f9-94c8f654a663-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ed1d3bb6-b7c2-4ce6-be6d-d12b307317cc_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets modified in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_37304468-39fe-46ad-a13f-a3587c104a93_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_7f741f47-a338-43bf-a11a-f162bfd4d4a7_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a84bcef3-a6e1-4954-8b10-d7c90116f2df_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_3d20d19d-cda7-4b24-a719-8506a3701da3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3840efff-aecd-468f-a3e5-f617829a46e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_79ef3e36-9763-4a76-8f41-c31e1ab0c946_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f15e95a1-fbdb-4423-8f59-3a62dfe81a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_00e1af17-f450-4699-9688-e6270d7a40a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary unrealized losses</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_49c05e06-bb46-4d2a-b5d8-49f64ee1b1a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_7c8dfad1-e1e7-4d6d-b514-624ae72c3004_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20190930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_91a5ade0-f050-44b8-99c3-5c37d178b460_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0024ba47-7030-4e80-8af5-8be0d447207b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_ad865e57-d90f-4401-998a-724ab8889428_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant to purchase shares of common stock, exercise price (in dollars per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2bfe38-72cb-4aea-9c30-efb23ca46ee8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_50815f2c-0418-4b7b-aa45-690e003e96d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfComponentsInLicenseAgreement_253e0573-0f9b-49de-86da-16cb3fd27e42_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfComponentsInLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of components in license agreement</link:label>
    <link:label id="lab_mgnx_NumberOfComponentsInLicenseAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfComponentsInLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfComponentsInLicenseAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfComponentsInLicenseAgreement" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfComponentsInLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfComponentsInLicenseAgreement" xlink:to="lab_mgnx_NumberOfComponentsInLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_ac10b677-fa17-4aa6-88ee-f690d0fd4845_terseLabel_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer</link:label>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_label_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer [Member]</link:label>
    <link:label id="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_documentation_en-US" xlink:label="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Commitment Public Underwritten Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:href="mgnx-20190930.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:to="lab_mgnx_FirmCommitmentPublicUnderwrittenOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_08416937-4086-429c-bd73-45221e8666e1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_12dbad7f-6602-42e4-adb9-1855ff4204a1_terseLabel_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering</link:label>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_label_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering [Member]</link:label>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_documentation_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember" xlink:href="mgnx-20190930.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FollowOnEquityOfferingMember" xlink:to="lab_mgnx_FollowOnEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_162a3688-f11e-451e-8b86-b66a939891bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_589c94fd-bec2-42e0-bf47-44e50677ef92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_01e99e22-2ace-45a6-9e0e-cd71e062c9c2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_877d362f-5b81-496f-b19b-16499561a85c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierDARTMember_68b451cc-77e9-4ad8-8e77-54ab905bd744_terseLabel_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier DART</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_label_en-US" xlink:label="lab_mgnx_ServierDARTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ServierDARTMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember" xlink:href="mgnx-20190930.xsd#mgnx_ServierDARTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierDARTMember" xlink:to="lab_mgnx_ServierDARTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f91d0c63-2efc-4833-97cf-68a58d1b780b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_600c38ae-4707-4cb3-bd40-ff953f348c4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_15e9f6a5-a6f0-4701-9183-c3c8532f79fc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e0518cf4-d4e1-4e9e-af45-4d71b3eecfbd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_70db208c-3a01-4585-978c-c66731cfcfcc_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments to third parties</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_69411b54-50b9-4a7d-974e-e635ae70fee3_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfPerformanceObligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementServicesMember_8b05db79-e1ad-4eb0-8dff-ff6ded6c929e_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementServicesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementServicesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6995f136-f3df-4b8f-8399-30c1a0601d57_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f746b578-afa6-461a-8779-3bd434938588_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a40a6f6e-9b07-4ec7-b588-ec4271eaf8ee_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fd139cd5-a2ab-41ae-9f00-898dfd021b14_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5d4f70b9-9dec-4613-b883-303b5ecce5ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4957f869-e1c0-4af4-9e34-27a77437028f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2d48b7b5-cb13-479d-a835-5ad09cae2212_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_298270cc-4aba-4b78-98db-98c792549f00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1515bb38-1cd4-4967-bf06-270a0cf5642a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f99e1a19-14e6-4fca-b8bd-a23c34fdb8bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_776ab141-9a8c-45ca-b929-bfa3c6047007_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e62e645e-4938-4c17-8a7c-c9d52a851cad_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_afcb5166-5824-4e52-a2f1-7964e993fa5d_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20190930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9ac020dd-737a-46cb-bc6d-a56e782adf5d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioInc.Member_bbbbf3b9-e0df-4f8c-a556-e98cb0e7872d_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention</link:label>
    <link:label id="lab_mgnx_ProventionBioInc.Member_label_en-US" xlink:label="lab_mgnx_ProventionBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionBioInc.Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member" xlink:href="mgnx-20190930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioInc.Member" xlink:to="lab_mgnx_ProventionBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9fde1dd7-50d5-4955-9e35-218ba4808cb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e5d2a503-c154-4fb7-af8c-f426561236b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9b89814e-447f-4feb-a40c-fa496cf72c31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_62a222f3-d849-4e93-91a2-f31961113165_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_079021ab-704c-498a-bbbd-05fc0bb0a151_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8ac5ad24-6a94-4c2d-bc2f-4574cd460172_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_59c89be7-de51-495d-9edc-e0aaf5e78338_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_e897e195-9c52-4995-ac38-0570f57cc03a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_c3d80647-b99a-4836-8d11-8793646ff07b_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7aee90d-31f5-40db-8049-c5127e389d0d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_ce723c46-7b18-423e-86ff-794b74910d1c_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20190930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_87b4facd-8fe4-4f4f-b6c4-e96e96359062_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3cd1832-08d0-4a6a-a1f0-578985f8b389_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f03770bb-c88b-40a1-998e-8e667eb9b4e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f068bc1a-0aec-4ce3-957c-4c07d40c1eb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_268854ad-3904-472a-bc3e-508441ec8437_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV-3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionPRV3279Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20190930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_25904791-b639-4ce7-98a1-dafb830a1f70_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20190930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f89604a2-4b4e-4eb8-bd1f-0610a994b3f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_39f45bac-6b91-4307-bdd1-dfdf8ffbe38b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4cb28862-4dd9-4bab-8c29-f452f633aeca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e902a980-3a96-4bea-817b-e017cf75673c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_455cad48-b271-49bb-aea3-9ac31101aadc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c9af1b6f-7e55-4822-ad21-357d1f77426c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9f24ac0e-f840-4abf-b3c3-aed1b8ec5d17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_653f1b6b-eae4-4371-a021-ac81dab29a68_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_d1f759ae-5c22-4023-8495-61ac98b3f9f9_terseLabel_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_label_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Six</link:label>
    <link:label id="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_documentation_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:href="mgnx-20190930.xsd#mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptionExerciseFee_2f1db9f1-5514-4547-9137-23c9b6fc4adc_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_label_en-US" xlink:label="lab_mgnx_OptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionExerciseFee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee" xlink:href="mgnx-20190930.xsd#mgnx_OptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFee" xlink:to="lab_mgnx_OptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MilestonePayment_acd72219-07f7-4157-bdc0-61e55af11626_terseLabel_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_mgnx_MilestonePayment_label_en-US" xlink:label="lab_mgnx_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MilestonePayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment" xlink:href="mgnx-20190930.xsd#mgnx_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MilestonePayment" xlink:to="lab_mgnx_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_b8911b7f-65c1-473f-ac99-321e154b491c_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20190930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f4cb5f2-7c62-4dbf-93b9-b791ca05bf75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6d42ff82-2516-4a2f-925d-31ce89e9c7a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_29168d52-c7ed-42a4-9995-97325816a2be_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_657fec4e-5685-4915-92f1-042957a14156_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_21db717c-8df4-4f38-93d7-ed4f6b4bbb6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_c7b4a77b-0301-4d7f-969c-f92d24351749_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_9d68a353-c4cf-4ed9-8e0d-1c31b6042b45_terseLabel_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_label_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:href="mgnx-20190930.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:to="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_396c9473-4a88-49e2-9b4a-b06da5c18b44_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_0c04698f-2846-4372-83ac-29e7fc0c7aae_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0e6ed936-87c5-4591-b2f8-08da0db3580c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_753c5b15-1470-40d9-a404-a2ee6c41a69b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_1a50dda5-37a1-42db-b7fd-321a524051d7_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20190930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_5064b4ac-d96c-4c46-b01e-65d352bcb1e6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bd1efe1b-114d-4121-a35e-ce1fd501c987_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_741456bb-54c7-4796-a14a-3c751044fe3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_1c89dfc4-f73b-44de-8de2-ce577e08513a_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d23ea5fc-ef79-4fe8-87c7-bb40046bf3be_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_db55c1ca-2672-4baa-a3bd-38edb43ac811_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8e118be4-46c4-4756-bbf2-5db3e2ab6fac_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_9529cda9-738f-4ebd-aa8a-4ba966e5999c_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_7661b357-779a-4800-9e6a-2e7b17758a67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12129f98-33f0-421a-a23d-a3a71055ba15_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_adbb4d94-a9b4-4d6b-a6e0-4d8b76a27872_terseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FundedValueOfBasePeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod" xlink:href="mgnx-20190930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod" xlink:to="lab_mgnx_FundedValueOfBasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_28131ba7-66d8-45bc-8934-3cca952bc6a1_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionLicenseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20190930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_d5f9db23-76dd-44ec-94c9-aa22463aeade_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInDeferredRent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:href="mgnx-20190930.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3879063e-6e6e-4643-aae2-102aa977cd9f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_6fbad3ef-17a6-40fc-b144-845f6f949f4e_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f8fed69f-9472-42bb-b0ab-2c35ea5f07f6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_ed5c1761-a0dc-4220-b991-fe098072fe3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_272c2451-c64b-4553-bc96-210c5ed2ad2d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cfd30da3-dec6-40a9-b181-e38f3912b7e2_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2bc0092c-897d-4ac9-b8a8-c1f901b42a0c_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Granted, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da81e5a-d96a-4783-b9ac-014e598e480c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3f7b368a-03f0-49dd-bae1-e3ee20351a59_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_cc830f5d-ae8c-4a8c-aa8f-5b3a27df79c1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0f12f848-d7cb-4f86-8109-77fd5bb3d96b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_28dd5dc6-b6f1-4b3b-970a-8282d49867b5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b760461e-4c67-451a-aabc-59813013d98a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5ee5e6d5-4071-4133-b99e-6dc2f71d6a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6473cf59-a561-4d17-8649-a68bcb356b6b_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_05102bea-7e78-475b-9820-73c285ac3559_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_696cac3a-570a-45bb-9516-c460e1419090_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3a860b16-9d5a-4b26-929b-3927d96f4390_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of adoption of accounting standards</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_32ce6750-d408-4b9d-a9e5-e913d8f5b437_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_us-gaap_DeferredRentCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6c9fc600-0679-4a66-b484-f5ee4841c144_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_96f7cfbb-14a6-4fcb-8262-d8fe96359f2d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_011457d5-e950-4410-ac86-0be0ccbb4508_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_dbd7ff10-7242-4d50-b177-f4ae1b90ea32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 48,914,284 and 42,353,301 shares outstanding at September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_de6c1e51-1637-4b99-ae26-c502b8992c32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6402ef10-4575-4ba7-b301-3727eaabfa17_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d0f96199-eef1-4c42-8894-3bf16109f32b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_9b251d30-5ec8-4812-a28b-1e9e7b518123_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssetPurchaseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20190930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_64f57716-7267-432e-9c93-a4e82e3ef56a_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcc37841-e9de-4492-8e63-718b4eaa7979_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_53339339-b000-4611-b7aa-f63bac224882_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6871816a-da9d-49aa-ae7b-2a2fe9e353c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f8149335-6077-4236-bdb7-741712aed83c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_bd4b1053-22dc-470f-a712-6bfa17702a9f_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8099407a-f1c6-4154-ba7d-2f35ecf701b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_785d0be0-6188-4550-8f5d-a154df435bb7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfExclusiveOptionsToLicense_c3418396-b0d7-48ac-ac9c-914ba2d9e8d3_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfExclusiveOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exclusive options to license</link:label>
    <link:label id="lab_mgnx_NumberOfExclusiveOptionsToLicense_label_en-US" xlink:label="lab_mgnx_NumberOfExclusiveOptionsToLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfExclusiveOptionsToLicense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfExclusiveOptionsToLicense" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfExclusiveOptionsToLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfExclusiveOptionsToLicense" xlink:to="lab_mgnx_NumberOfExclusiveOptionsToLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d5c79e45-1ae7-4b2d-a20f-12642f5e4007_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_15f1518d-c1c2-4306-ad85-2401655efea5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_42b5c53b-5912-480f-8818-5195580a1883_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d0f687cc-faec-40fa-a337-d9d90c54389d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_73cd890b-984d-4083-9543-3a14bd3bd148_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_aecff790-f073-471c-89bc-5aa53abb06af_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_be44f3ef-a6cf-44b9-976d-1fb6c993c2cf_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4541b835-eefb-4385-85d4-205500e8c70a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_59b7c14d-2ef0-43f3-bcb4-aebac682192e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1bfb99a2-5a44-451f-9241-231052aec3cc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_13af980f-bcf0-4859-b6d9-302da52cb7de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_b8dd2292-eea3-4476-a4b8-9e4868420c78_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20190930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6cf49da3-eadf-4b0b-83fe-040b1654a021_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_6bddf4ea-086b-4e30-8542-9433fe771b99_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20190930.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_0423fc7c-94b5-49cd-a565-9961d88f2abc_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction discount</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20190930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_440629b4-5dce-4a54-967f-0367dac93557_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_64de08d2-f227-4779-bab7-b04b68c02fd7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9f9c69af-d558-4e51-a6af-11e273519006_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e667414d-1866-4099-b6b8-60c5a3b87d9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_59571438-0942-4e77-a47b-5ce0166ba073_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_2acf5f7b-47d5-4c72-9b3f-90032f91f7f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6483bf94-7039-41cc-a819-7a0e9e58f515_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_acfde42c-a647-4a45-82ce-8aadde1e2677_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dfbdbaf5-f1d2-4ad5-8217-16fa8c9edcdb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e796c6f0-1270-40ca-a58a-91c746057f01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f7b9568-dc7f-4079-a105-677044aa0b3f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_d90f675a-1780-449e-86c1-4f1a0fee2437_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20190930.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a26d1ada-32ef-4837-b0f6-286e9444b347_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76feabb1-9124-4814-b5cf-42a803f6fe47_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_957f57a1-8632-406f-94bb-0b62006302e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_01017a41-1a41-4a4c-b6a5-1fc6ea541b56_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fe99032e-0c1c-40ba-91a6-881e9e9cd941_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0292da8b-be5e-4f25-9e99-d311b8a65f23_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_46370c5a-2868-4770-958e-ee6c33cf0fd6_terseLabel_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_label_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Six</link:label>
    <link:label id="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_documentation_en-US" xlink:label="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:href="mgnx-20190930.xsd#mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:to="lab_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f5599a30-0124-4d20-98be-86fcd63963b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2affb33c-a351-4507-b937-6ffffb326582_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fb144aba-c2ce-4f1d-a407-972885c503bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_498af148-1874-4958-a22d-669b431a6299_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bcff2daa-a329-4c77-8439-c247f476738f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7089a179-232e-4cfe-ab21-f84ce5ee7e40_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_b43daeb3-9658-4d2a-b6dd-71c092e15d13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_65010d06-187a-4f77-b79b-f7aaefff5b2b_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_757aac03-a4f4-452e-9264-7758939f48e6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_901be0c0-8aa3-4c81-8cbf-e31ff1abce6a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_58316f3b-56c5-48af-b910-236b735dc275_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_2034afa4-b83a-4caa-a4a6-863809aadd63_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20190930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_20a80288-bbeb-4e87-a404-cf38fe7b5f9b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fe5c5212-f0a5-4ef4-ba0b-0b373caf3bc9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_4b5c36b4-9093-4969-9cc8-112308e100ad_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offset to research and development costs under the collaboration agreement</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationArrangementOffsetToResearchAndDevelopmentCosts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:to="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c1a52410-88a9-4fe7-bede-11cebeb3ee97_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4636a544-1606-4a24-b499-3d4491e4e423_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_db50486b-2ee7-421f-9adb-c12b693b1de3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_102ca709-51ae-42db-b9ee-98995e1f71af_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0e904b19-6a51-40ed-aa24-360d1576726b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_18ede7a5-53d4-40bc-b2f2-d7f2380d76aa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d7048ae9-56d3-4570-94c9-30cb6ad037e1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8140d9fa-77d9-4c9e-974c-23b7636bdfc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_83a023a6-7469-4e48-aa24-351300a216c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_117751d4-e75a-4cc2-b58b-b3f27416ce72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_dc7dc238-17a4-4a60-a987-9c26b214873a_terseLabel_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_96e7f96d-ffe4-44bf-94d2-a7d8440fe073_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cc9d4c7e-ddc0-4359-b46d-e5e21f2932e3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d2d762a4-da2b-4b74-bc9c-3c3479113028_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0b4e558d-413b-47f7-b0b9-41c763c2248c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_828940e7-2e22-4e87-9e86-5eff3d766b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_05404a3e-0e09-4963-9cf3-f979dfe4575a_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20190930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4f176f64-6575-498b-bb12-ed629b79ab62_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5249d20c-e7a9-4a1b-8885-6ecd94ff1ad1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62f0ecd5-3dc7-497e-a7bc-c1958d1cdd51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ae0093b4-adf8-4b17-a64b-c99224266c19_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8d012e00-0c6f-4552-91b7-ac7eb6250cb8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ServierMember_9d7bb9b7-6eee-48a8-bb8a-15a63f5fe223_terseLabel_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_mgnx_ServierMember_label_en-US" xlink:label="lab_mgnx_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ServierMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember" xlink:href="mgnx-20190930.xsd#mgnx_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMember" xlink:to="lab_mgnx_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_de6bb470-3531-4267-9d14-341320a92434_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8d0221e8-b18d-492a-a7b1-dbc8c72cea1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09bfbd77-c338-4d28-b06b-e068f1df5a5f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_424da407-e2c9-40e7-b076-700ebc6b5b2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_42e0fb47-ecc4-473b-b9be-d3abbd2c7bbd_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_9f2f9027-f514-4bd1-adf3-1cfbdfe823fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c60968ae-53aa-47a6-8840-9df00e9f9699_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_5878f482-bec0-4c40-9028-dd911f7574c8_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20190930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_63c9c62c-c6f9-4410-8403-db92708281a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_42e6d2fd-daa0-44b9-865e-e51473625793_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f1dea100-69f9-4558-a1dd-87ed432cc406_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3f97fc3b-51ff-4c3a-ad58-b19455125464_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3b8ffa5e-ef33-4054-8de2-f965588905c5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_df28d752-8cf3-4efd-9fac-03d087b44876_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_19ed7843-fd21-4f10-914e-a6dc6a815d6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_20c201fe-99ce-41d5-be16-7c9107ed9eef_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20190930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73c8297a-4f6e-4254-b72c-67c288213158_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_08686167-3530-444a-96f4-dcd4beb86544_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_817075e2-669e-4ce8-ac69-0fcb226b0f59_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_8c56e5dc-592e-40ca-95c2-c75c92dc450d_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available under warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_bf6eeccc-3f41-4adc-ba4d-58a49010344e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_8de0caa7-5b5f-4ca0-92dd-706c1e85ed30_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_mgnx_NumberOfMilestonesAchieved_label_en-US" xlink:label="lab_mgnx_NumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMilestonesAchieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMilestonesAchieved" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMilestonesAchieved" xlink:to="lab_mgnx_NumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_930d32d0-41e2-4015-90da-85cc71c89d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b76d2058-e9cf-441a-b591-73ba6ba6ef7b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_87b230fd-3db3-40b7-9695-eb0cfefbf3a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a9feb6c7-bb3f-4e78-83d5-adc9c959e490_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_9634f3a7-2da3-40da-8d8a-19a4463bedab_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e06ba411-4dfa-41f7-80a7-7615674a3601_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c5c5d4a1-d823-48b5-9f1b-2a07ea9167e8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bba55bb9-4951-4d3e-b319-72a6781f7cf7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_65e3531b-7fe5-4d7c-bee3-850dc1e99e93_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_eded483c-49ec-46e9-87a6-4d82b42ec09f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2870baa8-a0a2-461c-b087-3f06650a52c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_45b9fcae-1963-4f64-96ff-ca86789532cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_57549a76-8c58-4651-8a13-6cdf49570ccf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4847dbac-5e86-4dcb-8d5c-6346df38bc0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3523aa17-5ae5-4b6c-ac64-7ca3202da374_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_88389b16-b942-4e01-b2aa-8a0af0ccae1e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_5f08b281-a9ec-473b-a98c-99b4cf3c0230_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5a34dcff-5dd5-4080-9ff3-37de5e22df51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bf67f6f1-7850-458a-b738-74d770d3b314_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1842fe5c-4bd5-4dbb-b183-c20a870d1d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f11c0a5f-3fb5-48fc-930f-acf894cf8301_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_9bc297ae-c96c-4839-b4e1-a796bd3515a4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d31b4e79-ce6c-403a-a9a4-cbe6a156bf64_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_11666b45-62f0-4adc-8caa-5e5cb10a35be_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5411c41a-1655-44ef-bce2-6feb2e8e0be5_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3373ea01-074e-494c-b854-381247342adb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_9a98f615-923d-4e78-bfe6-114c7bd9cc37_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_99a17fec-859e-4a95-b82c-6b94a1e83406_terseLabel_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants received, including change in value</link:label>
    <link:label id="lab_mgnx_FairValueOfWarrantsReceived_label_en-US" xlink:label="lab_mgnx_FairValueOfWarrantsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FairValueOfWarrantsReceived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived" xlink:href="mgnx-20190930.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FairValueOfWarrantsReceived" xlink:to="lab_mgnx_FairValueOfWarrantsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1749c7b8-913c-4b20-afe1-1fd35708fd2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9aee67f-267f-4b47-8d63-928df83f57ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_12011fc4-7bb4-4f0b-aa38-19e6ab1f25d6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_c5014270-aaac-4c35-be7f-5e75cacc060b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_1b3c44b5-6d8e-4af0-8f29-e1dca91b59d1_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment recognition period</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_label_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UpfrontPaymentRecognitionPeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:href="mgnx-20190930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="lab_mgnx_UpfrontPaymentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_50cb7bb5-5576-4d5c-901c-204ac7489d3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_6d637a66-5758-438a-bac6-8d5b93f0caeb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_738640d6-61c3-4f0d-9a87-da12daa313d3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f5ab1d53-dc48-414e-8ec9-f68fb38738db_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_605a1c0a-354a-471a-8c45-7fdd6cba98dd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_5e83a046-d0a4-4bb4-8f48-77029b6df20e_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20190930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_85d557b2-7b9b-4490-9734-948feabb61fb_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-allotment option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a3f5fa50-e399-4bf8-90d4-7843e217e2d4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea0296a0-a328-4316-a197-69dbefab29f3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa307a1f-4c66-4467-80de-14a7a86d11c8_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_68068b42-e85e-4b0f-b8c1-a4d34d9abf09_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e68cfc65-55c8-4777-aaf0-5522427d3a53_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_9e3628b1-b599-4529-8d7e-0434e98f70d6_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20190930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_564a4e4c-71c2-4638-b721-753208b44440_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV-031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionPRV031Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20190930.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_770e53c2-6573-4532-a1c1-168444969dda_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e66244fc-a748-4540-9346-e2fadcf5bd82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_06ea1faa-440e-4f8c-860f-0447edbda68e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_cc738b5a-5354-41dd-970d-661c3ce7d705_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2ce7b74c-02aa-400f-8c71-c41a800a5a1b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a2197053-4da7-40a6-aa7e-547c58ba5eef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e20e6663-315d-4264-a72d-d048b1e44dd5_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_5affb611-eb0f-400f-998a-cf23ff95eb80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2b5cc496-4ce6-466e-81b9-394cc136d4ae_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f5650be2-a5fa-4c55-a77b-e6f1ef76ffcb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_84b0aa0e-c267-42a9-88db-666b9b72d540_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_52f93181-9544-44e7-b629-04b233080390_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_148d6654-cb37-4539-a2a3-ad42f490afe5_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5a83e61a-7f00-4a5b-a74d-e56301e99f37_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e3f14bc0-e79a-4fde-a244-dfd07172971b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fb207904-5228-49ce-ac03-9bf55831a727_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_23058821-eca4-4e0e-b17e-2d75297ba995_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_536ced66-6754-41b0-b2e9-25275ac65fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cd9a06f1-d021-4463-ba69-cb02f4c978ae_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c529a9ee-724b-433f-b6e6-387bd63fe446_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_9eb9dfec-e23b-455b-81fe-ec6c4ac1ea5d_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="mgnx-20190930.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f5e00f6e-a621-4cef-ba25-08de83aa289f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ce2e47b0-91f2-4fae-ae2c-581d2a16c3d4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LesLaboratoiresServierMGD007Member_839192e5-984c-4528-8e1e-bf0b051b468a_terseLabel_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierMGD007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Les Laboratoires Servier MGD007</link:label>
    <link:label id="lab_mgnx_LesLaboratoiresServierMGD007Member_label_en-US" xlink:label="lab_mgnx_LesLaboratoiresServierMGD007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LesLaboratoiresServierMGD007Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierMGD007Member" xlink:href="mgnx-20190930.xsd#mgnx_LesLaboratoiresServierMGD007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LesLaboratoiresServierMGD007Member" xlink:to="lab_mgnx_LesLaboratoiresServierMGD007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_72885e75-e683-4f4e-a583-845aac95e094_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3f920d7e-2d01-4bef-8a6b-998a73cbfea7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_6e08d9b8-b440-4510-bca8-15bc801c0d9d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_c3c2354e-de7c-42b2-8afb-08cbe2cc8f7a_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20190930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aa8abe68-32cd-48eb-859c-0934459f6d1a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5a74c6d0-0e7f-46de-8302-1930b3fadfb9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_23d15360-8fa1-4481-a5f7-d856f05faea9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_98558f2b-4c6f-4de4-a09b-26b126dbb251_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6c78ac12-85e1-4577-a86e-c0baae5a46c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_1ad7734e-1bbf-4256-8b1b-fcd203ec94ac_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments and royalties on future sales under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_ce7dd05f-c217-4c5e-a0ea-7daf8fd139b5_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_ad704a7b-ffbf-435d-bf9a-39e5f568a2f3_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_ef110691-d974-498f-8373-e04073178a0d_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20190930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d4a4de91-52a5-46be-a5fd-67d78cfb1310_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ccd0641d-7a48-40d7-82b2-2c02c61014d9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_edc87abb-23e1-4903-bd47-feff34d16b63_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_d5e57e20-d7f3-4ef7-8f8d-30bdfbffdc4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d1702b69-07fa-4ed9-9088-fbce79316947_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d30faad6-a679-4414-91ee-a6557e22141f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_05d1d470-d9f0-49f4-a9b6-3022fd453e44_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_20bf4351-3b12-414e-97bd-9c6b21eafca2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2ebc9143-6c10-419f-b848-ad9933991513_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bc69f823-c69d-4e59-bc15-987b61fc005c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_40896b0c-1030-464a-ab98-292b940704f1_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20190930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4edc70d9-998b-4675-bc42-7e43714ba2c7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_84b8e4b7-2e56-4d30-b925-bcaa4062e129_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c5359f2-5d6a-4690-962f-dd0d5e989a59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ff627872-9e20-4001-ae9d-6bdc98aedb0c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mgnx-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2019 Workiva-->
<!--r:37c13bdf-fb46-46bd-829a-97a3fb2efa47,g:e81d9694-bb2f-41e2-94f9-94c8f654a663-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_18336c18-b86b-46f5-8d2c-c02fb7c913c0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_DocumentType_18336c18-b86b-46f5-8d2c-c02fb7c913c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fe3bce67-3df6-4eb2-8d3e-507c357b2135" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_DocumentQuarterlyReport_fe3bce67-3df6-4eb2-8d3e-507c357b2135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_af994278-397f-4b47-b00c-509be2d5d25f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_DocumentTransitionReport_af994278-397f-4b47-b00c-509be2d5d25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_97f8d63d-c012-4df7-8522-2b73cff97542" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_DocumentPeriodEndDate_97f8d63d-c012-4df7-8522-2b73cff97542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4e736acd-3734-40f9-a27e-ba30064ca753" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityFileNumber_4e736acd-3734-40f9-a27e-ba30064ca753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_52d7867a-dd6a-412d-900d-1223087b1c21" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_DocumentFiscalYearFocus_52d7867a-dd6a-412d-900d-1223087b1c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_921c7b88-d2b6-4e72-8692-9b2e4597e446" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_921c7b88-d2b6-4e72-8692-9b2e4597e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_879e7001-3de8-4702-80b1-8c9c18c974ba" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityRegistrantName_879e7001-3de8-4702-80b1-8c9c18c974ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e4e8bb64-8155-4ef6-a68b-bf8040b4c919" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityCentralIndexKey_e4e8bb64-8155-4ef6-a68b-bf8040b4c919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28e450c5-21a4-4535-94c7-38a5985f3006" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_CurrentFiscalYearEndDate_28e450c5-21a4-4535-94c7-38a5985f3006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d1237991-cbc3-4488-8bc6-4fcf48c0b942" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityInteractiveDataCurrent_d1237991-cbc3-4488-8bc6-4fcf48c0b942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_59d213c5-622c-4094-87ca-3bb2b4e4bc12" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityFilerCategory_59d213c5-622c-4094-87ca-3bb2b4e4bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e806429e-c79c-410e-a9ef-4ac269b6e578" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityEmergingGrowthCompany_e806429e-c79c-410e-a9ef-4ac269b6e578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_27eddca1-fe69-4193-9591-d33ca30175ae" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityCurrentReportingStatus_27eddca1-fe69-4193-9591-d33ca30175ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_39531d3d-27ec-48fe-96af-bdd5d93f6a84" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_Security12bTitle_39531d3d-27ec-48fe-96af-bdd5d93f6a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ecd4ada8-8f46-4d92-b819-51f02eec122b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4129e6c4-8e14-490f-b50a-3e4eac3e5db2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntitySmallBusiness_4129e6c4-8e14-490f-b50a-3e4eac3e5db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9782fdfb-5605-4db7-a835-c840107b23a1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_LocalPhoneNumber_9782fdfb-5605-4db7-a835-c840107b23a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_07d3d0c8-8035-49ac-b72b-1a4775070cf3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_CityAreaCode_07d3d0c8-8035-49ac-b72b-1a4775070cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_92ac2d3c-fefa-4e4b-81d6-18fb71873bc3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_TradingSymbol_92ac2d3c-fefa-4e4b-81d6-18fb71873bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_be258459-b9c8-4a2d-b629-9492ce8dff42" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_SecurityExchangeName_be258459-b9c8-4a2d-b629-9492ce8dff42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7a9577be-b122-4ff3-8ef0-e04e58b0bab9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityAddressPostalZipCode_7a9577be-b122-4ff3-8ef0-e04e58b0bab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd4981c2-f2b1-4bb4-aed5-9383cbdbb4db" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd4981c2-f2b1-4bb4-aed5-9383cbdbb4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c5734578-bba9-4efd-a9a3-ab69a1420acc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c5734578-bba9-4efd-a9a3-ab69a1420acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d6226b45-01c1-409e-bb35-4e5fbb47c917" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d6226b45-01c1-409e-bb35-4e5fbb47c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b3922b48-acf2-43d9-9433-dc312096f9e4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityAddressAddressLine1_b3922b48-acf2-43d9-9433-dc312096f9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_36ca9313-46ad-45ce-9584-145171ecdf75" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityAddressCityOrTown_36ca9313-46ad-45ce-9584-145171ecdf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6fda80f7-63f5-4961-8ee4-c3f3a5b301fb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityAddressStateOrProvince_6fda80f7-63f5-4961-8ee4-c3f3a5b301fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c34be285-fb06-409d-9fd6-bbef420a324b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_AmendmentFlag_c34be285-fb06-409d-9fd6-bbef420a324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4d81c765-eac2-4f15-ae08-bf3bf946b8ff" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4d94960a-e742-4984-9faf-10142716b82c" xlink:to="loc_dei_EntityShellCompany_4d81c765-eac2-4f15-ae08-bf3bf946b8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_249942c7-1c37-4e0c-9521-2902ecd8c27f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_87555528-6e13-4b01-be6f-06e865ee9047" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_249942c7-1c37-4e0c-9521-2902ecd8c27f" xlink:to="loc_us-gaap_AssetsAbstract_87555528-6e13-4b01-be6f-06e865ee9047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87555528-6e13-4b01-be6f-06e865ee9047" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_878964b1-4d6a-4942-964f-0bccad6c924d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_878964b1-4d6a-4942-964f-0bccad6c924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_5067f8c8-d5f8-4a97-90ff-cc26e8953b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:to="loc_us-gaap_Investments_5067f8c8-d5f8-4a97-90ff-cc26e8953b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5614c554-1cd2-4de6-88e5-a1f5bcab8951" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5614c554-1cd2-4de6-88e5-a1f5bcab8951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1b4b7527-b9b5-453f-8cbb-a4b321551397" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1b4b7527-b9b5-453f-8cbb-a4b321551397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_26340764-ab40-4771-9167-ba71b62c80ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:to="loc_us-gaap_OtherAssets_26340764-ab40-4771-9167-ba71b62c80ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ee4e014-3832-472a-b322-09c4d3cdd540" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f07b3585-2df6-46ac-80b0-a6db9c964f1f" xlink:to="loc_us-gaap_AssetsCurrent_9ee4e014-3832-472a-b322-09c4d3cdd540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0a6a7114-c777-40ac-8136-0f3e6237fdd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87555528-6e13-4b01-be6f-06e865ee9047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0a6a7114-c777-40ac-8136-0f3e6237fdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3cd8ffbc-72c0-433e-826a-31995d2b6bec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87555528-6e13-4b01-be6f-06e865ee9047" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3cd8ffbc-72c0-433e-826a-31995d2b6bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67703eb9-4256-4cd8-bdac-6daa7d286920" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_87555528-6e13-4b01-be6f-06e865ee9047" xlink:to="loc_us-gaap_Assets_67703eb9-4256-4cd8-bdac-6daa7d286920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_249942c7-1c37-4e0c-9521-2902ecd8c27f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9f531f59-22c6-4562-a8ea-e4f91bef7015" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9f531f59-22c6-4562-a8ea-e4f91bef7015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0cf61a19-e5b7-450f-b526-22704498a781" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0cf61a19-e5b7-450f-b526-22704498a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_999d2cb4-3761-4149-a4b3-7e34624f2c48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_999d2cb4-3761-4149-a4b3-7e34624f2c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_3b80e6e3-53a4-4c97-9fde-aeed9e64b36b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_3b80e6e3-53a4-4c97-9fde-aeed9e64b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e5adb8aa-0355-4c83-939f-ddcaf77b18b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e5adb8aa-0355-4c83-939f-ddcaf77b18b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7ce29416-5ddf-47d1-b2c6-c5b1ad7bcc85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7ce29416-5ddf-47d1-b2c6-c5b1ad7bcc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a673f748-374b-4c71-ba3e-d501fa53de59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fc5abdb-f784-49c0-aa60-f4f8870d642d" xlink:to="loc_us-gaap_LiabilitiesCurrent_a673f748-374b-4c71-ba3e-d501fa53de59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_058146ad-b35c-4769-b776-f2b042234cca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_058146ad-b35c-4769-b776-f2b042234cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b5c9268-3145-472c-b7c8-871790ecd8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7b5c9268-3145-472c-b7c8-871790ecd8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_72c6740b-8397-4d19-bf89-180b04b16bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_72c6740b-8397-4d19-bf89-180b04b16bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d8f571a3-100d-4828-af2e-5fc7b265e7df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_Liabilities_d8f571a3-100d-4828-af2e-5fc7b265e7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_44c47811-65dd-461c-9785-3bf65749b2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:to="loc_us-gaap_CommonStockValue_44c47811-65dd-461c-9785-3bf65749b2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25b25c6e-8193-4925-a9ac-182562bd15c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25b25c6e-8193-4925-a9ac-182562bd15c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4a61a148-1d80-43b0-a17b-70f409b62384" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4a61a148-1d80-43b0-a17b-70f409b62384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_313c085d-4297-47de-b159-2e7e09b7bd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_313c085d-4297-47de-b159-2e7e09b7bd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee17acfd-fd3c-425f-af5b-73026e7e5dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a8b8b19-415a-4f2c-bd34-7924d8428c3d" xlink:to="loc_us-gaap_StockholdersEquity_ee17acfd-fd3c-425f-af5b-73026e7e5dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_970e35a7-5a4e-49ac-b5f2-593ad432a8de" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19084310-a8de-44d8-8ea2-e5b26849d872" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_970e35a7-5a4e-49ac-b5f2-593ad432a8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f6f51e4f-44b5-4544-8558-29aed2a95afb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6da7372d-a279-4b65-a976-28690ff59bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f6f51e4f-44b5-4544-8558-29aed2a95afb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6da7372d-a279-4b65-a976-28690ff59bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_273a5c1e-e566-4157-b0c8-cb93a637d18f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6da7372d-a279-4b65-a976-28690ff59bb3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_273a5c1e-e566-4157-b0c8-cb93a637d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_44c9ca8f-719f-4edd-92d6-99786ea061c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_273a5c1e-e566-4157-b0c8-cb93a637d18f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_44c9ca8f-719f-4edd-92d6-99786ea061c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_536500cf-b415-4cae-993f-422392086898" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_273a5c1e-e566-4157-b0c8-cb93a637d18f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_536500cf-b415-4cae-993f-422392086898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ce5b2e34-e45b-4703-9e16-c28feffc9857" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_273a5c1e-e566-4157-b0c8-cb93a637d18f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ce5b2e34-e45b-4703-9e16-c28feffc9857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3923bbb4-139b-40fb-8b44-514fb6d2104d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3923bbb4-139b-40fb-8b44-514fb6d2104d" xlink:to="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:to="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0deabdb6-480d-4258-9b2c-3c568e3a0db0" xlink:to="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_4cd97435-4027-4bae-b904-107326e20dd5" xlink:href="mgnx-20190930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_4cd97435-4027-4bae-b904-107326e20dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_c927f8fb-e6d2-437a-b25c-50a352a1060b" xlink:href="mgnx-20190930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fadba991-660c-431c-9fe1-99d9fca00a04" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_c927f8fb-e6d2-437a-b25c-50a352a1060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6e8bb66-fbb7-4056-8d62-ee2bb75e6489" xlink:to="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f87c39ee-cbd2-4c5b-a7f0-e785b19f78fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_RevenuesAbstract_f87c39ee-cbd2-4c5b-a7f0-e785b19f78fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_51477a62-24d0-4fd4-a4d8-897489ccb13b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f87c39ee-cbd2-4c5b-a7f0-e785b19f78fc" xlink:to="loc_us-gaap_Revenues_51477a62-24d0-4fd4-a4d8-897489ccb13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d92f722e-44a6-41ad-b7af-36d8dacc972d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d92f722e-44a6-41ad-b7af-36d8dacc972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_14084345-2840-455c-9d67-a75bdd173ece" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_14084345-2840-455c-9d67-a75bdd173ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1a6959cc-f1e9-4c53-b16c-6b6e5a8dc5ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_CostsAndExpenses_1a6959cc-f1e9-4c53-b16c-6b6e5a8dc5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40455a55-b423-459b-b629-11fe869b7235" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_OperatingIncomeLoss_40455a55-b423-459b-b629-11fe869b7235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f8ce72f3-8c3f-45a2-98e2-183fc724d270" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f8ce72f3-8c3f-45a2-98e2-183fc724d270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74772854-45fe-4a29-b7ed-b1fbc0ebd4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b3afd11a-5788-4226-880f-c57d27da8dd2" xlink:to="loc_us-gaap_NetIncomeLoss_74772854-45fe-4a29-b7ed-b1fbc0ebd4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_24e876d4-07c8-4b84-8b44-45e7cf3c8801" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e677fe7b-7a83-4da7-8cc4-4d241fce6799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e677fe7b-7a83-4da7-8cc4-4d241fce6799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b097ebe8-1466-4a6d-a963-6b43c50a1b84" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b097ebe8-1466-4a6d-a963-6b43c50a1b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8705f1ff-d072-4bda-a675-34a5bd2e5906" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8705f1ff-d072-4bda-a675-34a5bd2e5906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9366ecc9-9841-48ed-854a-c297f2c8d9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7e458c69-6d04-4dd4-af86-0cd217bc204b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9366ecc9-9841-48ed-854a-c297f2c8d9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e48b596b-bfd7-4da4-bc5f-fbacca7c408c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e48b596b-bfd7-4da4-bc5f-fbacca7c408c" xlink:to="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3fa2bc86-218c-41e5-98e0-80254d3973b9" xlink:to="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_683b6c6f-bbce-4068-818f-0d06cf51092c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_CommonStockMember_683b6c6f-bbce-4068-818f-0d06cf51092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ef0c2092-1f56-40c8-bd89-4102bb54b971" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ef0c2092-1f56-40c8-bd89-4102bb54b971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ae76f76c-091d-486e-a3bb-8b116bd7054f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_RetainedEarningsMember_ae76f76c-091d-486e-a3bb-8b116bd7054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_51db73b0-0b90-4c34-ad3a-69e837e63482" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_edfdaa06-1db9-4687-82ae-28e506f5a56e" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_51db73b0-0b90-4c34-ad3a-69e837e63482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f1fe742-ad1a-42f5-a2a1-b8b0fb114e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e06963f3-e969-43e8-becc-3f427e8e4336" xlink:to="loc_us-gaap_StatementLineItems_4f1fe742-ad1a-42f5-a2a1-b8b0fb114e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f1fe742-ad1a-42f5-a2a1-b8b0fb114e85" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_7a513dc6-a459-4bff-b8ec-4423f6f64adc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_SharesIssued_7a513dc6-a459-4bff-b8ec-4423f6f64adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf06a89d-de24-453c-a616-89f26fb71f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf06a89d-de24-453c-a616-89f26fb71f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_241b88f5-1e5f-491f-bc6f-80f30bf0ed70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_241b88f5-1e5f-491f-bc6f-80f30bf0ed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3fd5a158-bb44-493f-8006-69ea598def8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3fd5a158-bb44-493f-8006-69ea598def8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51d31078-d8ad-4832-abde-e6494fedcf54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51d31078-d8ad-4832-abde-e6494fedcf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d8d57309-317e-42d3-8589-9ab5f667d479" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d8d57309-317e-42d3-8589-9ab5f667d479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_7ad8ed47-844e-44cc-a2d4-97a6652cee35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_7ad8ed47-844e-44cc-a2d4-97a6652cee35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3011b5ed-382e-4eac-9d89-d15595bc57f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3011b5ed-382e-4eac-9d89-d15595bc57f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_040c197e-d303-48eb-be37-f0967fe88bff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_040c197e-d303-48eb-be37-f0967fe88bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39696099-9234-4b61-972e-48f7bc2ddf98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_ProfitLoss_39696099-9234-4b61-972e-48f7bc2ddf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1fdd2fdb-2d0f-4585-be62-80124f96b48a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_SharesIssued_1fdd2fdb-2d0f-4585-be62-80124f96b48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccdbf380-d431-4c4b-926d-8c34511510ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d99f5b1-bcee-4068-bf0a-1813cf9737df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccdbf380-d431-4c4b-926d-8c34511510ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a81f65d-4246-49ec-81cd-0bab4398daa3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a81f65d-4246-49ec-81cd-0bab4398daa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ade07c5-a589-4753-9434-2f13a894a987" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a81f65d-4246-49ec-81cd-0bab4398daa3" xlink:to="loc_us-gaap_NetIncomeLoss_3ade07c5-a589-4753-9434-2f13a894a987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2cbfc813-75c2-4631-b88d-1eb8be33b473" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a81f65d-4246-49ec-81cd-0bab4398daa3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2cbfc813-75c2-4631-b88d-1eb8be33b473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8eab2105-567a-4366-a7e6-648ee41dcdfd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2cbfc813-75c2-4631-b88d-1eb8be33b473" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8eab2105-567a-4366-a7e6-648ee41dcdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f6c86de9-4142-46e9-8ee3-8195c6738bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2cbfc813-75c2-4631-b88d-1eb8be33b473" xlink:to="loc_us-gaap_ShareBasedCompensation_f6c86de9-4142-46e9-8ee3-8195c6738bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2cbfc813-75c2-4631-b88d-1eb8be33b473" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cd69fffc-a549-4302-bc71-9deebb1cda89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cd69fffc-a549-4302-bc71-9deebb1cda89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6abf92ec-3d79-4fa5-b5a3-903858bc3934" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_6abf92ec-3d79-4fa5-b5a3-903858bc3934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_76beec27-071d-49a4-9c0f-c95f6cf0cc54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_76beec27-071d-49a4-9c0f-c95f6cf0cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_84545672-e0bb-45c7-98cb-1f14d402211b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_84545672-e0bb-45c7-98cb-1f14d402211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_297fc0e9-e3d2-4cde-8278-2088b3acebd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_297fc0e9-e3d2-4cde-8278-2088b3acebd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_72ef68bc-9f4e-4578-beea-ee18df2c3112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_72ef68bc-9f4e-4578-beea-ee18df2c3112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9284ed20-fe86-404e-bcb0-c6e623d30251" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9284ed20-fe86-404e-bcb0-c6e623d30251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_8a0187d2-0985-4d29-a847-391b7f40fd1b" xlink:href="mgnx-20190930.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_8a0187d2-0985-4d29-a847-391b7f40fd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_cbf776c6-ae16-45dd-ab80-46204cc1787d" xlink:href="mgnx-20190930.xsd#mgnx_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5b134a5d-356a-4deb-b5a6-b546046664d2" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_cbf776c6-ae16-45dd-ab80-46204cc1787d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45191eb3-51e1-4320-bd01-4d68063cb693" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a81f65d-4246-49ec-81cd-0bab4398daa3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_45191eb3-51e1-4320-bd01-4d68063cb693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0fb68c6c-1bb9-4e6f-b1e9-09d3a1acd335" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0fb68c6c-1bb9-4e6f-b1e9-09d3a1acd335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_98bdc197-9259-48f4-95db-8c74c7152b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0fb68c6c-1bb9-4e6f-b1e9-09d3a1acd335" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_98bdc197-9259-48f4-95db-8c74c7152b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f3a77cae-66eb-4d55-acb0-af1412e8c32f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0fb68c6c-1bb9-4e6f-b1e9-09d3a1acd335" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f3a77cae-66eb-4d55-acb0-af1412e8c32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c30657d-ad65-46f1-8b3f-591736fcaa7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0fb68c6c-1bb9-4e6f-b1e9-09d3a1acd335" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c30657d-ad65-46f1-8b3f-591736fcaa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3418efe1-63d9-4626-8a0c-2206e01b88a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0fb68c6c-1bb9-4e6f-b1e9-09d3a1acd335" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3418efe1-63d9-4626-8a0c-2206e01b88a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_897e85c7-55b4-41b6-b450-37e8bc8405b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_897e85c7-55b4-41b6-b450-37e8bc8405b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5de0aa10-9bfa-42e3-b271-cf7f2ccb7215" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_897e85c7-55b4-41b6-b450-37e8bc8405b5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5de0aa10-9bfa-42e3-b271-cf7f2ccb7215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_eeddd05b-70d1-4977-b115-24284a8ce8cc" xlink:href="mgnx-20190930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_897e85c7-55b4-41b6-b450-37e8bc8405b5" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_eeddd05b-70d1-4977-b115-24284a8ce8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d839a25d-5869-416f-84f4-28f55bafae51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_897e85c7-55b4-41b6-b450-37e8bc8405b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d839a25d-5869-416f-84f4-28f55bafae51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c8fccc7-5748-46d8-ae44-c3f8be71aca4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c8fccc7-5748-46d8-ae44-c3f8be71aca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_268f3e2a-e71e-4257-aff7-40feb050bb57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_268f3e2a-e71e-4257-aff7-40feb050bb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d2ffe39-0ed3-46a2-ba22-0097053c0881" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d2ffe39-0ed3-46a2-ba22-0097053c0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_95e92ea2-b550-486a-97c8-988e62c6c767" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5c672ca7-59f0-4a01-a34f-e63351bbaedf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_95e92ea2-b550-486a-97c8-988e62c6c767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_071914b0-24cf-4c72-b33b-f52af7938751" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_95e92ea2-b550-486a-97c8-988e62c6c767" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_071914b0-24cf-4c72-b33b-f52af7938751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Details" xlink:type="simple" xlink:href="mgnx-20190930.xsd#Details"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_52b2c395-6b37-4129-ba9b-c5274a636752" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FairValueOfWarrantsReceived_8a42f3b2-12d1-4ec4-8911-e199a1ddece6" xlink:href="mgnx-20190930.xsd#mgnx_FairValueOfWarrantsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_52b2c395-6b37-4129-ba9b-c5274a636752" xlink:to="loc_mgnx_FairValueOfWarrantsReceived_8a42f3b2-12d1-4ec4-8911-e199a1ddece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6b41d98-c469-42ed-8fff-462c41f70ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9677c183-5990-4744-be41-78651cd3a8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6b41d98-c469-42ed-8fff-462c41f70ca1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9677c183-5990-4744-be41-78651cd3a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80a2b93-60de-41d6-97e8-76910c9d9714" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5be3985e-7acc-4c7f-a888-85997f1baeb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80a2b93-60de-41d6-97e8-76910c9d9714" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5be3985e-7acc-4c7f-a888-85997f1baeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ffb6b1f-2b57-4896-95bf-3e21e8f76494" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80a2b93-60de-41d6-97e8-76910c9d9714" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ffb6b1f-2b57-4896-95bf-3e21e8f76494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_530e5c78-0e6c-42ca-9dec-6ae02b77b7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5c690b8-e911-4d1d-890f-b0029bbc60c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_530e5c78-0e6c-42ca-9dec-6ae02b77b7e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5c690b8-e911-4d1d-890f-b0029bbc60c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cf9b8482-d380-4065-92a7-f22e2fed9f77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_530e5c78-0e6c-42ca-9dec-6ae02b77b7e0" xlink:to="loc_us-gaap_OperatingLeaseLiability_cf9b8482-d380-4065-92a7-f22e2fed9f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_718a20f0-432f-4117-a238-de06ee50c29e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_acae546b-e291-449e-97dd-aaee5df77e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_718a20f0-432f-4117-a238-de06ee50c29e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_acae546b-e291-449e-97dd-aaee5df77e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f6e0e1db-7a25-4e6f-ad7d-f0969bd7b4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_cfa7b250-1534-44f8-b1ad-960a77cb12c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f6e0e1db-7a25-4e6f-ad7d-f0969bd7b4cb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_cfa7b250-1534-44f8-b1ad-960a77cb12c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2d54ec8a-a1d8-464f-b111-709cba419921" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d54ec8a-a1d8-464f-b111-709cba419921" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1dc5fd81-1131-436f-ac77-901d7e22d610" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33b754dd-1ae2-403a-9c2f-86ea618c8bb3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1dc5fd81-1131-436f-ac77-901d7e22d610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7de9232e-e14c-44c3-8511-04e3ff2e66bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1dc5fd81-1131-436f-ac77-901d7e22d610" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7de9232e-e14c-44c3-8511-04e3ff2e66bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0808598d-9d79-49e8-ac56-a3e00a1b2b26" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_650f66bd-f5df-4571-b011-c5c89a6d3091" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_MoneyMarketFundsMember_650f66bd-f5df-4571-b011-c5c89a6d3091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_194997fd-db30-41ad-b191-68bbeee33960" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_194997fd-db30-41ad-b191-68bbeee33960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d139c248-5e77-404d-a3c7-49b0d11af820" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d139c248-5e77-404d-a3c7-49b0d11af820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f1cf0b0f-eb73-42ba-873c-9fa12e4496e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f1cf0b0f-eb73-42ba-873c-9fa12e4496e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_867a4435-f6c1-4744-b17c-c9a7ccc056df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_EquitySecuritiesMember_867a4435-f6c1-4744-b17c-c9a7ccc056df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_00ea527d-d3fd-49d6-8b82-931dcb4f39ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c565f3b7-38eb-49b1-a667-5d6cc7a25d85" xlink:to="loc_us-gaap_WarrantMember_00ea527d-d3fd-49d6-8b82-931dcb4f39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_013c0ace-44fb-4008-a537-50df401452a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3954a11c-fc68-48e0-865e-a936371c28c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3954a11c-fc68-48e0-865e-a936371c28c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a7941f9-14c8-4416-b676-fd3fa3e6b52a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a7941f9-14c8-4416-b676-fd3fa3e6b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_238a6032-13a9-4a7c-82df-32a75e8d682d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_082b4e90-e3d1-44e6-b27b-9570d73d46b5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_238a6032-13a9-4a7c-82df-32a75e8d682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_beb3aef3-1c74-49ea-9adc-d0ecc4d11798" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_030bb434-fd90-4e07-bab8-d5562c70179e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_beb3aef3-1c74-49ea-9adc-d0ecc4d11798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_beb3aef3-1c74-49ea-9adc-d0ecc4d11798" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a89e767e-9886-4af3-aff3-a1469734f3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a89e767e-9886-4af3-aff3-a1469734f3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a7091cf-5791-4030-ad53-5fb326af5ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a7091cf-5791-4030-ad53-5fb326af5ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a06a7dba-134e-4ba0-9e8b-c25fb4048cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a06a7dba-134e-4ba0-9e8b-c25fb4048cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7162d9a5-0fb1-4989-ab73-c46a987fbf52" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_85de6802-3f5d-4204-a2cb-4c6aaf70a27f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7162d9a5-0fb1-4989-ab73-c46a987fbf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b79224f2-784b-4535-b562-b20bc5cc1ba0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a100c0b6-11fc-412c-8e23-3ff76c96cf10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b79224f2-784b-4535-b562-b20bc5cc1ba0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a100c0b6-11fc-412c-8e23-3ff76c96cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1117b7be-52c5-4fee-a3aa-f58e206e6e70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_a26c7572-52b2-4df6-98a8-94f18d8e420f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1117b7be-52c5-4fee-a3aa-f58e206e6e70" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_a26c7572-52b2-4df6-98a8-94f18d8e420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a9a52605-f0c3-4993-8404-52aa018b8666" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a9a52605-f0c3-4993-8404-52aa018b8666" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_291a1cb6-ee09-4aea-8727-237b2659a7df" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_079ac7c9-067c-4c8c-93d6-c7639eb8fd25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_079ac7c9-067c-4c8c-93d6-c7639eb8fd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_88e9883c-5c8f-4d6b-9109-26fd66ba3cde" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_88e9883c-5c8f-4d6b-9109-26fd66ba3cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1df45129-4d8a-48d8-8580-43b975f28a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33326db8-31f5-4fe9-bc9d-72ea3038e9b8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1df45129-4d8a-48d8-8580-43b975f28a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_505157b9-a289-4d34-95cd-7356c6e47a5e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54bc3d75-5c17-4a98-9cc2-9200b8d11d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_54bc3d75-5c17-4a98-9cc2-9200b8d11d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1aeec617-6bff-4c6e-9046-58751d3af630" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1aeec617-6bff-4c6e-9046-58751d3af630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f76f565-14e8-40c9-a9be-0abe884d5d20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f76f565-14e8-40c9-a9be-0abe884d5d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f41508a2-efa3-43d5-b30e-dfc41cdb92f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f41508a2-efa3-43d5-b30e-dfc41cdb92f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_9fcb7ea3-0eb8-4a16-815d-6159eccf7c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_9fcb7ea3-0eb8-4a16-815d-6159eccf7c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_dcce9b95-3bfc-4b6e-8618-070f62130984" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_75ee08bf-403b-49dc-824d-dada70c00d78" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_dcce9b95-3bfc-4b6e-8618-070f62130984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Leases" xlink:type="simple" xlink:href="mgnx-20190930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e9b123b1-d4c4-4236-994f-9a79a80eb57a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_df129787-be52-474b-8c33-f23897f72a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e9b123b1-d4c4-4236-994f-9a79a80eb57a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_df129787-be52-474b-8c33-f23897f72a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d87e23e3-b7d2-4a63-b12d-2b3753dbc6da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e73199d6-9fe2-4ff0-aeb6-b7fe4bb20bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d87e23e3-b7d2-4a63-b12d-2b3753dbc6da" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e73199d6-9fe2-4ff0-aeb6-b7fe4bb20bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_99e5b7bd-69c9-4f50-9627-762182efdc8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d87e23e3-b7d2-4a63-b12d-2b3753dbc6da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_99e5b7bd-69c9-4f50-9627-762182efdc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_10b21782-ff6e-435e-8772-4c92dcc6b7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10b21782-ff6e-435e-8772-4c92dcc6b7b4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:to="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7ca96d86-4be4-49b9-80f8-8b3979cb2874" xlink:to="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_446ea61e-34ca-4919-833d-dd34bc5ccc63" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:to="loc_srt_MaximumMember_446ea61e-34ca-4919-833d-dd34bc5ccc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6ff2dae2-de1d-401a-bd4a-1b0c9a54c63c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7345ee88-71e6-460e-9d22-c5bc13af54f3" xlink:to="loc_srt_MinimumMember_6ff2dae2-de1d-401a-bd4a-1b0c9a54c63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e41a7dea-b78d-4028-9004-11e2246f001d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7dfef847-08bc-44be-ae6d-8bdfa2b8e319" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7dfef847-08bc-44be-ae6d-8bdfa2b8e319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4600a8b7-b0d1-4067-840e-a4fb634efe1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4600a8b7-b0d1-4067-840e-a4fb634efe1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_cb5a4191-b0b6-4bb3-b0e5-04212f70f105" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_cb5a4191-b0b6-4bb3-b0e5-04212f70f105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ea0bfcdf-2677-4a41-8088-0ea11a80aee0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ea0bfcdf-2677-4a41-8088-0ea11a80aee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a0330df3-956b-4975-83a0-254a4b1e931f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd456b6b-2c0a-444c-b5a8-b9d53eeacc4d" xlink:to="loc_us-gaap_OperatingLeasePayments_a0330df3-956b-4975-83a0-254a4b1e931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_37c6510d-df80-4fc6-8342-0a9df9185fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_10b21782-ff6e-435e-8772-4c92dcc6b7b4" xlink:to="loc_us-gaap_OperatingLeasePayments_37c6510d-df80-4fc6-8342-0a9df9185fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#LeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_aa0a8cef-e5c2-404c-b789-59f702491f60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_OperatingLeaseCost_aa0a8cef-e5c2-404c-b789-59f702491f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8f75cf34-cd1d-4804-add8-340cdff3e445" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_VariableLeaseCost_8f75cf34-cd1d-4804-add8-340cdff3e445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_41bfc60d-37f6-4495-a1e4-c4cc4188efc4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_SubleaseIncome_41bfc60d-37f6-4495-a1e4-c4cc4188efc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9b9f0498-39f0-402f-b299-4fe53aab6eca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LeaseCost_9b9f0498-39f0-402f-b299-4fe53aab6eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b2115292-1a93-4a42-ad7f-919cd82632b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b2115292-1a93-4a42-ad7f-919cd82632b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_81ca4c69-196b-40da-865e-29f74d03a0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_81ca4c69-196b-40da-865e-29f74d03a0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_68854c24-b1e7-4bb0-80f6-d132e4921790" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_68854c24-b1e7-4bb0-80f6-d132e4921790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90ae2d1e-42cd-4f2e-8e7e-80bdc24bce44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90ae2d1e-42cd-4f2e-8e7e-80bdc24bce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f40b1063-1674-45f8-9648-77d130d08f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f40b1063-1674-45f8-9648-77d130d08f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_d499676f-52a4-463d-9af5-38d1649d839a" xlink:href="mgnx-20190930.xsd#mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_d499676f-52a4-463d-9af5-38d1649d839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_ea6706af-1ae0-4322-8ac7-d3f20dff083f" xlink:href="mgnx-20190930.xsd#mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_ea6706af-1ae0-4322-8ac7-d3f20dff083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a827d60-1af0-4d7b-ac2b-7022841c69a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a827d60-1af0-4d7b-ac2b-7022841c69a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5539857-c956-4c06-97ec-58305704eb7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5539857-c956-4c06-97ec-58305704eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6361a1b9-d217-452d-aade-7614bff34680" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_021550cd-5542-43e7-86d4-f36cf2d17d14" xlink:to="loc_us-gaap_OperatingLeaseLiability_6361a1b9-d217-452d-aade-7614bff34680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29b26fe3-ee8a-4622-8c57-bed00e780dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9dd835a8-e942-4996-ba0b-2b109e55e3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29b26fe3-ee8a-4622-8c57-bed00e780dfb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9dd835a8-e942-4996-ba0b-2b109e55e3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9d506562-aa1d-4b9f-92c7-f664fc2e6e60" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9d506562-aa1d-4b9f-92c7-f664fc2e6e60" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8f4893f-cc6b-446b-a251-40166215ebad" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_d6c700e3-0568-413f-853b-f8d3da71fcf2" xlink:href="mgnx-20190930.xsd#mgnx_FirmCommitmentPublicUnderwrittenOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:to="loc_mgnx_FirmCommitmentPublicUnderwrittenOfferMember_d6c700e3-0568-413f-853b-f8d3da71fcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_81b840a9-e102-4616-bc42-50b76e48dd81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:to="loc_us-gaap_OverAllotmentOptionMember_81b840a9-e102-4616-bc42-50b76e48dd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember_bba87611-ce0c-4337-80db-de128a315805" xlink:href="mgnx-20190930.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1750369-e499-46d1-b5ce-1307abb10429" xlink:to="loc_mgnx_FollowOnEquityOfferingMember_bba87611-ce0c-4337-80db-de128a315805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5f0fe4c-7cea-4289-b06a-ac72764351dd" xlink:to="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce5625c6-6f45-49e0-98b2-aa46588ce990" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce5625c6-6f45-49e0-98b2-aa46588ce990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_ab03f5a8-3889-4440-85c4-4b16f6aa09b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_ab03f5a8-3889-4440-85c4-4b16f6aa09b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_625c5282-701d-41ae-b72f-dc7eeb8895f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c5691cb-bc0e-4105-a436-c413f8a64c85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_625c5282-701d-41ae-b72f-dc7eeb8895f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5753a61d-662d-4001-8a27-350ae1cbe012" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_eef11620-0093-4d17-b077-7655b7df94dc" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5753a61d-662d-4001-8a27-350ae1cbe012" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_eef11620-0093-4d17-b077-7655b7df94dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsIncyteDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_23cc4729-425f-4e1d-89e0-457994a21548" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_23cc4729-425f-4e1d-89e0-457994a21548" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09853ced-5b76-4d8c-9458-570812309990" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c8e7fc77-9307-4f71-993f-9bd631142f74" xlink:to="loc_srt_ProductsAndServicesDomain_09853ced-5b76-4d8c-9458-570812309990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_625bf79a-bc05-455e-a4c9-a12be32133ea" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_09853ced-5b76-4d8c-9458-570812309990" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_625bf79a-bc05-455e-a4c9-a12be32133ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f037310d-f817-4d5a-a115-25263af15c9b" xlink:to="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1dabba5-52b7-4717-b635-5672fa7ec469" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:to="loc_srt_MaximumMember_f1dabba5-52b7-4717-b635-5672fa7ec469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff404160-3a22-47be-8ca3-7c85ddafa5c1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a4d40d55-21db-41a2-8fb9-3c79cd0406a2" xlink:to="loc_srt_MinimumMember_ff404160-3a22-47be-8ca3-7c85ddafa5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f117bf4-3903-47b2-857e-0d155ff9a27e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c6bea469-84ff-4452-8fb4-b77f574cc9bd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f117bf4-3903-47b2-857e-0d155ff9a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_046cb4fc-2059-4c61-b117-d5e61f46e2b1" xlink:href="mgnx-20190930.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f117bf4-3903-47b2-857e-0d155ff9a27e" xlink:to="loc_mgnx_IncyteCorporationMember_046cb4fc-2059-4c61-b117-d5e61f46e2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63b87939-752d-4f7d-beec-3e00da01fba4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_50ab4884-1938-4a59-82e2-f7aaa698bf0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63b87939-752d-4f7d-beec-3e00da01fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_63b87939-752d-4f7d-beec-3e00da01fba4" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_514d032b-0a23-4a02-81c8-06eec082fed9" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_514d032b-0a23-4a02-81c8-06eec082fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember_c2c4a664-c22c-4b1c-ac13-74cda11c90f8" xlink:href="mgnx-20190930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_da8fcd6b-2327-4565-bc9c-7354d1a66a2f" xlink:to="loc_mgnx_IncyteMGA012AgreementServicesMember_c2c4a664-c22c-4b1c-ac13-74cda11c90f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d54e44b3-75ba-4d02-aaa1-b44a782d154d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_02b8c869-8059-449b-8d52-754fb0654c5a" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_NonRefundableUpfrontFees_02b8c869-8059-449b-8d52-754fb0654c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3f9dc68f-c3a0-4943-9033-9bfed4ba851d" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_3f9dc68f-c3a0-4943-9033-9bfed4ba851d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ca77e429-347b-408f-bb42-6f74c7950b84" xlink:href="mgnx-20190930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_ca77e429-347b-408f-bb42-6f74c7950b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e821aa42-c6ed-4038-83b4-065013c920f7" xlink:href="mgnx-20190930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e821aa42-c6ed-4038-83b4-065013c920f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_44761501-f0e0-4ea7-a3dd-1bf0ffaa962f" xlink:href="mgnx-20190930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_44761501-f0e0-4ea7-a3dd-1bf0ffaa962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_0baf94c0-bbbe-4771-8f8f-546b561740bb" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_NumberOfPerformanceObligations_0baf94c0-bbbe-4771-8f8f-546b561740bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_f8cd6f66-58f3-469b-865f-b644314fb62f" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_f8cd6f66-58f3-469b-865f-b644314fb62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4c71668c-032d-4235-a866-9547a6e14dea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_Revenues_4c71668c-032d-4235-a866-9547a6e14dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_82a0e086-06d5-47d2-a1be-bbedb26faf4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_82a0e086-06d5-47d2-a1be-bbedb26faf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3011e0b4-66a2-4ebd-b186-2d83a80143c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_322fd320-7335-4e97-936b-b7a065464379" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3011e0b4-66a2-4ebd-b186-2d83a80143c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsLesLaboratoiresServierDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4378f766-fca8-44a0-abd3-703a08f47696" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4378f766-fca8-44a0-abd3-703a08f47696" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d0646d7-4f1f-470f-9080-5fe7fca3b1db" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c69bd3e1-9745-426d-955b-51403e285dac" xlink:to="loc_srt_ProductsAndServicesDomain_4d0646d7-4f1f-470f-9080-5fe7fca3b1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_159cf2a9-1004-4651-8d33-dcca08957629" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4d0646d7-4f1f-470f-9080-5fe7fca3b1db" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_159cf2a9-1004-4651-8d33-dcca08957629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dd143d3e-9996-442a-8492-98c21b8911cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_43db08b2-9005-4236-8b9b-c4bee0d0f9e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dd143d3e-9996-442a-8492-98c21b8911cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LesLaboratoiresServierMGD007Member_067e9aa7-9995-41cb-8e05-f0c66fef9907" xlink:href="mgnx-20190930.xsd#mgnx_LesLaboratoiresServierMGD007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dd143d3e-9996-442a-8492-98c21b8911cb" xlink:to="loc_mgnx_LesLaboratoiresServierMGD007Member_067e9aa7-9995-41cb-8e05-f0c66fef9907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0445a8e-6946-46b1-a7ca-2107cc4c7c1b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_426aeee3-cbfc-45f9-8bdd-77376a0ca89a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0445a8e-6946-46b1-a7ca-2107cc4c7c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierMember_36609254-4250-4ce9-92bc-a23aa3272686" xlink:href="mgnx-20190930.xsd#mgnx_ServierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0445a8e-6946-46b1-a7ca-2107cc4c7c1b" xlink:to="loc_mgnx_ServierMember_36609254-4250-4ce9-92bc-a23aa3272686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc220327-0c20-4058-bbf3-e5d1fc9bcb06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7e6e39da-d1af-4755-8903-0315d995a9d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc220327-0c20-4058-bbf3-e5d1fc9bcb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ServierDARTMember_7e8eac79-72ef-4ecd-9d91-1d126c30f1ca" xlink:href="mgnx-20190930.xsd#mgnx_ServierDARTMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc220327-0c20-4058-bbf3-e5d1fc9bcb06" xlink:to="loc_mgnx_ServierDARTMember_7e8eac79-72ef-4ecd-9d91-1d126c30f1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76e2ae7c-d698-41c4-8c2c-3d79565fbefb" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b28d2080-dd46-4b69-a412-f81a9260699b" xlink:to="loc_srt_RangeMember_76e2ae7c-d698-41c4-8c2c-3d79565fbefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e308e0c2-861d-4eba-ba3d-a49d3870c712" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76e2ae7c-d698-41c4-8c2c-3d79565fbefb" xlink:to="loc_srt_MaximumMember_e308e0c2-861d-4eba-ba3d-a49d3870c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2bea0f19-5cac-41d3-a67c-12e1f6bff4c3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfExclusiveOptionsToLicense_b059ee09-0b1f-4ada-8297-473488ac46ce" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfExclusiveOptionsToLicense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfExclusiveOptionsToLicense_b059ee09-0b1f-4ada-8297-473488ac46ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_946cd959-a040-4921-8186-089f56b59df6" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NonRefundableUpfrontFees_946cd959-a040-4921-8186-089f56b59df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_e0251cae-cabe-4456-8860-4081cbb9d577" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_e0251cae-cabe-4456-8860-4081cbb9d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_201e3982-5aaa-4698-b984-674d7f1d706b" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfPerformanceObligations_201e3982-5aaa-4698-b984-674d7f1d706b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMilestonesAchieved_b9f00318-db67-4f8e-9bad-cf31ea1be504" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfMilestonesAchieved"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfMilestonesAchieved_b9f00318-db67-4f8e-9bad-cf31ea1be504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MilestonePayment_65ce7bb1-c8e9-4338-9022-0e3fa34c1224" xlink:href="mgnx-20190930.xsd#mgnx_MilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_MilestonePayment_65ce7bb1-c8e9-4338-9022-0e3fa34c1224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionExerciseFee_a306e75a-8022-479b-ad38-c7bcdb42ab6d" xlink:href="mgnx-20190930.xsd#mgnx_OptionExerciseFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_OptionExerciseFee_a306e75a-8022-479b-ad38-c7bcdb42ab6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfComponentsInLicenseAgreement_dfd63f36-fa89-4054-8f27-fb785388b753" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfComponentsInLicenseAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_NumberOfComponentsInLicenseAgreement_dfd63f36-fa89-4054-8f27-fb785388b753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_95eb017e-a78f-40ab-8dc5-31e4d7a7bdf5" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_95eb017e-a78f-40ab-8dc5-31e4d7a7bdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_26c91951-2f70-4080-bbe2-3bf64e7f2372" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_Revenues_26c91951-2f70-4080-bbe2-3bf64e7f2372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ba5edf39-ece9-4420-96a6-2ceeb677a615" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ba5edf39-ece9-4420-96a6-2ceeb677a615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2da05b7f-3656-4870-8dda-f39d9ecc0951" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2da05b7f-3656-4870-8dda-f39d9ecc0951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_31f94209-2634-43a0-bc0a-e47b7f3aa63b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_143462cc-4d80-42bb-8ebc-83d5f8b16895" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_31f94209-2634-43a0-bc0a-e47b7f3aa63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsRocheDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_18898a19-0208-4f2e-9269-fb77ac0d4e52" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_18898a19-0208-4f2e-9269-fb77ac0d4e52" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:to="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a16b960-f60a-41ab-ba60-e51ad2c8e2b6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d308a8f1-b2f0-4c36-bbb9-25e83850e1e7" xlink:to="loc_srt_ProductsAndServicesDomain_8a16b960-f60a-41ab-ba60-e51ad2c8e2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_83426aca-b5e5-4cff-b4d5-52bef5f1c409" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a16b960-f60a-41ab-ba60-e51ad2c8e2b6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_83426aca-b5e5-4cff-b4d5-52bef5f1c409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:to="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05ad1808-a4e3-4408-95aa-453cea52798c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_eda8eb0c-b05a-4cba-baeb-20f24a3aa7e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05ad1808-a4e3-4408-95aa-453cea52798c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_c1a5a0f1-087f-4c9e-932a-6ea1e98110e5" xlink:href="mgnx-20190930.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05ad1808-a4e3-4408-95aa-453cea52798c" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_c1a5a0f1-087f-4c9e-932a-6ea1e98110e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5f487ac7-1301-406c-b904-7b4c2b4fa884" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_93cc91e4-5e3d-47f6-9458-5e39e8521d3c" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_NonRefundableUpfrontFees_93cc91e4-5e3d-47f6-9458-5e39e8521d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_8fbd755a-7bf2-49b5-8fa0-30e2da983f85" xlink:href="mgnx-20190930.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_8fbd755a-7bf2-49b5-8fa0-30e2da983f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_134f6327-da6d-4362-a2cf-e6c15fac5e58" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_NumberOfPerformanceObligations_134f6327-da6d-4362-a2cf-e6c15fac5e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0e3352cb-5cbb-43f6-b856-41b832f20572" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0e3352cb-5cbb-43f6-b856-41b832f20572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_80348843-9635-40d7-9de9-460efbb30163" xlink:href="mgnx-20190930.xsd#mgnx_UpfrontPaymentRecognitionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_80348843-9635-40d7-9de9-460efbb30163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f6ed4cc9-f2a0-4bc1-b699-56ce0684657c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_Revenues_f6ed4cc9-f2a0-4bc1-b699-56ce0684657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_53a37079-f940-458a-be6b-5f5881cf77d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ContractWithCustomerLiability_53a37079-f940-458a-be6b-5f5881cf77d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7186ba4f-2b7c-422f-b5d2-f24240b12792" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7186ba4f-2b7c-422f-b5d2-f24240b12792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fb164e4-916a-4359-9c64-f3e993a872bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6c7e32cc-ef0e-4b2d-b204-92e40418efbe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3fb164e4-916a-4359-9c64-f3e993a872bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d57bdac6-5f7c-4671-9c65-835ce71e50ca" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d57bdac6-5f7c-4671-9c65-835ce71e50ca" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3da4825-2d70-40a1-9eef-1251eae5ffc5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_64600a1b-ecdf-4898-a4bd-0d0dc42f416b" xlink:to="loc_srt_ProductsAndServicesDomain_f3da4825-2d70-40a1-9eef-1251eae5ffc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_0bbe1dde-bc15-442c-9978-0dbde968de82" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3da4825-2d70-40a1-9eef-1251eae5ffc5" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_0bbe1dde-bc15-442c-9978-0dbde968de82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_897ac7a1-7daf-4eb5-9196-0f4c9b982524" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_0e36246a-3ba3-4061-9b5e-f88a25143b6f" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_0e36246a-3ba3-4061-9b5e-f88a25143b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_abfe07a6-a923-4fca-bd51-1eae0df924bb" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3f95a910-ffc2-445c-ac82-6902aa95f124" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_abfe07a6-a923-4fca-bd51-1eae0df924bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58eced0e-daee-400d-9cb9-4b2cb9251fe9" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93555c62-d26e-4b88-8adf-031d9c8ce8dc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58eced0e-daee-400d-9cb9-4b2cb9251fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_489c6185-f4d1-42c7-8cfb-055f0654f758" xlink:href="mgnx-20190930.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58eced0e-daee-400d-9cb9-4b2cb9251fe9" xlink:to="loc_mgnx_ZaiLabMember_489c6185-f4d1-42c7-8cfb-055f0654f758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_120b8f8e-c534-4b53-bb6a-d5ef670920a2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_2c41c1a1-95bd-4e29-bbea-329b5515f854" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_mgnx_NonRefundableUpfrontFees_2c41c1a1-95bd-4e29-bbea-329b5515f854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_1d9fd374-6776-423a-90cb-3536ff1aaafc" xlink:href="mgnx-20190930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_1d9fd374-6776-423a-90cb-3536ff1aaafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_42319374-076f-440e-8902-a7b57325343d" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_42319374-076f-440e-8902-a7b57325343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0b747e19-475a-42ca-808e-db1be811d1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_Revenues_0b747e19-475a-42ca-808e-db1be811d1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_408721d9-2202-4ae8-9af0-fcb1420fafc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ContractWithCustomerLiability_408721d9-2202-4ae8-9af0-fcb1420fafc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_70df73fe-6c55-40c7-80e6-8b84d47ae068" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_70df73fe-6c55-40c7-80e6-8b84d47ae068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b1209e48-bba9-4d5a-a9c9-ff4cfe72d7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ed6bfc00-6380-4c29-9363-a8e0846faf71" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b1209e48-bba9-4d5a-a9c9-ff4cfe72d7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_63991a38-a89f-4ea2-babe-2c5a345efc75" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_63991a38-a89f-4ea2-babe-2c5a345efc75" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_059533ab-472d-4ebc-9ea4-47fa89001779" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d3afc00c-598e-4be9-bbd6-7c837bfbf8a7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_059533ab-472d-4ebc-9ea4-47fa89001779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_d1745faa-485d-47d8-9f39-a047475833c6" xlink:href="mgnx-20190930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_059533ab-472d-4ebc-9ea4-47fa89001779" xlink:to="loc_mgnx_IMabBiopharmaMember_d1745faa-485d-47d8-9f39-a047475833c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37a4482c-f852-43af-ae1f-2e4bce4584af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_e0f5c359-d11d-4d34-b217-bcfb4538b77c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37a4482c-f852-43af-ae1f-2e4bce4584af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_83804d90-5944-421f-b56c-21430d50e3d3" xlink:href="mgnx-20190930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37a4482c-f852-43af-ae1f-2e4bce4584af" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_83804d90-5944-421f-b56c-21430d50e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53ca3395-7acd-48b4-b4e5-34bdc76d63bc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_39894340-abf9-4906-a0fa-765f63ec7a48" xlink:to="loc_srt_ProductsAndServicesDomain_53ca3395-7acd-48b4-b4e5-34bdc76d63bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d7c83c3-3cf2-4701-a9f7-d4de68c86349" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_3389b45a-f776-4564-9657-5300f35a4181" xlink:href="mgnx-20190930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_mgnx_NonRefundableUpfrontFees_3389b45a-f776-4564-9657-5300f35a4181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4c8a112c-f8ea-4bb8-86fc-48339060e81a" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_4c8a112c-f8ea-4bb8-86fc-48339060e81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_5f7ff765-89cf-4e05-9d48-189995b237aa" xlink:href="mgnx-20190930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_5f7ff765-89cf-4e05-9d48-189995b237aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8548a980-6a16-4719-9066-9c05272734fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_Revenues_8548a980-6a16-4719-9066-9c05272734fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_889fb5bc-4c2e-44d3-980b-5c2b21211058" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ContractWithCustomerLiability_889fb5bc-4c2e-44d3-980b-5c2b21211058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b095692-05bd-487b-9a34-ef72cd5d52e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b095692-05bd-487b-9a34-ef72cd5d52e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3da243a0-b85e-4829-bba4-be54738ea2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_41ee4e4a-acb4-4b2d-b1ff-35a0ad7400ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3da243a0-b85e-4829-bba4-be54738ea2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_091a4dbe-ec4e-4867-9ca9-1f7f23c5e20b" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_091a4dbe-ec4e-4867-9ca9-1f7f23c5e20b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2f8b58d-16b0-42ca-b6e5-6a3da0d04a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_25f0a68f-7845-4b1c-911b-91eb24235e10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2f8b58d-16b0-42ca-b6e5-6a3da0d04a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cfe0fc7c-e95f-4cd2-8e42-0e00eb643621" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2f8b58d-16b0-42ca-b6e5-6a3da0d04a5b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cfe0fc7c-e95f-4cd2-8e42-0e00eb643621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1804aa-e02d-4da1-9e4e-a4ef2f66a049" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6853c97a-a8c4-4ba9-9f52-dc96484c4237" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1804aa-e02d-4da1-9e4e-a4ef2f66a049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e6949ad0-7f57-4332-b29d-6f244ed79191" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9f1804aa-e02d-4da1-9e4e-a4ef2f66a049" xlink:to="loc_us-gaap_WarrantMember_e6949ad0-7f57-4332-b29d-6f244ed79191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_367a7107-0886-428a-8261-e392f8379450" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_be006754-b630-427c-8ae8-e3631908892f" xlink:to="loc_srt_ProductsAndServicesDomain_367a7107-0886-428a-8261-e392f8379450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_86edcf95-2c2b-44dc-9677-aa01b37d492f" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_367a7107-0886-428a-8261-e392f8379450" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_86edcf95-2c2b-44dc-9677-aa01b37d492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5411ad1c-4664-4249-a769-e331b828d3c1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_143b7854-0c5b-451c-bf44-5b603a274cd0" xlink:href="mgnx-20190930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_143b7854-0c5b-451c-bf44-5b603a274cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_8c949d7e-368d-4d0e-8707-9180211a6bcf" xlink:href="mgnx-20190930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851ac4b2-ec11-44b0-b9a9-8ea95c735ca5" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_8c949d7e-368d-4d0e-8707-9180211a6bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adee9a0-4250-45c5-bfb1-344b6b494813" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e34b3b5c-1167-4383-9d0f-f30ca0d2e395" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adee9a0-4250-45c5-bfb1-344b6b494813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member_aee90459-c0a9-4fa6-9fc3-506be302eef0" xlink:href="mgnx-20190930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8adee9a0-4250-45c5-bfb1-344b6b494813" xlink:to="loc_mgnx_ProventionBioInc.Member_aee90459-c0a9-4fa6-9fc3-506be302eef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a83adc0-63d7-457c-9c43-18d41f1e079c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_565d403b-4536-42fe-8757-f68f35753310" xlink:href="mgnx-20190930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:to="loc_mgnx_ProventionPRV3279Member_565d403b-4536-42fe-8757-f68f35753310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_9439d1a0-d22a-44c1-84ec-520960a105ac" xlink:href="mgnx-20190930.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3d513a76-8ccb-4d17-8b1f-3405b46949f8" xlink:to="loc_mgnx_ProventionPRV031Member_9439d1a0-d22a-44c1-84ec-520960a105ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a035ac5-b952-4bc5-b314-02d7f17abfe2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_520236ba-fb9f-4ccc-9c4c-ae7f7b320c7b" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_520236ba-fb9f-4ccc-9c4c-ae7f7b320c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_00220e81-5fb4-4558-b839-9ca876d0d023" xlink:href="mgnx-20190930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_00220e81-5fb4-4558-b839-9ca876d0d023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_2cd4324c-f61d-4a5a-ab27-b768706356c9" xlink:href="mgnx-20190930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_2cd4324c-f61d-4a5a-ab27-b768706356c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7b779a0b-49da-4815-89e6-35e297fd8c15" xlink:href="mgnx-20190930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_7b779a0b-49da-4815-89e6-35e297fd8c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_65bd8cb4-bba7-4188-ab42-36633975e8c3" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_NumberOfPerformanceObligations_65bd8cb4-bba7-4188-ab42-36633975e8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_0c43c657-67b8-4394-bfdc-0522d684a536" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_0c43c657-67b8-4394-bfdc-0522d684a536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_72de81c6-7b29-4f55-b45a-85066ab46a3f" xlink:href="mgnx-20190930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_72de81c6-7b29-4f55-b45a-85066ab46a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ae2cbda1-2391-43f3-802f-8b7d2baa4eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_Revenues_ae2cbda1-2391-43f3-802f-8b7d2baa4eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_6021aab7-486d-4c5c-9392-cf9dd9d96dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_6021aab7-486d-4c5c-9392-cf9dd9d96dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897a799c-9104-4904-99fa-5301c6e1d1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5f1a7ede-80a8-47a9-a935-98c71c114c7e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897a799c-9104-4904-99fa-5301c6e1d1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a5628083-17fe-44bd-9c05-332951d1cc60" xlink:href="mgnx-20190930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_a5628083-17fe-44bd-9c05-332951d1cc60" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2af4042-7a51-4f25-8095-1f4afffacd3e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8ffc5de3-0882-454a-8c35-1cad204e3da5" xlink:to="loc_srt_ProductsAndServicesDomain_d2af4042-7a51-4f25-8095-1f4afffacd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_9cb499e9-5c16-44ba-aa4b-25e9d04ea50f" xlink:href="mgnx-20190930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d2af4042-7a51-4f25-8095-1f4afffacd3e" xlink:to="loc_mgnx_RevenuesFromGrantsMember_9cb499e9-5c16-44ba-aa4b-25e9d04ea50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0e27aa5-0db2-4ff3-bf10-78395aaa1c62" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_94c7a688-0910-4e54-a5c5-350f67659e51" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0e27aa5-0db2-4ff3-bf10-78395aaa1c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_9fead7b2-ee89-4849-9828-090dd6ab19f2" xlink:href="mgnx-20190930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0e27aa5-0db2-4ff3-bf10-78395aaa1c62" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_9fead7b2-ee89-4849-9828-090dd6ab19f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf9b2c73-1e9b-46c3-9c9e-a267a7d398c4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45a126a3-e234-43fa-888f-2b063c1537ce" xlink:to="loc_srt_RangeMember_bf9b2c73-1e9b-46c3-9c9e-a267a7d398c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d073d77-72c5-4786-bff4-e0f1247a7daa" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf9b2c73-1e9b-46c3-9c9e-a267a7d398c4" xlink:to="loc_srt_MaximumMember_1d073d77-72c5-4786-bff4-e0f1247a7daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_37026fa2-4d31-4b1f-ae1d-898ee6b6a0e2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6b806cc0-2529-4b14-a1ae-d1f10ca3a215" xlink:href="mgnx-20190930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_6b806cc0-2529-4b14-a1ae-d1f10ca3a215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_b6c0f56b-62a6-4494-a942-aae76d5c5d03" xlink:href="mgnx-20190930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_FundedValueOfBasePeriod_b6c0f56b-62a6-4494-a942-aae76d5c5d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_09343c3f-2e70-4dc5-b54d-91e1ccb25808" xlink:href="mgnx-20190930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_09343c3f-2e70-4dc5-b54d-91e1ccb25808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_85898517-3e2a-40ad-bb89-62c3dc1c10c5" xlink:href="mgnx-20190930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_85898517-3e2a-40ad-bb89-62c3dc1c10c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_61d76fc9-03ed-45b0-af27-8f756b33a444" xlink:href="mgnx-20190930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_61d76fc9-03ed-45b0-af27-8f756b33a444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6647fda7-3c57-4505-8a46-54877d4863b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0b14e907-0b94-4823-b386-c223813f8d2f" xlink:to="loc_us-gaap_Revenues_6647fda7-3c57-4505-8a46-54877d4863b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_264b5d11-1bd1-4202-b8cd-8b0479f9c46e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6ed48aff-624b-4c57-bdc4-8e0f49577af6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_264b5d11-1bd1-4202-b8cd-8b0479f9c46e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6ed48aff-624b-4c57-bdc4-8e0f49577af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db68cdb6-a7a3-4fab-8f58-b6ac57e5991d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d18366c0-0fb8-443a-902f-e4281fec6dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db68cdb6-a7a3-4fab-8f58-b6ac57e5991d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d18366c0-0fb8-443a-902f-e4281fec6dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d15e349d-9e86-42e0-ab39-e11cf2827b48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db68cdb6-a7a3-4fab-8f58-b6ac57e5991d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d15e349d-9e86-42e0-ab39-e11cf2827b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_2b907b66-f1ad-4bc2-b1b3-da97169517c7" xlink:href="mgnx-20190930.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db68cdb6-a7a3-4fab-8f58-b6ac57e5991d" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_2b907b66-f1ad-4bc2-b1b3-da97169517c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_754f436c-4581-4d14-8cc4-45cb0ecfd812" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_754f436c-4581-4d14-8cc4-45cb0ecfd812" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:to="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5683e543-f1b6-43a2-8f9c-b5892562ad3b" xlink:to="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_f7bd30d9-4de3-40c2-bdec-9cb5cdc97d78" xlink:href="mgnx-20190930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_f7bd30d9-4de3-40c2-bdec-9cb5cdc97d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_ce1f1072-e9a3-45b4-892e-43eea0cdb25a" xlink:href="mgnx-20190930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_ce1f1072-e9a3-45b4-892e-43eea0cdb25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_10c1d5f1-7bf5-4bf6-8100-365d1a5cf94b" xlink:href="mgnx-20190930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4d70d632-2258-4316-be11-98a96b26d0a7" xlink:to="loc_mgnx_StockIncentivePlan2013Member_10c1d5f1-7bf5-4bf6-8100-365d1a5cf94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fda577a-564b-48db-9fda-8c0ffbace987" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15017e2c-f4e2-4b58-a01b-12ffe65d2fef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_15017e2c-f4e2-4b58-a01b-12ffe65d2fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_02c08ba6-404b-42d6-89fe-fd7530253cd2" xlink:href="mgnx-20190930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_02c08ba6-404b-42d6-89fe-fd7530253cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3ef15f67-2e05-45e6-ac57-65ce30df179a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_3ef15f67-2e05-45e6-ac57-65ce30df179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2cbf442b-ada7-4304-a698-b579ea8591f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2cbf442b-ada7-4304-a698-b579ea8591f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_48a46cf8-bda5-42f7-aca7-f19a667ab937" xlink:href="mgnx-20190930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_48a46cf8-bda5-42f7-aca7-f19a667ab937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_a89c4dc0-1d6d-49c9-b473-ebcab58ba460" xlink:href="mgnx-20190930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_a89c4dc0-1d6d-49c9-b473-ebcab58ba460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44057d95-e236-4409-a9eb-a900646a30b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44057d95-e236-4409-a9eb-a900646a30b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bba3df-d362-467e-be68-56bab0bbb799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2bba3df-d362-467e-be68-56bab0bbb799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_6849f95c-5f60-4c4f-b126-cde8e51133d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c393666f-1aba-4085-8466-60606e06a33c" xlink:to="loc_us-gaap_ProceedsFromStockPlans_6849f95c-5f60-4c4f-b126-cde8e51133d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_754f436c-4581-4d14-8cc4-45cb0ecfd812" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_64c81a21-a567-4394-9aad-ec4600ac3870" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9babe21e-0b13-4cb6-b3a1-cd03ede6f1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9babe21e-0b13-4cb6-b3a1-cd03ede6f1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3dd87835-5d29-4c02-b437-cdf206b6e2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5805964-e90d-4143-98ce-7b4c8752d053" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3dd87835-5d29-4c02-b437-cdf206b6e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dae3392a-e288-4634-a129-e4de8793cf02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46be1eb5-5d71-424f-8159-e28c6677c8c8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dae3392a-e288-4634-a129-e4de8793cf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3232040f-f4e6-47e0-b65e-bfa6c4e96f00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dae3392a-e288-4634-a129-e4de8793cf02" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3232040f-f4e6-47e0-b65e-bfa6c4e96f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47d6caf2-90c0-4ace-bfe7-249b7cd4fe6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47d6caf2-90c0-4ace-bfe7-249b7cd4fe6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:to="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c9311a00-2029-4e55-8489-b9ba4fd3ed8f" xlink:to="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_efdc46ea-c5aa-46f7-9042-41cd1a94b777" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:to="loc_srt_MinimumMember_efdc46ea-c5aa-46f7-9042-41cd1a94b777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fd2d876d-f8ae-464e-91a6-7ff725622da8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71075fff-fff7-455d-9d0c-0a21007f2949" xlink:to="loc_srt_MaximumMember_fd2d876d-f8ae-464e-91a6-7ff725622da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bd0e02c2-44b8-433e-a049-d606f5722a21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_309fab38-94a0-468f-9671-8dcdb0c8196c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_309fab38-94a0-468f-9671-8dcdb0c8196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_28d0317c-b654-48d1-bdf1-94368216a7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_28d0317c-b654-48d1-bdf1-94368216a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e691394a-fd0f-4b60-b0e1-905772f5798d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e691394a-fd0f-4b60-b0e1-905772f5798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9cb73c2f-ac9f-4ec3-afac-282b3bb61af4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b04ca0ae-5bd5-42a7-bcdf-d1c436bb9ed1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9cb73c2f-ac9f-4ec3-afac-282b3bb61af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20190930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_433817fd-f47c-46c0-a8ac-2681a552c61d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_433817fd-f47c-46c0-a8ac-2681a552c61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c01e8daa-10f9-49c4-a92f-45847c30e03a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c01e8daa-10f9-49c4-a92f-45847c30e03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62f7fc34-1c05-4ba1-b5f9-f8e376e05634" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62f7fc34-1c05-4ba1-b5f9-f8e376e05634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a297788b-49d2-4c11-91a8-6bb70666ef94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a297788b-49d2-4c11-91a8-6bb70666ef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c74c82e-a5ec-45e9-897f-b175b0383364" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c74c82e-a5ec-45e9-897f-b175b0383364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18959337-31fb-42ba-b227-d153ab7d6db3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_18959337-31fb-42ba-b227-d153ab7d6db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3205f876-fc2e-44e8-ae34-7fcd58cc7469" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d39ba714-513f-46bd-a776-e5f81e867951" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3205f876-fc2e-44e8-ae34-7fcd58cc7469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6eac6c49-4a25-4465-8de9-5ab5b14dff57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6eac6c49-4a25-4465-8de9-5ab5b14dff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_549bf394-608a-4827-94b9-7a4e328b4867" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_549bf394-608a-4827-94b9-7a4e328b4867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8e378d22-cb1f-4edc-b835-1ca2789db95f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8e378d22-cb1f-4edc-b835-1ca2789db95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_548f9e0f-f08e-4ad5-b410-301bbf310cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_548f9e0f-f08e-4ad5-b410-301bbf310cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1e8d4b6c-2fd1-40d8-9ae8-6188aa99ec06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1e8d4b6c-2fd1-40d8-9ae8-6188aa99ec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ae924eca-0269-40f4-9809-b7de757fd769" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ae924eca-0269-40f4-9809-b7de757fd769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49a65db6-302c-43fa-ad32-e757736cc804" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac23f1bb-ada2-4118-b15f-aeb5be51cea7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49a65db6-302c-43fa-ad32-e757736cc804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30c37cef-55f2-4256-a5e8-33a7afc2110e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30c37cef-55f2-4256-a5e8-33a7afc2110e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ec9b4124-7b1a-4d7b-9dec-b835a5c44a25" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ec9b4124-7b1a-4d7b-9dec-b835a5c44a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_440bedba-21e5-4a3e-9f43-e2a841cb1dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_440bedba-21e5-4a3e-9f43-e2a841cb1dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8ef1d1b5-1682-454c-a03f-e5574bffdfad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8ef1d1b5-1682-454c-a03f-e5574bffdfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5712e20a-c5d4-460a-90a5-463b62904aed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5712e20a-c5d4-460a-90a5-463b62904aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ee7e63af-dedf-4694-b0d9-a9fa6600cd35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8bbbacaa-96a8-49fe-8e16-28fbc9e4b5be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ee7e63af-dedf-4694-b0d9-a9fa6600cd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92b5eea6-7ede-4bc9-8a49-9ee09b046922" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92b5eea6-7ede-4bc9-8a49-9ee09b046922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e02fd27d-f512-4fcc-bdaa-f310b71b12be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e02fd27d-f512-4fcc-bdaa-f310b71b12be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0532addb-dc6a-4451-85bd-6b385c3b319e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0532addb-dc6a-4451-85bd-6b385c3b319e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_18fd64f3-e262-4f18-adce-50ce5006d74e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_18fd64f3-e262-4f18-adce-50ce5006d74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_471519e7-bd3e-4c4e-bdbb-9a4a4da3e4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_471519e7-bd3e-4c4e-bdbb-9a4a4da3e4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7471922a-d51a-4271-8d1b-04c63e5c094f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8f959b2-0ef5-4724-9bd1-68657a748bed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7471922a-d51a-4271-8d1b-04c63e5c094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20190930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bdf34aaf-dbba-464d-a5b5-94c57a59f32b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5ab44378-b152-4c52-93a9-654c9a00fe10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bdf34aaf-dbba-464d-a5b5-94c57a59f32b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5ab44378-b152-4c52-93a9-654c9a00fe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6771965760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 86,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">25,252<span></span>
</td>
<td class="nump">$ 6,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">78,300<span></span>
</td>
<td class="nump">146,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">176,127<span></span>
</td>
<td class="nump">160,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">78,868<span></span>
</td>
<td class="nump">46,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">97,259<span></span>
</td>
<td class="nump">112,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">67,321<span></span>
</td>
<td class="nump">46,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">67,321<span></span>
</td>
<td class="nump">46,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">11,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">11,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">85,564<span></span>
</td>
<td class="nump">100,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">85,564<span></span>
</td>
<td class="nump">100,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">11,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate equity securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">11,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate equity securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate equity securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Warrant | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Warrant | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Warrant | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6928324656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,657<span></span>
</td>
<td class="nump">$ 103,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember', window );">Firm Commitment Public Underwritten Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember', window );">Follow-On Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 118,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FirmCommitmentPublicUnderwrittenOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6772129776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (121,415)<span></span>
</td>
<td class="num">$ (126,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">8,119<span></span>
</td>
<td class="nump">5,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">14,081<span></span>
</td>
<td class="nump">12,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">20,080<span></span>
</td>
<td class="num">(7,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(5,612)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,621)<span></span>
</td>
<td class="num">(9,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="num">(913)<span></span>
</td>
<td class="num">(1,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(4,678)<span></span>
</td>
<td class="nump">9,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(7,114)<span></span>
</td>
<td class="num">(5,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(738)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(96,226)<span></span>
</td>
<td class="num">(126,006)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(214,178)<span></span>
</td>
<td class="num">(120,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">130,236<span></span>
</td>
<td class="nump">155,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,042)<span></span>
</td>
<td class="num">(24,239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(86,984)<span></span>
</td>
<td class="nump">11,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">118,657<span></span>
</td>
<td class="nump">103,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">119,675<span></span>
</td>
<td class="nump">104,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="num">(63,535)<span></span>
</td>
<td class="num">(9,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">220,128<span></span>
</td>
<td class="nump">211,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">156,593<span></span>
</td>
<td class="nump">201,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets modified in exchange for operating lease obligations</a></td>
<td class="nump">$ 6,408<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^KL!^LV[M_;'P15"W\N@OU!5!+ P04    "  !@69/F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    (  &!9D_:$F?H- ,  #H/   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULC5?;CILP%/P5Q <LV(9<5DFDW515*[72:JNVSR1Q$K2 *3C)
M]N]K#,M2GW'5EW";.6,S'I.SNJGFI3U+J8/7LJC:=7C6NKZ/HG9_EF76WJE:
M5N;)435EILUE<XK:NI'9P9+*(N)Q/(O*+*_"S<K>>VHV*W7115[)IR9H+V69
M-;\?9:%NZY"%;S>>\]-9=S>BS:K.3O*;U-_KI\9<16.50U[*JLU5%33RN X?
MV/U6\(Y@$3]R>6LGYT$WE9U2+]W%Y\,ZC+L1R4+N=5<B,X>KW,JBZ"J9<?P:
MBH:C9D><GK]5_V@G;R:SRUJY5<7/_*#/ZW 1!@=YS"Z%?E:W3W*84!H&P^R_
MR*LL#+P;B='8JZ*UO\'^TFI5#E7,4,KLM3_FE3W>^B=),M P@0\$_DZ(_TD0
M T&,!&85HGYD=JH?,IUM5HVZ!4WO5IUUBX+="_,R]]U-^^[L,S/;UMR];N)5
M=.W*#(C''L$G"#8B(E-[%.!(X)$3.O];8$L1 @L(. -AZ6)"3S ]@?3$TI,)
M/75> $7,L$ *!5)"GSL"%+'  C,H,"/TI2- $2S&"G.H,*=\YD@ ",<2"RBQ
MH'SA2 "(Q^DEE%A2OFLU@'B\9C&.4TPKN'8CC,=PY@DMHQ5<SP&&>TQG,+D/
MC-,*KNT(X_&=X?@R02NXSB.,QWJ&4\YHB+EK/L+XW,=19S3)G+@/,#[W<=X9
MC3,G[O]_Y!G./*.)%N330#'>-X9CSVBH!5EC .-;8SCYC.9:D#4&LN]Y8QQG
MG]-<B\1109C4HX*SSVFNQ<Q5 9BY1P5GG]-<BX6K C!+CPK./J>Y3MPUAC"^
M/R X^YSF.N&N"L!X_H5PG'U.<YT0]P'&YS[./J>Y3HC[ .-S'V>?TUPGCOO;
M 9-:3#5@EFP>+WTSPCL I^E.W-T,8%)?-O$.P&FZ4W>?01C//B/P#B!HNE-W
MGT$8S[=,X!U T'2G[K<,8'R[F< [@*#I3MV5!C!$)9IT(J5L3K9I:X.]NE2V
M8YS<'1O#!]L71N_POJO\FC6GO&J#G=*F'[)=RU$I+<U0XCNS$,^FD1TO"GG4
MW>G<G#=]-]=?:%4/G6HTMLN;/U!+ P04    "  !@69/LH/R]N,#   U$@
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MJL>R;*SSG<W<RCO;]/!XR.RQ:6^UNZ_Z4X+^H2FOPPE(]#B&6?T/4$L#!!0
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M3-UU-Q^;S#=#>UF.A*+[N=3F/U!+ P04    "  !@69/36E&"]L!  !A!
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;'U4VV[;, S]%4$?4/F6; UL
M TV*80,V(.BP[EFQZ0LJ69XDQ]W?3Q?7=1*O+Y9(G7-(2J334<@7U0!H],I9
MIS+<:-WO"%%% YRJ.]%#9TXJ(3G5QI0U4;T$6CH29R0*@BWAM.UPGCK?4>:I
M&#1K.SA*I ;.J?R[!R;&#(?XS?'4UHVV#I*G/:WA)^A?_5$:B\PJ9<NA4ZWH
MD(0JPP_A[I!8O ,\MS"JQ1[92DY"O%CC6YGAP"8$# IM%:A9SG  QJR02>//
MI(GGD):XW+^I?W&UFUI.5,%!L-]MJ9L,?\:HA(H.3#^)\2M,]6PPFHK_#F=@
M!FXS,3$*P93[HF)06O!)Q:3"Z:M?V\ZMHS_9W$^T=4(T$:*98&)_1(@G0OQ.
M<+=)?&:NU$>J:9Y*,2+I'ZNGMB?"76PNL[!.=W?NS%2KC/><A]LX)6<K-&'V
M'A,M,3."&/4Y1+068A_=T*/+ (=;Q'VR'B%>+2)V_/BBB/\()*L"B1-(+@0V
M5[?@,5N'Z1PFN"KC%K$-X^ J#[)X&0ZR=DVL4"&&3ML[6'CG.7F([,M>^?=F
M?GR[O\OXX?M!9=UV"IV$-GWC7K<20H/),;@S'=V8>9\-!I6VVT]F+WW7>T.+
M?AIH,O]5\G]02P,$%     @  8%F3X?I/Q^Q 0  T@,  !@   !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q]4]MNVS ,_15!'U E2I86@6V@Z3!LP 8$';8]
M*S9M"]7%D^2X^_M1LN-YG;$7BZ1Y#@\I*ANL>_$M0""O6AF?TS:$[LB8+UO0
MPM_9#@S^J:W3(J#K&N8[!Z)*(*T8WVP.3 MI:)&EV-D5F>V#D@;.COA>:^%^
MG4#9(:=;>@L\RZ8-,<"*K!,-?(7PK3L[]-C,4DD-QDMKB(,ZIX_;XVD?\U/"
M=PF#7]@D=G*Q]B4ZGZJ<;J(@4%"&R"#PN,(3*!6)4,;/B9/.)2-P:=_8/Z3>
ML9>+\/!DU0]9A3:G#Y144(M>A6<[?(2IGW>43,U_ABLH3(]*L$9IE4]?4O8^
M6#VQH!0M7L=3FG0.$_\-M@[@$X"_ ;"Q4%+^7@119,X.Q(VS[T2\XNV1XVS*
M&$RC2/]0O,?HM=@>#AF[1J(IYS3F\&7.G,&0?2[!UTJ<^#]PO@[?K2K<)?CN
M+X7WZP3[58)](MC_M\6UG(<W1=ABIAI<D[;)D]+V)FWR(CHO["-/=_(G?=SV
M+\(UTGARL0%O-LV_MC8 2MG<X0JU^,!F1T$=HGF/MAO7;'2"[:87Q.9G7/P&
M4$L#!!0    (  &!9D^A9*"(M0$  -(#   8    >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL?5/M;ML@%'T5Q ,4Q\F2+K(M-9VF35JEJ-/:W\2^ME&!ZP&.
MV[<?8->U-FM_@'LYY]P/+MF YL6V (Z\*JEM3EOGNB-CMFQ!<7N#'6A_4Z-1
MW'G3-,QV!G@524JR-$GV3'&A:9%%W]D4&?9."@UG0VRO%#=O)Y XY'1#WQV/
MHFE=<+ BZW@#/\']ZL[&6VQ6J80";05J8J#.Z=WF>-H%? 0\"1CLXDQ")1?$
MEV!\KW*:A(1 0NF" O?;%>Y!RB#DT_@]:=(Y9" NS^_J7V/MOI8+MW"/\EE4
MKLWI+245U+R7[A&';S#5\XF2J?@?< 7IX2$3'Z-$:>-*RMXZ5).*3T7QUW$7
M.N[#>+/=3[1U0CH1TIEP&^.P,5#,_ MWO,@,#L2,O>]X>.+-,?6]*8,SMB+>
M^>2M]UZ+S?YSQJY!:,*<1DRZQ,P(YM7G$.E:B%/Z#SU=IV]7,]Q&^G89_9"L
M"^Q6!7918/??$E<PA[^+9(N>*C!-G"9+2NQUG.2%=Q[8NS2^R0=\G/8';AJA
M+;F@\R\;^U\C.O"I)#=^A%K_P69#0NW"\>#/9ARST7#833^(S=^X^ -02P,$
M%     @  8%F3PAY%6:T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL?5/;;MP@$/T5Q >$->M<M+(M95-5K=1*JT1MGEE[;*. <0"OT[_/
M@!W7;:V^ #/,.7-F&++1V!?7 GCRIE7G<MIZWQ\8<V4+6K@KTT.'-[6Q6G@T
M;<-<;T%4$:05X[O=#=-"=K3(HN]DB\P,7LD.3I:X06MA?QU!F3&G"?UP/,JF
M]<'!BJP7#3R!_]&?+%IL8:FDALY)TQ$+=4[OD\,Q#?$QX*>$T:W.)%1R-N8E
M&%^KG.Z"(%!0^L @<+O  R@5B%#&Z\Q)EY0!N#Y_L'^.M6,M9^'@P:AG6?DV
MIW>45%"+0?E',WZ!N9YK2N;BO\$%%(8')9BC-,K%E92#\T;/+"A%B[=IEUW<
MQ^GF.IEAVP ^ _@"N(MYV)0H*O\DO"@R:T9BI][W(CQQ<N#8FS(X8ROB'8IW
MZ+T4R2W/V"40S3''*8:O8Y8(ANQ+"KZ5XLC_@?-M^'Y3X3["]W\HW&\3I)L$
M:21(_UOB5DSZ5Q*VZJD&V\1I<J0T0Q<G>>5=!O:>QS?Y'3Y-^W=A&]DY<C8>
M7S;VOS;& TK97>$(M?C!%D-![</Q%L]V&K/)\*:??Q!;OG'Q#E!+ P04
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M@4'X[0KWH%0@\C)^S9QT21F Z_,+^Z=8NZ_E(BS<H_HI*]?F]$!)!;48E'O
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M_ =;# F-"\?W_FRF,9L,A_W\@]CRC<N?4$L#!!0    (  &!9D]8PB,WM@$
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M@GGUN42R5N*8_$/_E*[S=ZL6=Y&_^\/B];I NBJ01H'TOSVN86[^*L(6AZK
M-'&<+"FQUW&4%]EY8N^2>"F_X>.X/W+3"&W)&9V_VG@!-:(#;V5SY6>H]2]L
M#B34+FQO_=Z,<S8&#KOI";'Y'1>_ %!+ P04    "  !@69/&((=\;0!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q]4V%OVR 0_2N('U 2
MDJY99%MJ.DV;M$E1IVV?B7VV48'S ,?=OQ]@U_-::U^ .^Z]>W<<V8#VR;4
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MLTK%)2C+M4(&ZAS?IH?C-N CX)G#8!=G%"HY:_T:C!]5CI.0$ @H75!@?KO
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M?H1:_\%F0T#MPG'OSV8<L]%PNIM^$)F_<?$74$L#!!0    (  &!9D_F)@\
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M/1E&2_'?X +"P7TF3J-2PH0OJD9CE5Q87"J2O<\K[\,ZS2=IMH3% ^@20->
M^Z!#9J&0^1.SK,RUFI">[WY@OL6[ W5W4WEGN(IPYI(WSGLI:;++R<43+9CC
MC*$;S">"./95@L8DCO2_<!H/WT<SW(?P_5;][C9.D$8)TD"0_E,BO2HQAMG'
M1;*H2!8A2*]$8ICL2H1L&B=!M^')&E2IL0_CLO&N4_% 0^,_X?-(?6>ZY;U!
M9V7=\PE-;I2RX%));EPNG9OBU1#06+^]<WL]O^79L&I8QI2L_XKR+U!+ P04
M    "  !@69/H58_7M0!  "<!   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6QM5&UOVR 0_BN('U!LDCA99%MJ.DV=M$E1I[6?B7U^4<&X@./NWP^P
MZWH97PQW//<\=V>.=)3J53< !KT+WND,-\;T1T)TT8!@^D[VT-F32BK!C#55
M372O@)4^2'!"HR@A@K4=SE/O.ZL\E8/A;0=GA?0@!%-_3L#EF.$8?SB>VKHQ
MSD'RM&<U_ +SNS\K:Y&%I6P%=+J5'5)09?@^/IX2A_> YQ9&O=HC5\E%RE=G
M?"\S'+F$@$-A' .SRQ4>@'-'9--XFSGQ(ND"U_L/]F^^=EO+A6EXD/RE+4V3
MX0-&)51LX.9)CH\PU[/#:"[^!UR!6[C+Q&H4DFO_1<6@C10SBTU%L/=I;3N_
MCM/)?CN'A0/H'$"7@(/7(9.0S_PK,RQ/E1R1FGK?,_>+XR.UO2F<T[?"G]GD
MM?5><QHE*;DZHAESFC!TA8D7!+'LBP0-29SH?^$T'+X)9KCQX9NU^F$7)M@&
M";:>8/M/B?N;$D.80UAD%Q39!0B^W(@$,'$4%DF"(DF (+X1"6%N^TU6MT.
MJOU<:%3(H?,SN?(NHW=/_>WZA$]S^Y.INNTTNDAC[ZB_2964!FPJT9TMN+%/
MQ6)PJ(S;[NU>30,S&4;V\UM E@<I_PM02P,$%     @  8%F3QA0>E_- 0
M800  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL?53;CILP%/P5Y ]8
M8R!A&P%2-U752JT4;=7VV8%#0.L+M9VP_?O:AB "J"_8YS SGL$V62_5FVX
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M!DPTQSPBCAL(DDP8;!U,-J)-&Y$7B&<"9)]N"\2; K$72!X<[!8Y!LS>8\2
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M9KC48]&UK6ZB>-.W9&_X+MC\ U!+ P04    "  !@69/FP8!*+("  ":"0
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M]^Z@NZG45;\7<?J7,\M_ 5!+ P04    "  !@69/YVF\Y#(#  "K#0  &0
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MC%,A'CR(AI[$]THWR.B!R]M0W%?MH;T=<%:J#Q*O^RJ:_P=02P,$%     @
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MQ+%N;D-U7W:G&MU#+2_ZQ,:['QNM_@=02P,$%     @  8%F3]H#A&Q6 @
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M;MP(#N!D#:Y?97XC%GPCW_'C[X+!?%[A\(&7 4!QX.8]"+J1+QA.?1P]\#H
M* YB5PP$<G,&3>IJ3<71MB#I%?S4*%/!)M:QS:U"4Y<=^]JT/UNO/VGZWOF3
MB&/52&_'E:[ZMC8?.%=4:PR>=%Z7NEV/"T8/RDP3/1=]S^H7BK=#/T;C1T'^
M'U!+ P04    "  !@69/U<G;U<@#  ">$   &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6R5F%N/JS84A?\*XOT WC:W41)IDE'52JTT.M5IGYG$N>@
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MVV1<<MM R/<9B$! 7)P&K 3OU/[O_YGTNN/?5UN/35 L42GOQ(MBM.'-6>J
MORQR^#P3F,0/+#&:6Q"O#<+[W#QK@"H!Q)!=P9=>%_!/=' VO7Y]2$HGCJZ/
M)0;RS69W@/V@Z*!G$GAZE:;*D (H_@-0(2I-]>3@Z@).G)04-HJ$&J(L$>96
M0.9+1@3&Z[1<5=$MT!D&QH%5YU&W)[& AEE6A5Z(.)8-?@:E5*Z+#"/X7)3P
M^:;8,+\'LVR#4;,:F<0M/830+4'WR6NB@YG6V($75_@4J<Z\0B09Q5<%"ID:
MN@4Q@CK ,YHM82A2T/"KVTW&4K2^*XO-[1T8+??DF8>7@6<JVF:VCPM0;\R
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M\(X_RBZ@X#B 1]9(J%0OA=&H%DJ*GXY'%61H,E:PF"5,+ 6@< 4(O54Q3Y>
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M'E"1@&4EZTE,-U#+UE[($R4P7BI8Y%>FJ7WU2$@>4YDTQBYNT(,HA[U/2LS
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MG\:BUE_*;1+6CZ5U2@Z3#1L;XEIMSFS"U"1T)\51-<O84ID)337P%OE'\0X
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MBVU 1JM+3O*F)3@:/5VL@KG?#6=A+29I2I4(1Y!-U\[!4\3)83C@+!G8/U'
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M,;,>9%,7'%0T+P,S=^]#[9 4,PJ<D5/ O<0")]GV?FS^JOBQJ;O":9>E #=
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MU"+"PQ917, NY#,2(EW4PUC<Y]9"*G;3[R@]""_EI!@!F1MH@RUD0Q-KR-@
M(-U5+XQ %Y( I<E0;IL5+U%[K_2OG9 6C&Z9@.4Y3[0+SE[1DQMUP7^'\;C7
M:\(P;O M]C,/X1A!'>UU.(89%>W99C"YY&P3MZ-3O-HN4[C@CLW($JKH5&6R
MG*4WI4C=Z/2=OIU8D(7TI5A-IQ^=@O4)% 84AU+U7O(8^@T_2FKFL+*D<U+@
M)-NRW9%?.]R-&D]WAFVQ;-F[7WJI3$")*:7S5;A;,[6TRAJ!8TW<KI]7 ,PG
MCLAUFK<TS[/>DG<Q"=#H.:D[N?+V\J9!RLF$J(23#L7*Q/TEAE%*+7)1-VU
M#Y-2>:C0QKDS#KG-8KT:VA.2#>ES#^B JTBWF*?4-W&&7&V)GP##%BDE0128
M@:;147J907=%I"?%E8T-I6S$_(YY^P:IVL8FV W*FX^E'DV<.KE/LF6B,KR"
MG+8O,,!'M:Y"->'H,7HXN4;?MHA$ *36Q;3&+6>*\]"%DM+[!.,.AT=Q?SAN
M.D<L:< ^(Q2I0Y[^0"GS2!(B_2_H).U;3E) P8M978A ^$XJ%>!1W%P@B\7-
M\4GEO7'H1/G&Z'NA^S 66K>ES9+J3OQJJO/\),^^TP17 GD;'C#!(?I@Z!&8
M'=;O+1\-_59GH'4M8<-&EOHMYOLUI#@E1J5\E]93O7XLN02VV^$]'"2'\.O1
MJ!-W1]*G$4<'-X?1H*VDK\A[WKES$S.*W#0OM&L6ON,6W&!>YG/8#NZ)".]@
M=KB?C\/P#'E\]W4!)X5OG  # 00KJV>(.3+^$Y!!F]7NU<#YW14EW\Y<&)S1
MB5 %SS^IU('3VT?Q47\2]T9]<IOKB[)4&*'4+%%>><4=CXTPVE8&EW',2^\%
M8T) I;62$N2$D4R4#D:\0T1@S!^;RT*5.ZW)U23701D5I>TCQ_TWP)$RF#7<
M>#:;W9*S1.I)I<MR+?J7]9@8PA+$^T/Q@%Z:V 0 ^X]*3I&[2Y>@OI-AN<QH
M,8?2(^VTI!)'H;W5/L?3AY>(:KZGK79KT/DIW'P4CR9'<7?<J+8]CY_WVL.A
M9N@A]!8M7U3FI\EZ31U>-5]U+O8P*NI))1>)&6ABD:%=;"I8=77X+<R#MO0[
M)NO3 %F_1[+?\COE&I$#1'^Z:JK!>Q7UXO%H2/\.!AWX=QQW^CWX=Q3W!^/H
M39H#V):L(!IW$-VC]WC4[\-_N_!?>&EP% UC4."C#\1?=P+H%3S>/YK OX-X
M..[#O]U!W)ET\4./&/B'NZ"S5F(BT51F%O,)4T%V2&>,U/V_;,<-#]-"+*"J
M7S"!EV:S,(P-"8P4KA!]^K7"?(FT@D\:/A'A/E('_>T3#NY4)A#.,U0) /:/
M&=(S"#'XG_KUOD"7-MUC->ZWQ[^+6M%XU![]+AJ-VQ/ZJ]?N_2ZZRJJ?6@O$
M*A4WIRZ!W?8 '^KA&SW^W&]WC?&ID=.HW1N27*O,CQ\"\ " @75'D5M38Y')
MN8]/;:3^+3MWJN@O@H9;^M-44/-4<8<+3?EQP!DXC'OC/N@& T1U $L?=C.)
MW@BKI1?W)X-X/.Y$7?AZ#""0E^D<]+H=$&+=0X1--SHS-7(6&?!,]PB$W6!P
M&/7Z[<' 7DK@C,=Q;S")AST\[3:0P+A-Z-^-QT!*3;SR6[DH@C60RG@0#T8=
MW SPJ&&;R ^(\,\I)6DBP:H\5&"I>%$9T/11?Q3W8/-RXAY.VQ^-V=\JH2MY
M)5%0B^C))D37ZGMNBWR1VSQH]_LB\W/2QHO]_,Q-UMHRO. WK[*9OQ1]_]%G
M+<:QV'MN\N? ;!S<M$S4O'6$UN037V:5'?^JA88VXN8J[2,5 O6>T4>PO,]>
M6=<#8+?;O+;MR6F\ZDUNB-6@9#$"2.@Y$#NRC*B8'#>D,?*S0DE$A[.4)U4<
MVM"@HS<4!_)&F>8J>4< 7W_#]6P^?0D9X3F*\#(&XK-MUW]]3)?]Z+#+<4&W
M8J74TOM)#T>&C[W97[YUB OS=G2T>_FLDFBV!/$9B1A8M<GJ6 =O/Q3S>?0#
M&HOW;6P$4Q:@8V2S2N;H'J/>][YH1Y-ONT>MV7VKTQMW^X=\&(MLJ9'S8_NZ
MC;L@E1]6MBEU(P+U-4;LP6JD1C0R@<5*R<#8B*[LXIMW%J 9<@/U;U"#EM87
M)5:GU-7D/B/9*SR\%3NV$:K+Y$&%1C@KGIN9 A H8%7"!"K+8YEDJ\KVTU=1
MMX,6*Q,56K2%O/=+S8&_G7X2<1KE2^\/=*R*UDE!TTH%A4C-QWHE=M=CW#DM
M<[]VT>J==4EJ>#^ZOKC\X7PJ&X98/OL;,#! HT3[ PVG#>>G2,-I!2C.\;8U
M>391%&6W!1CX%>6'+5+[8+#0CL "LQQSQ WK1/-"NB(H^XDCM17J'5EU)U-
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M=(XF@@8<Q\D CV0B4QTDK]?7O1\ 9@Z'G4/A=32W] K)80CHO'=);Q,>-]<
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M=BEO9Q+)^V;%0:.$;$BJ=Q\+XK*5$N_^*)H#1_T&BRB0K^\^@NG[_JR8QA\
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  !@69/\1+VC.X    K @  $0
M        @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  !@69/
MF5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    (  &!9D_:$F?H- ,  #H/   8              "
M ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  !@69/
MLH/R]N,#   U$@  &               @ %A#   >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @  8%F3_P>?:[G 0  ]00  !@
M     ( !>A   'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M  &!9D^FTAE(!P0  )(1   8              "  9<2  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  !@69/%7H$8O0&  "[*   &
M            @ '4%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @  8%F3QO_%NXF!   HQ(  !@              ( !_AT  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  &!9D]-:48+VP$  &$$
M   8              "  5HB  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  !@69/A^D_'[$!  #2 P  &               @ %K)
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @  8%F3Z%DH(BU
M 0  T@,  !@              ( !4B8  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    (  &!9D\(>15FM $  -(#   9              "
M 3TH  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @  8%F
M3^ZB= NS 0  T@,  !D              ( !*"H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  !@69/$XXH [4!  #2 P  &0
M        @ $2+   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   (  &!9D\(TOHYLP$  -(#   9              "  ?XM  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @  8%F3UC"(S>V 0  TP,
M !D              ( !Z"\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  !@69/&((=\;0!  #2 P  &0              @ '5,0
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  &!9D^9;M(H
MP@$  #<$   9              "  < S  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @  8%F3YT[4X>W 0  T@,  !D
M ( !N34  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  !
M@69/YB8/ +D!  #2 P  &0              @ &G-P  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  &!9D_L^,I2Q $  #<$   9
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M970R,RYX;6Q02P$"% ,4    "  !@69/QZ.!:54"   C"   &0
M    @ %I2   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M  &!9D^;!@$HL@(  )H)   9              "  ?5*  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @  8%F3W<E_M/' @  = H  !D
M             ( !WDT  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  !@69/]N!\PIL#  #B$   &0              @ '<4   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  &!9D]G_[JYPP,
M *@1   9              "  :Y4  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @  8%F3^=IO.0R P  JPT  !D              ( !
MJ%@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  !@69/
M7K\$TB$#   A#0  &0              @ $17   >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    (  &!9D\M*]4I[@(  &\+   9
M      "  6E?  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @  8%F3V^J7(HY P  H@X  !D              ( !CF(  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  !@69/62@Q((T"  !["0
M&0              @ '^90  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    (  &!9D]L;OFZ[0,  $(2   9              "  <)H  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @  8%F3]H#A&Q6
M @  ( @  !D              ( !YFP  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  !@69/U<G;U<@#  ">$   &0
M@ %S;P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  &!
M9D^NQRN2PP$  &8$   9              "  7)S  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @  8%F3_4]O/403@  M%,! !0
M         ( !;'4  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @
M 8%F3][D1/1' @  6@L   T              ( !KL,  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  !@69/]4'WS8,#   ?&0  #P              @ $@
MQ@  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  8%F3]G7G$23 0  )!<
M !H              ( !T,D  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @  8%F3Z8<<E^? 0  DQ<  !,              ( !F\L
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "X +@!T#   :\T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6772546544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 156,593<span></span>
</td>
<td class="nump">$ 220,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">97,823<span></span>
</td>
<td class="nump">12,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">9,503<span></span>
</td>
<td class="nump">29,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">12,019<span></span>
</td>
<td class="nump">6,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other current assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">276,233<span></span>
</td>
<td class="nump">269,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">49,966<span></span>
</td>
<td class="nump">56,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">25,252<span></span>
</td>
<td class="nump">6,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">351,451<span></span>
</td>
<td class="nump">332,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="nump">4,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">28,389<span></span>
</td>
<td class="nump">33,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">23,571<span></span>
</td>
<td class="nump">21,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,634<span></span>
</td>
<td class="nump">59,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">10,037<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">28,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">96,253<span></span>
</td>
<td class="nump">89,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 48,914,284 and 42,353,301 shares outstanding at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">866,372<span></span>
</td>
<td class="nump">732,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(611,686)<span></span>
</td>
<td class="num">(490,271)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">255,198<span></span>
</td>
<td class="nump">242,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 351,451<span></span>
</td>
<td class="nump">$ 332,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759230624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the Company's marketable debt and equity securities (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:51.947368%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.818713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.818713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.818713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">74,563&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">74,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">86,253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">86,276&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,555)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,557)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:52.344624%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.751105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">All available-for-sale marketable debt securities held as of September&#160;30, 2019 and December&#160;31, 2018 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2019 and December&#160;31, 2018 were in a loss position for less than 12 months.&#160; There were no unrealized losses on marketable debt securities at September&#160;30, 2019 or December&#160;31, 2018 that the Company determined to be other-than-temporary.</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes changes in market value of equity securities as gains or losses in other income (expense) in the consolidated statement of operations and comprehensive loss. The unrealized loss on corporate equity securities of </span></div>$7.6&#160;million was recognized as a loss in other income (expense) in the consolidated statement of operations and comprehensive loss during the three months ended September 30, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6926776112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employee Stock Purchase Plan</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2019, 25,722 shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $0.4&#160;million.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Employee Stock Option Plans</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2019, under the 2003 Plan, there were options to purchase an aggregate of 559,357 shares of common stock outstanding at a weighted average exercise price of $2.30 per share.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2019, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 9,938,263.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2019, there were options to purchase an aggregate of 6,689,172 shares of common stock outstanding at a weighted average exercise price of $22.55 per share under the 2013 Plan.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"/><td style="width:32.808260%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.781711%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.127434%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.601770%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.569912%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.896755%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.012389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.601770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,765&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,633&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,049&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,821&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:63.491924%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.767988%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.005874%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73.7% - 76.6%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67.8% - 72.2%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.4% - 2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td></tr></table></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity during the nine months ended September&#160;30, 2019:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:26.970588%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,273,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,384,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(210,261)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(199,944)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,248,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,074,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.9</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,936,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,367&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2019 and 2018 was $14.33 and $18.07, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2019 and 2018 was approximately $2.8 million and $4.0 million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2019 and 2018 was approximately $0.7 million and $0.9 million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2019 and 2018 was approximately $12.8 million and $11.9 million, respectively. As of September&#160;30, 2019, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately $40.8 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759127696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the Company's marketable debt and equity securities (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:51.947368%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.818713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.672515%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.818713%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.818713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619883%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,690&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">74,563&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">74,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">86,253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">86,276&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">19,102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,555)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">105,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(7,557)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:52.344624%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.751105%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.898380%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6773328464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741,000<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 38,996,000<span></span>
</td>
<td class="nump">$ 44,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options under agreement</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759235408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The components of lease cost for the nine months ended September 30, 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:86.888889%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,080&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Sublease income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(706)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,474&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the maturities of our operating lease liabilities were as follows (in thousands): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:85.573099%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426901%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,616&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">44,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(12,550)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31,538&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759257968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases&#160;<div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has non-cancelable operating leases for manufacturing, laboratory and office space in Rockville, Maryland and a non-cancelable operating lease for laboratory and office space in Brisbane, California.  A portion of the space under one of these leases is subleased to a third party.  All of these leases include one or more options to renew, with those renewal periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDA4_d48d60fa-3511-4c66-ad50-e72151633519">five</span> to 14 years.  At September&#160;30, 2019, the Company's weighted-average remaining lease term relating to its operating leases is seven years, with a weighted-average discount rate of  9.9%.   </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of its operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities.  During the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">nine months ended September 30, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">, the Company exercised the options to extend two leases for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfOTY1_57414c3c-a125-4d11-ab1b-84005d3778dc">five</span> years each, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to these leases.   The Company made cash payments of $4.8 million for operating leases during the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">nine months ended September 30, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">  As of September&#160;30, 2019, the Company&#8217;s ROU assets were valued at $20.9 million and are included in Other assets on the consolidated balance sheet.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The components of lease cost for the nine months ended September 30, 2019 were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:86.888889%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.111111%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Operating lease cost</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,080&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">Sublease income</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(706)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Net lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,474&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As of September&#160;30, 2019, the maturities of our operating lease liabilities were as follows (in thousands): </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:85.573099%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.426901%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Remainder of 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,616&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,720&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,568&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,621&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">44,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Present value adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(12,550)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">31,538&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6927165568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOn September 13, 2019, a class action suit, entitled Todd Hill v. MacroGenics, Inc. (Case No. 8:19-cv-02713), was filed in the U.S. District Court for the District of Maryland against the Company and certain of its officers and/or directors, alleging violations of securities laws during 2019.  The suit asserts certain claims under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's margetuximab Phase 3 SOPHIA study.  The Company believes this suit is without merit and plans to vigorously defend against these claims.  Currently, no reserve has been established for any potential liability related to this suit.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6928790448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">5,273,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">2,384,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(210,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(199,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">7,248,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,273,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">4,074,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">6,936,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 22.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">16.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</a></td>
<td class="num">(23.44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">20.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">22.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 20.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 11,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">5,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 11,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 14.33<span></span>
</td>
<td class="nump">$ 18.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">12,800<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 40,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6772011440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Provention (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>performance_obligation </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741,000<span></span>
</td>
<td class="nump">$ 20,798,000<span></span>
</td>
<td class="nump">$ 38,996,000<span></span>
</td>
<td class="nump">$ 44,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member', window );">Provention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Number of shares available under warrants (in shares) | shares</a></td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">License Agreement | Provention | Provention PRV-3279</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Warrant to purchase shares of common stock, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention | Provention PRV-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Warrant to purchase shares of common stock, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 170,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payments to third parties</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Increase in valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6928360432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 86,253,000<span></span>
</td>
<td class="nump">$ 86,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">86,276,000<span></span>
</td>
<td class="nump">86,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Loss on corporate equity securities</a></td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,690,000<span></span>
</td>
<td class="nump">11,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,695,000<span></span>
</td>
<td class="nump">11,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">74,563,000<span></span>
</td>
<td class="nump">74,563,000<span></span>
</td>
<td class="nump">12,738,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 74,581,000<span></span>
</td>
<td class="nump">$ 74,581,000<span></span>
</td>
<td class="nump">$ 12,735,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84241550&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6773510224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Proceeds from royalties (percent)</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Proceeds from royalties (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6926774224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FairValueOfWarrantsReceived', window );">Fair value of warrants received, including change in value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FairValueOfWarrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FairValueOfWarrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>31
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20190930.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 225,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20190930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20190930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 331,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 16,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 21
   },
   "keyCustom": 36,
   "keyStandard": 242,
   "memberCustom": 28,
   "memberStandard": 19,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Leases",
     "role": "http://macrogenics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ie631656618b44857967833397e06fec9_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ie631656618b44857967833397e06fec9_D20180101-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Leases (Tables)",
     "role": "http://macrogenics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i1b731627c2204358b5c33793a78b3b6f_I20190930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Leases Narrative (Details)",
     "role": "http://macrogenics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Lease Costs (Details)",
     "role": "http://macrogenics.com/role/LeaseCostsDetails",
     "shortName": "Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ied9b88caa01b437aa817087abe6032ec_D20180401-20180430",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Collaboration and Other Agreements - Incyte (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
     "shortName": "Collaboration and Other Agreements - Incyte (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i58c33273de6d410b9cdecf2a5c0debe0_D20171001-20171231",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Collaboration and Other Agreements - Les Laboratoires Servier (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
     "shortName": "Collaboration and Other Agreements - Les Laboratoires Servier (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ia69015b5eb8740b6a029ef0b991a9402_I20120930",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Collaboration and Other Agreements - Roche (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
     "shortName": "Collaboration and Other Agreements - Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "idd651a75afdd4d7d95c4e21996253290_D20180101-20180131",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i15fcf5925096408aa871268b0c41f70a_D20181101-20181130",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i833fd612177d43f59a1880ab85e387fc_D20190101-20190930",
      "decimals": "-5",
      "lang": null,
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Collaboration and Other Agreements - Provention (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
     "shortName": "Collaboration and Other Agreements - Provention (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d60a3d64db24aa9a59ec712ca6f3772_I20180531",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i001658d77bd94901a9b62964e1c8daef_D20150915-20150915",
      "decimals": "INF",
      "lang": null,
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "ib491d902a8ad49b795070a44de412e95_I20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "id8841551e05040c396f8fa6fcf8186df_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i49611ab05b844f1fb78cf779db2fe26d_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i49611ab05b844f1fb78cf779db2fe26d_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mgnx:FairValueOfWarrantsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1406401 - Statement - Details",
     "role": "http://macrogenics.com/role/Details",
     "shortName": "Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "mgnx:FairValueOfWarrantsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i0d073e73b1854f88ad587afa842c298d_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20190930.htm",
      "contextRef": "i5f10c7f52f7b4ba484c7a0eba502e770_I20180101",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - mgnx-20190930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - mgnx-20190930.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 49,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "AdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Additional development funding options under agreement"
       }
      }
     },
     "localname": "AdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AssetPurchaseAgreementMember",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20190930",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationArrangementOffsetToResearchAndDevelopmentCosts",
        "terseLabel": "Offset to research and development costs under the collaboration agreement"
       }
      }
     },
     "localname": "CollaborationArrangementOffsetToResearchAndDevelopmentCosts",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
        "terseLabel": "Warrant to purchase shares of common stock, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
        "terseLabel": "Number of shares available under warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction discount"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Proceeds from additional development funding options under agreement"
       }
      }
     },
     "localname": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member",
        "terseLabel": "F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc."
       }
      }
     },
     "localname": "F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FairValueOfWarrantsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "FairValueOfWarrantsReceived",
        "terseLabel": "Fair value of warrants received, including change in value"
       }
      }
     },
     "localname": "FairValueOfWarrantsReceived",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FirmCommitmentPublicUnderwrittenOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Firm Commitment Public Underwritten Offer",
        "label": "Firm Commitment Public Underwritten Offer [Member]",
        "terseLabel": "Firm Commitment Public Underwritten Offer"
       }
      }
     },
     "localname": "FirmCommitmentPublicUnderwrittenOfferMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FollowOnEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Follow-On Equity Offering",
        "label": "Follow-On Equity Offering [Member]",
        "terseLabel": "Follow-On Equity Offering"
       }
      }
     },
     "localname": "FollowOnEquityOfferingMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FundedValueOfBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "FundedValueOfBasePeriod",
        "terseLabel": "Base period"
       }
      }
     },
     "localname": "FundedValueOfBasePeriod",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInDeferredRent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementServicesMember",
        "terseLabel": "Incyte MGA012 Agreement - Services"
       }
      }
     },
     "localname": "IncyteMGA012AgreementServicesMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesLaboratoiresServierMGD007Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LesLaboratoiresServierMGD007Member",
        "terseLabel": "Les Laboratoires Servier MGD007"
       }
      }
     },
     "localname": "LesLaboratoiresServierMGD007Member",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Six",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Six",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due Year Six",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Six",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "MilestonePayment",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfComponentsInLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfComponentsInLicenseAgreement",
        "terseLabel": "Number of components in license agreement"
       }
      }
     },
     "localname": "NumberOfComponentsInLicenseAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfExclusiveOptionsToLicense": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfExclusiveOptionsToLicense",
        "terseLabel": "Number of exclusive options to license"
       }
      }
     },
     "localname": "NumberOfExclusiveOptionsToLicense",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfMilestonesAchieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "NumberOfMilestonesAchieved",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Commercialization of molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfPerformanceObligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_OptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "OptionExerciseFee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "OptionExerciseFee",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
        "terseLabel": "Potential milestone payments to third parties"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement",
        "terseLabel": "Potential milestone payments and royalties on future sales under agreement"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProventionBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionBioInc.Member",
        "terseLabel": "Provention"
       }
      }
     },
     "localname": "ProventionBioInc.Member",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionLicenseAgreementMember",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionPRV031Member",
        "terseLabel": "Provention PRV-031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionPRV3279Member",
        "terseLabel": "Provention PRV-3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Revenue From Collaborative Agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Revenue From Government Agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]",
        "terseLabel": "Stock Option and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_ServierDARTMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ServierDARTMember",
        "terseLabel": "Servier DART"
       }
      }
     },
     "localname": "ServierDARTMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ServierMember",
        "terseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_UpfrontPaymentRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UpfrontPaymentRecognitionPeriod",
        "terseLabel": "Upfront payment recognition period"
       }
      }
     },
     "localname": "UpfrontPaymentRecognitionPeriod",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab Collaboration And License Agreement",
        "label": "Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Labs Collaboration and License Agreement"
       }
      }
     },
     "localname": "ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20190930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r31",
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r73",
      "r103",
      "r105",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r104"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r32",
      "r34",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss), after tax, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r110",
      "r111",
      "r137",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r111",
      "r131",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r33",
      "r36",
      "r37",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r70",
      "r191",
      "r199"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r30"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r75",
      "r78"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r21",
      "r59"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r166"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 48,914,284 and 42,353,301 shares outstanding at September 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r101",
      "r102",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r101",
      "r102",
      "r104"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r101",
      "r102",
      "r104"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect of adoption of accounting standards"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "terseLabel": "Increase in valuation"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r25",
      "r167"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r27",
      "r167"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r57",
      "r69"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r99",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Loss on corporate equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r8",
      "r12",
      "r81",
      "r194",
      "r197",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Corporate equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r161",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r158",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r159",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r159",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r159",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r159",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r157",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r157",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestructuringReserve": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.",
        "label": "Increase (Decrease) in Restructuring Reserve",
        "terseLabel": "Lease exit liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r189",
      "r196",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r180",
      "r182"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r192",
      "r201"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r38",
      "r40",
      "r42",
      "r58",
      "r65",
      "r195",
      "r204"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r174",
      "r182"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r170",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r179",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r63",
      "r66",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r11",
      "r190",
      "r198"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r39",
      "r41",
      "r147",
      "r148",
      "r151"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r25"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments, Available-for-sale Securities",
        "terseLabel": "Other-than-temporary unrealized losses"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r48",
      "r50",
      "r76"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r112",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r83"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r48",
      "r49",
      "r76"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r38",
      "r40",
      "r53",
      "r70",
      "r72",
      "r147",
      "r149",
      "r150",
      "r154",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r84",
      "r202"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r141",
      "r208"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r98",
      "r200"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r45",
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r178",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets modified in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r111",
      "r130",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r111",
      "r130",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r112",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r28",
      "r62",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)",
        "verboseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r116",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share instruments newly issued under a share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "negatedTerseLabel": "Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r126",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r109",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Stock Granted, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r91",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued or sold (in shares)",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r91",
      "r98",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r91",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r74"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r145",
      "r146",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r176",
      "r182"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r106",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r106",
      "r108",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r175",
      "r182"
     ],
     "calculation": {
      "http://macrogenics.com/role/LeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable Lease, Cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/LeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109243414&loc=d3e3913-113898"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r209": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r211": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r212": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r213": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r214": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6903143040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">48,914,284<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6770148240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,248,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,248,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,273,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,398<span></span>
</td>
<td class="nump">$ 4,573<span></span>
</td>
<td class="nump">$ 14,081<span></span>
</td>
<td class="nump">$ 12,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction discount</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,938,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,938,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,689,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,689,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,765<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="nump">6,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,633<span></span>
</td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 7,049<span></span>
</td>
<td class="nump">$ 5,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6928795296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember', window );">Zai Labs Collaboration and License Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6926774224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Incyte</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $150.0 million upfront payment from Incyte when the transaction closed in 2017.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. Through December&#160;31, 2018, the Company had recognized $15.0 million in development milestones under this agreement.  If MGA012 is commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.  </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company evaluated the Incyte Agreement under the provisions of ASU No. 2014-09, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Revenue from Contracts with Customer</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">s and all related amendments (collectively, ASC 606) and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three deve</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">lopment milestones totaling $15.0 million related to MGA012 meeting certain clinical proof-of-concept criteria.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  During the three and nine months ended September 30, 2019, there were no adjustments to the transaction price of the Incyte Agreement.  </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:42pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018.  During the three months ended September 30, 2019 and 2018, the Company recognized no revenue and revenue of $10.5 million, respectively, under the Incyte Agreement.  The Company recognized revenue of $0.1 million and $13.6 million under the Incyte Agreement during the nine months ended September 30, 2019 and 2018, respectively.  Revenue recognized during the three and nine months ended September 30, 2018  included $10.0&#160;million in development milestones. </span></div><div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of MGA012 (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the three months ended September 30, 2019 and 2018, the Company recognized revenue of $4.9 million and $6.1&#160;million, respectively, for services performed under the Incyte Clinical Supply Agreement. The Company recognized revenue of $13.1 million and $16.0&#160;million for services performed under the Incyte Clinical Supply Agreement during the nine months ended September 30, 2019 and 2018, respectively.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Les Laboratoires Servier </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab.  During the term of the agreement, Servier did not exercise its options for either MGD007 or the third DART molecule.  In July 2019, Servier informed the Company of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  As a result of this termination, the Company will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company.  The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. </span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company determined that the $20.0 million upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.  Two milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone in 2014, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management&#8217;s judgment, was the best measure of progress towards satisfying the performance obligation.  The Company recognized $0.5&#160;million and $1.4&#160;million in revenue during the three and nine months ended September 30, 2018, respectively, related to the transaction price allocated to the MGD007 option.  All revenue related to the upfront payment was recognized by December 31, 2018.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative </span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">arrangement within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (ASC 808).  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company is recognizing the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. As noted above, in July 2019, Servier informed the Company of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  Therefore, the Company reassessed the end date of its performance obligations under the contract to be January 2020.  </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> During the three months ended September&#160;30, 2019 and 2018, the Company recognized revenue of $4.7 million and $0.3 million, respectively, related to the flotetuzumab license grant fee.  The Company recognized revenue related to the flotetuzumab license grant fee of $5.1 million and $0.9 million during the nine months ended September 30, 2019 and 2018, respectively.  At September&#160;30, 2019, $7.5 million of revenue related to the flotetuzumab license grant fee was deferred, all of which was current.  At December&#160;31, 2018, $12.6&#160;million of revenue related to the flotetuzumab license grant fee was deferred, $0.9&#160;million of which was current and $11.7 million of which was non-current.</span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and reimbursements received from Servier are recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three months ended September 30, 2019 and 2018, the Company recorded approximately $1.4 million and $2.1 million, respectively, as an offset to research and development expense under this collaborative arrangement.  During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $3.4 million and $4.9 million, respectively, as an offset to research and development expense under this collaborative arrangement.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Zai Lab</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-enhancing anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million, less foreign withholding tax of $2.5 million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities.  The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate.  Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract.  The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule.  The Company determined that the $25.0 million (less foreign withholding tax of $2.5 million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price.  The standalone selling price of each performance obligation was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the </span></div><div style="margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> &#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate.  The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  During the three and nine months ended September 30, 2019, the Company recognized revenue of $4.0 million and $12.1 million, respectively, related to the Zai Lab Agreement.  At September&#160;30, 2019, $9.0 million of revenue was deferred under this agreement, all of which was current. At December&#160;31, 2018, $21.1 million of revenue was deferred under this agreement, $16.1 million of which was current and $5.0 million of which was non-current.</span></div><div style="text-indent:31.5pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">During the three months ended September 30, 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and MGD013 (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of margetuximab and MGD013.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three and nine months ended September 30, 2019, the Company recognized revenue of $1.2 million related to the Zai Lab Clinical Supply Agreements.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">I-Mab Biopharma</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In July 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan, will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered double-digit royalties (ranging from mid teens to twenty percent) on annual net sales in its territories.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study.  The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation.  The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities.  The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million.    I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> &#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three and nine months ended </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">September 30, 2019, the Company recognized revenue of $1.1 million under the I-Mab Agreement.  At September&#160;30, 2019, $14.4 million of revenue was deferred under this agreement, $4.4 million of which was current and $10.0 million of which was non-current.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Roche</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets  (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies, to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company would be responsible for its own expenses during the research period.  In August 2019, Roche informed the Company of its intention to terminate the Roche Agreement effective November 2019. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million which was received in January 2018. The Company was also eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales.  As of September 30, 2019, the Company has not recognized any milestone revenue under this agreement.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license was capable of being distinct, but was not distinct in the context of the contract because it had limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there was one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $10.0 million.  The potential milestone payments were fully constrained and have been excluded from the transaction price.  Any consideration related to sales-based royalties would be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore were also excluded from the transaction price. </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The $10.0 million transaction price was being recognized over the expected research period, which was originally 30 months, using a cost-based input method to measure performance.  Upon notice of Roche's intent to terminate the agreement in August 2019, the recognition period was adjusted to end in November 2019. The Company recognized revenue under this agreement of $1.8 million and $1.0 million during the three months ended September&#160;30, 2019 and 2018, respectively.  The Company recognized revenue under this agreement of $3.8 million and $3.0 million during nine months ended September 30, 2019  and 2018, respectively.  At September&#160;30, 2019, $2.2 million of revenue was deferred under this agreement, all of which was current.&#160;At December&#160;31, 2018, $6.0 million of revenue was deferred under this agreement, $4.0 million of which was current and $2.0 million of which was non-current.&#160;</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Provention</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement).  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones.  As of September 30, 2019, the Company has not recognized any milestone revenue under this agreement.  If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Provention Asset Purchase Agreement).  As partial consideration for the Provention Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">milestones and up to $225.0 million in commercial milestones.  If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant, which represents the relative fair value of each performance obligation.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in May 2018.  The warrants are reported in Other assets on the December&#160;31, 2018 consolidated balance sheet and were revalued at each reporting period based on current Black-Scholes parameters until the warrants were exercised.  The resulting increase or decrease is reflected in Other income (expense) on the consolidated statement of operations and comprehensive loss.  There was no material change in the valuation of the warrants during the three and nine months ended September 30, 2018.  The warrants were valued at $1.9 million as of December&#160;31, 2018, and through the date that they were exercised, the Company recorded an increase in the valuation of the warrants of $20.5 million.  In July 2019, the Company exercised the warrants on a cashless basis, and the remaining shares of Provention's common stock acquired are reported in Marketable securities on the September&#160;30, 2019 balance sheet.  </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">NIAID Contract</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Agreement). Under the NIAID Agreement, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.</span></div>The NIAID Agreement includes a base period of up to $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $10.8 million.  During the three months ended September 30, 2019 and 2018, the Company recognized revenue of  under the NIAID Agreement of $0.8 million and $0.2 million, respectively.  During the nine months ended September 30, 2019 and 2018, the Company recognized revenue of  under the NIAID Agreement of $1.5 million and $0.6 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6926767664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:28.633284%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">176,127&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">78,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:29.323529%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(b)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">160,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">112,702&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(a) Total assets measured at fair value at September&#160;30, 2019 includes approximately $78.3 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet and $1.9&#160;million reported in other assets on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6928382096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 20,900<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 31,538<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6913661408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease, Cost</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">4,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2019</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">5,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">6,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">6,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix', window );">2024</a></td>
<td class="nump">5,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix', window );">Thereafter</a></td>
<td class="nump">11,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">44,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(12,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 31,538<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due Year Six</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_LesseeOperatingLeaseLiabilityPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774305712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Roche (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>performance_obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member', window );">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement', window );">Potential milestone payments and royalties on future sales under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Upfront payment recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774239280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,859,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 299,238<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 611,270<span></span>
</td>
<td class="num">$ (312,340)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(49,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,024,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">247,276<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">615,284<span></span>
</td>
<td class="num">(368,355)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">103,259<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">103,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(43,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,229,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">312,036<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">723,196<span></span>
</td>
<td class="num">(411,599)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(34,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,248,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">282,643<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">727,849<span></span>
</td>
<td class="num">(445,628)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">242,877<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">732,727<span></span>
</td>
<td class="num">(490,271)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">118,657<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">118,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(45,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,805,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">320,617<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">855,417<span></span>
</td>
<td class="num">(535,288)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 242,877<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">732,727<span></span>
</td>
<td class="num">(490,271)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="nump">2,384,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,914,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 255,198<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">866,372<span></span>
</td>
<td class="num">(611,686)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,805,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">320,617<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">855,417<span></span>
</td>
<td class="num">(535,288)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(31,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,893,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">294,451<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">860,983<span></span>
</td>
<td class="num">(567,055)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">5,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(44,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,631)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,914,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 255,198<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">$ 866,372<span></span>
</td>
<td class="num">$ (611,686)<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243414&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418191&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6772245776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,917,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6914205328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements and Disclosures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="text-indent:36pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"/><td style="width:28.633284%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.536377%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.789396%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at September 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67,321&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Government-sponsored enterprises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">85,564&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(a)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">176,127&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">78,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">97,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:29.323529%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.617647%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Other Observable Inputs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,488&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">100,214&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;">Total assets measured at fair value</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;">(b)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">160,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">46,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">112,702&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(a) Total assets measured at fair value at September&#160;30, 2019 includes approximately $78.3 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">(b) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet and $1.9&#160;million reported in other assets on the consolidated balance sheet.</span></div><div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759166464">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (6,479,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (6,479,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6771898192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Les Laboratoires Servier (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2012 </div>
<div>USD ($) </div>
<div>performance_obligation </div>
<div>exclusive_license</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>component</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfComponentsInLicenseAgreement', window );">Number of components in license agreement | component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfExclusiveOptionsToLicense', window );">Number of exclusive options to license | exclusive_license</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMilestonesAchieved', window );">Number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under the collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Les Laboratoires Servier MGD007 | Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfComponentsInLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfComponentsInLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfExclusiveOptionsToLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfExclusiveOptionsToLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_LesLaboratoiresServierMGD007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_LesLaboratoiresServierMGD007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6926780640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"/><td style="width:32.808260%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.781711%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.127434%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.601770%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.569912%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.896755%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.012389%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.601770%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,765&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,347&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,633&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,049&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,821&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">14,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">12,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:15pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:63.491924%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.767988%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.005874%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">0%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">73.7% - 76.6%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">67.8% - 72.2%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">1.4% - 2.6%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2.4% - 3.1%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.25 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity during the nine months ended September&#160;30, 2019:</span></div><div style="margin-bottom:9pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"/><td style="width:26.970588%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535294%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.205882%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,273,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">2,384,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">16.87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(210,261)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">3.11&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited or expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">(199,944)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">23.44&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7,248,529&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.3</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,733&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2019:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">4,074,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">22.13&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5.9</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">5,849&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">6,936,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">20.98&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">7.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">11,367&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6753232528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6757354192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019.</span></div><div style="margin-top:5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> (ASU 2016-02) during the nine months ended September 30, 2019, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2018.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases.  Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.  The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated.  Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4 million and operating lease liabilities of $27.7 million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets.  Refer to Note 4, Leases, for additional disclosures required by ASC 842. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Recently Issued Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> (ASU 2018-18). The amendments provide guidance on whether certain </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6772537120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,852<span></span>
</td>
<td class="nump">46,218<span></span>
</td>
<td class="nump">143,352<span></span>
</td>
<td class="nump">143,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,833<span></span>
</td>
<td class="nump">9,584<span></span>
</td>
<td class="nump">34,174<span></span>
</td>
<td class="nump">29,953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">56,685<span></span>
</td>
<td class="nump">55,802<span></span>
</td>
<td class="nump">177,526<span></span>
</td>
<td class="nump">173,855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(37,944)<span></span>
</td>
<td class="num">(35,004)<span></span>
</td>
<td class="num">(138,530)<span></span>
</td>
<td class="num">(129,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(6,687)<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">17,115<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,631)<span></span>
</td>
<td class="num">(34,029)<span></span>
</td>
<td class="num">(121,415)<span></span>
</td>
<td class="num">(126,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive loss</a></td>
<td class="num">$ (44,642)<span></span>
</td>
<td class="num">$ (34,047)<span></span>
</td>
<td class="num">$ (121,389)<span></span>
</td>
<td class="num">$ (126,748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
<td class="num">$ (3.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">48,902,766<span></span>
</td>
<td class="nump">42,239,327<span></span>
</td>
<td class="nump">47,796,957<span></span>
</td>
<td class="nump">40,462,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue From Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 17,984<span></span>
</td>
<td class="nump">$ 20,617<span></span>
</td>
<td class="nump">$ 37,468<span></span>
</td>
<td class="nump">$ 43,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue From Government Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 1,528<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001125345-19-000112-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-19-000112-xbrl.zip
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MR<LV1-?H?,QLGUJ#)HV=P$5<I%U%8:R("D1B/R8--J7@*>@)=:N((BA:DC?
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MW_4??*^J_4PWN.)=LK/? 5!+ P04    "  !@69/I-HEXC4'  "H)@  %0
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M!FG:(BVDV]OI<D0^!B*DNT3*,U/[#Z^]3>+B"VD*%4?Q[T4GR^:U3'1F2L\
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MOFZ(%1;,G&WN7M*?O+L_L,"FM2P:C?TE@0<OON\OG^V;!?N.8_@-4$L#!!0
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MXX\)+2.BAJ:ULDN)+UIS=.C97EK:WD)P.\^2./ZVU_*=!OVI5I:P#(UL7AN
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M@I4/3K&$2Z47$OD,VS!AE:NI)865@<$K0=Q7L7U?,T/1D4O"+;6AP0I>:5-
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MYJZ>D8<H1Z[P]@WWBQ??>PAL4FE96^RM!#5^\&5Y]6RNY?X'@L%O4$L#!!0
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M,FM)S!@.)-,L:OC+J2@X,T+05_X-,\@+81GS*C*$M$42.[BQ\BQ:;U1Z[.$
MW@[>L-M_TR\&_UPY' Q.WKQ^'4W?KO:*@]=P\#4T564(9Q2OC$\]MT4[OSKY
M[.QL-1TI+R (T==YMS\P71<FY_MP?79Y9C^XU8/>Z6OX(=U>W[E]__;-S^CD
MUOCU_]3??7"'H6.RNP\9]K,#8TZ^?H?Q#_>\1W[^T$O@]!+MO!L2RI/3.P?=
MZPLZQA6]@]#-77_5]3KE:R!-T?6]!QF\YJT'3%[[^M:O!X7I]F.OZ)@!$"S=
MA6=(W6KCX/Y&?NLF)"/BZB;]'B-8/@;9Z(S)!7#KXT?.3C];T[_J^_.OSA]C
MAK76K\M?QZ<^?%*BXDV"^3N<&3]<O![]N +D#<:__;,3!J:63LS"?X;YZ3]7
MUGO= 8ADUKPX@0:ZT;=_K@S"^>!U^9#7;__7__I??P[R03N\G0CPGZ]'W_]\
M/;JK[?F+MW_Z_+36'URTPS]7?-X_:9N+-]U>-\"S\_,WZ<10C#[FWH=N^1%^
M;\ =B]R-'GT^V OQGRLY\DC2(*G%BK.HE/%<21.-8L01K?R7C9)!& AZ3:41
MIG#U^>"-[?7:P72C::=^[YI.:E3(WZQ!\WUZA:VV.5BIY1Y.]_33A=WHG;XC
M>Z<M6A_ZH\W3_6U]M'NT=UC??D\:G1W4V'[/]H_>G]4WVGE]PYVW"!P[.CQN
M;._G^]N;[!UMM%N7/=1J_G7<.-K/&QM[Q[O;+53?6..MHS5:_]R 8RVVO['7
M:77V#G>W%'I']B]:GYUH--?.ZLW]HWIGJ[-_].]V8^,]K6]O\L;E&FX=_76X
MV]RD<,XY?#_UVUNYW?XH6DUWL;_AT.[&X7']<N>LL7%P5K\\.*]OO+^H=UI\
MM^EP@VR>0=O&UWR"9_'N?O/DL''Y[^/&Y7NVN_W^LGZT!O=8N]S=V(1[[%SL
M'QW#<S_2]!ZM3^KB77-S4/^ SM\UU[X(3J@T#&?62YPQA5"FN?*9D#$HK;T*
MV*R\W5I[]V'SS]>WP)T^UM>(3CBYE?>=:;>"*;;@2+_"]EO8HIO81JJ1C(QF
M,02:,>[!0'+",^M<Q!CZWA"\\C;U_\R@_1ONW_,5N$\"%]\$USO.(Y(F(S[X
MC,GH,JV%R9AWP0HCE0IHY>U[^H+0;G;!@ERL [B%:>]T?3C_[W"QD+!^8OY?
M_V[OD_:I/>IAN/]YHU.'^^QWZIV/J+'ASEK-8UK?^)2G>]0!WOK&)JUOJ?/Z
MY=H7:C#CEJ(LN@C>*9(\T\:)3'!#F;1.> W0('#F,.&4\1>$:'U8%+?TZF;7
M;X#;_LNAM/E%:26UHSKSW(+86"DS38A( F0@4H"(P=J5MUF&"?BB#T"T51B7
M',[:L)N/ !KV/>BT#X>FF'A>$^0LTQ"T(&( ,Z:MU!Q)9" V"0R3H/F7G6O
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M'DB32;"&J-,PS@3R8!\XO*_PEC*E0=.,/# V\<"6H&1W5EF&ITXT45.;:"+
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M5TQ0%[^RC'.HLGYX4*%B\ES87#0=)C,%$91Q'J)<PDBPUC(2':'1$RZ,(@O
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MW&BZ^:VAMOLK-3;/3](8[C)F0YW4',P9<3($)K"P043CI%$NJD =6H!LZ,(
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M<* ]^9ZT8[O7'Z;IUL;VAI/MFFI[>?^X4GF5RILWE<<JE5>IO$=5WJB,85
M+4IU]W?1<\$G#5?ILU],G_VD.GO6&=0C=;93S:/^42WQB\RCUGCE[6[S7YM[
MU1SJ7UB3S;5G5LVAKIRRQY481^"5O0L'ICURQ\HM'Q=VC+5\FY_T)MGS:KJY
MU1>S;\ $LF\JK!>"JC)*SY@NP&N5::I,TZ/^-5MYFY*=M2WC!KVB2A(LV6+N
M,V_ /?:FTNH_I]5%I=0KI?ZH4I<K;S?/#W.;5^LT586/E2+X914!G+SR]@.
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MZ89-<W)(-]Q--\R\FE*U@:D>#.CB Z"R!9S6 C(J&04*;U2C&Z3H<LE(-ZS
MZ?DR_;(9ZKOJN2@/>"US6R?KUJ7A:=-1]PZ#JVC5:-S7XSRKO_1\Z/6G_9W/
MRZ<FP_C'^V&_[L#XOZ>E59.SMEEY3_KO4_KR]L/ ^C/AIHE@;?K[+2)S:QL
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M;5<Y:@] ]N<FDN_1L@PDS"3,),PDS"3,FY4R(YOT,:*B<WFOX*)7/&>(N@A
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MVBB@X\DQX:U/Z()QBAGFL;I2R$5VBJ)]ZZNHYH;O!644"@U6&5D5%?/@F1;
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M)/9;"LLA9>V#2/6"T!>-+'FN,E/%<'<S2!</^1)15V-!SV5XBT5=E)&@A!:
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MB:O>P7)5&-:X<LFGWSFB ='YK$FR)GD@3:)<]*1,^0@7>1F5P=%(*@/'\*_
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M*!W:$;N#P]4:5A8PL#\ /9V /&WMJ  !H&=0O6&T(/>+=L=4[I,>_MX93$8
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MDXQ1S2^^Y-+[+_^2KREMF)$WO!^OD<N^%$PRI6YX>Q[XDQ[X3WJJ7A&H[O6
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M*(T!<4X5TC):$!IMI54\.(ISJY!^MLIN]97R$&LLYMU8W1O0@:#7@ X>.<I
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MR%X=FJ]9P<RK,NS]:S9H!MLT=^@/:S/9W<QZN :HN9REJ=ZNP:)5"-Z5)>N
MG_YEAV6"#A'93%*<,U@@49/>9#0:9@58FGQ*+T\E0_/FFMTL '4/2EF5G..:
M@^"6^%_ZI;GZU);N$_ASNRD['3+'5>JUFMYQ)8M3NIX6M^I'LV]EXA@(DY\U
MK4$;!.\< AO8"M LXY:NL4T!W3%X<D88GV=;8$4Y-L9H'W#"F#(P*>#O%:<:
M+$KE5*^8EBVYY/WMR:?7Y.#R1#(G"8U@12ACB"?CD<,04X6$60R)RBA810Z_
M.9*JX9'UV;LV[[NJ&S:34\PSPDW/6]W!UNJGK!%\3?:0T[-9Q]6] 8U2'%5<
M*[4T;SV?[U)2_[PZ//T\SZ>VBTNRN9%.(X-<<[M]ELGS_B0N\"G,8=B5F<UM
M=;5\-<GLVE'Z>Z]0+ECPLLZ+#U(?ABQZ':@Z2%I5$YC#8^>W:S&V%P-;)2TJ
MHH;-X-LVSJV/37ZA)LO?>"1@YTZS#V&G%E2W?V]/FY;"U1-:O+6FUK FL,B+
ML$ 7W7FUYB%WFB?<6:0G6G&'RFHV=$-S#V6C1IG,GV.-IBA,0O6/ZXZ=S,J0
M!X3T5EK[2OEEZ,?EK7/_;CV58*>IA=1=2F%4+E.OR%Q6*M^A\E0RD'MGSD'1
M=G3:3>T,DU[SN+/I)+:]O!UA>W8M@4)9MV[C>K>;]691:1>GI<(HR/5<?[,5
M 5-;9.KR7S1RG7<D+I!,+'&(+$CR\E,LL#)U%^\ZNHA)G!_.R5E#]U>1:,W#
M\(R''VRL(;;'=QY,+(SULC7._3I^P%L1[%@)'HQP(CJM.';28FIBPLX88L&4
MT(<S'UN"G25B5/\QLTU0G;B1%D6BP,M1R2/-;$2,8FNU39YXNM%V;#BP_RBG
M(XM0-R[8:3]M ]AA:#_;&(%]KUQDJZ"&=<PN=T+7WLO3VM*S/-B!.26'NR<R
M^* TR?T6X&)QPBUR)F(DI=-2<X>=33>%!6M)YQOWHI!<Y#1G[7ME1VP<IU<;
M>5Q<G,-A^ZN$]77;[WS XR8SVEKSVW"Q7!LS;#7_HQ;DXUT"4<.7T/SWH.$Y
M7J!4:4E?6@VYP$VTAK)X8W"[XN'>@CRDN'(Y93I_HH:WI5QBE89F ?%4T6/T
M"\]9#J_G##2YH7W3:6GOM=Q8)UQBS@O&N("-,IK*2$7R1D9FDZYPRKPIJ_*'
M("%LD<F3W>K9PT]\2@XHG!*<$JPXYDAI2^&4N)29>2WR23.O'0%SC,',KR,@
M[%"&%.&IQ:&9'<+GW#K[2_-\LLNQER%P3_</]W[)1$R#9C#.BEO5*0E4M_&#
M6+I2ZS3QRU%-95,NN!O  >EGZ2TR^/3EWFZ&(Y8,YQ)A4N7^SQF3FM1^8X/*
M"9@NLR/=Q:'Y3 &_O6>S#+C_>7V8XS\_@@]##!-82HRX=@IQ$3, B3$4- _,
M".=,,D]^O9;A9$5EU_W>YZ,R1^E:1V+.R12R_N]/($H>]TNR? VQR0H#7,8,
MY,S$IM@UAZ>EK[O\H.1WZI3ICSZMI^FQZC#%E->_CCAOE0OFVHS$8EZDS7W5
M[?4%\UNSC#V.1OL6JIQ:XLWI>#2H2*C&<UZ"7#++:.(Y]U<IG\)RV<H[;H'?
M[V;AM'*7+^O%<O!0\*(V3WLL=*-YV%HNW4U'EQ:,;<W:<=64+]?OQ.:FVSOU
MN"F<:/ .YY8FHJ.Q4C"OE.?!>,\?I+EIB\5J&3M?"/"FKPX^'5P>';]G1Z]/
M1)0*(AB..'>Y38G5JE6YF(DW<KN'SEVWJVW:B["LNV+P5*;M4(0YIR,H<:E9
M*JC+X+S2U)LM!N_+[;LXN#Q)(4DE5$*)*8LX\0S!X<.(8 4;PCQF.+>G/5L=
MW+#2C-:@;>_='KL,#%YRT=8D!Y8C^P89<5$KIMV"&5A+A[F<RUBR)^"%KC *
M_NAF>'=2*B2S[.#TK!M]J* XUR%CYGB8&HEFN[6BVV%D\CWRM:9Q/.Y/1P7P
MD[]Q8?N+0)6[3;DT)("+GA3+LY$YIIIRKB#V =<1:ZEBR=-\AG->57-?U,OQ
M,OZ\&<:#XUUV>+Q_$JG#U"2':&0&<9FIQ#B!F#-:&P)G@K!T$P/A L5J+\78
M1'F-W"V4D?YWTE*YSW)5IY/1J5.+I5Q;+I9UTAR5N;ZXV>"@"AYS5E6+P>N9
M@C*JN/0S&7Y&$^_ 7O>K4K.ORXQKOE5ZT$;C::-S5BN_<-5<^2V8*-^_J ?,
M#JL'+,"=#Q6HJ3^=UIK47N<[UK_XK+=A .9*+7BQ*I<OV/S*Y*QP[6]LAELX
MPAV=WRXGW/=9;Z\:XE**\3;/F\GYL3*VIL:!+=RGH>^/'R_*M-), -RE:NU/
MWM?<O['R4$.\B$7MSIOW.A-LRH3.YM7K/KT;RY +<( *D-(M,-REMWK;%7U-
M5S3Y?KNB;^IR7NJ*QM@X+<#^,!MY%%('Q6, C4B4<!X<VG5M ]^7Z] ],SET
MK^LY$P^*L,%^::R_DX%$U3LMU!5[7:[&1\CZ7#UR[VF]T$VO=G=?:HCW]<,1
M<\YB-"RYQL4X3>>R"^%&@G>@I#4RQ^D.$V.H,XZO]Z;ND\M_WCS!9']8 ^56
MQ\'^;%G]@^,7Y."3SV/VL)(BH"CSD TJ/(+UCR@P[&BP OXB-\P5:G=V\H\%
M.PW2L)*7OR6X9Z?VL@I!=.ND+#@S.\6&-V[0L@^4G;MKT*)%8RRWK"^;[/ZT
MPH;G%O<&8NJR*V.KH46C>5A7/\#:>+!>CHU8UVMX:Z<MF*YUGAITWEHO\Y9A
M4;7NRR\[6<]@$/\O.Y[KYA1D)_J^8.YM#/7U#OC^Y>&[W0>)H;I>?%;ZL_/8
M)'R',?6GK4O<JH!E4HI;G/V*KV(^#.=X/OQBB;:D.7X+(Z86V=0;CMWNK:J,
M]LYC8\#=+:0;"PF21]]HLV%OP*VNRUDU8">T5,:;M5T7R=S$WC6:IWG"_'1W
M8L+_+EW>VU*>U%/5OS3OB24T@%I6,=.*D<@MQ"@:9\I24.#$;GE/OE@B?>_@
MZO#RA)B@&38>"2M][FBP2$-0B(*,FD2=(N,N<Z"HA^,O(%YZYF@21@N>E(+H
MTC-%##$\RD3-MF;VY;;\T\'NB>4\,6L8 HU $0\F#_G$&#$3O1$\")6W'#]C
MMZ8V7O))%]S!=9G1&WA/[G2YNRH<;)RT6GDOG>/1@(>8>=1])"+S:$2\94EY
M6/>0'GSZ\X20Y(-P 6GA,].22$@S0Y&RDJF4Z;2ES@B8!V1)2<+S2*G3$.ES
M2HT5RNKH0+8=Q=Z&;87V@??Y<._@Q+FHN: !@;NO$ >%CG1R+*L6*YWF\&^:
M5<LUC%H/QH"\.]WDS.S<29"BT<8ZAH,(EA.N#%$I"!$E811C5\VD_CP]T8P-
M_R^$W\W,\'_W:VCK3RU48+I.5,"<L"@0QD+FH=0464$D4DD+(QDXBQK?B9'X
M6^_H\QS6_<2PR&9CK=1!>^50"C:/QE$".4LI"B&Q&(7(R=HGOZHUX)W-ZF/S
M(-$;W(AJ2FLUR&:G@-+A4G/64U_M6:57&HA%K5;:R8UW8FM+FE'F; J>@0@J
ML%+!82.H"T:Q4$U_OM]@PJU:N4'Z^,&[]R<R2H%=A,@GE905R"$$/AS%(*BB
M#&N20*T0NH;)?Q%#]$ B]ST)SU:#[8L#\'>\)TDH)E&4.F,0,?BU249$'%,,
M8RM8V.#OK(C0BJJYL\?[K87B<#3T6[D0!Y]>G%!NHR?*9Y) GK,J#&G+P8,Q
MR4D<G? XCP\BUZ55%F0"?@,U)N@'3U >WS*1WQ8&U_16YOQ])A&HJFFC62%2
MJJMLG8'7"[G,BG1C4N601Z"MVR+<.)11[5EYMSGY KO<\)#-+U>(G_ZYFXTG
M]?3VNHTN+/:@5K.MNTT!F2$CI=PX>EV=H+E1"R(:3N#!0S4X/+.,-<6SC.MJ
MV!VJZMW%.)[!=TN);S29=,.NU6K&P\Z\&Q?^B3SM_F,I80RN[J3FP#ASGF>*
M: UQ 83STA&?O*">P?_5HYT_,V.\W* ]&G9P%$=E8XY';^IMV1V&SNB1Y[G>
M\O,JP'FZ\>/!\9_T8/>$PPYPX1WB5%O$4U+(>>$0LRQ2DIB*2JV':M]_,!;A
MTC*7F9 -:!F<<S_>8)UP%'#K^& C9[8B<I^YJ ?B:&\7%Q[)3[N%75=@88BT
MB(9($">&(2<21H:G@*6B4GG[Y%=Z37IP.2-]9Q7:5 ?[DR7<Y +Q35<-WC$[
M]<!:T'J;JV92*3A=2FEME<9"F60)A-4B/D0:>ROB]W8##\C1,80'$BP5UP;E
MDDKN4DG(!?BK,8(82K40F2F,/:3JTYY(QR@$LEQS$8SCS#,O?"0I<&,?;NC:
M5B[N)1<4GN=$)&&$)P19DTUB< Y9YR-R"B<?=>+)Z.L'3WPM???#L83_9?N9
M\?I'XTS='_8.1Q]:2G!]%TIPD)"6KVV1'KQ>K-[3Y@]S\N&%@4_-CZMFJE+)
M/:VH%98'/FTDNBW-O_WA(/_2\[/^T.[T_CD"2_O_P;]V>@=@[F;E L>V?VDK
MPK3<(I-W)TYGV82ZG8*V.C^?P>K$X9D=^@J!->VC?[YX0[.M'OE!>:S\H1N%
MIC\F]]\1!M_ON7[;[KY C%632E>IO08UZ4<%RY6Q1VXP\N\S'2T$6Z_V$"G/
M^N_=WQ&;SR(:%?Q4ACOFR4=-:&9[Y;SE/Y;@K3>=G8_&59QV%D$1@]R<EDD
MYZ4Y(K]6AK#.VW!LF4'5G\"[94S4>::-0^UK'+_9WWMQV'F3?H:OQ7;>5&>'
MGK4;69"I@VA#;]WOU0'WI$,PN=P,=W4/6N*<IA#?S8G;T*FT<E)VVH]6&P-7
MJ:GN"&8@(GFP)51@(SG6UFI%J-0.>TZ2PK:R]J2Q]H1L68L?S)2_AF=^?2*U
M<AR\;D28X(B#2X<<\02Q('5D0D=N*80NUP%?=WH%#YD34G"^B^8]&PTJD*C]
M^)A%8DZ[73.]'-N/_YT__L\L'"3[>3$7F&SDB(J482\0!!@1*-*>.YZ(E]*4
MN/:Z(?+S''";.\S8W1:S2DSA*IW,SLL(Q:IY,,UN8WI!LA;M9V4'VU:*9=.Q
MZ%3X0G7:\(+-+K)EO-.0>FQ-PBI@Y0R7DEGM0V04Q!9[@:7]C"I\D<]7C;WM
MA!_V#G.!?V;II8>?_$GB7J8\\T@&"U%*#F%U;M]1+ @A34X^D">_$GXM]^+2
MM-\J)=[LP,+P7W!A;0C]JONF=42*D(%U7&Q_'<U YZ#0/^U/>^/1E1V4BD!Q
M9H>S,B1TVIO8[)<TM8$\8G+2G*9SN)Z++;MS=HK#N]FD\LG@B6OG"8Z:[X_]
M[+R:BSFY7^7E^W%I-K/EKW@UMV++?WA6\\M1.[?4PQU*J6.RLZ#%6H(VPFK6
M\WLT-'4:K^<WRI)1+T3+3M3ZNXT__DO/QW&AE+@=R_3#4VEW2F0_.9GVR@[F
M!YFOSL(\WK4"5 IS[:RB38TE94TK,<U+"@\,P>HDSDG7O;TH;&NP8BYF^6^V
M8Z=E#F@WJ-^6\K).Z9#0EKK[M2,MVH5;0J&L1( K'7KPG$54('AN3B8\QX9G
M6*J?CF-5;-VT&PL/8[M4^M?*_EW)#;>1T+=S%_Z\/-P[?8A(J/=T&PG]>,(!
MUWF 2.B7]33>C6?R_=!X%R?FP?B<BQ+=]..65_8:,LJ.XJU:5LO[%7<XM@/'
MJH;+RJSGDF6^9K.B)>P$CV%@Q[?)+#=.SSP=>IOX8,Y4;=?R0L_@4H.E\+3:
MW9K;>HEM=[I @PT&K.*2SC%NM9UVVB!RFE!Y \9S?I62-,W>5CT;KM"*+?
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MS3*UB>E$1\MAV+INEGJN:E$SJ"H\;YZP>H]!JO6\U+;6G>#9X*B6&OMH4&W
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M_ZSW-%]]WEA=?E(0?N]R=G5PE0L<ON0K.K44$#CX;W?<P9S*'[[:G2<P+?T
MDU[O:773!1!>)_?0OFU.W^WT8"//JD3+L,T)#G*V$B+CEMZLZ0AOD7Z3G;JX
MU%QUCADL\QA:1&!^E_(\\)/GX]%D<K!;=2OLS:;V)7AT+8RPE,'AG28QK]+B
MC(=*1U8[DH%]ZZ@VJK>N$!G3G,A+LW%)TFTNT&=9* G6===[49&GU?GNIMR;
MUR)G5G-%*2>X,Q9C=#ELYK4L#.AK5[J=S@=BN3L[!=U=NZG5,_=+\28N(N9
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MG39_LLYY>K8"5M_4V0"AD6)1,4<@<$E:VR"TLLEJ3CT%_WAMX+(D+?XLAMD
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M:W1<VVQ7#8%&"KUF9GPWHXZ-*%.S+;@;KFJ*+/A$4R;4=Z)O]#VJE,H'*%V
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M<[G6D$K3/BC/&F$I.2!PHOCX)=%N=@$JG3KV*;1O&<#FU2]_>J;E@#H-94)
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MLR_:[W_U83SWQJ7^1^_R#MZ!?9S_N@!_Z->_KL[NX9TG.OI#Q'))Z+JR;ID
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M)>28G(UX"&O S)6'Z#X!R&=@?P0TI-,+ U_C9(&OG!9I"@/OC\#&1BL'J/=
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MCJ2/Q^;?_T8ED$;@EWM1,NR1=$!\6C!URW8]T&\*$V!R[CLBPV,<&640,DL
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M-[E4XY4*5Z3KFLA>2J_2<69O&X=PWJZ%7EES:I$]%NJSS-8 ^A]_<W3=_N&
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MIL71;#P<FFB7'TY7U:42'O5\H%X5\4T1&A) %D 60&X$D+&+AJ;_(, LP"S
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M==<^1NO+!>^Z,> 18%CT"]F":.=QXO6CLLB&Z 2R-MTT7;%%Q>[=:A)1>/Y
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M@6$1JM^!/7^ZJB"K\*9G">;LXVC6$7C3(BS4,B!;BB. +(#<?B#K L@"R,<
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M?@9N.&;77?'N9PQ<5;J:J[M.ZRBN*::EZJZ^YO-/Y$"M*>'V&AIWGQ4:?W+
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MD;OV4!1)NJZ38<*D6%0=#/K20:X&ME&%]FWJL,. [GI1-AZ(]$@6$(O$DQN
M5OCR!](OQH4T\8='DJ8D9J53?0J"* !R@A_)KGU*DP= +][]$;@95_#D'LC%
MZ@DCY]=N.,FPCNZG(O592<[)??"=[_1ZW7D8)I*'3Y9^I:D?P0.SPX'Q_ES
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M'KA(Q4OP(=2S%&A @6P5&0B"$:\!9VY8Y5GT)=FD+XG>LKXD3=$&FSH0[V%
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MI,.$U8V:O<9=T22FH])5A?%F>5KPVH#UZ:]7O''C"C^L$&R]X.,<S2M0T:]
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M%"M7UWU.7.%3;-T2C_Z9<4>!EPUF9)#0@:]AC L&OHV+L/)9?"'8>!.>/<V
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M?Z"$SL=Z9(I!QO-$@8#[S)CN6Y[^IA7C+?HB$G&6#^=G^?PDS4U%M+Z>B#[
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M&08LM8_-M)2!X]=6CA\I3_)$_/@*S<=+-_%IZC&MTL3E/L=L&&:!VJL6 DG
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M5,Q5;=\Y-Y6G+O'[_\3E8W[YJ(O@]]AQ&.H"M\9X@CY]^!]02P,$%     @
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M$;BA 82P",XX!*Y($)(YYZ*\+J&+[LQXFMS$S\AZT4(F+37/<3B=7+Y39&F
MT O._NUN*.?B7+US.^.3D_%H]MS?W? ,!QR]3<@=$,,C"%]LBW0&F!',2,:9
M0=JB:S>!7._8%:9L]V%KW&<)9+/\;.L#%B-Z8:'/4;D^7*/0;?MP\8GGD[.3
MD]DSH9OBR>7WB[FNRH#IN*+,SQ6;>["NYK=C[$K?W?#0=7%OM.-.NZD;7@$W
MD(SP%%T$E:@&80,%)U!"(%2)X)*V"EMPX6%HB["#?9WLJ*R7:GQY@U/7C3#N
MNGZ4O:#)=L@>3Y$ZQI>8NM!-!S)Y(Z.78"(GN=LB@J-!@&*&>F6TQY!:\.5A
M:(OPA7^=?*FLEWKVY0N.@^DQ]IG IST>XVC2O<>][$N?X/YX,ME^[[K\[2&^
M&O=';HA'&,[Z/ !PLAW_]VPR+4[U:YP>I+?NXR :9X*CQ=,U!D0TN4O9T06O
MD@K$!YTB:6*0ZO=E$4:*KY.13ZWY:A3>[YSOAC-(.V=]G_$,N/0D-Z8AZB0S
M&)G <94C-"LP"XA[(IMX?K>A5!B?X[/1='+H/A4E7':0Q) H4QK,3/%("%B'
M C2GD7L7E)*\T1"; V>3O, UV3!GE*PK_YJVNC_#.*^'BGFMI "3LC$0C'OP
M/"2PQ!MF466/H\F4?B>B3?+\ZC.B@A:JD2)[#YB;CV\R@IW\LYM>PG$J2*VU
M!'0D^Y_$&C Z>Z+!.$DEBRS9)M/PG8@VR;VK3(HZ6JA&BMF$/J>+5IID8K1@
MF"K^0G$V)4N@4&%BDJ#5J@4E[L"S2=Y594+4T$ U.NR,1]/>A>D?W?1X)_ML
MV;7[C.W3ERF-A1"T!N)U]MVH5F"]L+GS5&?#Q3@AKLV2TL/@%B&*_#J)4ETW
M]8S(*?99(*-W^^@F> L399IXG@A$E[+#[UR>Z*P,H(5"J9/U@9HFMN1>6(LP
M17V=3*FHCWHNZ62"T\^]0QI$IJ2$H*W-#I#)X6@*$B)55E"'(?O%3=S0JRC6
M-I9N<KP]BN5'B;+?YY@W^__;TQW7]Y^R],\7@Z.D*O!LPA/W1=K:@6.<0U0Q
MD!P$,*V;>-P+H=ND>&QUAMRRE-454VT8[(W>X_E2R&206P@8G01./ $1 P<K
M) 5,)D_N J65N@4SKF#8I.BKGOY7%7+-^'NV%O & V;Z^2&^QB]^?B+2\9B[
MXE"5X$^#329;8VV44VB"C*U"\#M!;5+ 58\'U=10C1B'/9ZZ+NY^/,71Y/,:
M$==<<B4D)%F6 P+38 )EH&4TUJ!FROH6C)B+9I-"K7I46%_P=4/N\YX-@C'*
M!G39 :.Y2]12\*)P4@;)/,=@C6T69I]CV*2(J9Z^5Q5RB[V&[(K,V9%!KYQW
M.:#W25,0GF5\WKFR\!.BEMI(;#(-/ 2L8L<'DEDFG(A@G-6YCXKG((:[_*M&
MEP-4%WP3#^<*ADWR<*MRXB;C5Y5[-<;/Z8\(D7)E)6A21C!Q!(P0I3\LS[=*
M<.*:;#X]Q.J-V6:H3X,UM5 YWA^@%29R:T +D;O":+;A0C(@B3.=8FX[Q7:!
M?MU%BY2C0A6D N^ES*$$5WE4Y<C"&F<$8R''C$W6L>Y9M-B$B'TI'=]RT5>6
M<$6??'R*_?33X="-IGE EE%S>G%889#=#VHT]R"#"" TSX/2*P86"4JADO*R
M"7_O [5)MJP"!:K)OX6'_GH\"I=+ZU[G254F8#3E@#%/J& ,RZ"(8DR@4(V&
M_UPTFQ>PK\6!]27>PG$?1")B))0 HC=Y(C8Z3\G$ 7/.1I\B9S$\JO]:Y<R3
M")*$<GQ0*($@1/#@?$3@VI?L$VZC;6+35MO6?0+G?"F]W^.'KR+PAL<]KHRL
MR&B,:")0EKU!P7@ 1VD HIGS+.IH9)/]E_M ;=*T5HL,U930>J_V"BS/J$O"
MS*QN9FMB$CR/ 1(&G@*73F*3H.U!9)LTY]4B2%UU/,XYD"O@>,2@LE4#'IC(
M72]S/K$4F)61Y0G?,LH>_2C(<HQY@F-#:S&FA6IN\.;'YS?EM9]_KYV&>.@*
MSF.<=KFAZTC6S$F\_N26"8KW]*%J_N;1V_SZZ^[KMT<'KPX.=]]LO]W+?]U^
M_7+GX-?#-[N_[+X^VOM]=__@:.WDSB5:JBS85?M8*2WTOM2&R[2%PW$_LQ[3
M:=_YLVG947P[/N? P%O'D42?_3NE01@6(9MF#3IB8LB,IZ%=>+@Z[G5GBMS$
ME_8&CB2FM.,0V>Q,13%LJ#G8)(BPQGE"FF2;7D.Q25'%8[+JYDRQNFKJKJ34
MR!<RG!LET8!4(LN!*@G&!YG11^M52%P*\=BCJW9ZV&,%-T_)R2<A1/W@Z<JX
MHAA<Y()!V5L#$90!XS@%BI1(Y91%U68+_S:6]5."W^/HK.P?&NJ#T!%,"-EW
MQ,3!1_2YB\J$K&*F91.W_A+ 1EGP-75^.[]W!2%7#.PFT[+K>'$09C)0HNPF
M*@*)*U;.QUFP3'@(E"C-I G>-S&L-X$L:2#AJ]+Y6E)OJ'N:P]"$''C,YE,P
MX\"3<OQ)8PB66Q2FR4K/_;I?Q6Y-,,NGG/E]F4?7<#S;/KIX^H!J9J0@&HC@
M9=,[\*Q":P"=YSPA4BV:&.A[46V2A5N+%[?-6RU=5./]/W"4A_,P(]J.)]VH
MFTS+X'Z/EZ 881A-0" AT>Q*> 0C&().G#M!*&K9)/WQ 5R;Y#)6I4A-?50C
MR?5@25@1\C\/6H4 0F$V^X0G",9&R:-6RC4YG'=/'%O'6]51A*@<0BB[J;F;
MNA01<4!ML)1PZUA\&F_U:4W@ZMJ_<T%_1:'7#;U?CT?CZX N!YG"[&5(PB!P
MDP>PD %LCJ= $ZF5EAD:;<+P^V%MDLVKR(EZJGBLE?JKB[%';P]V_NN7@_V7
MNV^.=O_[M[VW_ZJYR#SGZ0T7EA_J2[-5^YWMHU]>[1_\476!_LM#&XKL#N25
MEMU+1HZ;'!_VX_==?MJ+3[]-,.Z-7G4C-PIYJ&R'[!J<[YH)DJ,EJ2P$8F(.
MF#T%%TV"&#0*IDB.H)N<6UD<8H6CB $Q3EYE8[0WF9R5:JH'Z6JI.(*4,4<Y
MT!!3-D,NFZ% 1388U/-( P;>Y.#&@\@V;#9OP:DY!Q<K:FOMB;^8C<^8BE!F
M& Y.B\ FNQ^Q#UT60W'BCPX/#\]RC.:*)^]3E*E4!HO,E'T!R<'P$$&B)^B9
M]8&%A^S3:DUOV&3?DC*/H)N:D= \49PGU5X7!4F!,,L%E#RM_)(<6%>.,7E'
M:'0,19O<]L4AKFV1W:=9'O';\7;X]UG7X]V;%"_13P<L18XY" 8F<M@J0HYB
M#142O+!)1,:%;5-N=TF<2UKKMJNMC0AWRUPW5&7-9(3/<TK!E$W"KVY:8'TZ
M2'<#+N?D973& [."Y! SD\0F8R P&UE^28(VR;1;$>]78/JKT^\1-%N/AC?'
MRIU)&@/D-B)/ 4P*IJ2H<;":"8B8'#+">#!M/-*%(2YY;O3;-'9U%%AO+RK+
MX$9]EC=9 'T7IA@OZK=<?^/*)P^Q[\99:*$OAV9?XOG/_/OPK%SHL?LQNT^C
M=_C&37$W)0S3010B4NHL4%,<*6IU]L&C 6T,*B$$YZ[)$O_C=K.1Y_=Y2?.J
M$TPC9S(2H-0P$$;-RIIF3]A(;VBPC+89]8M#W*2 =(/9/N?06 L./$5T@I1&
MB3*'VZD4FM8R@J>T;%E%;I57#E63LBJK1B=/O,7WU7-T70ZTYNB\Q80@HE7$
M4U"T7/A4MCD]HP$4X9%JXXDP38[?K+JF^;19-U\_1]?E0&N.SK/SE)*2JA;
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M@JP?>F0%.2Z%NK6,WI;EI1:2NGAP>WG-ZT%KJ:TQF!=\<GNYW3\D:UP \QG
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MT\1:G\9J<([P3ZPY?YB/OE)(\PE_.ZT:/2X+48]/YS4?KJ88KDH=E+684J
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MPZ5'SF[^Z.PNJ,M86F8.]3F8/246]8&2R8&9^-!AJY22-I,7JD0Q3!<,+*9
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M0\Y%NV [F1VEST/\BGD00^%<D<>4HZV)Y1Y9B)!9*DI@K<8TO!O]T>WO>.J
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MJH3?9;\ZD@63JPN!I!-<U]L:S4(H4#DY:#5%D45L4KC45< GC+DF-KR.M7"
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M8>-9Y6MD0I:"UF19L$E6?N\CV7W:S8Z1?"VM8:]8Z#M-_16MR9-OB(LU[IR
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MZJ#[3KG0URQV0C@NV6/[>OTI%[9&/%'*!0L2)TBYT(=B#BD7+%BR3+E@4]+
MA;7-W699QP!ZJ93DZW?JK?RKO7!N;B:4N:[W?BE?KYH]J'?J5C29Z181S9*
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MXH'[JN5GNFI#\SS7513+7'2#9)O_LOYU[^S91_U)D_G&<8G?2UTSTJ1]>V[
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MP 1E&<1Q',"L3A:MA4<H',6,.5W5.5G+W/2E!3E07TX3:2<H5],SLH)TS+0
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MB(N,!"8!,Q:ZUV81)+JOPH@BS$3$!,+98EUHK;%T!>MBG?KJMO#QOJ*?3!V
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M/.1"BF???JM,P(;7*Q,D1GLBMWR=/S0QZLP2)(F3# J>*BT,*8$4!3'4\X4
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M7K*[>'>05:1#/,IU/!>*_)[ALZAWXA-\]DP\/K_G\.[ <9Q67\S_O_S/3?Y
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M$[%Z8]I[HM;KD4V?R-4;FR<3O?HK?6"@>\[-WG#U07*9/YB*WLIU=U4^D"3
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MB]"RTN0@5LONC8%)"3MI1NJ4['3_DZJ2+N65WZSY;(N,XY045%L%N::$%$'
MBI2#O. IQFF2)<@J$'5@_U/CB8,L1$W!!-#1(.JJ$/W^9F5<C(ZWX5R'R,[4
M" A\:+KQB[E[0L%AR'G-(.@HPK@I X?A<Y(C<& SPWCPH]SL'5.S&.<X3_+"
MY%HU,8.0 I(K" 07D$F&<P2AB\O]H/6I.="-M];=;7X(&$Z*N$ R!7E.]++
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MNI(NJL0;%OUV$5([T\D+4(&GN -&P\OD7-(_2)&<D\Y>ID3.)9TO%LBY^,(
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ME=73GM$:D]X-X_56QMLM6FMTL%6T?\N-'<KU9O:!_CE_V#XT#@\H!2]B$R5
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MN/YZ*1KNF5.2TVGL,H)2Q)?#( !U%,8IGYV](T__<)1T)7#<(VGP)X5!]-2
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M>%M=;MM?\33B<F(S>B$% G*5R/--$IRF\X4IE*4(-"8.,O.S"W&-(*XO1'1
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MM3Y3Y%!S!-'7G4$Q!L3 (@B*6SUJC1('N<KO3.&X:3$'H./6B_8@.GDTEN6
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M"K1#8-6G1L8&V&5!W97@O9;2X8>S6?UW7V\5VOUVO9Z.V..^,LNL*;6J'^O
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MY4 VNCAP!U*/TDRZ$:F?2MZQL-& @U!VL_R2/Y+!MWO*SSL1MP6(1D7'47!
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M4:IQ+X4F_%C9'U9:<9SPNC+"WKOBAUS')-#/_[9<;%5SA9>U5UK,)(O2QEQ
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M0.,-O\'M_J+^JQX=__-?_P]02P$"% ,4    "  !@69/4C!,AC\'  "F)@
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M=#,R+3)Q,S(P,3DN:'1M4$L! A0#%     @  8%F3]R-0M8EB@$ I<04 !$
M             ( ! 1<  &UG;G@M,C Q.3 Y,S N:'1M4$L! A0#%     @
M 8%F3U#+44_0#0  .X@  !$              ( !5:$! &UG;G@M,C Q.3 Y
M,S N>'-D4$L! A0#%     @  8%F3W0 ]\02%@  !]L  !4
M ( !5*\! &UG;G@M,C Q.3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    (  &!9D\L
M+6A? T@  #(+ P 5              "  9G% 0!M9VYX+3(P,3DP.3,P7V1E
M9BYX;6Q02P$"% ,4    "  !@69/92DP,(23  #S1 8 %0
M@ '/#0( ;6=N>"TR,#$Y,#DS,%]L86(N>&UL4$L! A0#%     @  8%F3\99
MCFQ=90  &\ $ !4              ( !AJ$" &UG;G@M,C Q.3 Y,S!?<')E
:+GAM;%!+!08     "@ * )8"   6!P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6929616768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">67.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.60%<span></span>
</td>
<td class="nump">72.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6928571072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 20,798<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="nump">$ 44,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>mgnx-20190930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20190930"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20190930.xsd" xlink:type="simple"/>
    <context id="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i675263e40bbe4a209433798168310a91_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="ib491d902a8ad49b795070a44de412e95_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id8841551e05040c396f8fa6fcf8186df_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic670a1b26e2f445cb693f4e6b6d75b2f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8076bbde2d05426b988cb552d4160afc_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i473ba08d93ee45e2bf84bce5d72899d3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1ef682dfc0994eada511c90370c63e40_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ia506c971040142629fb54680daa17aec_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id3d8b967295d4ec9beb9dbef66e34136_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i7334327c1546457482bf0f7e50ce6898_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0b2625cfee254fe5bd022c71b569cc34_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie631656618b44857967833397e06fec9_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i31e93adb4e9549699596389a12799940_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id2c511f31dc24326ad7dda4999bb920f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic5bd8f3576744dbb9937b8fc5acb46bd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7115c5927b1044988cbc4a7afac5d19a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8211c596a57b4c8fa51ea79890dd7fd5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie40997f1539d4ab78b1902ae37f3fdbf_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6863787b8d794480a8e855a8efc726d1_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i94bbc3aa63a547e194fd20c0df543168_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i48f30fa4821c4564ab5fe93c1b6e9f4e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i38db183877eb40599f50bca9a09200a9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id38b3296be924219aedc8c2eac6ad11a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i68e42f1c79454e00b8d9a683c228e703_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i19998d9cec804861820443cfaaf99f10_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iccb4236637bd4d5e9a049f4a03f8595e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icfb2976a10e846e7966cb2ab49d1a67d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4ac59364cc9747a995f2b060f07c9b31_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8f5adf28c49448eba2120a76eb379e91_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i296abc347cdb4669b94752b68583d9c5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9d08ec7e8585431cbf339ad2f7e1c149_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i33faead3aa0448498b5977cd7bbe6061_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ief68b2a51bab47d1894d15d2313d332a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if0c2f4879451425f8a8974eba32bbf5f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idbed938c680f40789e9a484426d074c8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98a63b971bd34028b45b145cba0b2395_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia5528d6cd30546e5a8d7c4dcbfa0313a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i13e9f3ebcbed4a0a8cdb4c0df74931e7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i684c983bf3ed4ec4802b47cfd412ab10_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic74709fe8a874de7af154d53f79304e0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i83af315ef660490aa4b885bfa9bfce6c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i49611ab05b844f1fb78cf779db2fe26d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if9e76d66eb5f46628e171bfe49684857_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i019d56ef285043cfae4cfcebb2c90346_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2d80a56bb96a476ebd48eb643b2f43d6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i54746da158ce4bce9b69918fb58a959a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8f60dd2a66844bda84a962daf15eed87_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i5f10c7f52f7b4ba484c7a0eba502e770_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="id482aef724c247d3a9dad505cdf6170c_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i333effd5cb7d4295a431b14185556574_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i0d6d9c3f705947458160b1cd76174085_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i2eeaeba07b544a28b10787dd76e88301_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i95c80d7a709547958bf97b952bcb83fc_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ifa0fd024aaec4139811a323c7b840f17_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ib506aba19db74035bc8bbc02c41b43cb_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i240b880a602c492dbfb61a21ea0eb5d3_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i6ce004d28e074994bd7938f6ed719131_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i060f194c4a45460da0f50336db3489cb_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i847ef2f18d3f476a94b52dd7c886fec4_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i54b623b2879241278c6132571917a008_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i3a2bd0e8af1e4fa99300ecb39dac4805_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i31943445cf4647e9815814b40fe5c41f_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="iff0ebde6ab2d4004af640da15e05f719_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ifdea36b22a3849cd89bae3b8659e5552_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i1529ce9d9dec4e3999d400290ac6620c_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i55dc213d33f2452082c642024e4aaf21_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="id724f6a4b17744aaa91365c7ec213e22_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6dade5ca02694388a0ce84360f1c804f_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i95278dd6162e4f89b1e87fc5805eec36_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic0b6df7d2858470ea7228c5343664f9b_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i2a57474836104a719e68ea78c743320b_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i7f5eef8cd6f14c31b7d9d7c5922d0d4d_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i23fb65c6630f44d69f9baec8764c89e3_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i7bec1f6fecbe4fe790e9626d4040450f_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i650df15d071a48f9ad308100e9f9db92_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i74b903135a134cf39caaf1b9a70d3c0a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8b30a1a7cd3c4c3baa990fca6174db72_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i969e411a7436433db0a30ec91a49470c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia458119b7c404a179ca653e35a01c75b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i33f08df369b2427988e6e11513fa5c38_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3676d61890504a29b1b2f0c9b97bc5b3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8bbdfd41050a436d9d2e70b388d897ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1c7f5c48a4c34073a0af4d2bcef83f3a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4cee49232b1741e1b7292d30a0182e3d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9d90c76657d84918a66e5ac0515f67d3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib44ab6273835479c9cbe51aed6705e61_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i15dd70d707b34d789add5ecfa27969eb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ica36a3f9d76444ff8117f05911db0082_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i701cae7e28bf44fba78f29f859d17485_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2e816985f0354d14990486b7d9fa32d9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5ebf9c8cbcd9454c9ca1746e3cabb812_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1b731627c2204358b5c33793a78b3b6f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4c7335cfa2cb4a56be2db7b2843f2bd1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iaf30c1ba1e914625955d4027a7c9d97d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7d96d8c704af4109b4494741538a09c3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i15b61365f4c84504907452a393c0c978_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6a312ffda8e1499fb683210529f71461_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idbc438e0b3164ea1934a0d52645e75fe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie77cb2cbbcc3497190e5e9611541ef32_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i13959021e84d4dcc881071aedc143536_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ief653dd50f314a66ae8d96c62f649c59_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic07d10f6477546e0b1b1d3e46b8fad47_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9ba076567c05486081a550f00fdc2edc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6ed260be42124aabb60094700d2e6d2d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i21bd9e893e294ae78c62758ac0007634_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i701fe9109c104be898d66144c5fdff56_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0fcdaba997e14e45bc26beec23bd7875_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if69a1a642f0d4979adb8ba239f6c10b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie0c9d0e3bc9048688ea0d0890580f4e4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iecf61485c1a34f73be6f360b91caaacd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i943c3dc5d31148128af05f6e108c9796_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id7d4bf814515415abde86a6c80fbe736_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i603ed4709303491bbaf26a1b755d1deb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i752d1ee7e5c441c790664845ece3aec0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i87490ba462994db1b1ee01e11796fad2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0e83105b10aa4d8fa9264667fda8c681_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i154da4d6fbc040f69cb4f170cc223a94_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id57dfc841ee9417094c91d03520271a9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7038fb1eaaed4930bef39d8439888cd3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic1cf9464dcb34891a718fe65cec9ab21_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5fcef9f911324937acdbe37c9ab67e7b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ied9b88caa01b437aa817087abe6032ec_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3ceb7095584d49fc80652713cb7854c3_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FirmCommitmentPublicUnderwrittenOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ic890dfa175f245fe8e241c46e046dbaf_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i41e82e0130f64686907e6f18d7557650_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ic58db151e3a448e7b3ee73f0be5d0b0d_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i45db6deb036b486ba26f489e393fc752_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="if64c499ae2254674a5686716390e3f83_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i9e3a6e8ec3fa4af0b64eee0e868f565a_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i58c33273de6d410b9cdecf2a5c0debe0_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i368bb594cc624e83a77bf733371fae70_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="id820317bddf4434e96ff1a911394e774_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idd9449b1c89445c48a12627858463cf0_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i48390acd93f242ebbb42fc23fd256a82_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i518fa15db0064fec812c4b780bc7655b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i15f5e76a013f47d39dc0003413f9d4a4_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iae18551f4d2a403db5bd358b0c682d8a_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i73a39827bd724ee6a7232870c129f33d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbb4c3a370434273bd0aefee45b77bf2_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i3a3b1d36356f4d3eac2cc22fbf399979_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic81e31ef601944c49da28eddf02a77de_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i9db3c7b4a5914f65b0e7482d13d66f9f_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ibfec87d8a5404f13b27eab46f40228ef_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6bec22401c70482e823b9a2e5d36d610_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idf29abb47caf4681942fe396155e2ac1_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6ed40dc4661a49b8968604842ade9122_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a118b8388e14ba9b1059b88d91a8477_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ice1c157abfbe45f194053705b2702f65_I20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="ib959c0e3f072409998cd0f0023270469_D20120901-20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-09-01</startDate>
            <endDate>2012-09-30</endDate>
        </period>
    </context>
    <context id="ia69015b5eb8740b6a029ef0b991a9402_I20120930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="i75bf3bc533454969826e25fc96e3af8f_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i970f2dcb0eab418e9a653c77c4d9cc4f_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i70674713bb8e4d3683f61a49dbc782c9_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:LesLaboratoiresServierMGD007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i91dc53f73fa84402824473c88b70867e_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i7828f41496b2476a96ab41b01992b9b4_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="ia12d8b77e71f41e4ad0b803eac53f1a0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c6c3b2f59854f77ae4c3719194e6f29_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i09b6a87cc6bb4e9fa8724ece15b105e0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5c4e22b89924229a57a8eb74bb20cad_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie989ab30d5da4147917fd55e613200bb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6f8323bafdc34797924db0952bd973d0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i27244fec8880414bb6b1cfc52c333374_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic146a3b466194000a57ac908f0e5c5be_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="iacab77e6779347788a780579fa1a685e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8c16b322b44845d9b43c3c5ce1fd49af_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i30a9f07d07b94663a8cde320960c506a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie4087c84e7e44db6bae261d20124a913_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i55adada0a7564bdf9cfe077725d854b9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i08e4673e6a2a448182624726fd572b76_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a5eb519ef2e4cbc8181141d7cd9276d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5c21a31445540e69dbc3a6f5f639ab6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie953d43978514183bcdd8c7b4ab3ab96_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idd651a75afdd4d7d95c4e21996253290_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i2eb1aca92da74f588459f1372f4a49b2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3b2a9d94d2dd4bea92a57ffb8904cbee_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie736d7bf024b4ae28e4589d3b604e1df_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5739a109487c4754a883c99176a1efd9_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i054926fddff24ee5807d883aad5e2a1f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i62c1e47bb3ef4615991f7912494745cf_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i54fd08a4f3f743b49797b697a1ce3106_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i02cc1ebe209c402a8c800be888313cd7_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ie967f030aa6b4bc8aa81afe083e3c526_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i8e2cd88b1fe140d6a7dfa35faadde661_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i5c8b2113702b464282bfe3e9b94f4d74_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ib9214916d72546d59baaee9785a7e087_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie723c1c82d87464d9ed56b45a59bacc5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i273a5f224d3e4ecf828034c5e3e0f859_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7a77af8c6e3e41ff8d11e8fe34dc64fc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i49febe140c734397af0ac451febc2e05_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i372a9ad3922943f491a1fa7dd2c30d5d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i422a064f422b48ae8e9a505da5963ed5_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i6e1a6fcd218941a6baa89073c11c5da2_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i93ea6f505d99415186f0268a4bba80ef_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i454fbe875e5b4db7a40944d31eb23a84_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9b030de878e8406ebf1f621232078e07_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic3e00c8e472e49d588cd53f7014d9b81_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib66184941d714664ae08c0e838d10181_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1a913a00b68549eeb34e0b8808b5269e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icff895ca6df94222b46a51a086d8de19_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic79500c2c7ee4616be6fac7a8cf8e3c0_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i5ccfecbf14a74088903da62adfcb0fa7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if31b162e8e37461f9128da55a95f93e6_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8ff8158fdeb940b6918114f76ea442b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic0c8668b262748c89e872fcfa0fb50dc_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ie8d755c340e64be8bdab95b9056b73dc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idfa5b8cd82a44f608083484c65993b70_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ied09d3487eed4159b54d3625844a0195_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6891ca0af0c243698d6979e49cb85830_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ife5de15de5594f5286936ecb877c1796_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i3a3d1e16084d4603bb861c52410f4c34_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performance_obligation">
        <measure>mgnx:performance_obligation</measure>
    </unit>
    <unit id="exclusive_license">
        <measure>mgnx:exclusive_license</measure>
    </unit>
    <unit id="milestone">
        <measure>mgnx:milestone</measure>
    </unit>
    <unit id="component">
        <measure>mgnx:component</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGFibGU6YTcyZDc0ODhkMzIwNDgwMzgxMDQyMmY5OTc1N2EwZGEvdGFibGVyYW5nZTphNzJkNzQ4OGQzMjA0ODAzODEwNDIyZjk5NzU3YTBkYV8yLTEtMS0xLTA_65237a41-bd71-4800-958d-67fe899d8e1a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGFibGU6YTcyZDc0ODhkMzIwNDgwMzgxMDQyMmY5OTc1N2EwZGEvdGFibGVyYW5nZTphNzJkNzQ4OGQzMjA0ODAzODEwNDIyZjk5NzU3YTBkYV80LTEtMS0xLTA_f3907f43-fee3-45d9-9525-bccf11101a21">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGFibGU6YTcyZDc0ODhkMzIwNDgwMzgxMDQyMmY5OTc1N2EwZGEvdGFibGVyYW5nZTphNzJkNzQ4OGQzMjA0ODAzODEwNDIyZjk5NzU3YTBkYV81LTEtMS0xLTA_dc55f07a-2ded-47fc-996a-4dceb6a788e0">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGV4dHJlZ2lvbjo1MDAxNmMyYWZmMmU0NDcwYTk3MDViMGE5MTc1MDE3MF8xMzA_3a145b30-fcff-4075-9ac6-65a347bc6d90">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80L2ZyYWc6NTAwMTZjMmFmZjJlNDQ3MGE5NzA1YjBhOTE3NTAxNzAvdGV4dHJlZ2lvbjo1MDAxNmMyYWZmMmU0NDcwYTk3MDViMGE5MTc1MDE3MF8xMzE_89879c39-d5ba-4b77-9226-4dca9b08f4bb">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMi0xLTEtMS0w_22a5eb3f-dcda-4957-8cb7-2400dfcd1d46"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMi0zLTEtMS0w_e427ca02-80a5-4f53-b7d3-7c14d282f103"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMy0xLTEtMS0w_e7161534-90cd-4a36-ac84-a2c18eb5d430"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfMy0zLTEtMS0w_1b5e3368-363f-4e56-83cd-199a620a4b1f"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfNC0xLTEtMS0w_718e3d04-0f39-429e-b49a-251d3f46540d"
      unitRef="shares">48914284</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yMi9mcmFnOjQ2MDA3ZDUyZWU3NjRiOWM5NjEyMGFmYWY3NzFhNDI0L3RhYmxlOjY2NTkzYWFmZmRmNjRjNzJhMDFlZjQxZjQ2YjQ3MDcyL3RhYmxlcmFuZ2U6NjY1OTNhYWZmZGY2NGM3MmEwMWVmNDFmNDZiNDcwNzJfNC0zLTEtMS0w_e896a41c-def4-463e-b4eb-af920b11a858"
      unitRef="shares">42353301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic1cf9464dcb34891a718fe65cec9ab21_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDA4_d48d60fa-3511-4c66-ad50-e72151633519">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfOTY1_57414c3c-a125-4d11-ab1b-84005d3778dc">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ied09d3487eed4159b54d3625844a0195_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy0xLTEtMS0w_748009d2-9a3c-44a7-80cf-97f9c5a4716d"
      unitRef="number">0.737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6891ca0af0c243698d6979e49cb85830_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy0zLTEtMS0w_eb9e18a6-f02a-457e-88dc-feaae2b1244f"
      unitRef="number">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ife5de15de5594f5286936ecb877c1796_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy00LTEtMS0w_26078d02-d3ab-4428-8af8-8d4cde6e29e9"
      unitRef="number">0.678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3a3d1e16084d4603bb861c52410f4c34_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfMy02LTEtMS0w_c390dc2b-2f4f-4eca-ade4-b4809c087335"
      unitRef="number">0.722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ied09d3487eed4159b54d3625844a0195_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC0xLTEtMS0w_8f633f2b-18bf-495b-8cbf-076330e01528"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6891ca0af0c243698d6979e49cb85830_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC0zLTEtMS0w_0bff143f-5851-45a9-addb-5e1aac950e3e"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ife5de15de5594f5286936ecb877c1796_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC00LTEtMS0w_889f94b0-933d-4f42-b2d3-a5d620baaa7a"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3a3d1e16084d4603bb861c52410f4c34_D20180101-20180930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81OC9mcmFnOmMyY2QwMTZhMmRlNjQzYjQ5Njk1ZjQ4MmY0YTQ5YjUxL3RhYmxlOjlmMmFlN2MxOGRhZjQwMDU4MjkzY2I5YjVjMjM1ZTlkL3RhYmxlcmFuZ2U6OWYyYWU3YzE4ZGFmNDAwNTgyOTNjYjliNWMyMzVlOWRfNC02LTEtMS0w_d7eef47f-dde9-417c-a748-97f5c83f87fa"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <dei:DocumentType
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl84Mg_b004dc42-6409-464b-ba37-168cf449a467">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZDhmOTIwOGM4Njc0NGM3MTgwZjRmNWM5OWE2MmVlOTQvdGFibGVyYW5nZTpkOGY5MjA4Yzg2NzQ0YzcxODBmNGY1Yzk5YTYyZWU5NF8wLTAtMS0xLTA_01718024-262b-4517-9dfc-6f047f876b3e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xMTg_14e8a085-8730-4b34-81ce-3e2f099b4c05">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6OTQzN2Q5ZGQ5YWM5NDg4NWI4ZTNmMzQyOTg4NGIxMzYvdGFibGVyYW5nZTo5NDM3ZDlkZDlhYzk0ODg1YjhlM2YzNDI5ODg0YjEzNl8wLTAtMS0xLTA_7a4a6bdc-6894-4cdf-981a-685e45443ae9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yMTA_6d294b9b-c99c-46f5-860e-21469b6f09e0">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yMTM_9aa12fde-16df-41ba-97e3-c6098166199d">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8wLTAtMS0xLTA_cf6b29b8-38f6-4f5e-8808-01dd151eddbc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8wLTEtMS0xLTA_ba7de26c-d882-4468-b893-7362b1bace84">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxZDM5OTI0Nzc1MWY0NGVlODRlYmZmZjY2MTc5ZTA4M181_c691109e-d356-4962-8aa6-bc19e8ccbdcc">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxZDM5OTI0Nzc1MWY0NGVlODRlYmZmZjY2MTc5ZTA4M184_83c3b9fd-da5f-4ac1-a420-2ac5cb0c9d92">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoxZDM5OTI0Nzc1MWY0NGVlODRlYmZmZjY2MTc5ZTA4M18xMg_823db30a-d1c6-47ed-91bb-e30de883d208">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6NDYwYzU4ZGQ0MjdjNDJhMGE5NDkxYjkxZDU0Y2Y0NTkvdGFibGVyYW5nZTo0NjBjNThkZDQyN2M0MmEwYTk0OTFiOTFkNTRjZjQ1OV8zLTEtMS0xLTA_183285a1-7b91-4773-bf89-108107416ea3">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yNzM_b6e9443f-6897-46af-8b54-42cf822882c9">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8yNzY_6d6012a1-1c98-466e-97c8-e7a33b933f05">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6N2NkNDMwNzEzNmM0NGQ0ZTk4ZWU4YjRkY2FlNjE4MjQvdGFibGVyYW5nZTo3Y2Q0MzA3MTM2YzQ0ZDRlOThlZThiNGRjYWU2MTgyNF8xLTAtMS0xLTA_606bfada-2316-43c6-aa23-2ef74eea29dc">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6N2NkNDMwNzEzNmM0NGQ0ZTk4ZWU4YjRkY2FlNjE4MjQvdGFibGVyYW5nZTo3Y2Q0MzA3MTM2YzQ0ZDRlOThlZThiNGRjYWU2MTgyNF8xLTEtMS0xLTA_6fad3a0f-bdf9-40cf-aec6-0ede0bf8915b">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6N2NkNDMwNzEzNmM0NGQ0ZTk4ZWU4YjRkY2FlNjE4MjQvdGFibGVyYW5nZTo3Y2Q0MzA3MTM2YzQ0ZDRlOThlZThiNGRjYWU2MTgyNF8xLTItMS0xLTA_9594fc4d-f76c-4686-ade9-7c44d9455e7d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTQw_b0aeeeb4-f852-40f2-a36a-dfbaca71121c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTQx_d36fb424-9cb7-44fe-818c-dcfaa62326d4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZTJjYjIyM2EzZGI5NDUwNGIwNzU3YTdiZWVmYmNkMTUvdGFibGVyYW5nZTplMmNiMjIzYTNkYjk0NTA0YjA3NTdhN2JlZWZiY2QxNV8wLTAtMS0xLTA_39d7291f-2507-4976-bf2c-ceac9983a9c6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZTJjYjIyM2EzZGI5NDUwNGIwNzU3YTdiZWVmYmNkMTUvdGFibGVyYW5nZTplMmNiMjIzYTNkYjk0NTA0YjA3NTdhN2JlZWZiY2QxNV8yLTMtMS0xLTA_f69883dd-acd1-4616-9677-2502e0e97a22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGFibGU6ZTJjYjIyM2EzZGI5NDUwNGIwNzU3YTdiZWVmYmNkMTUvdGFibGVyYW5nZTplMmNiMjIzYTNkYjk0NTA0YjA3NTdhN2JlZWZiY2QxNV80LTEtMS0xLTA_07ca1a31-4408-4d12-ba8d-dabd897408c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTQy_c452b81e-95ef-4daf-85c5-deb4a99e44c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i675263e40bbe4a209433798168310a91_I20191101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xL2ZyYWc6N2RiZDZmZGIzMWJiNDQ1NGJiNDhkY2YwM2Q3NmRlYTIvdGV4dHJlZ2lvbjo3ZGJkNmZkYjMxYmI0NDU0YmI0OGRjZjAzZDc2ZGVhMl8xOTMx_8c106d6a-173a-48bd-8fac-324af63f9c02"
      unitRef="shares">48917095</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNC0xLTEtMS0w_09f78667-30ce-424b-a3ea-09bb807b9612"
      unitRef="usd">156593000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNC0zLTEtMS0w_164075fd-0fe5-41f8-99aa-4bc301adfc0f"
      unitRef="usd">220128000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNS0xLTEtMS0w_d94d853d-160d-4b59-9ae9-87ccd802aa0b"
      unitRef="usd">97823000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNS0zLTEtMS0w_fd4d3810-82a8-482b-81b5-c8860161769b"
      unitRef="usd">12735000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNi0xLTEtMS0w_4b6f95f3-e694-4630-a5eb-428293c276c2"
      unitRef="usd">9503000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNi0zLTEtMS0w_6c3e6b2e-7b22-4cc6-891b-a96dc35ad656"
      unitRef="usd">29583000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNy0xLTEtMS0w_c5d23d61-ac19-4c64-9e9f-685b5620563c"
      unitRef="usd">12019000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfNy0zLTEtMS0w_fb4bb519-9489-4351-bd24-54a0eb820fec"
      unitRef="usd">6406000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOC0xLTEtMS0w_cf2e4667-62f7-4db8-a309-443418982c3e"
      unitRef="usd">295000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOC0zLTEtMS0w_2fe0c782-aeb3-4539-8bdf-cf63ef0af81b"
      unitRef="usd">272000</us-gaap:OtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOS0xLTEtMS0w_b0d0dc82-7f26-4681-a386-79fb9460089c"
      unitRef="usd">276233000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfOS0zLTEtMS0w_773bb720-55fa-46b4-b393-070a303f97ed"
      unitRef="usd">269124000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTAtMS0xLTEtMA_28623869-b483-4d9d-b8e0-0dd339ec8cec"
      unitRef="usd">49966000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTAtMy0xLTEtMA_a34a4155-efbc-42ed-81fb-3a16bf1e38cd"
      unitRef="usd">56712000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTItMS0xLTEtMA_c7378be5-e46b-4174-bf4d-c63ff30f80d2"
      unitRef="usd">25252000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTItMy0xLTEtMA_3f5ad9c3-357f-48dc-b5a8-8e59ebe880f0"
      unitRef="usd">6294000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTMtMS0xLTEtMA_04b5c901-4dd1-4273-94c2-c370ddbbb3a1"
      unitRef="usd">351451000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTMtMy0xLTEtMA_f2737e59-6fab-458f-9662-e453c242a751"
      unitRef="usd">332130000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTctMS0xLTEtMA_9adde04e-d163-439e-ae0e-39251c6a2f4d"
      unitRef="usd">2543000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTctMy0xLTEtMA_28ed8391-311f-47d0-b67d-e3baceb4f11f"
      unitRef="usd">4005000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTgtMS0xLTEtMA_aeb5a8a9-ef16-4b81-9574-4bd47ccc7820"
      unitRef="usd">28389000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTgtMy0xLTEtMA_65dd1fd6-c886-40f2-803c-680423ef617b"
      unitRef="usd">33021000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTktMS0xLTEtMA_9fe46577-cfd6-456d-bf75-1eeeb5840787"
      unitRef="usd">23571000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMTktMy0xLTEtMA_80cf0338-b6b9-4bce-84f5-9f039c6357b7"
      unitRef="usd">21721000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjAtMS0xLTEtMA_400ef1ac-feb2-44f2-8f90-d68faf8a8857"
      unitRef="usd">0</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjAtMy0xLTEtMA_c05c4ffb-d1c1-41c1-a3b6-7909ce29c22f"
      unitRef="usd">1018000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjEtMS0xLTEtMA_9dcb05f9-3b3a-4534-b387-ca3c37f58c3e"
      unitRef="usd">2956000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjEtMy0xLTEtMA_a85dcb1d-212f-44e5-b66a-9a1a38b9b2dd"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjItMS0xLTEtMA_2bece2e3-f0e8-4f32-a23a-71e58748be5f"
      unitRef="usd">175000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjItMy0xLTEtMA_bc6dc633-608e-4773-9936-636a28591bef"
      unitRef="usd">175000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjMtMS0xLTEtMA_9aa6a7d0-ee2e-4d12-ab43-53ac880f9a39"
      unitRef="usd">57634000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjMtMy0xLTEtMA_cc4d6194-2d63-4872-8d74-d6cbff3fb1a6"
      unitRef="usd">59940000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjQtMS0xLTEtMA_2624405e-2630-4b10-b1f9-268d35a625b5"
      unitRef="usd">10037000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjQtMy0xLTEtMA_2a37be7d-6291-4c09-bd19-61b6b79b77df"
      unitRef="usd">19001000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjUtMS0xLTEtMA_7a5e02ca-44ae-4870-941f-640182ee1383"
      unitRef="usd">28582000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjUtMy0xLTEtMA_a23a3e66-8441-4600-812d-32a25462d15d"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjYtMS0xLTEtMA_3842952f-24af-4c6f-9299-98ab0ed120f8"
      unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjYtMy0xLTEtMA_33b02f1a-ae65-48c7-8a48-88efe84794af"
      unitRef="usd">10312000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjgtMS0xLTEtMA_099d202b-7115-4622-9a86-16ea7879b9ac"
      unitRef="usd">96253000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMjgtMy0xLTEtMA_cfefa3b9-4d8d-40f0-b714-d599fe2cf3e6"
      unitRef="usd">89253000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzAtMS0xLTEtMA_917056ca-6087-4612-abe7-1391befe1461"
      unitRef="usd">489000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzAtMy0xLTEtMA_cede14f2-c3c0-4216-a4c8-dc29f7b6718c"
      unitRef="usd">424000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzEtMS0xLTEtMA_83e167e8-0c83-4ce8-ba0a-5e7e6d4ad7e6"
      unitRef="usd">866372000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzEtMy0xLTEtMA_b8f85e72-c5d8-4714-88cb-337665b57eb8"
      unitRef="usd">732727000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzItMS0xLTEtMA_780c0f25-f4a1-4cd1-8336-2966434f311f"
      unitRef="usd">23000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzItMy0xLTEtMA_8b6e92b2-71e9-48a9-9def-bc8a419ca907"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzMtMS0xLTEtMA_76117e31-a08c-4584-81b4-07bf989ace11"
      unitRef="usd">-611686000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzMtMy0xLTEtMA_be7f6bce-296b-4bac-a9ed-66c46b318b87"
      unitRef="usd">-490271000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzQtMS0xLTEtMA_99a2e05f-a6dd-41a4-ad91-af4c6681acb7"
      unitRef="usd">255198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzQtMy0xLTEtMA_e0fc95b9-32ad-4210-bd68-e24eb07af1c1"
      unitRef="usd">242877000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzUtMS0xLTEtMA_9b138a71-a320-4a54-b9fe-0f64e50646b3"
      unitRef="usd">351451000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8xOS9mcmFnOmE2NzYxMGM1OWNlMjRmOWViMWM0NWFkYTJlNmNhOTdlL3RhYmxlOmE1Yjc0NGFlM2EwNjQ5MjdiZWY2YWZiYzViNWNkNWY2L3RhYmxlcmFuZ2U6YTViNzQ0YWUzYTA2NDkyN2JlZjZhZmJjNWI1Y2Q1ZjZfMzUtMy0xLTEtMA_7b7da4c2-c39e-4954-aa07-de8931799fee"
      unitRef="usd">332130000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ic670a1b26e2f445cb693f4e6b6d75b2f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy0xLTEtMS0w_08bcf249-7411-4d74-97ec-cab7f07c450b"
      unitRef="usd">17984000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8076bbde2d05426b988cb552d4160afc_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy0zLTEtMS0w_540ea6ea-b18c-43f0-8c6c-0809bd69d8de"
      unitRef="usd">20617000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i473ba08d93ee45e2bf84bce5d72899d3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy01LTEtMS0w_80f497c5-1c6a-477a-b228-344cf2003f74"
      unitRef="usd">37468000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ef682dfc0994eada511c90370c63e40_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMy03LTEtMS0w_15bc8cd2-493e-406a-9caf-04682f177321"
      unitRef="usd">43670000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia506c971040142629fb54680daa17aec_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC0xLTEtMS0w_5fc7fe32-e8d3-4b1b-99e3-18f803833518"
      unitRef="usd">757000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3d8b967295d4ec9beb9dbef66e34136_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC0zLTEtMS0w_a73e43a9-508d-49da-85c4-7a673be45daa"
      unitRef="usd">181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7334327c1546457482bf0f7e50ce6898_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC01LTEtMS0w_52f0a20e-48cc-454c-a9ec-4b08a9d25e83"
      unitRef="usd">1528000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b2625cfee254fe5bd022c71b569cc34_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNC03LTEtMS0w_e418430c-8657-4fed-b594-036f332905ab"
      unitRef="usd">657000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS0xLTEtMS0w_e6a44181-b0a3-49f8-b8a0-4023ece0ed66"
      unitRef="usd">18741000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS0zLTEtMS0w_de330eb7-501f-4795-bb60-375541f69f49"
      unitRef="usd">20798000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS01LTEtMS0w_c0fbc13f-2ba6-48b8-b013-2273e23b8bbb"
      unitRef="usd">38996000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNS03LTEtMS0w_e3b135f6-bb76-42c5-b81f-fabab6a377a4"
      unitRef="usd">44327000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy0xLTEtMS0w_49316c0d-ce53-4a35-ab7a-5cdb5de7056e"
      unitRef="usd">44852000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy0zLTEtMS0w_8afbcc56-feab-4d8a-89f4-2d37c6b2c8a3"
      unitRef="usd">46218000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy01LTEtMS0w_798b8b1c-a226-47eb-96e4-f1747230e23d"
      unitRef="usd">143352000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfNy03LTEtMS0w_7a65a2a6-f3b8-4a78-bb56-d09f51c24b8f"
      unitRef="usd">143902000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC0xLTEtMS0w_e15b3a1d-e9cb-4afb-9826-4e5404b535eb"
      unitRef="usd">11833000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC0zLTEtMS0w_15b97bfa-148d-4da8-85dd-d6cd9e348f63"
      unitRef="usd">9584000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC01LTEtMS0w_be58308b-f320-42f8-b8fe-0220264fe012"
      unitRef="usd">34174000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOC03LTEtMS0w_11b8b223-bc4e-4dd6-a740-670e03cde818"
      unitRef="usd">29953000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS0xLTEtMS0w_74c13f0e-4533-4393-87d8-ccbde7372278"
      unitRef="usd">56685000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS0zLTEtMS0w_bdf4b4d3-83c4-41f0-93dc-9563bfb88019"
      unitRef="usd">55802000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS01LTEtMS0w_202d2bff-c24a-4479-8d2f-76127920c571"
      unitRef="usd">177526000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfOS03LTEtMS0w_f8e767df-2554-4de2-a73d-becad4d30431"
      unitRef="usd">173855000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtMS0xLTEtMA_15f0ff07-c45e-4978-8dfa-234bedbccb4e"
      unitRef="usd">-37944000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtMy0xLTEtMA_08e31a81-c3b2-4379-98fe-e4ded6abdde4"
      unitRef="usd">-35004000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtNS0xLTEtMA_f6a2b1bc-8794-445e-8d21-1897f3239f02"
      unitRef="usd">-138530000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTAtNy0xLTEtMA_4bad4d23-37e7-435b-b74e-75b9375b74bc"
      unitRef="usd">-129528000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtMS0xLTEtMA_36969f25-f5f8-420b-9a41-5cd21bf90b1e"
      unitRef="usd">-6687000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtMy0xLTEtMA_bbb57271-5b14-4904-98aa-842d97a2ece9"
      unitRef="usd">975000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtNS0xLTEtMA_73b3f081-6ac8-4bff-84f8-533baa7f6abc"
      unitRef="usd">17115000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTEtNy0xLTEtMA_98d4122e-d27b-4ee7-916c-ea84541bec45"
      unitRef="usd">2719000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItMS0xLTEtMA_7e9b190d-11e3-4792-88f3-3f6cea119162"
      unitRef="usd">-44631000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItMy0xLTEtMA_7c4d8937-16d7-4cd2-948a-1c40d538f043"
      unitRef="usd">-34029000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItNS0xLTEtMA_f2844cf8-5627-432a-acc8-88af6f98f1dc"
      unitRef="usd">-121415000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTItNy0xLTEtMA_07da916c-acef-4993-86de-e99a1826bd5d"
      unitRef="usd">-126809000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtMS0xLTEtMA_6f57799f-637e-4211-b3f1-cbf7d074a3ff"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtMy0xLTEtMA_e5adbfa7-db6b-43b3-96b8-939d5c1974f3"
      unitRef="usd">-18000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtNS0xLTEtMA_c25f534c-0dc4-4bda-836d-5549a6a18c81"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTQtNy0xLTEtMA_5da52e43-38a5-422b-bed2-223da2eaae97"
      unitRef="usd">61000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtMS0xLTEtMA_4b78263b-467a-4318-af0a-a5cbbbdb0916"
      unitRef="usd">-44642000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtMy0xLTEtMA_a2a758c3-4ef2-4506-8b30-2924232a1ff7"
      unitRef="usd">-34047000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtNS0xLTEtMA_b475245c-7460-49ae-84c5-d4466352313c"
      unitRef="usd">-121389000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTUtNy0xLTEtMA_8334e74f-a513-413f-8dde-49edec346772"
      unitRef="usd">-126748000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctMS0xLTEtMA_a9845b41-4b19-4666-b02a-8a3491954c87"
      unitRef="usdPerShare">-0.91</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctMy0xLTEtMA_54abad7a-27df-405e-9b88-a28f1f9a18b1"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctNS0xLTEtMA_2d4c9171-c081-4f23-bc95-8a74cdb17c4e"
      unitRef="usdPerShare">-2.54</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTctNy0xLTEtMA_6b430ca2-66f4-402d-bcd2-4c3eac4fa362"
      unitRef="usdPerShare">-3.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtMS0xLTEtMA_c7ae04b2-a347-416c-833f-843094f4e82e"
      unitRef="shares">48902766</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtMy0xLTEtMA_4f30d43c-6a61-47dd-886c-1cc30314bdac"
      unitRef="shares">42239327</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtNS0xLTEtMA_1c07ca43-c330-49ff-968d-20dd154101f1"
      unitRef="shares">47796957</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yNS9mcmFnOjMzNTJkYzEzZGNjMzQyNzdhNTQ5MmMwNmY4NWZlM2U0L3RhYmxlOmQyYTUwZTRmZjAxZDQ1Njc5MTE0ZDdkYTZlN2Y3ZmM3L3RhYmxlcmFuZ2U6ZDJhNTBlNGZmMDFkNDU2NzkxMTRkN2RhNmU3ZjdmYzdfMTgtNy0xLTEtMA_af4659fb-8ca3-4e58-89fa-08bee14ea003"
      unitRef="shares">40462658</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i31e93adb4e9549699596389a12799940_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xLTEtMS0w_6d099a48-b422-4d33-bd2b-11aa9e4d3167"
      unitRef="shares">42353301</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31e93adb4e9549699596389a12799940_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0zLTEtMS0w_748c2d94-5ada-46d7-b649-d2e1fbf6675c"
      unitRef="usd">424000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2c511f31dc24326ad7dda4999bb920f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy05LTEtMS0w_a6b90205-df70-4475-995a-66b51ae50e28"
      unitRef="usd">732727000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5bd8f3576744dbb9937b8fc5acb46bd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xMS0xLTEtMA_b53cd580-aca7-4991-b221-c316d25513b0"
      unitRef="usd">-490271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7115c5927b1044988cbc4a7afac5d19a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xMy0xLTEtMA_dede03a6-5110-4e0e-ab27-8bfa4e748103"
      unitRef="usd">-3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMy0xNS0xLTEtMA_03e3a079-b7e5-43b3-b13f-9bb4b02082bd"
      unitRef="usd">242877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNC05LTEtMS0w_3e125afe-0a3f-4c62-b40e-beab3b622afc"
      unitRef="usd">3750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNC0xNS0xLTEtMA_08019706-30b7-48c5-a56e-f5aced603451"
      unitRef="usd">3750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS0xLTEtMS0w_77201495-ff2d-47de-9b07-51979a925f13"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS0zLTEtMS0w_16468b3b-d0af-466f-bd13-719eae92a79c"
      unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS05LTEtMS0w_c5757815-a7ce-46cc-a91d-ed2c41df0232"
      unitRef="usd">118594000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNS0xNS0xLTEtMA_b9ca51ee-c6f2-4367-be9e-b98513caa10f"
      unitRef="usd">118657000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi0xLTEtMS0w_9f39e4db-3771-4ea2-9cfe-f7434df80722"
      unitRef="shares">126707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ic2a2b28ec461415fbae9a985e07d5467_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi0zLTEtMS0w_a0b59610-9316-48ca-bd52-533322e16639"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="icf23327df95f42fd9b38814381d2ac60_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi05LTEtMS0w_4d0f044b-6223-4778-831c-d5eaab042da0"
      unitRef="usd">346000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNi0xNS0xLTEtMA_4ef40b20-e1f3-40fe-b42f-f2fc92a01b8e"
      unitRef="usd">347000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8211c596a57b4c8fa51ea79890dd7fd5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNy0xMy0xLTEtMA_a7981477-5115-408e-b781-98c0300df4c3"
      unitRef="usd">3000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfNy0xNS0xLTEtMA_f49211cc-eb70-4167-9cf0-b8c353c7089c"
      unitRef="usd">3000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="ie40997f1539d4ab78b1902ae37f3fdbf_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOC0xMS0xLTEtMA_175482fd-bcf8-43a3-a3ac-7a31e303cf8d"
      unitRef="usd">-45017000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1510032c6b2e4be58c7b09b1206ccfef_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOC0xNS0xLTEtMA_ef53d273-f62a-4e4a-af6f-c9b0313d085e"
      unitRef="usd">-45017000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i6863787b8d794480a8e855a8efc726d1_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xLTEtMS0w_be368fdf-8aaf-4834-883e-37375969fa31"
      unitRef="shares">48805008</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6863787b8d794480a8e855a8efc726d1_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0zLTEtMS0w_7959b767-455e-410b-9575-1ac43df37a0f"
      unitRef="usd">488000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94bbc3aa63a547e194fd20c0df543168_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS05LTEtMS0w_8160f4dc-6606-4ca3-b9ce-01ed8575e485"
      unitRef="usd">855417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48f30fa4821c4564ab5fe93c1b6e9f4e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xMS0xLTEtMA_a9742852-442c-417f-af15-6816a3f9d0ae"
      unitRef="usd">-535288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38db183877eb40599f50bca9a09200a9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xMy0xLTEtMA_3d5e18b9-e509-466a-ab01-0a1dabc8a2fd"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id38b3296be924219aedc8c2eac6ad11a_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfOS0xNS0xLTEtMA_7d81db50-10fc-46b0-bbe4-a1688809509b"
      unitRef="usd">320617000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i68e42f1c79454e00b8d9a683c228e703_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTAtOS0xLTEtMA_933b81ab-1f7a-4604-97d6-8111980edeb1"
      unitRef="usd">4933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTAtMTUtMS0xLTA_a94e021c-80e8-4f36-b192-3f0fe6c41882"
      unitRef="usd">4933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="iccb4236637bd4d5e9a049f4a03f8595e_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtMS0xLTEtMA_53166655-6f3b-418e-8adb-e35cc030a5ad"
      unitRef="shares">88443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="iccb4236637bd4d5e9a049f4a03f8595e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtMy0xLTEtMA_b14de136-dc59-45f6-b8a6-e52fd364ef97"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i68e42f1c79454e00b8d9a683c228e703_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtOS0xLTEtMA_e62e4119-4aed-40a5-bd14-96ef54d93901"
      unitRef="usd">633000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTEtMTUtMS0xLTA_105d63df-e6e5-442d-97e7-6c04e239d6e5"
      unitRef="usd">634000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="icfb2976a10e846e7966cb2ab49d1a67d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTItMTMtMS0xLTA_65173840-0087-49d7-80c9-fc0c972f2371"
      unitRef="usd">34000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTItMTUtMS0xLTA_b791779d-87f3-4291-be80-af4ce07a9202"
      unitRef="usd">34000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="i4ac59364cc9747a995f2b060f07c9b31_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTMtMTEtMS0xLTA_956529eb-c62b-46f8-9314-9528c9896b9d"
      unitRef="usd">-31767000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i19998d9cec804861820443cfaaf99f10_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTMtMTUtMS0xLTA_a3dc45b4-c4ff-4284-845e-efe14cda0708"
      unitRef="usd">-31767000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i8f5adf28c49448eba2120a76eb379e91_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMS0xLTEtMA_791c1f3d-5bcc-4a98-88f0-2b8343cdf411"
      unitRef="shares">48893451</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f5adf28c49448eba2120a76eb379e91_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMy0xLTEtMA_5243536e-71f5-495a-88c7-a2814888c2e7"
      unitRef="usd">489000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i296abc347cdb4669b94752b68583d9c5_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtOS0xLTEtMA_6a1e07ee-2921-41e5-9dec-144abec5a642"
      unitRef="usd">860983000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d08ec7e8585431cbf339ad2f7e1c149_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMTEtMS0xLTA_32ed8746-edb5-43c1-a938-ae69167a7fac"
      unitRef="usd">-567055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33faead3aa0448498b5977cd7bbe6061_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMTMtMS0xLTA_407a79e1-e584-4b42-9850-f345459c503c"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief68b2a51bab47d1894d15d2313d332a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTQtMTUtMS0xLTA_04668bca-dec4-4433-9927-ab273d85665f"
      unitRef="usd">294451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if0c2f4879451425f8a8974eba32bbf5f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTYtOS0xLTEtMA_62280b1d-f29c-48d9-b4b3-89368eca9cc3"
      unitRef="usd">5352000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTYtMTUtMS0xLTA_ce2c183b-f652-4a83-b3ab-1e636eac72d8"
      unitRef="usd">5352000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="idbed938c680f40789e9a484426d074c8_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTgtMS0xLTEtMA_38c2239b-4c09-4db4-9134-c13edbee4ef4"
      unitRef="shares">20833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="if0c2f4879451425f8a8974eba32bbf5f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTgtOS0xLTEtMA_3eeaf1c9-abb2-4604-824a-c9aeceaf40fb"
      unitRef="usd">37000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMTgtMTUtMS0xLTA_dece1ded-a216-405c-ab87-f3b5378bff3c"
      unitRef="usd">37000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i98a63b971bd34028b45b145cba0b2395_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjAtMTMtMS0xLTA_c30fa655-56be-4c79-b82b-1380cfaa44a5"
      unitRef="usd">-11000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjAtMTUtMS0xLTA_4a76117c-77a8-4669-b37d-bebbc9e21b58"
      unitRef="usd">-11000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="ia5528d6cd30546e5a8d7c4dcbfa0313a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjEtMTEtMS0xLTA_8e3fdf0c-4069-459d-9f09-52a009dd7181"
      unitRef="usd">-44631000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i98a63b971bd34028b45b145cba0b2395_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjEtMTMtMS0xLTA_0374451e-406a-4aea-aae3-b58c452046c9"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjEtMTUtMS0xLTA_844f23cf-a946-4636-951a-c5bd20584aa9"
      unitRef="usd">-44631000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i13e9f3ebcbed4a0a8cdb4c0df74931e7_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMS0xLTEtMA_5b3a831e-8e2f-4367-9843-bc43e04af6c9"
      unitRef="shares">48914284</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13e9f3ebcbed4a0a8cdb4c0df74931e7_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMy0xLTEtMA_776961f1-74dd-42b5-a12b-b5951a28c75b"
      unitRef="usd">489000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i684c983bf3ed4ec4802b47cfd412ab10_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItOS0xLTEtMA_28c0d1a7-5cec-4157-b291-fb26a1201ac8"
      unitRef="usd">866372000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic74709fe8a874de7af154d53f79304e0_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMTEtMS0xLTA_a9494a46-f82d-44e8-9bab-5dd6d51e8478"
      unitRef="usd">-611686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83af315ef660490aa4b885bfa9bfce6c_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMTMtMS0xLTA_e4d090d4-5ee7-4d69-9ff9-65efa45b5176"
      unitRef="usd">23000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOjA4NzcyY2VhMTA2YzQ2MmRiMjkxMzBmOTExZDZiZmEzL3RhYmxlcmFuZ2U6MDg3NzJjZWExMDZjNDYyZGIyOTEzMGY5MTFkNmJmYTNfMjItMTUtMS0xLTA_cb575426-8573-4d0a-a062-1feb0ff5d0ac"
      unitRef="usd">255198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i49611ab05b844f1fb78cf779db2fe26d_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xLTEtMS0w_52f8d727-192a-4f38-96c2-42a35c27e362"
      unitRef="shares">36859077</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49611ab05b844f1fb78cf779db2fe26d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0zLTEtMS0w_96064da9-9ec6-4b5a-8eff-6503df197ab0"
      unitRef="usd">369000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9e76d66eb5f46628e171bfe49684857_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi05LTEtMS0w_1549c6be-8531-447b-b376-1aa1150b88ed"
      unitRef="usd">611270000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i019d56ef285043cfae4cfcebb2c90346_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xMS0xLTEtMA_f7ac4793-a50b-463b-8571-8d3fe4859601"
      unitRef="usd">-312340000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d80a56bb96a476ebd48eb643b2f43d6_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xMy0xLTEtMA_826dc971-7122-43d9-9508-10858a7a7ac9"
      unitRef="usd">-61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54746da158ce4bce9b69918fb58a959a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMi0xNS0xLTEtMA_94b53518-98f9-48af-9835-e7796039437d"
      unitRef="usd">299238000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i8f60dd2a66844bda84a962daf15eed87_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMy0xMS0xLTEtMA_65f3864c-55fc-4012-b9b6-0502ca9c5962"
      unitRef="usd">-6479000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i5f10c7f52f7b4ba484c7a0eba502e770_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMy0xNS0xLTEtMA_17250b31-f6c6-4bfb-bcad-0b30e627dd62"
      unitRef="usd">-6479000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id482aef724c247d3a9dad505cdf6170c_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNC05LTEtMS0w_a8146a92-33e2-477a-8106-65c9d440ad6e"
      unitRef="usd">3386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNC0xNS0xLTEtMA_b0116cc8-55b6-4a30-8ea7-2b7ab703fb22"
      unitRef="usd">3386000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i333effd5cb7d4295a431b14185556574_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS0xLTEtMS0w_999e3df9-f15c-4843-9bc6-2479dd45c210"
      unitRef="shares">165546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i333effd5cb7d4295a431b14185556574_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS0zLTEtMS0w_145a3e9c-c82e-4be6-8c3e-876d4d86157c"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="id482aef724c247d3a9dad505cdf6170c_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS05LTEtMS0w_4ebdf34d-fe09-43f0-abe9-2adc10ae44d3"
      unitRef="usd">628000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNS0xNS0xLTEtMA_ed193e4a-f829-4785-b078-de8d4f3bb730"
      unitRef="usd">629000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i0d6d9c3f705947458160b1cd76174085_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNi0xMy0xLTEtMA_483ec058-fb95-46e7-8f3c-c0b1d660b004"
      unitRef="usd">38000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNi0xNS0xLTEtMA_14c8eac4-062e-4915-94af-3ef54cb82432"
      unitRef="usd">38000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="i2eeaeba07b544a28b10787dd76e88301_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNy0xMS0xLTEtMA_13777e64-da4c-4d32-9304-d1af8a644f3f"
      unitRef="usd">-49536000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i02a5726b8b67458a8bea3010d4c4c25a_D20180101-20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfNy0xNS0xLTEtMA_f13dde54-87ea-4df8-a4e8-c957b3c535b1"
      unitRef="usd">-49536000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i95c80d7a709547958bf97b952bcb83fc_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xLTEtMS0w_bacddca9-949e-49be-8da6-d472280493cc"
      unitRef="shares">37024623</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95c80d7a709547958bf97b952bcb83fc_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0zLTEtMS0w_b9227aa9-cad8-4413-bf9a-560d425b2373"
      unitRef="usd">370000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa0fd024aaec4139811a323c7b840f17_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC05LTEtMS0w_04473200-02bf-400e-b879-777ccc594a86"
      unitRef="usd">615284000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib506aba19db74035bc8bbc02c41b43cb_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xMS0xLTEtMA_02c082e6-7fef-418e-9d34-ac7e9ee8d711"
      unitRef="usd">-368355000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i240b880a602c492dbfb61a21ea0eb5d3_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xMy0xLTEtMA_bc7d2e85-3e32-4fcd-96ca-800ba71ea6ac"
      unitRef="usd">-23000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ce004d28e074994bd7938f6ed719131_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOC0xNS0xLTEtMA_f8ec8fb9-5527-4ccd-a828-29675854f314"
      unitRef="usd">247276000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i060f194c4a45460da0f50336db3489cb_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOS05LTEtMS0w_cfe6d012-55a6-45fa-bdfc-4bedbc07e55a"
      unitRef="usd">4209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfOS0xNS0xLTEtMA_318d52f1-fd05-417d-8f0d-d273e3c4f261"
      unitRef="usd">4209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtMS0xLTEtMA_994ee3c4-6f6b-434d-845f-e758d423533c"
      unitRef="shares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtMy0xLTEtMA_8f7fb863-18a4-44b5-a69c-901229be3c24"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i060f194c4a45460da0f50336db3489cb_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtOS0xLTEtMA_2cbbb1e5-c0a8-4976-9f8f-d109e2e25cb7"
      unitRef="usd">103207000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTAtMTUtMS0xLTA_61188545-f5f1-4d7b-b370-b93fffb57e6c"
      unitRef="usd">103259000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i7b6327b91a854d4ba92303fb2c0afa88_D20180401-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTEtMS0xLTEtMA_25b9d045-1075-44ca-86b1-b8605d1d2143"
      unitRef="shares">29388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i060f194c4a45460da0f50336db3489cb_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTEtOS0xLTEtMA_d0d2e8f1-a5cb-47b5-9261-755642fb5e37"
      unitRef="usd">496000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTEtMTUtMS0xLTA_75fdfd1c-e6ea-445c-a413-34567ed2c403"
      unitRef="usd">496000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i847ef2f18d3f476a94b52dd7c886fec4_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTItMTMtMS0xLTA_f6ac0411-c812-4db7-bd87-cb6b7c2bd513"
      unitRef="usd">40000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTItMTUtMS0xLTA_16955486-1bf2-4c3c-b85f-b5ea69d582ae"
      unitRef="usd">40000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="i54b623b2879241278c6132571917a008_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTMtMTEtMS0xLTA_44d31c1e-654a-4a1c-b511-197a87808d40"
      unitRef="usd">-43244000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6d7a5346b409455c94802cf3b5b49d96_D20180401-20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTMtMTUtMS0xLTA_c21d9ba1-da3f-41fe-ab7d-157cddd4349f"
      unitRef="usd">-43244000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i3a2bd0e8af1e4fa99300ecb39dac4805_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMS0xLTEtMA_cf5977dc-1202-4b7d-80f5-aa89a262e466"
      unitRef="shares">42229011</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a2bd0e8af1e4fa99300ecb39dac4805_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMy0xLTEtMA_118cd179-9d46-4daa-8eef-0e5332110e43"
      unitRef="usd">422000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31943445cf4647e9815814b40fe5c41f_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtOS0xLTEtMA_c43a4314-d863-43a1-888d-9d270bfe9432"
      unitRef="usd">723196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff0ebde6ab2d4004af640da15e05f719_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMTEtMS0xLTA_f846f573-5262-42d4-afd9-460772895cef"
      unitRef="usd">-411599000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdea36b22a3849cd89bae3b8659e5552_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMTMtMS0xLTA_39c3253f-52c8-4637-8545-b99d449b30ca"
      unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1529ce9d9dec4e3999d400290ac6620c_I20180630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTQtMTUtMS0xLTA_6acbe20a-7599-436d-b5ca-2c0bdd9e92a0"
      unitRef="usd">312036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i55dc213d33f2452082c642024e4aaf21_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTYtOS0xLTEtNzA_901683cd-2c78-44db-9114-5a81a1b71a92"
      unitRef="usd">4522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTYtMTUtMS0xLTcw_38b6519a-febf-4b51-84c9-3d3d932ca5cd"
      unitRef="usd">4522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="id724f6a4b17744aaa91365c7ec213e22_D20180701-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTgtMS0xLTEtNzA_7189124d-82ff-4ca0-8d7f-cc2d8a0ba9d7"
      unitRef="shares">19064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i55dc213d33f2452082c642024e4aaf21_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTgtOS0xLTEtNzA_7a691ebe-17d3-4db7-8ba2-ca9d1efaac3e"
      unitRef="usd">131000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMTgtMTUtMS0xLTcw_baa0b570-ae4e-4478-9b45-c35d07048bca"
      unitRef="usd">131000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6dade5ca02694388a0ce84360f1c804f_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjAtMTMtMS0xLTcw_0c9731de-5728-47a0-9291-21d5ea8b31dc"
      unitRef="usd">-17000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjAtMTUtMS0xLTcw_5e2f7117-04ff-49a1-8e4b-89d8ee876763"
      unitRef="usd">-17000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="i95278dd6162e4f89b1e87fc5805eec36_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjEtMTEtMS0xLTcw_3abce489-fca9-4087-bccf-e08542f9ea24"
      unitRef="usd">-34029000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjEtMTUtMS0xLTcw_860c3e92-55af-4bc7-83b8-61f7f763cdef"
      unitRef="usd">-34029000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="ic0b6df7d2858470ea7228c5343664f9b_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMS0xLTEtNzA_a315fe4d-95c6-4df7-8dae-29b85f4b0802"
      unitRef="shares">42248075</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0b6df7d2858470ea7228c5343664f9b_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMy0xLTEtNzA_5867e8a6-4186-4dec-996c-7e1d3a83e25a"
      unitRef="usd">422000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a57474836104a719e68ea78c743320b_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItOS0xLTEtNzA_d78d133c-0687-479c-918b-dfc2a2bfa11f"
      unitRef="usd">727849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f5eef8cd6f14c31b7d9d7c5922d0d4d_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMTEtMS0xLTcw_613c08f5-77c1-464a-85af-6b42d63a5a27"
      unitRef="usd">-445628000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23fb65c6630f44d69f9baec8764c89e3_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMTMtMS0xLTcw_95dc35b2-5910-4e54-a19f-c8aa1cdb94e5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bec1f6fecbe4fe790e9626d4040450f_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8yOC9mcmFnOjgwZWY3YTRhYWMxMzRmMjdiZjFkOWVjNDE5OTgyZDEyL3RhYmxlOmMzOTY5MTVmMzVjNDQ5Mzc5ZTBhNDkzNmI3Y2MyM2QyL3RhYmxlcmFuZ2U6YzM5NjkxNWYzNWM0NDkzNzllMGE0OTM2YjdjYzIzZDJfMjItMTUtMS0xLTcw_c9a5cdec-691b-48e6-b7a8-f3706c45a4a4"
      unitRef="usd">282643000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMy0xLTEtMS0w_811fb0c6-50ee-4697-8958-5aa345842af0"
      unitRef="usd">-121415000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMy0zLTEtMS0w_74000aec-937d-4ca5-9e84-8a5942ee80d6"
      unitRef="usd">-126809000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNS0xLTEtMS0w_e3547635-6c57-400a-b170-a976461aada9"
      unitRef="usd">8119000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNS0zLTEtMS0w_dadc0398-b09e-4565-8a0c-09fbf79dc87e"
      unitRef="usd">5268000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNi0xLTEtMS0w_6d887ee3-b33f-4efc-bd32-ad74c9afbe5c"
      unitRef="usd">14081000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfNi0zLTEtMS0w_4cf64ce3-003f-4195-9e6a-e2bcc50049e5"
      unitRef="usd">12168000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOC0xLTEtMS0w_f41effd7-3ec9-4ea7-8f43-6f9e611da9e2"
      unitRef="usd">-20080000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOC0zLTEtMS0w_e7c91555-68bc-48a5-93eb-83421020e7fd"
      unitRef="usd">7328000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOS0xLTEtMS0w_90b080d0-a8cb-43be-869d-e7eab709341a"
      unitRef="usd">5612000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfOS0zLTEtMS0w_dd5b332a-215d-44d9-b346-fc21595f8487"
      unitRef="usd">1164000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTAtMS0xLTEtMA_cdee9301-e750-4c3a-9312-9252a427a575"
      unitRef="usd">2621000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTAtMy0xLTEtMA_56f41ddd-5beb-47f1-aa8c-dc2bbb6f49e7"
      unitRef="usd">9293000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTEtMS0xLTEtMA_b154f17c-3cc5-43fc-8e3b-9ebdce047cf7"
      unitRef="usd">-913000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTEtMy0xLTEtMA_b9095690-4c36-47da-8a09-16251386df23"
      unitRef="usd">-1465000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTItMS0xLTEtMA_e55231b3-b7ff-4d54-88ec-84a1deac49e9"
      unitRef="usd">-4678000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTItMy0xLTEtMA_d079b269-3a62-4bee-bc25-b8a21ef8631e"
      unitRef="usd">9460000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInRestructuringReserve
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTMtMS0xLTEtMA_8f4c9064-0c2a-4b22-ac56-bf7f74382aad"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInRestructuringReserve>
    <us-gaap:IncreaseDecreaseInRestructuringReserve
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTMtMy0xLTEtMA_3dc11974-bdbd-48dd-b164-e43334c6301f"
      unitRef="usd">-298000</us-gaap:IncreaseDecreaseInRestructuringReserve>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTQtMS0xLTEtMA_f7d03593-4dbb-4037-898b-edd60f6ca54f"
      unitRef="usd">3847000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTQtMy0xLTEtMA_70d53324-7ed8-41af-8b7e-599ef568ade4"
      unitRef="usd">0</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTUtMS0xLTEtMA_106c2bc9-b71d-4b34-8af3-4cba247f7efd"
      unitRef="usd">-7114000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTUtMy0xLTEtMA_1a7e0ca9-83da-4851-aaa4-cd87c46c85f3"
      unitRef="usd">-5807000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTYtMS0xLTEtMA_a516b889-d7cf-49e2-8d6e-46d8ec4209ac"
      unitRef="usd">0</mgnx:IncreaseDecreaseInDeferredRent>
    <mgnx:IncreaseDecreaseInDeferredRent
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTYtMy0xLTEtMA_0100639b-8a64-462d-a4fb-91f512ce6fd9"
      unitRef="usd">-738000</mgnx:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTctMS0xLTEtMA_290c65b4-9fda-415e-9a17-a63416f6b6ef"
      unitRef="usd">-96226000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTctMy0xLTEtMA_66201a18-68d0-4d5e-a02c-f9916b56d66b"
      unitRef="usd">-126006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTktMS0xLTEtMA_d7329833-3c6e-4d8b-af30-72131ad44245"
      unitRef="usd">214178000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMTktMy0xLTEtMA_88f826f6-c407-4511-b7ac-7a001fa80334"
      unitRef="usd">120039000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjAtMS0xLTEtMA_7ce79604-7164-4779-a070-9589242b690c"
      unitRef="usd">130236000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjAtMy0xLTEtMA_41e6a784-1e03-41b6-a5de-4eec5102a769"
      unitRef="usd">155848000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjEtMS0xLTEtMA_c05c341e-302f-4f27-a2e0-b53ae1e34479"
      unitRef="usd">3042000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjEtMy0xLTEtMA_03e26fff-cfb9-409e-aa72-7abc904c824a"
      unitRef="usd">24239000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjItMS0xLTEtMA_055fe4bd-9ed2-44e4-91f6-17f6ec188148"
      unitRef="usd">-86984000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjItMy0xLTEtMA_02e3d2cd-bfa9-43a8-a4cb-95cfdd9e6496"
      unitRef="usd">11570000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjQtMS0xLTEtMA_d328b796-4498-47f3-a8bc-e4a7f17c7ee3"
      unitRef="usd">118657000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjQtMy0xLTEtMA_fd6afc1a-67d8-4efd-a6dc-2f01d281f433"
      unitRef="usd">103259000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjUtMS0xLTEtMA_e633eb07-b401-4d79-be78-8cebd5518c11"
      unitRef="usd">1018000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjUtMy0xLTEtMA_8030b7ad-2228-4d98-b8b9-a7d8db827efd"
      unitRef="usd">1257000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjYtMS0xLTEtMA_50a47596-c247-485f-bf82-155ea84af0d0"
      unitRef="usd">119675000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjYtMy0xLTEtMA_f1439e2e-efa0-4e80-b29d-54cbfb001bb1"
      unitRef="usd">104516000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjctMS0xLTEtMA_60810bb6-e318-4f88-9f9d-b7ea7b0d9126"
      unitRef="usd">-63535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjctMy0xLTEtMA_18662004-f7cb-4ccc-b2b0-6c98f8436c2d"
      unitRef="usd">-9920000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjgtMS0xLTEtMA_4310a952-77c1-425b-aba4-67217efd567f"
      unitRef="usd">220128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i54746da158ce4bce9b69918fb58a959a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjgtMy0xLTEtMA_596c8d0a-01f8-493f-a64b-8089e9cc45d3"
      unitRef="usd">211727000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjktMS0xLTEtMA_8f81af59-132e-4974-8de0-1cdfe062a609"
      unitRef="usd">156593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7bec1f6fecbe4fe790e9626d4040450f_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMjktMy0xLTEtMA_14fd5b81-9be9-4b78-ae18-0b6dda9a4617"
      unitRef="usd">201807000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzItMS0xLTEtMA_d4081274-e38b-4864-b9e1-addc439bb891"
      unitRef="usd">6408000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzItMy0xLTEtMA_6be95d6b-25ef-4b1a-800c-0f1316e18b0e"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzMtMS0xLTEtMA_44a8ba7a-7ea6-489e-9ed1-85eebd8b07e8"
      unitRef="usd">0</mgnx:FairValueOfWarrantsReceived>
    <mgnx:FairValueOfWarrantsReceived
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zMS9mcmFnOmEyZjdjYjkxZGZmODRkNGY4Y2E0MjMwOTY2NGFmNDkzL3RhYmxlOjljM2Y5MTE5YzM0MDQ1NGE4NjViNjBlMTUwNTQ3ODZkL3RhYmxlcmFuZ2U6OWMzZjkxMTljMzQwNDU0YTg2NWI2MGUxNTA1NDc4NmRfMzMtMy0xLTEtMA_0a62e0d7-3721-42aa-98d8-60e248b6665d"
      unitRef="usd">6130000</mgnx:FairValueOfWarrantsReceived>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNTgxNQ_10d554be-3e6e-489f-beb5-abb8a393f655">Basis of Presentation and Significant Accounting Policies&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; (ASU 2016-02) during the nine months ended September 30, 2019, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases.  Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.  The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated.  Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4 million and operating lease liabilities of $27.7 million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets.  Refer to Note 4, Leases, for additional disclosures required by ASC 842. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; (ASU 2018-18). The amendments provide guidance on whether certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNTgxNw_0f856326-c69d-4c6e-825a-321f166f6aa2">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNTgxOQ_d5213f4c-e741-4294-a253-4cae2a75079a">&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases.  Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.  The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated.  Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4 million and operating lease liabilities of $27.7 million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets.  Refer to Note 4, Leases, for additional disclosures required by ASC 842. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt; (ASU 2018-18). The amendments provide guidance on whether certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i650df15d071a48f9ad308100e9f9db92_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNDIwMA_306b94ea-5114-4825-be76-fea32b3788d4"
      unitRef="usd">16400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i650df15d071a48f9ad308100e9f9db92_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF8zNy9mcmFnOjAyYjM1N2MzZjk1ZDQwZGViOTVlNzJjMjdiNTNjOGUwL3RleHRyZWdpb246MDJiMzU3YzNmOTVkNDBkZWI5NWU3MmMyN2I1M2M4ZTBfNDI0Nw_a6f7984e-76fa-4c1d-a30d-b65c44a2fbb9"
      unitRef="usd">27700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMzMxNQ_ae36ea98-2682-46e2-80bf-bf5b3fe88dc3">Fair Value of Financial Instruments&lt;div style="text-indent:36pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable, accrued expenses and common stock warrants.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.633284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.323529%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(b)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;112,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;(a) Total assets measured at fair value at September&#160;30, 2019 includes approximately $78.3 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;(b) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet and $1.9&#160;million reported in other assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:15pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of Level 3 securities is determined using the Black-Scholes option-pricing model.  There were no transfers between levels during the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMzMxNg_136b2c68-27f2-44c0-b90e-661cde1c81e3">&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.633284%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.789396%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.323529%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.617647%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:100%;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:6.5pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(b)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;160,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;112,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;(a) Total assets measured at fair value at September&#160;30, 2019 includes approximately $78.3 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;(b) Total assets measured at fair value at December&#160;31, 2018 includes approximately $146.2 million reported in cash and cash equivalents on the balance sheet and $1.9&#160;million reported in other assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74b903135a134cf39caaf1b9a70d3c0a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC0xLTEtMS0w_5225913b-6355-4fb6-8555-34b999904e01"
      unitRef="usd">67321000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b30a1a7cd3c4c3baa990fca6174db72_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC0zLTEtMS0w_84294bbc-7c9a-4996-8b74-c8fc16dfb583"
      unitRef="usd">67321000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i969e411a7436433db0a30ec91a49470c_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC01LTEtMS0w_e7017ef6-d3dc-4104-b040-773780db1878"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia458119b7c404a179ca653e35a01c75b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNC03LTEtMS0w_02c21f9c-b1a5-4240-95ae-ec056acb6e50"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33f08df369b2427988e6e11513fa5c38_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi0xLTEtMS0w_32635046-ac20-4bc1-9c93-71a6e132e8bb"
      unitRef="usd">11695000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3676d61890504a29b1b2f0c9b97bc5b3_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi0zLTEtMS0w_38b1add8-6856-40fc-94f4-950f2adfc819"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bbdfd41050a436d9d2e70b388d897ba_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi01LTEtMS0w_a74ae2d3-d4a2-40ae-99a9-6906b0ef0307"
      unitRef="usd">11695000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c7f5c48a4c34073a0af4d2bcef83f3a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNi03LTEtMS0w_4d7d25ca-413d-4ca0-b555-40ea873c8f75"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cee49232b1741e1b7292d30a0182e3d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy0xLTEtMS0w_7fe483f0-2033-4012-a8d4-b491f591791a"
      unitRef="usd">85564000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d90c76657d84918a66e5ac0515f67d3_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy0zLTEtMS0w_31c81b69-26ac-4769-b01b-6e1dcfbd7731"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib44ab6273835479c9cbe51aed6705e61_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy01LTEtMS0w_9b590b0b-e783-4ff0-b1f3-30b6103675c2"
      unitRef="usd">85564000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15dd70d707b34d789add5ecfa27969eb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfNy03LTEtMS0w_bdaf8fc0-c2d1-4492-b4de-87661b664994"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica36a3f9d76444ff8117f05911db0082_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0xLTEtMS05Nw_261e9194-4cdd-4c18-957f-3628be7c2058"
      unitRef="usd">11547000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i701cae7e28bf44fba78f29f859d17485_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0zLTEtMS05Nw_d5d61f83-3b79-4615-877f-f552ffe6158f"
      unitRef="usd">11547000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e816985f0354d14990486b7d9fa32d9_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS01LTEtMS0xMjA_9560fa50-25d7-40ef-90b0-f0b1e16da1cc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ebf9c8cbcd9454c9ca1746e3cabb812_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS03LTEtMS0xMjA_4d898f53-570e-483c-aa7b-615ffb2290de"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1b731627c2204358b5c33793a78b3b6f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0xLTEtMS0w_ac5655f8-a44d-47e0-9234-5e19fe598dba"
      unitRef="usd">176127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4c7335cfa2cb4a56be2db7b2843f2bd1_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS0zLTEtMS0w_8292de48-7795-4e2c-9c6c-e28649d488c4"
      unitRef="usd">78868000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf30c1ba1e914625955d4027a7c9d97d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS01LTEtMS0w_ad8d9234-6c43-44df-b307-58ce5067dae4"
      unitRef="usd">97259000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d96d8c704af4109b4494741538a09c3_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmYzNjEzMWJkNzdhNTQyNmNhODI1OWUyMWE0Y2M5MGY3L3RhYmxlcmFuZ2U6ZjM2MTMxYmQ3N2E1NDI2Y2E4MjU5ZTIxYTRjYzkwZjdfOS03LTEtMS0w_a4f00e0e-bb41-4277-9c7b-b6e802eb7a36"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i15b61365f4c84504907452a393c0c978_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC0xLTEtMS0w_480c3aad-a300-4fe4-891b-0aeae1b19f67"
      unitRef="usd">46257000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a312ffda8e1499fb683210529f71461_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC0zLTEtMS0w_445319cd-8991-4311-b5ba-f8d19c41239f"
      unitRef="usd">46257000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idbc438e0b3164ea1934a0d52645e75fe_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC01LTEtMS0w_3ce215b9-b8bd-4f50-821a-5a7b90711c87"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie77cb2cbbcc3497190e5e9611541ef32_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNC03LTEtMS0w_fe468557-9a6c-4e21-8fb9-4f74612bc410"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13959021e84d4dcc881071aedc143536_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS0xLTEtMS0w_583727ee-3aaf-4c7c-8de1-ba04b5007a70"
      unitRef="usd">12488000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief653dd50f314a66ae8d96c62f649c59_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS0zLTEtMS0w_f01584ba-5c98-4e3c-8b85-50d0399be43f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic07d10f6477546e0b1b1d3e46b8fad47_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS01LTEtMS0w_cdcf855a-4aef-49b0-ba37-804cb242c1f3"
      unitRef="usd">12488000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ba076567c05486081a550f00fdc2edc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNS03LTEtMS0w_a7d56e35-ccc3-47a9-ad28-6e9406301d3d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ed260be42124aabb60094700d2e6d2d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy0xLTEtMS0w_f4dfd70f-4e4b-4021-8539-5c089408a04a"
      unitRef="usd">100214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i21bd9e893e294ae78c62758ac0007634_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy0zLTEtMS0w_864abaea-2500-47ae-8f1a-b8c16a284159"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i701fe9109c104be898d66144c5fdff56_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy01LTEtMS0w_dfb3f3f3-c9f2-4a72-b36b-51878a88e3aa"
      unitRef="usd">100214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fcdaba997e14e45bc26beec23bd7875_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfNy03LTEtMS0w_e243aef3-d74b-4eba-a60f-e8863acd0352"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if69a1a642f0d4979adb8ba239f6c10b1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC0xLTEtMS0w_732724fd-81f2-4a4c-9d9d-acd7946cc7e9"
      unitRef="usd">1890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0c9d0e3bc9048688ea0d0890580f4e4_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC0zLTEtMS0w_b95dcd06-db3f-4ec6-9a55-7f8cc201e90c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecf61485c1a34f73be6f360b91caaacd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC01LTEtMS0w_f2bafbd8-a7b5-402a-9157-cf399f4a4920"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i943c3dc5d31148128af05f6e108c9796_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOC03LTEtMS0w_9af578d7-4f91-46ed-8db7-0729340a9885"
      unitRef="usd">1890000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7d4bf814515415abde86a6c80fbe736_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS0xLTEtMS0w_225fafca-1ead-4fdc-befe-2dfcc084889c"
      unitRef="usd">160849000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i603ed4709303491bbaf26a1b755d1deb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS0zLTEtMS0w_db184504-e10d-4de5-8c1f-21e0a5ae125d"
      unitRef="usd">46257000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i752d1ee7e5c441c790664845ece3aec0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS01LTEtMS0w_0e508e60-d736-4c7b-b0db-a626b345a807"
      unitRef="usd">112702000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i87490ba462994db1b1ee01e11796fad2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RhYmxlOmIzMjk0ZTllZGNjNjRkM2U5ZWE3M2MwYjI4MzA0NWUwL3RhYmxlcmFuZ2U6YjMyOTRlOWVkY2M2NGQzZTllYTczYzBiMjgzMDQ1ZTBfOS03LTEtMS0w_d960d283-ade3-4869-808c-3a2e932b8e1d"
      unitRef="usd">1890000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1b731627c2204358b5c33793a78b3b6f_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMjU1OQ_32cf147e-dd43-4a96-95f9-79da2e154d77"
      unitRef="usd">78300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id7d4bf814515415abde86a6c80fbe736_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMjcyMw_52af976a-f5df-4dfd-abe7-a03ba0b67f63"
      unitRef="usd">146200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id7d4bf814515415abde86a6c80fbe736_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80MC9mcmFnOmRmNmM3ZTQ4ZmI3NzQwZWFiYTc0NWQyZDEyMmEyMzcwL3RleHRyZWdpb246ZGY2YzdlNDhmYjc3NDBlYWJhNzQ1ZDJkMTIyYTIzNzBfMjc4OQ_1acc8e41-bb43-435b-9a7e-733ef8db384b"
      unitRef="usd">1900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfNDk5_b7f65d5a-6b68-44f2-bc17-f4751a880a78">Marketable Securities&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the Company's marketable debt and equity securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.947368%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.818713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.818713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.818713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.344624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.751105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;All available-for-sale marketable debt securities held as of September&#160;30, 2019 and December&#160;31, 2018 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2019 and December&#160;31, 2018 were in a loss position for less than 12 months.&#160; There were no unrealized losses on marketable debt securities at September&#160;30, 2019 or December&#160;31, 2018 that the Company determined to be other-than-temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes changes in market value of equity securities as gains or losses in other income (expense) in the consolidated statement of operations and comprehensive loss. The unrealized loss on corporate equity securities of &lt;/span&gt;&lt;/div&gt;$7.6&#160;million was recognized as a loss in other income (expense) in the consolidated statement of operations and comprehensive loss during the three months ended September 30, 2019.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfMzI5ODUzNDg4NDI2Mw_3cffb0fa-4f1d-45ec-b031-a92c877a64d2">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the Company's marketable debt and equity securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:51.947368%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.818713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.672515%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.818713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.818713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;105,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;97,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.344624%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.751105%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536377%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.898380%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy0xLTEtMS0w_64055e67-1088-4056-a363-ee3c0abf8f68"
      unitRef="usd">11690000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy0zLTEtMS0w_84078d3d-0669-4164-b268-e18448781b74"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy01LTEtMS0w_a1417a08-e703-4fc0-8645-4c5db57bd361"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e83105b10aa4d8fa9264667fda8c681_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfMy03LTEtMS0w_5a5583a0-50ed-45f8-b717-b159c8168cb8"
      unitRef="usd">11695000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC0xLTEtMS0w_310f2d58-675f-4b29-a4bb-6fd64e9834a1"
      unitRef="usd">74563000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC0zLTEtMS0w_e06636d7-85ec-43e6-b875-8dcb1fba74c4"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC01LTEtMS0w_354f9b2a-b1b6-46df-9e2a-b67753ae78a3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i154da4d6fbc040f69cb4f170cc223a94_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNC03LTEtMS0w_3811aa89-f5cf-4d6c-8c30-f2e9caa0e6ea"
      unitRef="usd">74581000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS0xLTEtMS0yMzI3_1e828494-d60b-4b82-9c0d-bc8fbb327f7a"
      unitRef="usd">86253000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS0zLTEtMS0yMzI3_519bc235-8eef-41ee-a17c-e5bcd1c75ec4"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS01LTEtMS0yMzI3_5b411a0c-be63-4323-8d44-5ef024c14b51"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjdjYWE2NjE4NjM3NjQ5YjM5N2RlZjJjMWYwNDBhZDNmL3RhYmxlcmFuZ2U6N2NhYTY2MTg2Mzc2NDliMzk3ZGVmMmMxZjA0MGFkM2ZfNS03LTEtMS0yMzI3_8c5996a8-cddb-4fc9-beda-c99793c771a9"
      unitRef="usd">86276000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id57dfc841ee9417094c91d03520271a9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC0xLTEtMS0w_21a75178-7162-41bb-b094-125c4146824e"
      unitRef="usd">12738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id57dfc841ee9417094c91d03520271a9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC0zLTEtMS0w_29962fc8-6b33-4f60-8a58-a04d8c71fbdb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id57dfc841ee9417094c91d03520271a9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC01LTEtMS0w_84a40486-c9ed-4580-a439-c678832e7449"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id57dfc841ee9417094c91d03520271a9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RhYmxlOjlhMmUwZGMyMGMyOTQyNTdhNTBkZmU1M2NkZjA0NTkyL3RhYmxlcmFuZ2U6OWEyZTBkYzIwYzI5NDI1N2E1MGRmZTUzY2RmMDQ1OTJfNC03LTEtMS0w_dacace6b-896c-41c9-939d-e6a825e08247"
      unitRef="usd">12735000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfNDEy_969dbfc4-cd3f-43f8-b898-01f89fe99591"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
      contextRef="i7038fb1eaaed4930bef39d8439888cd3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfNDEy_a59b281e-7886-473f-9396-a4986beeb5c1"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80My9mcmFnOjFhNTAyZDI1MmVlZDQ3NDA4MWJhZDQ5ZTg5MTNmOTkyL3RleHRyZWdpb246MWE1MDJkMjUyZWVkNDc0MDgxYmFkNDllODkxM2Y5OTJfMzI5ODUzNDg4NDY4OA_ca3d333e-67a6-4322-90a4-a64130df3344"
      unitRef="usd">-7600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTQ3Ng_7734206b-a589-4042-9419-f5d653529668">Leases&#160;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has non-cancelable operating leases for manufacturing, laboratory and office space in Rockville, Maryland and a non-cancelable operating lease for laboratory and office space in Brisbane, California.  A portion of the space under one of these leases is subleased to a third party.  All of these leases include one or more options to renew, with those renewal periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDA4_d48d60fa-3511-4c66-ad50-e72151633519"&gt;five&lt;/span&gt; to 14 years.  At September&#160;30, 2019, the Company's weighted-average remaining lease term relating to its operating leases is seven years, with a weighted-average discount rate of  9.9%.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon adoption of ASC 842 on January 1, 2019, it was not reasonably certain that the Company would extend any of its operating leases, therefore the options to extend the lease terms were not recognized as part of the ROU assets or lease liabilities.  During the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;nine months ended September 30, 2019&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;, the Company exercised the options to extend two leases for an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfOTY1_57414c3c-a125-4d11-ab1b-84005d3778dc"&gt;five&lt;/span&gt; years each, therefore the Company remeasured the lease liability and adjusted the carrying amount of the ROU asset related to these leases.   The Company made cash payments of $4.8 million for operating leases during the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;nine months ended September 30, 2019.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;  As of September&#160;30, 2019, the Company&#x2019;s ROU assets were valued at $20.9 million and are included in Other assets on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease cost for the nine months ended September 30, 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.888889%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.111111%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019, the maturities of our operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.573099%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426901%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5fcef9f911324937acdbe37c9ab67e7b_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNDE0_1fbb485a-e728-4e24-b247-a13933d383d8">P14Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNTIw_6b964148-a747-4e9b-a627-3a4745d6a847">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfNTY2_0438023a-f35e-44ff-ad51-eebd2da1bc0f"
      unitRef="number">0.099</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTEzNw_e9975148-0d16-4f04-93ce-a9aef3fdcd82"
      unitRef="usd">4800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTIyNw_e132cfdf-36d8-40e4-9f2b-550511308309"
      unitRef="usd">20900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTQ3Nw_be47a5e4-68e2-4e65-bfff-e61049391259">&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of lease cost for the nine months ended September 30, 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.888889%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.111111%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMC0xLTEtMS0w_769d540d-93a5-4660-9275-323ecf7036d9"
      unitRef="usd">4080000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMS0xLTEtMS0w_458c94e5-877f-48d4-b508-8856da764f8d"
      unitRef="usd">1100000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMi0xLTEtMS0w_9a87729f-aa92-4202-b203-41524b9db66d"
      unitRef="usd">706000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOjg4YjRhMjcyOTA0YTQyNThhNzIzNDI3ZmFjN2ZlMWEzL3RhYmxlcmFuZ2U6ODhiNGEyNzI5MDRhNDI1OGE3MjM0MjdmYWM3ZmUxYTNfMy0xLTEtMS0w_5a674690-a3b8-40a6-b115-9634ce61a0a7"
      unitRef="usd">4474000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RleHRyZWdpb246YmM1Y2RkMTQyZDg5NDk0Njk4MWI2ZTFiMjE0NDg5YjBfMTQ3OA_1fb0ac40-ab49-413b-ab4a-152e80c62c6f">&lt;div style="text-indent:36pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September&#160;30, 2019, the maturities of our operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:85.573099%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.426901%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Remainder of 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMC0xLTEtMS0w_62dd1beb-a7cf-44c7-ad64-84b7c6a0679b"
      unitRef="usd">1616000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMS0xLTEtMS0w_942106da-bf9d-4a6c-932d-b6edc79eea39"
      unitRef="usd">5928000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMi0xLTEtMS0w_2405d79d-b751-4d01-8102-9a46914446e8"
      unitRef="usd">6537000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfMy0xLTEtMS0w_91a5116d-d5f5-4f86-9eb6-b0c620fa3578"
      unitRef="usd">6720000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNC0xLTEtMS0w_627917f4-ab90-4f26-bbb6-032cb86dd0d3"
      unitRef="usd">6568000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <mgnx:LesseeOperatingLeaseLiabilityPaymentsDueYearSix
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNS0xLTEtMS0w_6a583fe0-e037-464f-9f21-b59e1e25f001"
      unitRef="usd">5621000</mgnx:LesseeOperatingLeaseLiabilityPaymentsDueYearSix>
    <mgnx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNi0xLTEtMS0w_cb5c86cc-8768-41cf-9b50-95a891f09c43"
      unitRef="usd">11098000</mgnx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfNy0xLTEtMS0w_73d1add5-27a4-465c-bbb5-87e0e734d3c2"
      unitRef="usd">44088000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfOC0xLTEtMS0w_e293fc34-d723-4775-b16f-0a92eb13da48"
      unitRef="usd">12550000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80Ni9mcmFnOmJjNWNkZDE0MmQ4OTQ5NDY5ODFiNmUxYjIxNDQ4OWIwL3RhYmxlOmU3NWZhMmE5OWVmNzQzNGFhYmFlYTQxNjlhZjgxODk4L3RhYmxlcmFuZ2U6ZTc1ZmEyYTk5ZWY3NDM0YWFiYWVhNDE2OWFmODE4OThfOS0xLTEtMS0w_b18128b6-4bd8-43c8-aef2-0cb4d350c15c"
      unitRef="usd">31538000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTExMA_931ccca6-827c-4024-8f57-746f094f0c09">Stockholders' Equity&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share.  Upon closing, the Company received net proceeds of approximately $103.0 million from this offering, net of underwriting discounts and commissions and other offering expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2019, the Company completed a &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;firm-commitment underwritten public&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;common stock at a price of $20.00 per share.  The Company received net proceeds of approximately $118.7 million from this offering, net of underwriting discounts and commissions and other offering expenses.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ied9b88caa01b437aa817087abe6032ec_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTQx_69c8204a-89cf-4925-bf9a-8f90b5cd2a0f"
      unitRef="shares">4500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i3ceb7095584d49fc80652713cb7854c3_I20180430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTg1_6e19cc88-12b3-45a6-9b6b-eb2082bbb9ce"
      unitRef="usdPerShare">21.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic890dfa175f245fe8e241c46e046dbaf_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMzQz_242d22f5-d0bf-4db6-8af0-b4a4c9db37ec"
      unitRef="shares">675000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i41e82e0130f64686907e6f18d7557650_I20180430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMzk3_0012cd24-3a7e-439c-9cfe-92b59b13e42b"
      unitRef="usdPerShare">21.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ied9b88caa01b437aa817087abe6032ec_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfNDc3_89dd2406-266d-415c-bad3-bb94cf2aa5ea"
      unitRef="usd">103000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic58db151e3a448e7b3ee73f0be5d0b0d_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfNjkx_ca9c2384-571f-4a91-988a-5ed22bef105a"
      unitRef="shares">5500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i45db6deb036b486ba26f489e393fc752_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfNzM1_cb2d2db5-9da1-405e-9a91-c55119cf285b"
      unitRef="usdPerShare">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if64c499ae2254674a5686716390e3f83_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfODkz_fb02f8b8-f64f-4bb9-8fee-b36f6259aca5"
      unitRef="shares">825000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i9e3a6e8ec3fa4af0b64eee0e868f565a_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfOTQ3_7ae2e4d6-64d8-4aac-9dcb-619d16586fd4"
      unitRef="usdPerShare">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic58db151e3a448e7b3ee73f0be5d0b0d_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF80OS9mcmFnOjYxZTZkOGJmMGRjOTRjMDE5MDAyMDk0YjI5NDA1ZDU2L3RleHRyZWdpb246NjFlNmQ4YmYwZGM5NGMwMTkwMDIwOTRiMjk0MDVkNTZfMTAxMw_ec1c722c-22ed-4427-86ea-618a6a74db20"
      unitRef="usd">118700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc2NzQ_85cb1fe9-7735-4e78-841d-4c9d0f188bb9">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Incyte&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012 (also known as INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a $150.0 million upfront payment from Incyte when the transaction closed in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Incyte Agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. Through December&#160;31, 2018, the Company had recognized $15.0 million in development milestones under this agreement.  If MGA012 is commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of MGA012, subject to a separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company evaluated the Incyte Agreement under the provisions of ASU No. 2014-09, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;s and all related amendments (collectively, ASC 606) and identified the following two performance obligations under the agreement: (i) the license of MGA012 and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three deve&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;lopment milestones totaling $15.0 million related to MGA012 meeting certain clinical proof-of-concept criteria.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  During the three and nine months ended September 30, 2019, there were no adjustments to the transaction price of the Incyte Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs.  These clinical activities were substantially completed as of June 30, 2018.  During the three months ended September 30, 2019 and 2018, the Company recognized no revenue and revenue of $10.5 million, respectively, under the Incyte Agreement.  The Company recognized revenue of $0.1 million and $13.6 million under the Incyte Agreement during the nine months ended September 30, 2019 and 2018, respectively.  Revenue recognized during the three and nine months ended September 30, 2018  included $10.0&#160;million in development milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of MGA012 (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the clinical supply of MGA012.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.   During the three months ended September 30, 2019 and 2018, the Company recognized revenue of $4.9 million and $6.1&#160;million, respectively, for services performed under the Incyte Clinical Supply Agreement. The Company recognized revenue of $13.1 million and $16.0&#160;million for services performed under the Incyte Clinical Supply Agreement during the nine months ended September 30, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Les Laboratoires Servier &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2012, the Company entered into a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) and granted it exclusive options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as flotetuzumab (also known as MGD006 or S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India (Servier Agreement). In 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab.  During the term of the agreement, Servier did not exercise its options for either MGD007 or the third DART molecule.  In July 2019, Servier informed the Company of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  As a result of this termination, the Company will regain full exclusive, worldwide commercialization rights to develop and market flotetuzumab. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon execution of the agreement, Servier made a nonrefundable payment of $20.0 million to the Company.  The Company evaluated the Servier Agreement under the provisions of ASC 606 and concluded that Servier is a customer prior to the exercise of any of the three options.  The Company identified the following material promises under the arrangement for each of the three molecules:  (i) a limited evaluation license to conduct activities under the research plan and  (ii)  research and development services concluding with an option trigger data package.  The Servier Agreement also provided exclusive options for an exclusive license to research, develop, manufacture and commercialize each subject molecule. The Company evaluated these options and concluded that the options were not issued at a significant and incremental discount, and therefore do not provide material rights.  As such, they are excluded as performance obligations at the outset of the arrangement. The Company determined that each license and the related research and development services were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each molecule, resulting in a total of three performance obligations; one for flotetuzumab, one for MGD007, and one for the third DART molecule. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determined that the $20.0 million upfront payment from Servier constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the three performance obligations based on their relative standalone selling price. The milestone payments that the Company was eligible to receive prior to the exercise of the options were excluded from the transaction price, as all milestone amounts were fully constrained based on the probability of achievement.  Two milestones were achieved in 2014 when the Investigational New Drug (IND) applications for flotetuzumab and MGD007 were cleared by the Food and Drug Administration (FDA).  Upon achievement of each milestone in 2014, the constraint related to the $5.0 million milestone payment was removed and the transaction price was re-assessed. This variable consideration was allocated to each specific performance obligation in accordance with ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management&#x2019;s judgment, was the best measure of progress towards satisfying the performance obligation.  The Company recognized $0.5&#160;million and $1.4&#160;million in revenue during the three and nine months ended September 30, 2018, respectively, related to the transaction price allocated to the MGD007 option.  All revenue related to the upfront payment was recognized by December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;As discussed above, in 2014, Servier exercised its option to obtain a license to develop and commercialize flotetuzumab in its territories and paid the Company a $15.0 million license grant fee.  Upon exercise, the Company's contractual obligations include (i) granting Servier an exclusive license to its intellectual property, (ii) technical, scientific and intellectual property support to the research plan and (iii)  participation on an executive committee and a research and development committee. Under the terms of the Servier Agreement, the Company and Servier share costs incurred to develop flotetuzumab during the license term. Due to the fact that both parties share costs and are exposed to significant risks and rewards dependent on the commercial success of the product, the Company determined that the arrangement is a collaborative &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;arrangement within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASC 808).  The arrangement consists of two components; the license of flotetuzumab and the research and development activities, including committee participation, to support the research plan.  Under the provisions of ASC 808, the Company has determined that it will use ASC 606 by analogy to recognize the revenue related to the license.  The Company evaluated its performance obligation to provide Servier with an exclusive license to develop and commercialize flotetuzumab and determined that its transaction price is equal to the license grant fee payment of $15.0 million and Servier consumes the benefits of the license over time as the research and development activities are performed. Therefore, the Company is recognizing the transaction price over the development period, using an input method according to research and development costs incurred to date compared to estimated total research and development costs. As noted above, in July 2019, Servier informed the Company of its intention to terminate the Servier Agreement effective January 15, 2020, unless sooner agreed to by the parties.  Therefore, the Company reassessed the end date of its performance obligations under the contract to be January 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; During the three months ended September&#160;30, 2019 and 2018, the Company recognized revenue of $4.7 million and $0.3 million, respectively, related to the flotetuzumab license grant fee.  The Company recognized revenue related to the flotetuzumab license grant fee of $5.1 million and $0.9 million during the nine months ended September 30, 2019 and 2018, respectively.  At September&#160;30, 2019, $7.5 million of revenue related to the flotetuzumab license grant fee was deferred, all of which was current.  At December&#160;31, 2018, $12.6&#160;million of revenue related to the flotetuzumab license grant fee was deferred, $0.9&#160;million of which was current and $11.7 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The research and development activities component of the arrangement is not analogous to ASC 606, therefore the Company follows its policy to record expense incurred as research and development expense and reimbursements received from Servier are recognized as an offset to research and development expense on the consolidated statement of operations and comprehensive loss during the development period.  During the three months ended September 30, 2019 and 2018, the Company recorded approximately $1.4 million and $2.1 million, respectively, as an offset to research and development expense under this collaborative arrangement.  During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $3.4 million and $4.9 million, respectively, as an offset to research and development expense under this collaborative arrangement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Zai Lab&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan for (i) margetuximab, an immune-enhancing anti-HER2 monoclonal antibody, (ii) MGD013, a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million, less foreign withholding tax of $2.5 million, which was received in January 2019.  Assuming successful development and commercialization of margetuximab, MGD013 and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones. In addition, Zai Lab would pay the Company double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and MGD013:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities.  The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate.  Activities related to margetuximab and MGD013 are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract.  The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule.  The Company determined that the $25.0 million (less foreign withholding tax of $2.5 million) upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price.  The standalone selling price of each performance obligation was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement.  Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate.  The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  During the three and nine months ended September 30, 2019, the Company recognized revenue of $4.0 million and $12.1 million, respectively, related to the Zai Lab Agreement.  At September&#160;30, 2019, $9.0 million of revenue was deferred under this agreement, all of which was current. At December&#160;31, 2018, $21.1 million of revenue was deferred under this agreement, $16.1 million of which was current and $5.0 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended September 30, 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and MGD013 (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of margetuximab and MGD013.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three and nine months ended September 30, 2019, the Company recognized revenue of $1.2 million related to the Zai Lab Clinical Supply Agreements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan, will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered double-digit royalties (ranging from mid teens to twenty percent) on annual net sales in its territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territories, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study.  The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities.  As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation.  The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities.  The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million.    I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt; &#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three and nine months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;September 30, 2019, the Company recognized revenue of $1.1 million under the I-Mab Agreement.  At September&#160;30, 2019, $14.4 million of revenue was deferred under this agreement, $4.4 million of which was current and $10.0 million of which was non-current.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2017, the Company entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets  (Roche Agreement).  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies, to select a bispecific format and lead product candidate.  Roche would then further develop and commercialize any such product candidate.  Each company would be responsible for its own expenses during the research period.  In August 2019, Roche informed the Company of its intention to terminate the Roche Agreement effective November 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Roche Agreement, Roche received rights to use certain of the Company&#x2019;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of $10.0 million which was received in January 2018. The Company was also eligible to receive up to $370.0 million in potential milestone payments and royalties on future sales.  As of September 30, 2019, the Company has not recognized any milestone revenue under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the Roche Agreement under the provisions of ASC 606 and identified the following promises under the agreement: (i) the non-exclusive, non-transferable, non-sublicensable license to the Company's intellectual property and (ii) the performance of certain activities during the research period.  The Company determined that the license was capable of being distinct, but was not distinct in the context of the contract because it had limited value to Roche without the research activities required to be performed by the Company.  Therefore, the Company concluded that there was one performance obligation under the agreement.  The Company determined that the transaction price of the Roche Agreement was $10.0 million.  The potential milestone payments were fully constrained and have been excluded from the transaction price.  Any consideration related to sales-based royalties would be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Roche and therefore were also excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The $10.0 million transaction price was being recognized over the expected research period, which was originally 30 months, using a cost-based input method to measure performance.  Upon notice of Roche's intent to terminate the agreement in August 2019, the recognition period was adjusted to end in November 2019. The Company recognized revenue under this agreement of $1.8 million and $1.0 million during the three months ended September&#160;30, 2019 and 2018, respectively.  The Company recognized revenue under this agreement of $3.8 million and $3.0 million during nine months ended September 30, 2019  and 2018, respectively.  At September&#160;30, 2019, $2.2 million of revenue was deferred under this agreement, all of which was current.&#160;At December&#160;31, 2018, $6.0 million of revenue was deferred under this agreement, $4.0 million of which was current and $2.0 million of which was non-current.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Provention&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, the Company entered into a License Agreement with Provention Bio, Inc. (Provention), pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement).  As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones.  As of September 30, 2019, the Company has not recognized any milestone revenue under this agreement.  If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Also in May 2018, the Company entered into an Asset Purchase Agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Provention Asset Purchase Agreement).  As partial consideration for the Provention Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share.  The warrant expires on May 7, 2025.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;milestones and up to $225.0 million in commercial milestones.  If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant, which represents the relative fair value of each performance obligation.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in May 2018.  The warrants are reported in Other assets on the December&#160;31, 2018 consolidated balance sheet and were revalued at each reporting period based on current Black-Scholes parameters until the warrants were exercised.  The resulting increase or decrease is reflected in Other income (expense) on the consolidated statement of operations and comprehensive loss.  There was no material change in the valuation of the warrants during the three and nine months ended September 30, 2018.  The warrants were valued at $1.9 million as of December&#160;31, 2018, and through the date that they were exercised, the Company recorded an increase in the valuation of the warrants of $20.5 million.  In July 2019, the Company exercised the warrants on a cashless basis, and the remaining shares of Provention's common stock acquired are reported in Marketable securities on the September&#160;30, 2019 balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Agreement). Under the NIAID Agreement, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.&lt;/span&gt;&lt;/div&gt;The NIAID Agreement includes a base period of up to $7.5 million to support development of MGD014 through IND application submission with the FDA, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024. In 2017, NIAID exercised the first option in the amount of up to $10.8 million.  During the three months ended September 30, 2019 and 2018, the Company recognized revenue of  under the NIAID Agreement of $0.8 million and $0.2 million, respectively.  During the nine months ended September 30, 2019 and 2018, the Company recognized revenue of  under the NIAID Agreement of $1.5 million and $0.6 million, respectively.</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i58c33273de6d410b9cdecf2a5c0debe0_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTcx_ce35254d-d45d-4ac4-98f3-12163b4cad64"
      unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i368bb594cc624e83a77bf733371fae70_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODM5_641bfa86-6e48-4684-80d9-aedc20250c8d"
      unitRef="usd">420000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i368bb594cc624e83a77bf733371fae70_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODkz_88abe69d-26f0-4674-a171-d725faf23cdc"
      unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id820317bddf4434e96ff1a911394e774_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTYx_33ddb037-63cd-4b45-bf18-5d1aad15255b"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="idd9449b1c89445c48a12627858463cf0_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTEwMw_db6f54aa-aa89-4cdb-bc28-9d540bd7e261"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i48390acd93f242ebbb42fc23fd256a82_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTEwOQ_aa0838fe-874d-45a3-81ef-8c23f6a3d9c1"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i518fa15db0064fec812c4b780bc7655b_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTkwMQ_30317e05-0f2b-43c8-96d4-a0ac408e70db"
      unitRef="performance_obligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i368bb594cc624e83a77bf733371fae70_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjY3OA_3f5f409b-7bea-4081-a0e5-4f4776cfaf74"
      unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="id820317bddf4434e96ff1a911394e774_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDI4Mg_248ae9c4-f2f5-4aa7-b625-a07484fb0ffb"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i15f5e76a013f47d39dc0003413f9d4a4_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDYxNw_49355ec5-5b89-43ba-9909-2fe785a556ae"
      unitRef="usd">150000000.0</us-gaap:Revenues>
    <us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="iae18551f4d2a403db5bd358b0c682d8a_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDc0Mg_f5f12717-4d5f-4757-99b0-78b22cc30674"
      unitRef="usd">4000000.0</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues
      contextRef="i73a39827bd724ee6a7232870c129f33d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTE5MA_69bc1f6c-a8b1-40b1-9b7f-1b446d40e842"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbb4c3a370434273bd0aefee45b77bf2_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTIxNg_263d1cd1-a409-4874-9159-c766e10261d2"
      unitRef="usd">10500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a3b1d36356f4d3eac2cc22fbf399979_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTI5Nw_89377d63-3328-4708-bb23-b0c73d8d9abc"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic81e31ef601944c49da28eddf02a77de_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNTMwNA_2994918f-5788-4596-a656-7c36611cc026"
      unitRef="usd">13600000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i9db3c7b4a5914f65b0e7482d13d66f9f_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMzI5ODUzNDk0NDQ1MA_0d88b7d3-97bc-4374-a785-eec612dc2834"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ibfec87d8a5404f13b27eab46f40228ef_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMzI5ODUzNDk0NDQ1MA_3c44d91d-4e7e-4988-8ebd-ec71f4b1547f"
      unitRef="usd">10000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i6bec22401c70482e823b9a2e5d36d610_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjE2MQ_3fe5a9bd-3ea6-4f79-bec5-bebf55ebb94e"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf29abb47caf4681942fe396155e2ac1_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjE2OA_e1ce7906-7bdf-45cf-b8cc-0d759f361384"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ed40dc4661a49b8968604842ade9122_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjI2NQ_9308ada0-9282-4bf4-b55a-c187563f7bb5"
      unitRef="usd">13100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a118b8388e14ba9b1059b88d91a8477_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjI3Mg_d61ce730-56b5-4692-9ef2-ccd709200d99"
      unitRef="usd">16000000.0</us-gaap:Revenues>
    <mgnx:NumberOfExclusiveOptionsToLicense
      contextRef="ice1c157abfbe45f194053705b2702f65_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNjU3MQ_622a481f-40d9-4331-8b8b-3dbb417ef4ba"
      unitRef="exclusive_license">3</mgnx:NumberOfExclusiveOptionsToLicense>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ib959c0e3f072409998cd0f0023270469_D20120901-20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNzQ1Mw_63b612e1-8233-4f9c-b082-df03edf26e53"
      unitRef="usd">20000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NumberOfExclusiveOptionsToLicense
      contextRef="ice1c157abfbe45f194053705b2702f65_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNzYyNg_622a481f-40d9-4331-8b8b-3dbb417ef4ba"
      unitRef="exclusive_license">3</mgnx:NumberOfExclusiveOptionsToLicense>
    <mgnx:NumberOfPerformanceObligations
      contextRef="ia69015b5eb8740b6a029ef0b991a9402_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODcxOA_328f496a-e173-47fc-83ae-320aa8afc1c2"
      unitRef="performance_obligation">3</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="ice1c157abfbe45f194053705b2702f65_I20120930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfODg1NA_6dcd7811-9b8b-414a-b9e0-66b8684b0baf"
      unitRef="usd">20000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:NumberOfPerformanceObligations
      contextRef="ia69015b5eb8740b6a029ef0b991a9402_I20120930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTA1Ng_328f496a-e173-47fc-83ae-320aa8afc1c2"
      unitRef="performance_obligation">3</mgnx:NumberOfPerformanceObligations>
    <mgnx:NumberOfMilestonesAchieved
      contextRef="i75bf3bc533454969826e25fc96e3af8f_D20140101-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTM2Ng_0fffc904-78a2-47bf-874a-cf83c8b17ab0"
      unitRef="milestone">2</mgnx:NumberOfMilestonesAchieved>
    <mgnx:MilestonePayment
      contextRef="i75bf3bc533454969826e25fc96e3af8f_D20140101-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfOTYxNA_19350660-48b7-45ef-b833-d84d395bb9f9"
      unitRef="usd">5000000.0</mgnx:MilestonePayment>
    <us-gaap:Revenues
      contextRef="i970f2dcb0eab418e9a653c77c4d9cc4f_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwOTk3OQ_5e679914-44be-493f-b833-7bef5f1c8938"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70674713bb8e4d3683f61a49dbc782c9_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwOTk5Mw_fdf6757f-f37a-41c3-8e90-1078e43c030f"
      unitRef="usd">1400000</us-gaap:Revenues>
    <mgnx:OptionExerciseFee
      contextRef="i91dc53f73fa84402824473c88b70867e_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTA3NTI_e2b029fb-2e39-46ba-941a-ceaadd43513f"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <mgnx:NumberOfComponentsInLicenseAgreement
      contextRef="i7828f41496b2476a96ab41b01992b9b4_I20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTE1Mzc_aa00765d-e6ea-425c-92be-d30b2da592b6"
      unitRef="component">2</mgnx:NumberOfComponentsInLicenseAgreement>
    <mgnx:OptionExerciseFee
      contextRef="i91dc53f73fa84402824473c88b70867e_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTIwNjA_e2b029fb-2e39-46ba-941a-ceaadd43513f"
      unitRef="usd">15000000.0</mgnx:OptionExerciseFee>
    <us-gaap:Revenues
      contextRef="ia12d8b77e71f41e4ad0b803eac53f1a0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwODMyNw_19d8309c-5a6c-40da-882b-d6e81e8fe34b"
      unitRef="usd">4700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c6c3b2f59854f77ae4c3719194e6f29_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMwODMzMA_a44f3a93-1202-4d98-9600-39ec954d574b"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09b6a87cc6bb4e9fa8724ece15b105e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2MzY_11fcd5bd-85c6-4f5f-8392-7a637f026168"
      unitRef="usd">5100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5c4e22b89924229a57a8eb74bb20cad_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2NDM_bbe8452d-13f7-494e-8fb3-39ea6b84ea62"
      unitRef="usd">900000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie989ab30d5da4147917fd55e613200bb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2OTA_7d0413e5-0056-43c2-a516-7f8596303e80"
      unitRef="usd">7500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie989ab30d5da4147917fd55e613200bb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI2OTA_a68d8c7b-fdaf-4775-ba22-ddf3ee5596ab"
      unitRef="usd">7500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6f8323bafdc34797924db0952bd973d0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI4Mjk_6e650bec-5f39-467b-82b4-ed52723081f0"
      unitRef="usd">12600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6f8323bafdc34797924db0952bd973d0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI5MDM_cc1f5736-e684-440f-8f6e-1b37300a53d2"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6f8323bafdc34797924db0952bd973d0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTI5MzE_24aec17c-9ef4-40d3-8a45-09fb60eb5c02"
      unitRef="usd">11700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i27244fec8880414bb6b1cfc52c333374_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMTY2MA_409345cb-428a-4ff7-bc5b-3a3e21f37e77"
      unitRef="usd">1400000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="ic146a3b466194000a57ac908f0e5c5be_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfNDM5ODA0NjU3MzA3Mg_d505916a-2de1-4193-b5f0-94fd067267ca"
      unitRef="usd">2100000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="iacab77e6779347788a780579fa1a685e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTM1OTM_c644f489-574b-41cf-bd89-9951922855ba"
      unitRef="usd">3400000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts
      contextRef="i8c16b322b44845d9b43c3c5ce1fd49af_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTM2MDA_5f595c11-a98a-4dbb-abce-b70fce8f4f98"
      unitRef="usd">4900000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTQ0NjQ_687b49fa-1354-4855-b1c1-3d68e358e4a2"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTQ1MDA_e50beae4-25f6-4f4b-95d2-8c4b4f1c669a"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i30a9f07d07b94663a8cde320960c506a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTQ2Nzc_f4c6f730-6daa-474b-86ea-73d55697e671"
      unitRef="usd">140000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTYwNDg_687b49fa-1354-4855-b1c1-3d68e358e4a2"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="i15fcf5925096408aa871268b0c41f70a_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTYwODQ_e50beae4-25f6-4f4b-95d2-8c4b4f1c669a"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <us-gaap:Revenues
      contextRef="ie4087c84e7e44db6bae261d20124a913_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxMTI_ac4d5650-73e2-4cae-a873-6fb7ca66df9e"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55adada0a7564bdf9cfe077725d854b9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxMTk_05a632ba-341b-4264-a65a-ce989e1f911d"
      unitRef="usd">12100000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i30a9f07d07b94663a8cde320960c506a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxNzk_ddb77f89-0c02-4cb6-b63f-f66ebd20d864"
      unitRef="usd">9000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i30a9f07d07b94663a8cde320960c506a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgxNzk_f4de5ea6-db8e-49ad-b7e9-bde9faed7b20"
      unitRef="usd">9000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgyOTI_d2562646-0614-4ab9-a09a-0d7664b47168"
      unitRef="usd">21100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgzNDE_64a4734b-2819-4c81-9450-c6398a3578e0"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie1aa52f0cb7843179e95efedcec4e2a3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTgzNjk_c186a9cc-a1b6-4934-8689-b93c53cabf64"
      unitRef="usd">5000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Revenues
      contextRef="i08e4673e6a2a448182624726fd572b76_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjIyOQ_a57cd98d-7d6d-4870-9bdd-645338446dd4"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a5eb519ef2e4cbc8181141d7cd9276d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjIyOQ_fb9871cb-a88a-4f41-8b3f-67dd1d0c2ff7"
      unitRef="usd">1200000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI1Mw_6bcd51f3-adb6-4fba-8dc2-e22112ec96bb"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI2OQ_29443cef-da0e-42b4-924c-0ae6f2c2bfc6"
      unitRef="usd">135000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjUzMw_6bcd51f3-adb6-4fba-8dc2-e22112ec96bb"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzM0OTE3NA_f7b2cdc8-9e59-48fd-ad7c-3632f3f699f4"
      unitRef="usd">1000000.0</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <us-gaap:Revenues
      contextRef="i833fd612177d43f59a1880ab85e387fc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI3Nw_1e4d5711-b101-42d7-9d48-2628f4683d61"
      unitRef="usd">1100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie953d43978514183bcdd8c7b4ab3ab96_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI3Nw_dc3d3127-e0e8-45c4-951e-d29b21a28b11"
      unitRef="usd">1100000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjI5MQ_a914fe67-71e8-4f17-bbe0-e48ad8db55af"
      unitRef="usd">14400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjMwNA_964b464e-2398-4151-96ec-0759bff7d05d"
      unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if5c21a31445540e69dbc3a6f5f639ab6_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjMxNw_29f297bc-9449-46b2-b337-a5b04e0e5c07"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="idd651a75afdd4d7d95c4e21996253290_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTkyODE_70435f5c-6205-4838-b12e-ca4c27bfa405"
      unitRef="usd">10000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement
      contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMTkzNzE_f61cbfc7-bee8-4f20-bc5d-0ed01e79f24e"
      unitRef="usd">370000000.0</mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjAxMTI_c7500f53-e60a-4223-a38a-d85f6710aee5"
      unitRef="performance_obligation">1</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjAyMzc_f380a30f-f382-4060-9fb9-dbea36d2ce2c"
      unitRef="usd">10000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i2eb1aca92da74f588459f1372f4a49b2_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA1OTk_12778c8d-64f7-4f04-aa3d-cfba5e9d8e95"
      unitRef="usd">10000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:UpfrontPaymentRecognitionPeriod
      contextRef="i3b2a9d94d2dd4bea92a57ffb8904cbee_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA2ODQ_d3ba9020-564a-4a89-8f5f-b5d30af8aa54">P30M</mgnx:UpfrontPaymentRecognitionPeriod>
    <us-gaap:Revenues
      contextRef="ie736d7bf024b4ae28e4589d3b604e1df_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA4MDA_362a885a-6de0-4bf3-8a7e-3d58ce26c775"
      unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5739a109487c4754a883c99176a1efd9_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMjk5Mw_856961f4-a60d-4bc3-95c3-af6f1e80e450"
      unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i054926fddff24ee5807d883aad5e2a1f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA4NjM_0c73764f-8979-4e83-8f1d-6eb61e422c3a"
      unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62c1e47bb3ef4615991f7912494745cf_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxMzE1NA_3f62b5e0-2c6e-44ed-8921-b7f23e4be529"
      unitRef="usd">3000000.0</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i54fd08a4f3f743b49797b697a1ce3106_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjA5Mjg_904affc6-3cbe-483d-b0aa-86ba609fe9c3"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjEwMTA_27a55a5e-f7f9-4b2a-ad69-556e4a35c06e"
      unitRef="usd">6000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjEwNTk_2cba9ac6-3b90-4cf8-bf82-ae70f3aa536f"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i1b2456890ea1455aaf0d9fcc02acef6f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjEwODc_82801e15-087b-45cd-abee-970e6826c1c8"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i02cc1ebe209c402a8c800be888313cd7_D20180531-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE2NzU_f835c783-c95b-4a24-bd42-4715cdbfd041"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="ie967f030aa6b4bc8aa81afe083e3c526_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE4NzE_07728fc8-af9f-44cc-b94d-79d09391c00c"
      unitRef="usd">65000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="ie967f030aa6b4bc8aa81afe083e3c526_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5MjU_770284c9-a8df-41bb-8a20-ae65270e24af"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i8e2cd88b1fe140d6a7dfa35faadde661_D20180531-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjI5Nzg_ddf85c6b-ecdd-443e-b124-84abcbed2a00"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i5c8b2113702b464282bfe3e9b94f4d74_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjMxNzQ_9920dfb9-ca2a-44a8-83c3-1c97507bc344"
      unitRef="usd">170000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i5c8b2113702b464282bfe3e9b94f4d74_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjMyMTI_7177f7fc-4a82-4f01-9ed4-a25d631f9c2f"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="i5c8b2113702b464282bfe3e9b94f4d74_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjM1OTA_5e9ed124-85fb-4c2a-9753-037543bed0ec"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjQxOTI_c986e23c-e6b3-45d2-b554-56d8873e3ae4"
      unitRef="performance_obligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjQzODU_7e198599-e0a4-4775-88c5-8a7cae1c2c60"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="i0d60a3d64db24aa9a59ec712ca6f3772_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjQ0NTQ_2b117f1d-1b87-49a3-aff9-c33448546366"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="ib9214916d72546d59baaee9785a7e087_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjU0Njg_289e040d-9a5f-4f31-8e58-70e85a2fbe31"
      unitRef="usd">6100000</us-gaap:Revenues>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if69a1a642f0d4979adb8ba239f6c10b1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxODE1MQ_035e8c1d-7431-465a-8898-8c92a47f10dc"
      unitRef="usd">1900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ie723c1c82d87464d9ed56b45a59bacc5_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjE5OTAyMzMxNTk5OQ_1e682a94-eb61-4881-9cc3-eab12e58ecb0"
      unitRef="usd">20500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjY0NzU_f4188fd8-9e7f-4b82-aa15-633dabf22772"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:FundedValueOfBasePeriod
      contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjcwNDQ_c3687ccc-01c6-4c9a-b16d-ca8296b8daea"
      unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
    <mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjcxNDY_3a05a80c-abf8-4611-8a3c-c9db76771119"
      unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="i001658d77bd94901a9b62964e1c8daef_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjcyOTQ_a1e392d9-4a40-4404-8508-a27ea02c623d"
      unitRef="usd">24500000</mgnx:TotalPotentialValueUnderAgreement>
    <mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i273a5f224d3e4ecf828034c5e3e0f859_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc0NDQ_b69c0e0b-0b95-421a-94f3-75d489890b0e"
      unitRef="usd">10800000</mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement>
    <us-gaap:Revenues
      contextRef="i7a77af8c6e3e41ff8d11e8fe34dc64fc_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc1MzU_b628d699-09d1-485b-88e5-0ea122a2e605"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49febe140c734397af0ac451febc2e05_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc1NDI_3b5c774a-c13e-4734-854a-2ce058e169d9"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i372a9ad3922943f491a1fa7dd2c30d5d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc2NDc_571c08b4-8a40-4905-bd68-4dd003682762"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i422a064f422b48ae8e9a505da5963ed5_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81Mi9mcmFnOjBjNWI4MWIzMTk2NDRjNGM5NGQwZTM5ZGY0ODQ0ODhkL3RleHRyZWdpb246MGM1YjgxYjMxOTY0NGM0Yzk0ZDBlMzlkZjQ4NDQ4OGRfMjc2NTQ_d609e9c9-05f0-409a-81b4-3de65d4837ab"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY1Ng_082d0e3a-fc76-4edd-8569-3aecbbc6ec5e">Stock-Based Compensation&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;market value of the Company&#x2019;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2019, 25,722 shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $0.4&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2019, under the 2003 Plan, there were options to purchase an aggregate of 559,357 shares of common stock outstanding at a weighted average exercise price of $2.30 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2019, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 9,938,263.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2019, there were options to purchase an aggregate of 6,689,172 shares of common stock outstanding at a weighted average exercise price of $22.55 per share under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.808260%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.781711%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.127434%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.601770%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.569912%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.896755%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.012389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.601770%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.491924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.767988%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.005874%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.7% - 76.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67.8% - 72.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4% - 3.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.970588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt; (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,273,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(210,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(199,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,248,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,074,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,936,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2019 and 2018 was $14.33 and $18.07, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2019 and 2018 was approximately $2.8 million and $4.0 million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2019 and 2018 was approximately $0.7 million and $0.9 million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2019 and 2018 was approximately $12.8 million and $11.9 million, respectively. As of September&#160;30, 2019, the total unrecognized compensation expense related to non-vested stock options, net of related forfeiture estimates, was approximately $40.8 million, which the Company expects to recognize over a weighted-average period of approximately 2.6 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6e1a6fcd218941a6baa89073c11c5da2_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDI3_eb42780c-5553-4f21-9492-ab387b7ef448"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i93ea6f505d99415186f0268a4bba80ef_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNjI2_c626bec0-ada6-4e8a-9f86-d986815f1815"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i93ea6f505d99415186f0268a4bba80ef_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfODcz_cba998e7-893d-47aa-bd91-bbb9717e354f"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i454fbe875e5b4db7a40944d31eb23a84_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMTAwMw_ea64e9f7-70b2-4b76-8700-73e0c4e564c5"
      unitRef="shares">25722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i9b030de878e8406ebf1f621232078e07_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMTExMw_ba8a6dd4-7845-44a0-9d34-8cae30437fdd"
      unitRef="usd">400000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic3e00c8e472e49d588cd53f7014d9b81_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMTk3Ng_a6466a68-5ca4-4302-88d6-cbe5105c2f94"
      unitRef="shares">559357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic3e00c8e472e49d588cd53f7014d9b81_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjA1NA_cc75f57a-84c1-4160-9da7-9e6de1a25762"
      unitRef="usdPerShare">2.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="ib66184941d714664ae08c0e838d10181_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjQ2Ng_8ab92f48-b99d-4771-baeb-e0d09d062e9a"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i1a913a00b68549eeb34e0b8808b5269e_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjQ4MQ_5598da1d-a772-48e4-94eb-8d8fa54a078d"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib66184941d714664ae08c0e838d10181_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMjgyMw_38b30594-b73c-4d66-b6d7-d56ca045d1ad"
      unitRef="shares">9938263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib66184941d714664ae08c0e838d10181_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMzM5OQ_47077669-eb13-4022-8c50-079fd342ed35"
      unitRef="shares">6689172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib66184941d714664ae08c0e838d10181_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfMzQ3Nw_61bd1b19-3711-4cd5-852e-341960a81ebb"
      unitRef="usdPerShare">22.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY1OA_af44e020-c3e0-411b-acf0-ccfadb316016">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.808260%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.781711%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.127434%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.601770%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.569912%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.896755%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:2.012389%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.601770%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icff895ca6df94222b46a51a086d8de19_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi0xLTEtMS0w_22759e17-3c2c-4d4a-850b-44ce6215df4b"
      unitRef="usd">2765000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic79500c2c7ee4616be6fac7a8cf8e3c0_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi0zLTEtMS0w_3a3705cc-bed3-489a-9f68-543d52467a02"
      unitRef="usd">2440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ccfecbf14a74088903da62adfcb0fa7_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi01LTEtMS0w_b554a278-e15d-4149-a7d8-e350cc9e26a4"
      unitRef="usd">7032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if31b162e8e37461f9128da55a95f93e6_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMi03LTEtMS0w_f1da6259-58b4-4c76-af20-f30cd444f3c3"
      unitRef="usd">6347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ff8158fdeb940b6918114f76ea442b3_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy0xLTEtMS0w_e27c79d1-7c13-4186-9f00-262c10f1eab9"
      unitRef="usd">2633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic0c8668b262748c89e872fcfa0fb50dc_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy0zLTEtMS0w_c4c6171c-6ff3-498e-b8bd-8fe67e09f257"
      unitRef="usd">2133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8d755c340e64be8bdab95b9056b73dc_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy01LTEtMS0w_ab4fb905-e322-49f4-bdde-2b4651dcacc5"
      unitRef="usd">7049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idfa5b8cd82a44f608083484c65993b70_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfMy03LTEtMS0w_09ef2bee-a7bc-4b0d-80a5-ddc553d05ebb"
      unitRef="usd">5821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37d4ad1050064cadb049dc970e8a689e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC0xLTEtMS0w_825ca174-bbd3-44b9-b573-22a9154ebf41"
      unitRef="usd">5398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i73c913cb2c7642749ebb3a78cb43d0a4_D20180701-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC0zLTEtMS0w_f19902df-1565-4cbb-8eb5-3eb6dc23678c"
      unitRef="usd">4573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC01LTEtMS0w_cf1d2b07-598b-402c-9c5b-45b86e5a9c12"
      unitRef="usd">14081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOmU3YTNiODQ4ZmUyNjRmOGE4Y2QzOTc3NWYxMzQwZWM5L3RhYmxlcmFuZ2U6ZTdhM2I4NDhmZTI2NGY4YThjZDM5Nzc1ZjEzNDBlYzlfNC03LTEtMS0w_cd810bac-93a1-44fa-b237-2cc275e95a60"
      unitRef="usd">12168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY2MA_e413e755-fecf-4c78-adf0-2b501f201c0f">&lt;div style="text-indent:36pt;margin-top:15pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:63.491924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.767988%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.005874%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.7% - 76.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;67.8% - 72.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4% - 3.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfMi0xLTEtMS0w_75f7ea0a-120a-44c3-8a8f-fae2dd2e7e7f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfMi0zLTEtMS0w_1cbde17d-f9e3-4a04-afcf-97de5218d9ac"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfNS0xLTEtMS0w_d0cb0cd8-fa97-4afb-b79f-4dd2f8596d44">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjY3MTM3Zjg4MGQ4ZjRmZGZiMjhiZDQ0MGQ3MGFkMDQyL3RhYmxlcmFuZ2U6NjcxMzdmODgwZDhmNGZkZmIyOGJkNDQwZDcwYWQwNDJfNS0zLTEtMS0w_4bddb3aa-23e7-4643-9b8f-cd306b052928">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY2Mg_9cb4ad33-22ba-4522-aafd-725217f18ea4">&lt;div style="text-indent:36pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:26.970588%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535294%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.205882%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt; (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,273,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,384,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(210,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(199,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,248,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2019:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,074,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,936,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman';color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMS0xLTEtMS0w_eccef515-a06b-47e1-bb8e-f1f3a7719691"
      unitRef="shares">5273964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id8841551e05040c396f8fa6fcf8186df_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMS0zLTEtMS0w_65436f3a-1caf-4e7f-9e51-42bfefc41965"
      unitRef="usdPerShare">22.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7038fb1eaaed4930bef39d8439888cd3_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMS01LTEtMS0w_e24faea8-33e1-46c3-94dd-dfa1fa23e55d">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMi0xLTEtMS0w_d5f91844-ad4c-4459-9886-2528fce45be1"
      unitRef="shares">2384770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMi0zLTEtMS0w_e5583ce1-afbc-436f-b518-3eadd7c46082"
      unitRef="usdPerShare">16.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMy0xLTEtMS0w_740a90fb-e86a-4960-aab9-cfcc0f25210a"
      unitRef="shares">210261</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfMy0zLTEtMS0w_78b84773-598e-499c-9e86-16b6a16b4d87"
      unitRef="usdPerShare">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNC0xLTEtMS0w_4f4e9998-db91-4a32-a3b5-df84fa3ae395"
      unitRef="shares">199944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNC0zLTEtMS0w_9df755da-7d57-4f86-aa3b-c9b5a185ac35"
      unitRef="usdPerShare">23.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS0xLTEtMS0w_46f1309d-74db-4c93-84da-740458d59164"
      unitRef="shares">7248529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS0zLTEtMS0w_b766a0b6-de77-4f3e-96ce-9c2e4757f562"
      unitRef="usdPerShare">20.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS01LTEtMS0w_42c92d70-97e9-4c6b-8a10-8cf23c750085">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNS03LTEtMS0w_320e5d91-8bbe-4414-b1a9-15406f3cc168"
      unitRef="usd">11733000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy0xLTEtMS0w_e4326e24-9acb-40fc-a6df-cacfebcabb9f"
      unitRef="shares">4074460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy0zLTEtMS0w_87e6f5f8-66e5-49e0-b23b-f2aea9d944f1"
      unitRef="usdPerShare">22.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy01LTEtMS0w_3551a425-cc8c-4ab6-a862-f16659137ae1">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfNy03LTEtMS0w_0bbb8abb-1d8e-4a2b-b48c-ffc956f5ae89"
      unitRef="usd">5849000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC0xLTEtMS0w_80b816da-5a79-483e-b1a3-bd04377c8bb5"
      unitRef="shares">6936223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC0zLTEtMS0w_3f713a84-33a0-45da-827a-c9f8db48c6d6"
      unitRef="usdPerShare">20.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC01LTEtMS0w_4ae4f550-9206-45f5-b757-6dd92ec266ab">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RhYmxlOjVlYTllMTIyM2JlYTQ3ZjJiYzEwM2I0MTc1ZWIwOThiL3RhYmxlcmFuZ2U6NWVhOWUxMjIzYmVhNDdmMmJjMTAzYjQxNzVlYjA5OGJfOC03LTEtMS0w_72fc3f03-c969-4666-89d6-6aeca3b45335"
      unitRef="usd">11367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDAxNg_0308fbcb-0391-4fb0-b905-ea5831d56cf3"
      unitRef="usdPerShare">14.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDAyMw_6ffc5f53-44ed-48a0-9689-5d2253740c0a"
      unitRef="usdPerShare">18.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDE0Mw_892eb53c-1033-4e89-b3bf-8e6fdcdcee17"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDE1MA_28176e6a-3637-4e28-8d82-b34f7577f46f"
      unitRef="usd">4000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDI3MQ_8974067c-041a-441b-a8b0-ea7887460c78"
      unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDM5ODA0NjUxNTg0Mg_cfad3ab3-6931-494d-a470-a3f9729b7081"
      unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDM4NQ_b458281f-aa7c-4972-9368-561ba313fc49"
      unitRef="usd">12800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ie631656618b44857967833397e06fec9_D20180101-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDM5Mg_ffe0f4c2-2641-4338-8660-2659d30e75ea"
      unitRef="usd">11900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib491d902a8ad49b795070a44de412e95_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDU1Ng_5131f985-999c-4a9f-b028-2ee060e84498"
      unitRef="usd">40800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF81NS9mcmFnOjFlZjJjODU3N2Q0MzRlMDZhNTY0ZjQ1ZjgwM2RkMmIzL3RleHRyZWdpb246MWVmMmM4NTc3ZDQzNGUwNmE1NjRmNDVmODAzZGQyYjNfNDY0Nw_f060afaa-4094-4f33-b3d7-b3f8f54861ce">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0d073e73b1854f88ad587afa842c298d_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMGQ2NmI0NGQ4ZjQwMDliMDcxY2I0NjhkNGZiZGE4L3NlYzo0YTBkNjZiNDRkOGY0MDA5YjA3MWNiNDY4ZDRmYmRhOF82MS9mcmFnOmE4MTNjM2Q3MmZjOTQ1ZjA5NWM5ZWM4NzNmYTEzODRiL3RleHRyZWdpb246YTgxM2MzZDcyZmM5NDVmMDk1YzllYzg3M2ZhMTM4NGJfMzI5ODUzNDg4NzA2Mg_ca59af99-2544-492e-84f4-ca712ad71b2e">Commitments and ContingenciesOn September 13, 2019, a class action suit, entitled Todd Hill v. MacroGenics, Inc. (Case No. 8:19-cv-02713), was filed in the U.S. District Court for the District of Maryland against the Company and certain of its officers and/or directors, alleging violations of securities laws during 2019.  The suit asserts certain claims under Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's margetuximab Phase 3 SOPHIA study.  The Company believes this suit is without merit and plans to vigorously defend against these claims.  Currently, no reserve has been established for any potential liability related to this suit.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>225</ContextCount>
  <ElementCount>278</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1406401 - Statement - Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Details</Role>
      <ShortName>Details</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Leases Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseCostsDetails</Role>
      <ShortName>Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Collaboration and Other Agreements - Incyte (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Collaboration and Other Agreements - Les Laboratoires Servier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsLesLaboratoiresServierDetails</Role>
      <ShortName>Collaboration and Other Agreements - Les Laboratoires Servier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Collaboration and Other Agreements - Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsRocheDetails</Role>
      <ShortName>Collaboration and Other Agreements - Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CollaborationandOtherAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Collaboration and Other Agreements - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsProventionDetails</Role>
      <ShortName>Collaboration and Other Agreements - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20190930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - mgnx-20190930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - mgnx-20190930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20190930.htm">mgnx-20190930.htm</File>
    <File>exhibit31-1q32019.htm</File>
    <File>exhibit31-2q32019.htm</File>
    <File>exhibit32-1q32019.htm</File>
    <File>exhibit32-2q32019.htm</File>
    <File>mgnx-20190930.xsd</File>
    <File>mgnx-20190930_cal.xml</File>
    <File>mgnx-20190930_def.xml</File>
    <File>mgnx-20190930_lab.xml</File>
    <File>mgnx-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6927168576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In April 2018, the Company completed a firm-commitment underwritten public offering, in which the Company sold 4,500,000 shares of its common stock at a price of $21.25 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 675,000 shares of the Company's common stock at a price of $21.25 per share.  Upon closing, the Company received net proceeds of approximately $103.0 million from this offering, net of underwriting discounts and commissions and other offering expenses. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2019, the Company completed a </span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">firm-commitment underwritten public</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share.  Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#8217;s </span></div>common stock at a price of $20.00 per share.  The Company received net proceeds of approximately $118.7 million from this offering, net of underwriting discounts and commissions and other offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759127696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2018 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Recently Adopted Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, which requires lessees to recognize a right-of-use (ROU) asset and a lease liability for all leases with terms greater than 12 months and also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases.  Subsequent to the issuance of ASU 2016-02, the FASB clarified the guidance through several ASUs, with the resulting guidance collectively referred to as ASC 842. The Company adopted ASC 842 effective January 1, 2019, using the optional transition method provided under ASU 2018-11, which did not require adjustments to comparative periods nor require modified disclosures in those comparative periods. The Company has elected not to recognize leases with terms of one year or less on the balance sheet. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances. For leases where the Company is the lessee, ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.  The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated.  Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has lease agreements which require payments for lease and non-lease components and has elected the practical expedient not to separate non-lease components from lease components for all classes of underlying assets. </span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">As a result of the cumulative impact of adopting ASC 842, the Company recorded operating lease ROU assets of $16.4 million and operating lease liabilities of $27.7 million as of January 1, 2019, primarily related to real estate leases, based on the present value of the future lease payments on the date of adoption. The ROU asset is included in Other assets on the consolidated balance sheets.  Refer to Note 4, Leases, for additional disclosures required by ASC 842. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Recently Issued Accounting Standards</span></div><div style="text-indent:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">In November 2018, the FASB issued ASU 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;"> (ASU 2018-18). The amendments provide guidance on whether certain </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:115%;">transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. The guidance will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted and should be applied retrospectively. The Company does not anticipate the adoption of this standard will have a material impact on its consolidated financial statements.</span></div><div style="text-indent:36pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
